```
Welcome to STN International!  Enter x:x

LOGINID:sssptaul25rxt

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2           "Ask CAS" for self-help around the clock
 NEWS  3  SEP 09   CA/CAplus records now contain indexing from 1907 to the
                   present
 NEWS  4  Jul 15   Data from 1960-1976 added to RDISCLOSURE
 NEWS  5  Jul 21   Identification of STN records implemented
 NEWS  6  Jul 21   Polymer class term count added to REGISTRY
 NEWS  7  Jul 22   INPADOC: Basic index (/BI) enhanced; Simultaneous Left and
                   Right Truncation available
 NEWS  8  AUG 05   New pricing for EUROPATFULL and PCTFULL effective
                   August 1, 2003
 NEWS  9  AUG 13   Field Availability (/FA) field enhanced in BEILSTEIN
 NEWS 10  AUG 15   PATDPAFULL: one FREE connect hour, per account, in
                   September 2003
 NEWS 11  AUG 15   PCTGEN: one FREE connect hour, per account, in
                   September 2003
 NEWS 12  AUG 15   RDISCLOSURE: one FREE connect hour, per account, in
                   September 2003
 NEWS 13  AUG 15   TEMA: one FREE connect hour, per account, in
                   September 2003
 NEWS 14  AUG 18   Data available for download as a PDF in RDISCLOSURE
 NEWS 15  AUG 18   Simultaneous left and right truncation added to PASCAL
 NEWS 16  AUG 18   FROSTI and KOSMET enhanced with Simultaneous Left and Righ
                   Truncation
 NEWS 17  AUG 18   Simultaneous left and right truncation added to ANABSTR
 NEWS 18  SEP 22   DIPPR file reloaded
 NEWS 19  SEP 25   INPADOC: Legal Status data to be reloaded

 NEWS EXPRESS  April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT
               MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
               AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:17:21 ON 29 SEP 2003
```

AN 1994:261080 CAPLUS
DN 120:261080
TI **Intrathecal** injection of lysine acetylsalicylic acid in the rat: a neurotoxicological study
AU Svensson, B. A.; Karlsten, R.; Kristensen, J. D.; Sottile, A.; Bennett, A.; Gordh, T. Jr.
CS Dep. Anat., Uppsala Univ., Uppsala, Swed.
SO Acta Anaesthesiologica Scandinavica (1993), 37(8), 799-805
CODEN: AANEAB; ISSN: 0001-5172
DT Journal
LA English
CC 1-11 (Pharmacology)
AB Lysine acetylsalicylic acid has been reported to induce analgesic effects in humans after **intrathecal** (i.t.) injection. Before conducting further studies in humans with this drug, it is important to evaluate potential toxicol. effects on the spinal cord in animals. In the present study the effects of chronic **intrathecal** administration of provocative doses of lysine acetylsalicylic acid (L-ASA) on the rat spinal cord were evaluated using light and electron microscopy and a quant. morphometric method. The authors also investigated the effects of single doses of the drug on the spinal cord blood flow (SCBF) using the laser-Doppler flowmetry technique. No histopathol. changes or differences in no. or d. of neuronal cells could be seen after chronic administration of L-ASA as compared to controls. The SCBF decreased immediately after i.t. injection of a large dose (4 mg) of L-ASA and returned to predrug levels within 10 min. At the end of the expt. metabolic acidosis was detected, indicating a systemic effect of acetylsalicylic acid. It is concluded that no neurotoxic effects on the spinal cord were seen after chronic i.t. injection of L-ASA. From a neurotoxicol. point of view, the authors' findings do not contraindicate the spinal use of L-ASA in humans.
ST lysine acetylsalicylic acid toxicity spinal cord; analgesic lysine acetylsalicylic acid toxicity
IT Analgesics
(lysine acetylsalicylic acid as, neurotoxicity of, to spinal cord, after **intrathecal** injection)
IT Spinal cord
(lysine acetylsalicylic acid neurotoxicity to, after **intrathecal** injection)
IT Nerve, toxic chemical and physical damage
(lysine acetylsalicylic acid toxicity to, in spinal cord, after **intrathecal** injection)
IT Acidosis
(neurotoxic effect of lysine acetylsalicylic acid in relation to, in spinal cord, after **intrathecal** injection)
IT Circulation
(of spinal cord, lysine acetylsalicylic acid effect on, neurotoxicity after **intrathecal** injection in relation to)
IT **62952-06-1**
RL: PRP (Properties)
(neurotoxicity of, to spinal cord, after **intrathecal** injection)

=>

AN 1994:261080 CAPLUS
DN 120:261080
TI **Intrathecal** injection of lysine acetylsalicylic acid in the rat: a neurotoxicological study
AU Svensson, B. A.; Karlsten, R.; Kristensen, J. D.; Sottile, A.; Bennett, A.; Gordh, T. Jr.
CS Dep. Anat., Uppsala Univ., Uppsala, Swed.
SO Acta Anaesthesiologica Scandinavica (1993), 37(8), 799-805
CODEN: AANEAB; ISSN: 0001-5172
DT Journal
LA English
CC 1-11 (Pharmacology)
AB Lysine acetylsalicylic acid has been reported to induce analgesic effects in humans after **intrathecal** (i.t.) injection. Before conducting further studies in humans with this drug, it is important to evaluate potential toxicol. effects on the spinal cord in animals. In the present study the effects of chronic **intrathecal** administration of provocative doses of lysine acetylsalicylic acid (L-ASA) on the rat spinal cord were evaluated using light and electron microscopy and a quant. morphometric method. The authors also investigated the effects of single doses of the drug on the spinal cord blood flow (SCBF) using the laser-Doppler flowmetry technique. No histopathol. changes or differences in no. or d. of neuronal cells could be seen after chronic administration of L-ASA as compared to controls. The SCBF decreased immediately after i.t. injection of a large dose (4 mg) of L-ASA and returned to predrug levels within 10 min. At the end of the expt. metabolic acidosis was detected, indicating a systemic effect of acetylsalicylic acid. It is concluded that no neurotoxic effects on the spinal cord were seen after chronic i.t. injection of L-ASA. From a neurotoxicol. point of view, the authors' findings do not contraindicate the spinal use of L-ASA in humans.
ST lysine acetylsalicylic acid toxicity spinal cord; analgesic lysine acetylsalicylic acid toxicity
IT Analgesics
(lysine acetylsalicylic acid as, neurotoxicity of, to spinal cord, after **intrathecal** injection)
IT Spinal cord
(lysine acetylsalicylic acid neurotoxicity to, after **intrathecal** injection)
IT Nerve, toxic chemical and physical damage
(lysine acetylsalicylic acid toxicity to, in spinal cord, after **intrathecal** injection)
IT Acidosis
(neurotoxic effect of lysine acetylsalicylic acid in relation to, in spinal cord, after **intrathecal** injection)
IT Circulation
(of spinal cord, lysine acetylsalicylic acid effect on, neurotoxicity after **intrathecal** injection in relation to)
IT **62952-06-1**
RL: PRP (Properties)
(neurotoxicity of, to spinal cord, after **intrathecal** injection)

=>

AN 1994:261080 CAPLUS
DN 120:261080
TI **Intrathecal** injection of lysine acetylsalicylic acid in the rat: a neurotoxicological study
AU Svensson, B. A.; Karlsten, R.; Kristensen, J. D.; Sottile, A.; Bennett, A.; Gordh, T. Jr.
CS Dep. Anat., Uppsala Univ., Uppsala, Swed.
SO Acta Anaesthesiologica Scandinavica (1993), 37(8), 799-805
CODEN: AANEAB; ISSN: 0001-5172
DT Journal
LA English
CC 1-11 (Pharmacology)
AB Lysine acetylsalicylic acid has been reported to induce analgesic effects in humans after **intrathecal** (i.t.) injection. Before conducting further studies in humans with this drug, it is important to evaluate potential toxicol. effects on the spinal cord in animals. In the present study the effects of chronic **intrathecal** administration of provocative doses of lysine acetylsalicylic acid (L-ASA) on the rat spinal cord were evaluated using light and electron microscopy and a quant. morphometric method. The authors also investigated the effects of single doses of the drug on the spinal cord blood flow (SCBF) using the laser-Doppler flowmetry technique. No histopathol. changes or differences in no. or d. of neuronal cells could be seen after chronic administration of L-ASA as compared to controls. The SCBF decreased immediately after i.t. injection of a large dose (4 mg) of L-ASA and returned to predrug levels within 10 min. At the end of the expt. metabolic acidosis was detected, indicating a systemic effect of acetylsalicylic acid. It is concluded that no neurotoxic effects on the spinal cord were seen after chronic i.t. injection of L-ASA. From a neurotoxicol. point of view, the authors' findings do not contraindicate the spinal use of L-ASA in humans.
ST lysine acetylsalicylic acid toxicity spinal cord; analgesic lysine acetylsalicylic acid toxicity
IT Analgesics
(lysine acetylsalicylic acid as, neurotoxicity of, to spinal cord, after **intrathecal** injection)
IT Spinal cord
(lysine acetylsalicylic acid neurotoxicity to, after **intrathecal** injection)
IT Nerve, toxic chemical and physical damage
(lysine acetylsalicylic acid toxicity to, in spinal cord, after **intrathecal** injection)
IT Acidosis
(neurotoxic effect of lysine acetylsalicylic acid in relation to, in spinal cord, after **intrathecal** injection)
IT Circulation
(of spinal cord, lysine acetylsalicylic acid effect on, neurotoxicity after **intrathecal** injection in relation to)
IT **62952-06-1**
RL: PRP (Properties)
(neurotoxicity of, to spinal cord, after **intrathecal** injection)

=>

AN 1997:454047 CAPLUS
DN 127:60626
TI Method of delaying onset of **Alzheimer**'s disease symptoms with a non-steroidal anti-inflammatory agent and/or a histamine H2 receptor-blocking agent
IN Breitner, John C. S.; Welsh, Kathleen A.
PA Duke University, USA
SO U.S., 10 pp.
CODEN: USXXAM
DT Patent
LA English
IC ICM A61K031-60
ICS A61K031-615; A61K031-54; A61K031-44; A61K031-425; A61K031-42; A61K031-415; A61K031-40; A61K031-38; A61K031-34; A61K031-195; A61K031-19
NCL 514570000
CC 1-11 (Pharmacology)
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5643960	A	19970701	US 1994-228019	19940415
	US 6025395	A	20000215	US 1997-843217	19970414
PRAI	US 1994-228019		19940415		

AB A method is disclosed for preventing or delaying the onset of **Alzheimer**'s disease and related neurodegenerative disorders. The method involves the administration to individuals at risk of developing the disease (or disorder) a non-steroidal anti-inflammatory agent and/or a histamine H2 receptor-blocking agent. The invention also relates to a method of treating **Alzheimer**'s disease and related neurodegenerative disorders that involves the use of such agents.
ST **Alzheimer** disease NSAID H2 antihistaminic; neurodegenerative disease NSAID H2 antihistaminic
IT Apolipoproteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(E, .epsilon.4 or .epsilon.2 allele at locus for; non-steroidal anti-inflammatory agent and/or histamine H2 receptor-blocking agent for preventing, delaying, or treating **Alzheimer**'s disease and related neurodegenerative disorders)
IT Antihistamines
(H2; non-steroidal anti-inflammatory agent and/or histamine H2 receptor-blocking agent for preventing, delaying, or treating **Alzheimer**'s disease and related neurodegenerative disorders)
IT Nervous system
(degeneration; non-steroidal anti-inflammatory agent and/or histamine H2 receptor-blocking agent for preventing, delaying, or treating **Alzheimer**'s disease and related neurodegenerative disorders)
IT **Alzheimer**'s disease
Narcotics
Susceptibility (genetic)
(non-steroidal anti-inflammatory agent and/or histamine H2 receptor-blocking agent for preventing, delaying, or treating **Alzheimer**'s disease and related neurodegenerative disorders)
IT Glucocorticoids
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(non-steroidal anti-inflammatory agent and/or histamine H2 receptor-blocking agent for preventing, delaying, or treating **Alzheimer**'s disease and related neurodegenerative disorders)
IT Anti-inflammatory agents
(nonsteroidal; non-steroidal anti-inflammatory agent and/or histamine H2 receptor-blocking agent for preventing, delaying, or treating **Alzheimer**'s disease and related neurodegenerative disorders)

IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(.epsilon.4 or .epsilon.2 allele, for apolipoprotein E; non-steroidal anti-inflammatory agent and/or histamine H2 receptor-blocking agent for preventing, delaying, or treating **Alzheimer**'s disease and related neurodegenerative disorders)

IT **50-78-2**, Aspirin 103-90-2, Acetaminophen 22204-53-1, Naproxen
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(non-steroidal anti-inflammatory agent and/or histamine H2 receptor-blocking agent for preventing, delaying, or treating **Alzheimer**'s disease and related neurodegenerative disorders)

=>

AN 1999:103337 CAPLUS
DN 130:280248
TI Increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-.gamma. in **Alzheimer**'s disease brains
AU Kitamura, Yoshihisa; Shimohama, Shun; Koike, Hideyasu; Kakimura, Jun-Ichi; Matsuoka, Yasuji; Nomura, Yasuyuki; Gebicke-Haerter, Peter J.; Taniguchi, Takashi
CS Department of Neurobiology, Kyoto Pharmaceutical University, Kyoto, 607-8412, Japan
SO Biochemical and Biophysical Research Communications (1999), 254(3), 582-586
CODEN: BBRCA9; ISSN: 0006-291X
PB Academic Press
DT Journal
LA English
CC 14-10 (Mammalian Pathological Biochemistry)
Section cross-reference(s): 1
AB Recent studies suggest that inflammatory events are assocd. with plaque formation in the brains of patients with **Alzheimer**'s disease (AD). Treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) of these patients appears to slow the progression of disease. The authors assessed the occurrence of cyclooxygenases (COX-1 and -2) and peroxisome proliferator-activated receptor-.gamma. (PPAR.gamma.) in temporal cortex from normal and AD brains using specific antibodies. In AD brains, protein levels of COX-1 were increased in both cytosolic and particulate fractions, and COX-2 protein was also increased in the particulate fraction. PPAR.gamma. level was increased in the cytosolic fraction but not in the particulate fraction. Thus, expression levels of COX-1, COX-2, and PPAR.gamma. may change in AD brains. In addn., several NSAIDs which are also PPAR.gamma. activators, such as indomethacin, inhibited COX-2 expression in glial cells. These results suggest that PPAR.gamma. activators have inhibitory effects on inflammatory events in AD brains. (c) 1999 Academic Press.
ST brain cyclooxygenase peroxisome proliferator activated receptor gamma **Alzheimer** disease
IT Cytoplasm
(cytosol; increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-.gamma. in brains from humans with **Alzheimer**'s disease)
IT Gene
(expression; increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-.gamma. in brains from humans with **Alzheimer**'s disease)
IT **Alzheimer**'s disease
Encephalitis
Neuroglia
(increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-.gamma. in brains from humans with **Alzheimer**'s disease)
IT Anti-inflammatory agents
(nonsteroidal; increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-.gamma. in brains from humans with **Alzheimer**'s disease)
IT Brain
(temporal cortex; increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-.gamma. in brains from humans with **Alzheimer**'s disease)
IT Peroxisome proliferator-activated receptors
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)
(.gamma.; increased expression of cyclooxygenases and peroxisome

proliferator-activated receptor-.gamma. in brains from humans with **Alzheimer**'s disease)

IT 39391-18-9
RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence); PROC (Process)
(1 and 2; increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-.gamma. in brains from humans with **Alzheimer**'s disease)

IT **50-78-2**, Aspirin 53-86-1, Indomethacin 41598-07-6, PGD2 87893-55-8 123653-11-2, NS398
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-.gamma. in brains from humans with **Alzheimer**'s disease)

RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Bauer, M; Eur J Biochem 1997, V243, P726 CAPLUS
(2) Bonventre, J; Nature 1997, V390, P622 CAPLUS
(3) Chang, J; Neurobiol Aging 1996, V17, P801 CAPLUS
(4) Clemens, J; Stroke 1996, V27, P527 CAPLUS
(5) Farooqui, A; Neurochem Int 1997, V30, P517 CAPLUS
(6) Forman, B; Cell 1995, V83, P803 CAPLUS
(7) Gattaz, W; Biol Psychiatry 1995, V37, P13 MEDLINE
(8) Guastadisegni, C; FEBS Lett 1997, V413, P314 CAPLUS
(9) Jiang, C; Nature 1998, V391, P82 CAPLUS
(10) Kitamura, Y; Neurosci Lett 1997, V237, P17 CAPLUS
(11) Lehmann, J; J Biol Chem 1997, V272, P3406 CAPLUS
(12) Lehtonen, J; Biochemistry 1996, V35, P9407 CAPLUS
(13) Lukiw, W; J Neurosci Res 1997, V50, P937 CAPLUS
(14) Mangelsdorf, D; Cell 1995, V83, P835 CAPLUS
(15) Mirra, S; Neurology 1991, V41, P479 MEDLINE
(16) Morita, I; J Biol Chem 1995, V270, P10902 CAPLUS
(17) Nogawa, S; J Neurosci 1997, V17, P2746 CAPLUS
(18) Oka, A; NeuroReport 1997, V8, P1161 CAPLUS
(19) Pasinetti, G; Neuroscience 1998, V87, P319 CAPLUS
(20) Ricote, M; Nature 1998, V391, P79 CAPLUS
(21) Rogers, J; Neurology 1993, V43, P1609 MEDLINE
(22) Sanz, O; Neuroscience 1997, V80, P221 CAPLUS
(23) Shimohama, S; J Neural Transm 1990, V30(Suppl), P69
(24) Shimohama, S; J Neurochem 1995, V64, P2629 CAPLUS
(25) Shimohama, S; Neurology 1993, V43, P1407 MEDLINE
(26) Spencer, A; J Biol Chem 1998, V273, P9886 CAPLUS
(27) Stephenson, D; Neurobiol Dis 1996, V3, P51 CAPLUS
(28) Tocco, G; Exp Neurol 1997, V144, P339 CAPLUS
(29) Vane, J; Ann Rev Pharmacol Toxicol 1998, V38, P97 CAPLUS

=>

AN 1998:780621 CAPLUS
DN 130:232124
TI Peripheral administration of novel anti-inflammatories can attenuate the effects of chronic inflammation within the CNS [central nervous system]
AU Hauss-Wegrzyniak, Beatrice; Willard, Lauren B.; Del Soldato, Piero; Pepeu, Giancarlo; Wenk, Gary L.
CS Memory and Aging, Division of Neural Systems, Arizona Research Laboratories, University of Arizona, Tucson, AZ, 85724, USA
SO Brain Research (1999), 815(1), 36-43
CODEN: BRREAP; ISSN: 0006-8993
PB Elsevier Science B.V.
DT Journal
LA English
CC 1-7 (Pharmacology)
AB This study investigated whether nitroflurbiprofen (NFP) or nitro-aspirin can reduce the inflammatory response induced by continuous infusion of lipopolysaccharide (LPS) into the 4th ventricular space of the rat brain for 30 days. The chronic LPS infusion produced an extensive inflammation that was particularly evident in the hippocampus, subiculum and entorhinal and piriform cortices. Daily peripheral administration of NFP dose-dependently attenuated the brain inflammation, as indicated by the decreased d. and reactive state of microglial cells. Daily peripheral administration of nitro-aspirin also attenuated the brain inflammation, but to a much lesser degree than NFP. The results demonstrated that nonsteroidal anti-inflammatory drugs can reduce brain inflammation and that NFP is an effective anti-inflammatory agent.
ST brain inflammation inhibition nitroflurbiprofen nitroaspirin; nonsteroidal antiinflammatory drug brain inflammation
IT Encephalitis
(nitroflurbiprofen and nitroaspirin inhibition of)
IT **Alzheimer**'s disease
(nitroflurbiprofen and nitroaspirin inhibition of brain inflammation in relation to)
IT Anti-inflammatory agents
(nonsteroidal; brain inflammation inhibition by nitroflurbiprofen and nitroaspirin as)
IT **17336-14-0** 158836-71-6, Nitroflurbiprofen
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(brain inflammation inhibition by)
RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Aisen, P; Am J Psychiatr 1994, V151, P1105 MEDLINE
(2) Allison, M; N Engl J Med 1992, V327, P749 MEDLINE
(3) Altstiel, L; Prog Neuropsycho-Pharmacol Biol Psychiatr 1991, V15, P481 CAPLUS
(4) Banati, R; Glia 1993, V7, P111 MEDLINE
(5) Bannwarth, B; Therapie 1986, V41, P409 CAPLUS
(6) Breder, C; Brain Res 1996, V713, P64 CAPLUS
(7) Breitner, J; Neurobiol Aging 1996, V17, P789 MEDLINE
(8) Burrel, R; Crit Rev Microbiol 1990, V17, P188
(9) Cacabelos, R; Meth Find Exp Clin Pharmacol 1994, V16, P141 MEDLINE
(10) Chiang, C; Dev Neurosci 1994, V16, P212 CAPLUS
(11) Das, S; Neuron 1995, V14, P447 CAPLUS
(12) Eikelenboom, P; Virchows Arch B Cell Pathol 1989, V56, P259 MEDLINE
(13) Elmquist, J; J Comp Neurol 1997, V381, P119 CAPLUS
(14) Greenblatt, D; Arzneimittel-Forschung 1983, V33, P1671 CAPLUS
(15) Griffin, W; Proc Natl Acad Sci USA 1989, V86, P7611 MEDLINE
(16) Hauss-Wegrzyniak, B; Brain Res 1998, V794, P211 CAPLUS
(17) Hauss-Wegrzyniak, B; Brain Res 1998, V780, P294 CAPLUS
(18) Jenkinson, M; Br J Rheumatol 1989, V28, P86 MEDLINE

(19) Kitagawa, H; J Pharmacol Exp Therap 1990, V253, P1133 CAPLUS
(20) Macnaughton, W; Life Sci 1989, V45, P1869 CAPLUS
(21) McGeer, P; Brain Res Rev 1995, V21, P195 MEDLINE
(22) McGeer, P; Lancet 1990, V335, P1037 MEDLINE
(23) McGeer, P; Neurosci Lett 1988, V79, P195
(24) McGeer, P; Neurosci Lett 1989, V107, P341 MEDLINE
(25) Mrak, R; Human Pathol 1995, V26, P816 MEDLINE
(26) Myllykangas-Luosujarvi, R; Br J Rheumatol 1994, V33, P501 MEDLINE
(27) Rogers, J; Drug Res 1995, V45, P439 CAPLUS
(28) Rogers, J; Neurobiol Aging 1996, V17, P681 MEDLINE
(29) Rogers, J; Neurology 1993, V43, P1609 MEDLINE
(30) Roth, S; Ann Intern Med 1988, V109, P353 MEDLINE
(31) Santini, G; Eur J Pharmacol 1996, V316, P65 CAPLUS
(32) Sheng, J; Neurobiol Aging 1996, V17, P761 CAPLUS
(33) Strauss, S; Lab Invest 1992, V66, P223 MEDLINE
(34) Vandenabeele, P; Immunol Today 1991, V12, P217 CAPLUS
(35) Wallace, J; Gastroenterology 1994, V107, P173 CAPLUS
(36) Wallace, J; Trends Pharmacol Sci 1992, V13, P129 MEDLINE
(37) Watson; Paxinos 1986

=>

DN 130:105154
TI Molecular characterization of the neuroprotective activity of salicylates
AU Grilli, M.; Pizzi, M.; Goffi, F.; Benarese, M.; Gerardi, G. M.; Memo, M.; Spano, P. F.
CS Division of Pharmacology Department of Biomedical Sciences and Biotechnologies School of Medicine, University of Brescia, Brescia, Italy
SO Advances in Behavioral Biology (1998), 49(Progress in Alzheimer's and Parkinson's Diseases), 99-103
CODEN: ADBBBW; ISSN: 0099-6246
PB Plenum Publishing Corp.
DT Journal
LA English
CC 1-11 (Pharmacology)
AB Aspirin and its metabolite sodium salicylate prevent glutamate-induced neurotoxicity in rats. The neuroprotective effect of aspirin does not appear to correlate with the anti-inflammatory properties of this compd.
ST neuroprotectant salicylate antiinflammatory neurodegenerative disorder **Alzheimer**
IT Transcription factors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(NF-.kappa.B (nuclear factor .kappa.B); mol. characterization of the neuroprotective activity of salicylates)
IT Nervous system
(degeneration; mol. characterization of the neuroprotective activity of salicylates)
IT Anti-**Alzheimer**'s agents
(mol. characterization of the neuroprotective activity of salicylates)
IT Cytoprotective agents
(neuroprotectants; mol. characterization of the neuroprotective activity of salicylates)
IT Anti-inflammatory agents
(nonsteroidal; mol. characterization of the neuroprotective activity of salicylates)
IT 54-21-7, Sodium salicylate
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); MFM (Metabolic formation); THU (Therapeutic use); BIOL (Biological study); FORM (Formation, nonpreparative); USES (Uses)
(mol. characterization of the neuroprotective activity of salicylates)
IT **50-78-2**, Aspirin 69-72-7D, analogs
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(mol. characterization of the neuroprotective activity of salicylates)
RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Amin, A; Proc Natl Acad Sci USA 1995, V92, P7926 CAPLUS
(2) Curran, T; Cell 1988, V55, P395 CAPLUS
(3) Gallo, V; Proc Natl Acad Sci USA 1982, V79, P7919 CAPLUS
(4) Garthwaite, G; Neurosci Lett 1989, V97, P316 CAPLUS
(5) Grilli, M; Int Rev Cytol 1993, V143, P1 CAPLUS
(6) Grilli, M; J Biol Chem 1995, V270, P26774 CAPLUS
(7) Grilli, M; J Biol Chem 1996, V271, P15002 CAPLUS
(8) Grilli, M; Science 1996, V274, P1383 CAPLUS
(9) Guerrini, L; Proc Natl Acad Sci USA 1995, V92, P9077 CAPLUS
(10) Insel, P; Goodman and Gilman's The Pharmacological Basis of Therapeutics 1996, P617
(11) Kaltschmidt, C; Mol Cell Biol 1994, V14, P3981 CAPLUS
(12) Kaltschmidt, C; Proc Natl Acad Sci USA 1995, V92, P9618 CAPLUS
(13) Kopp, E; Science 1994, V265, P956 MEDLINE
(14) Lipton, S; New Engl J Med 1995, V330, P613
(15) McGeer, P; Brain Res Rev 1995, V21, P195 MEDLINE

(16) Pizzi, M; Eur J Neurosci 1996, V8, P1516 MEDLINE
(17) Pizzi, M; Mol Pharmacol 1996, V49, P586 CAPLUS
(18) Rogers, J; Neurology 1993, V43, P1609 MEDLINE
(19) Yan, S; Nature Med 1995, V1, P693 CAPLUS

=>

AN 1998:338114 CAPLUS
DN 129:12755
TI Use of selected nonsteroidal antiinflammatory compounds for the prevention and the treatment of neurodegenerative diseases
IN Grilli, Mariagrazia; Pizzi, Marina; Memo, Maurizio; Spano, Pierfranco
PA Universita' Degli Studi di Brescia - Dipartimento di Scienze Biomediche, Italy; Grilli, Mariagrazia; Pizzi, Marina; Memo, Maurizio; Spano, Pierfranco
SO PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K031-00
ICS A61K031-60
CC 1-11 (Pharmacology)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9820864	A2	19980522	WO 1997-EP6323	19971113
	WO 9820864	A3	19981015		

W: JP, US
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

PRAI IT 1996-MI2356 19961113
OS MARPAT 129:12755
AB Nonsteroidal antiinflammatory compds. are used for the prevention and the treatment of neurodegenerative diseases, e.g. Alzheimer's disease and **Parkinson**'s disease.
ST neurodegenerative disease nonsteroidal antiinflammatory drug; **Parkinson** disease nonsteroidal antiinflammatory drug; Alzheimer disease nonsteroidal antiinflammatory drug; NSAID neurodegenerative disease
IT Transcription factors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(AP-1 (activator protein 1); nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT Nervous system
(Huntington's chorea; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT Transcription factors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(NF-.kappa.B (nuclear factor .kappa.B); nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT Glutamate receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(NMDA-binding; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT Nervous system
(amyotrophic lateral sclerosis; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT Nervous system
(ataxia telangiectasia; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT Nervous system
(degeneration; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT AIDS (disease)
(dementia assocd. with; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT Mental disorder

(dementia, multi-infarct; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT Brain
(dentate gyrus; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT Mental disorder
(diffuse Lewy body disease; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT Brain
(hippocampus, sector CA1; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT Brain
(hippocampus, sector CA3; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT Infection
(infective neurodegenerative disease; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT Nerve, disease
(injury; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT Metabolism
(metabolic neuropathies; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT Epilepsy
(neurodegenerative processes related to; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT Prion diseases
(neurodegenerative syndromes in; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT Hypoxia, animal
(neuropathy from; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT Brain, disease
(neuropathy, ischemic; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT Nerve, disease
(neuropathy; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT Cytoprotective agents
(neuroprotectants; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT Anti-Alzheimer's agents
Anti-ischemic agents
Antiparkinsonian agents
Multiple sclerosis
(nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT Glutamate receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT Anti-inflammatory agents
(nonsteroidal; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT Nerve, disease
(peripheral neuropathy, ischemic; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT Brain, disease
Spinal cord
Spinal cord
(trauma; nonsteroidal antiinflammatory compds. for prevention and

treatment of neurodegenerative diseases)

IT 50-99-7, D-Glucose, biological studies
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)
(blood; glycemic damage-assocd. neuropathy; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)

IT 53-86-1, Indomethacin 56-86-0, L-Glutamic acid, biological studies 6384-92-5, NMDA
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)

IT 50-33-9, Phenylbutazone, biological studies 50-33-9D, Phenylbutazone, metabolites **50-78-2**, Acetylsalicylic acid **50-78-2D**, Acetylsalicylic acid, derivs. 54-21-7, Sodium salicylate 58-15-1, Aminopyrine 58-15-1D, Aminopyrine, metabolites 60-80-0, Antipyrine 60-80-0D, Antipyrine, metabolites 65-45-2, Salicylamide 65-85-0, Benzoic acid, biological studies 65-85-0D, Benzoic acid, metabolites, biological studies **69-46-5**, Calcium acetylsalicylate 87-28-5, Glycol salicylate 89-57-6, Mesalamine 118-57-0, Acetaminosalol 119-36-8, Methyl salicylate 129-20-4, Oxyphenbutazone 129-20-4D, Oxyphenbutazone, metabolites **134-55-4**, Phenyl acetylsalicylate 147-90-0, Morpholine salicylate 303-38-8, 2,3-Dihydroxybenzoic acid 303-38-8D, 2,3-Dihydroxybenzoic acid, metabolites 487-48-9, Salacetamide 490-79-9, Gentisic acid 550-97-0, 1-Naphthyl salicylate 552-94-3, Salsalate **580-02-9**, Methyl acetylsalicylate 599-79-1, Sulfasalazine **5003-48-5**, Benorylate 5104-49-4, Flurbiprofen 5104-49-4D, Flurbiprofen, metabolites 5663-71-8 6385-02-0, Sodium meclofenamate 6385-02-0D, Sodium meclofenamate, metabolites 13539-59-8, Apazone 13539-59-8D, Apazone, metabolites 13586-98-6 15307-86-5, Diclofenac 15307-86-5D, Diclofenac, metabolites 15687-27-1 15687-27-1D, metabolites 15722-48-2, Olsalazine 21256-18-8, Oxaprozin 21256-18-8D, Oxaprozin, metabolites 22071-15-4, Ketoprofen 22071-15-4D, Ketoprofen, metabolites 22204-53-1, Naproxen 22204-53-1D, Naproxen, metabolites 22494-27-5, Flufenisal 22494-42-4 26171-23-3, Tolmetin 26171-23-3D, Tolmetin, metabolites 29679-58-1, Fenoprofen 29679-58-1D, Fenoprofen, metabolites 30653-83-9, Parsalmide 36322-90-4, Piroxicam 36322-90-4D, Piroxicam, metabolites 36364-49-5, Imidazole salicylate 37933-78-1, Lysine acetylsalicylate 38194-50-2, Sulindac 38194-50-2D, Sulindac, metabolites 41340-25-4, Etodolac 41340-25-4D, Etodolac, metabolites 42924-53-8, Nabumetone 42924-53-8D, Nabumetone, metabolites 51803-78-2, Nimesulide 51803-78-2D, Nimesulide, metabolites 53597-27-6, Fendosal 59804-37-4, Tenoxicam 59804-37-4D, Tenoxicam, metabolites 62992-61-4, Etersalate 71125-38-7, Meloxicam 71125-38-7D, Meloxicam, metabolites 74103-06-3, Ketorolac 74103-06-3D, Ketorolac, metabolites 111406-87-2, Zileuton 111406-87-2D, Zileuton, metabolites
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)

IT 7440-70-2, Calcium, biological studies 39391-18-9, Cyclooxygenase
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)

=>

AN 1993:175822 CAPLUS
DN 118:175822
TI Cure for diabetes, bronchitis, arthritis, and arteriosclerosis
IN Carantinos, Spyros
PA Australia
SO Pat. Specif. (Aust.), 11 pp.
CODEN: ALXXAP
DT Patent
LA English
IC ICM A61K031-19
ICS A61K033-30; A61K031-215
CC 63-6 (Pharmaceuticals)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	AU 629520	B2	19921008	AU 1988-26677	19881208
	AU 8826677	A1	19890608		
PRAI	AU 1987-5803		19871208		

AB A pharmaceutical contg. ferric ammonium citrate in admixt. with ZnO and optionally including aspirin, NaHCO3, and citric acid is effective in treating arthritis, bronchitis, diabetes, arteriosclerosis, broken bones, **Parkinson**'s disease, high blood cholesterol, liver cirrhosis, and enlargement of the prostate gland.

ST ferric ammonium citrate zinc oxide pharmaceutical

IT Antiarteriosclerotics
Anticholesteremics and Hypolipemics
Antidiabetics and Hypoglycemics
(ferric ammonium citrate and zinc oxide as)

IT Cirrhosis
Parkinsonism
(treatment of, ferric ammonium citrate and zinc oxide for)

IT Inflammation inhibitors
(antiarthritics, ferric ammonium citrate and zinc oxide as)

IT Prostate gland
(disease, hyperplasia, treatment of, ferric ammonium citrate and zinc oxide for)

IT Bronchi
(diseases, bronchitis, treatment of, ferric ammonium citrate and zinc oxide for)

IT Bone, disease
(fracture, treatment of, ferric ammonium citrate and zinc oxide for)

IT **50-78-2**, Aspirin 59-43-8, Vitamin B1, biological studies
77-92-9, Citric acid, biological studies 94-20-2, Chlorpropamide
144-55-8, Sodium bicarbonate, biological studies
RL: BIOL (Biological study)
(pharmaceuticals contg. ferric ammonium citrate and zinc oxide and, for treatment of infections and immune diseases)

IT 1314-13-2, Zinc oxide, biological studies
RL: BIOL (Biological study)
(pharmaceuticals contg. ferric ammonium citrate and, for treatment of infections and immune diseases)

IT 1185-57-5, Ferric ammonium citrate
RL: BIOL (Biological study)
(pharmaceuticals contg. zinc oxide and, for treatment of infections and immune diseases)

=>

AN 1998:700744 CAPLUS
DN 130:60774
TI Nonsteroidal anti-inflammatory drugs increase tumor necrosis factor production in the periphery but not in the central nervous system in mice and rats
AU Sacco, Silvano; Agnello, Davide; Sottocorno, Marcello; Lozza, Gianluca; Monopoli, Angela; Villa, Pia; Ghezzi, Pietro
CS Laboratory of Neuroimmunology, "Mario Negri" Institute for Pharmacological Research, Milan, 20157, Italy
SO Journal of Neurochemistry (1998), 71(5), 2063-2070
CODEN: JONRA9; ISSN: 0022-3042
PB Lippincott-Raven Publishers
DT Journal
LA English
CC 1-7 (Pharmacology)
AB Nonsteroidal anti-inflammatory drugs (**NSAIDs**), which inhibit prostaglandin (PG) synthesis, augment prodn. of tumor necrosis factor (TNF) in most exptl. models. We investigated the effect of two **NSAIDs**, indomethacin and ibuprofen, on the prodn. of TNF in the CNS induced by intracerebroventricular injection of lipopolysaccharide (LPS). Indomethacin and ibuprofen, administered i.p., augmented (three- to ninefold) the levels of TNF in serum and peripheral organs of mice injected i.p. with LPS and in rats with adjuvant arthritis (up to a sevenfold increase). However, **NSAIDs** (i.p. or intracerebroventricularly) did not increase brain TNF prodn. induced by i.v. LPS. In fact, indomethacin decreased (1.4-1.8-fold) TNF levels in the spinal cord of rats with exptl. autoimmune encephalomyelitis and in the cortex of rats with focal cerebral **ischemia**. Systemic administration of iloprost inhibited serum TNF levels after i.p. LPS, whereas intracerebroventricular injection of iloprost or PGE2 did not inhibit brain TNF induced by intracerebroventricular LPS. Both peripheral and central TNF productions were inhibited by cAMP level-elevating agents or dexamethasone. Thus, a PG-driven neg. feedback controls TNF prodn. in the periphery but not in the CNS.
ST antiinflammatory **NSAIDs** TNF peripheral central nervous system
IT Anti-inflammatory agents
Brain
(**NSAIDs** increase TNF prodn. in peripheral but not central nervous system in mice and rats)
IT Tumor necrosis factors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(**NSAIDs** increase TNF prodn. in peripheral but not central nervous system in mice and rats)
IT Encephalomyelitis
(autoimmune; **NSAIDs** increase TNF prodn. in peripheral but not central nervous system in mice and rats)
IT Nervous system
(central; **NSAIDs** increase TNF prodn. in peripheral but not central nervous system in mice and rats)
IT Brain, disease
(**ischemia**; **NSAIDs** increase TNF prodn. in peripheral but not central nervous system in mice and rats)
IT Anti-inflammatory agents
(nonsteroidal; **NSAIDs** increase TNF prodn. in peripheral but not central nervous system in mice and rats)
IT Nervous system
(peripheral; **NSAIDs** increase TNF prodn. in peripheral but not central nervous system in mice and rats)
IT 53-86-1, Indomethacin 15687-27-1, Ibuprofen
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES

(Uses)
(**NSAIDs** increase TNF prodn. in peripheral but not central nervous system in mice and rats)
IT 60-92-4, CAMP
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(**NSAIDs** increase TNF prodn. in peripheral but not central nervous system in mice and rats)
RE.CNT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE

(1) Aggarwal, B; J Biol Chem 1985, V260, P2345 CAPLUS
(2) Asanuma, M; Neurosci Lett 1997, V225, P109 CAPLUS
(3) Bagby, G; J Appl Physiol 1994, V77, P1542 CAPLUS
(4) Benigni, F; Mol Med 1995, V1, P568 CAPLUS
(5) Breder, C; J Comp Neurol 1993, V337, P543 CAPLUS
(6) Breitner, J; Annu Rev Med 1996, V47, P401 CAPLUS
(7) Brosnan, C; Neurology 1995, V45(Suppl 6), PS16
(8) Bruce, A; Nature Med 1996, V2, P788 CAPLUS
(9) Di Santo, E; Cytokine 1997, V9, P300 CAPLUS
(10) Di Santo, E; Eur J Pharmacol 1997, V336, P197 CAPLUS
(11) Di Santo, E; Neuroimmunomodulation 1995, V2, P149 CAPLUS
(12) Dickson, D; Glia 1993, V7, P75 MEDLINE
(13) Dinarello, C; Am J Med 1982, V72, P799 CAPLUS
(14) Dinarello, C; Rev Infect Dis 1988, V10, P168 CAPLUS
(15) Faggioni, R; Infect Immun 1995, V63, P1473 CAPLUS
(16) Fattori, E; J Exp Med 1994, V180, P1243 CAPLUS
(17) Gahring, L; Neuroimmunomodulation 1996, V3, P289 CAPLUS
(18) Grundmann, H; J Infect Dis 1992, V165, P501 CAPLUS
(19) Haley, T; Br J Pharmacol 1957, V12, P12 CAPLUS
(20) Honda, A; J Biol Chem 1993, V268, P7759 CAPLUS
(21) Irani, D; J Immunol 1997, V158, P2318 CAPLUS
(22) Knudsen, P; J Immunol 1986, V137, P3189 CAPLUS
(23) Lipton, J; Peptides 1991, V12, P795 CAPLUS
(24) Liu, T; Stroke 1994, V25, P1481 CAPLUS
(25) Martich, G; J Exp Med 1991, V173, P1021 CAPLUS
(26) Meistrell, M; Shock 1997, V8, P341
(27) Mengozzi, M; Immunology 1994, V82, P207 CAPLUS
(28) Mustafa, M; Am J Dis Child 1990, V144, P883 MEDLINE
(29) Mustafa, M; J Clin Invest 1989, V84, P1253 CAPLUS
(30) Nataf, S; Acta Neurol Scand 1993, V88, P97 CAPLUS
(31) Noel, P; Life Sci 1990, V47, P1023 CAPLUS
(32) Olsson, T; Neurology 1995, V45(Suppl 6), PS11
(33) Reder, A; J Neuroimmunol 1994, V54, P117 CAPLUS
(34) Renz, H; J Immunol 1988, V141, P2388 CAPLUS
(35) Ruddle, N; J Exp Med 1990, V172, P1193 CAPLUS
(36) Saez-Llorens, X; Animicrob Agents Chemother 1990, V34, P837 CAPLUS
(37) Saukkonen, K; J Exp Med 1990, V171, P439 CAPLUS
(38) Schooltink, H; FEBS Lett 1992, V314, P280 CAPLUS
(39) Selmaj, K; Neurology 1995, V45(Suppl 6), PS44
(40) Shigeno, T; Surg Neurol 1985, V24, P47 MEDLINE
(41) Sironi, M; Int J Immunopharmacol 1992, V14, P1045 CAPLUS
(42) Sommer, N; Nature Med 1995, V1, P244 CAPLUS
(43) Spengler, R; Infect Immun 1989, V57, P2837 CAPLUS
(44) Stewart, W; Neurology 1997, V48, P626 MEDLINE
(45) Sugimoto, Y; J Biol Chem 1992, V267, P6463 CAPLUS
(46) Sugimoto, Y; Neuroscience 1994, V62, P919 CAPLUS
(47) van der Poll, T; J Immunol 1995, V155, P5397 CAPLUS
(48) Watabe, A; J Biol Chem 1993, V268, P20175 CAPLUS
(49) Zuckerman, S; Eur J Immunol 1989, V19, P301 CAPLUS

=>

AN 1998:605885 CAPLUS
DN 129:339797
TI Influence of aspirin on nerve injury of experimental **cerebral ischemia** in rabbits
AU Liu, Shi-Xiang; Hou, Jing-Bian; Yang, Qing-Zhou; Zhang, Jia-Lin; Huang, Li-Chun; Liang, Yan
CS Dep. Neurol., Kunming Gen. Hosp., Kumming, 650032, Peop. Rep. China
SO Zhongguo Bingli Shengli Zazhi (1997), 13(2), 162-164
CODEN: ZBSZEB; ISSN: 1000-4718
PB Jinan Daxue
DT Journal
LA Chinese
CC 1-11 (Pharmacology)
AB Platelet play an important role in **cerebral** ischemial nerve injury. Aspirin (ASA) had been used to treat and prevent stroke in clinic. 30 Rabbits were randomly divided into A, B and C groups. In group A ASA was given orally at a daily dosage of 15 mg/kg per rabbit for 5 days before **cerebral ischemia**; group B **cerebral ischemia** without giving ASA, and group C was normal rabbits as controls. The **cerebral** ischemial model was produced by occluding bilateral carotid arteries and bleeding from femoral artery. The results indicated that there was an obvious decrease of platelet aggregation and TXA2 and had no significance changes in free radicals increasing and Ca2+ rising from **cerebral** tissue in group A. The **cerebral** edema of group A was less severe than group B. It seemed that ASA had a protective effect on the nerve injury of **cerebral ischemia**. The derangement of ASA, platelet, free radicals and calcium ions interrelation and their significance on the nerve injury should be further studied.
ST aspirin nerve injury brain **ischemia** TXA2
IT Brain, disease
(**cerebral** cortex, **ischemia**; influence of aspirin on nerve injury of exptl. **cerebral ischemia** in rabbits)
IT Platelet aggregation inhibitors
(influence of aspirin on nerve injury of exptl. **cerebral ischemia** in rabbits)
IT Nerve, disease
(injury; influence of aspirin on nerve injury of exptl. **cerebral ischemia** in rabbits)
IT Cytoprotective agents
(neuroprotectants; influence of aspirin on nerve injury of exptl. **cerebral ischemia** in rabbits)
IT **50-78-2**, Aspirin
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(influence of aspirin on nerve injury of exptl. **cerebral ischemia** in rabbits)
IT 57576-52-0, Thromboxane A2
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(influence of aspirin on nerve injury of exptl. **cerebral ischemia** in rabbits)

=>

DN 126:14735
TI Diaspirin cross-linked hemoglobin resuscitation improves cerebral perfusion after **head** injury and shock
AU Chappell, James E.; McBride, Whitney J.; Shackford, Steven R.
CS Department Surgery, University Vermont, Burlington, VT, 05401, USA
SO Journal of Trauma: Injury, Infection, and Critical Care (1996), 41(5), 781-788
CODEN: JOTRFA; ISSN: 1079-6061
PB Williams & Wilkins
DT Journal
LA English
CC 1-12 (Pharmacology)
AB Shock assocd. with traumatic brain injury (TBI) doubles the mortality of TBI alone by inducing a secondary ischemic injury. Rapid correction of cerebral perfusion pressure (CPP) is thought to be essential to improving outcome. Diaspirin cross-linked Hb (DCLHb) has been shown to improve cerebral blood flow, increase mean arterial pressure (MAP), and reduce lesion size in models of occlusive cerebral ischemia but has not been evaluated in a model of TBI combined with hemorrhagic shock. The authors studied the effects of DCLHb resuscitation in a porcine model of cryogenic TBI and hemorrhagic shock (MAP = 50 mmHg). After combined insults, animals were randomized to receive a bolus of 4 mL/kg of either lactated Ringer's soln. or DCLHb. Lactated Ringer's soln. was then infused in both groups to maintain MAP at baseline. Shed blood was returned 1 h after the initiation of resuscitation (R1). Animals were studied for 24 h. DCLHb infusion resulted in a significantly greater MAP at R1 and R24 (95 vs. 82 and 99 vs. 85 mm Hg, resp.) and a significantly greater CPP at R1 and R24 (83 vs. 68 and 89 vs. 71 mm Hg, resp.). Intracranial pressure was lower in the DCLHb group, but this difference was not significant. There was no significant difference between the groups in cerebral oxygen delivery. DCLHb animals required less fluid to maintain MAP (12,094 vs. 15,542 mL). These data suggest that DCLHb is beneficial in the early resuscitation of **head** injury and shock and that further investigation is warranted.
ST diaspirin crosslinked Hb brain **trauma** shock; resuscitation hemorrhagic shock diaspirin crosslinked Hb
IT Hemoglobins
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(crosslinked, with diaspirin; diaspirin cross-linked Hb resuscitation improves cerebral perfusion after **head** injury and shock)
IT Shock (circulatory collapse)
(hemorrhagic; diaspirin cross-linked Hb resuscitation improves cerebral perfusion after **head** injury and shock)
IT Respiration, animal
Respiration, animal
Therapy
Therapy
(resuscitation; diaspirin cross-linked Hb resuscitation improves cerebral perfusion after **head** injury and shock)
IT Brain, disease
(**trauma**; diaspirin cross-linked Hb resuscitation improves cerebral perfusion after **head** injury and shock)
IT **578-19-8D**, Diaspirin, Hb cross-linked derivs.
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(diaspirin cross-linked Hb resuscitation improves cerebral perfusion after **head** injury and shock)

=>

```
 NEWS 38  AUG 18  Simultaneous left and right truncation added to ANABSTR

 NEWS EXPRESS  April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT
               MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
               AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:07:02 ON 15 SEP 2003

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'REGISTRY' ENTERED AT 15:07:15 ON 15 SEP 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   14 SEP 2003  HIGHEST RN 585509-69-9
DICTIONARY FILE UPDATES:  14 SEP 2003  HIGHEST RN 585509-69-9

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2003

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available.  See HELP
PROPERTIES for more information.  See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> e acetominophen
E1            1     ACETOMIDO/BI
E2            1     ACETOMIDOPHENYL/BI
E3            0 --> ACETOMINOPHEN/BI
E4            2     ACETOMONO/BI
E5            1     ACETOMONOLAUR/BI
E6            1     ACETOMONOLAURIN/BI
E7            1     ACETOMORPHIN/BI
E8            1     ACETOMORPHINE/BI
E9            7     ACETOMORPHOL/BI
```

```
E10           1      ACETOMORPHOLI/BI
E11           6      ACETOMORPHOLIDE/BI
E12           1      ACETOMORPHOLIDI/BI

=> e acetominophen
E1            1      ACETOMIDO/BI
E2            1      ACETOMIDOPHENYL/BI
E3            0 --> ACETOMINOPHEN/BI
E4            2      ACETOMONO/BI
E5            1      ACETOMONOLAUR/BI
E6            1      ACETOMONOLAURIN/BI
E7            1      ACETOMORPHIN/BI
E8            1      ACETOMORPHINE/BI
E9            7      ACETOMORPHOL/BI
E10           1      ACETOMORPHOLI/BI
E11           6      ACETOMORPHOLIDE/BI
E12           1      ACETOMORPHOLIDI/BI

=> acetominophen
ACETOMINOPHEN IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> e acetominophen
E1            1      ACETOMIDO/BI
E2            1      ACETOMIDOPHENYL/BI
E3            0 --> ACETOMINOPHEN/BI
E4            2      ACETOMONO/BI
E5            1      ACETOMONOLAUR/BI
E6            1      ACETOMONOLAURIN/BI
E7            1      ACETOMORPHIN/BI
E8            1      ACETOMORPHINE/BI
E9            7      ACETOMORPHOL/BI
E10           1      ACETOMORPHOLI/BI
E11           6      ACETOMORPHOLIDE/BI
E12           1      ACETOMORPHOLIDI/BI

=> e nsaid
E1            2      NSAF/BI
E2            4      NSAH9/BI
E3            9 --> NSAID/BI
E4            1      NSAN/BI
E5            1      NSANI/BI
E6            1      NSANIDI/BI
E7            1      NSANIDINE/BI
E8            2      NSANT1/BI
E9            6      NSAP1/BI
E10          16      NSB/BI
E11           2      NSB1/BI
E12           1      NSB105/BI

=> s e3
L1            9 NSAID/BI

=> d l1 9

L1   ANSWER 9 OF 9  REGISTRY  COPYRIGHT 2003 ACS on STN
RN   204298-06-6  REGISTRY
CN   DNA (rat liver NSAID-regulated gene protein-specifying cDNA
     594-nucleic acid) (9CI)  (CA INDEX NAME)
OTHER NAMES:
```

```
CN   8: PN: WO0138579 PAGE: 13 claimed DNA
FS   NUCLEIC ACID SEQUENCE
MF   Unspecified
CI   MAN
SR   CA
LC   STN Files:   CA, CAPLUS, TOXCENTER

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
               1 REFERENCES IN FILE CA (1937 TO DATE)
               1 REFERENCES IN FILE CAPLUS (1937 TO DATE)


=> d l1 1

L1   ANSWER 1 OF 9  REGISTRY  COPYRIGHT 2003 ACS on STN
RN   534782-70-2  REGISTRY
CN   DNA (human clone D104 gene KIAA0101 protein cDNA plus flanks) (9CI)  (CA
     INDEX NAME)
OTHER NAMES:
CN   2: PN: US20030100540 SEQID: 2 claimed DNA
CN   DNA (human clone D104 gene NRG-1 (NSAID regulated gene 1) protein
     cDNA plus flanks)
FS   NUCLEIC ACID SEQUENCE
MF   Unspecified
CI   MAN
SR   CA
LC   STN Files:   CA, CAPLUS, TOXCENTER, USPATFULL

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
               1 REFERENCES IN FILE CA (1937 TO DATE)
               1 REFERENCES IN FILE CAPLUS (1937 TO DATE)


=> e aspirin
E1            1     ASPIRALIS/BI
E2            1     ASPIRDROPS/BI
E3           52 --> ASPIRIN/BI
E4            2     ASPIRINA/BI
E5            1     ASPIRINATE/BI
E6            1     ASPIRISINE/BI
E7           11     ASPIRO/BI
E8            1     ASPIROCH/BI
E9            2     ASPIROCHLORINE/BI
E10           1     ASPIROCHOLINE/BI
E11           1     ASPIROCHYL/BI
E12           4     ASPIRYL/BI

=> s e3
L2           52 ASPIRIN/BI

=> e indomethacin
E1            1     INDOMETACINE/BI
E2            1     INDOMETHA/BI
E3           52 --> INDOMETHACIN/BI
E4            1     INDOMETHACINATE/BI
E5            1     INDOMETHACINE/BI
```

```
E6            1      INDOMETHACINOYL/BI
E7            1      INDOMETHAPHEN/BI
E8            1      INDOMETHIN/BI
E9            1      INDOMETHINE/BI
E10           2      INDOMIDE/BI
E11           1      INDOMOD/BI
E12           1      INDOMOLYBDO/BI

=> s e3
L3           52 INDOMETHACIN/BI

=> e ketoprofin
E1            1      KETOPROFENATO/BI
E2            1      KETOPROFENE/BI
E3            0 --> KETOPROFIN/BI
E4            7      KETOPROGESTER/BI
E5            7      KETOPROGESTERONE/BI
E6            1      KETOPRON/BI
E7            1      KETOPROP/BI
E8            1      KETOPROPAMIDE/BI
E9            1      KETOPROPAN/BI
E10           1      KETOPROPANE/BI
E11           1      KETOPROPANOIC/BI
E12           2      KETOPROPHEN/BI

=> e ketoprofen
E1            2      KETOPRO/BI
E2            1      KETOPROF/BI
E3           50 --> KETOPROFEN/BI
E4            1      KETOPROFENATO/BI
E5            1      KETOPROFENE/BI
E6            7      KETOPROGESTER/BI
E7            7      KETOPROGESTERONE/BI
E8            1      KETOPRON/BI
E9            1      KETOPROP/BI
E10           1      KETOPROPAMIDE/BI
E11           1      KETOPROPAN/BI
E12           1      KETOPROPANE/BI

=> s e3
L4           50 KETOPROFEN/BI

=> e trilisatr
E1            4      TRILISA/BI
E2            1      TRILISATE/BI
E3            0 --> TRILISATR/BI
E4           12      TRILITH/BI
E5           12      TRILITHATE/BI
E6            1      TRILITHE/BI
E7           26      TRILITHIO/BI
E8            1      TRILITHIOAL/BI
E9            1      TRILITHIOALLEN/BI
E10           1      TRILITHIOALLENYL/BI
E11           2      TRILITHIOANILINE/BI
E12           2      TRILITHIOBENZENE/BI

=> e trilisate
E1            1      TRILIS/BI
E2            4      TRILISA/BI
E3            1 --> TRILISATE/BI
E4           12      TRILITH/BI
E5           12      TRILITHATE/BI
```

```
E6            1     TRILITHE/BI
E7           26     TRILITHIO/BI
E8            1     TRILITHIOAL/BI
E9            1     TRILITHIOALLEN/BI
E10           1     TRILITHIOALLENYL/BI
E11           2     TRILITHIOANILINE/BI
E12           2     TRILITHIOBENZENE/BI

=> s e3
L5            1 TRILISATE/BI

=> s salicylamide
L6         1158 SALICYLAMIDE

=> s sodium salicylate
         274664 SODIUM
           2322 SALICYLATE
L7           30 SODIUM SALICYLATE
                (SODIUM(W)SALICYLATE)

=> s salicylic acid
           6741 SALICYLIC
        6074610 ACID
L8         6694 SALICYLIC ACID
                (SALICYLIC(W)ACID)

=> dhis
DHIS IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> his
HIS IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> d his

     (FILE 'HOME' ENTERED AT 15:07:02 ON 15 SEP 2003)

     FILE 'REGISTRY' ENTERED AT 15:07:15 ON 15 SEP 2003
                E ACETOMINOPHEN
                E ACETOMINOPHEN
                E ACETOMINOPHEN
                E NSAID
L1              9 S E3
                E ASPIRIN
L2             52 S E3
                E INDOMETHACIN
L3             52 S E3
                E KETOPROFIN
                E KETOPROFEN
L4             50 S E3
                E TRILISATR
                E TRILISATE
L5              1 S E3
L6           1158 S SALICYLAMIDE
L7             30 S SODIUM SALICYLATE
L8           6694 S SALICYLIC ACID
```

```
=> e acetominophen
E1            1     ACETOMIDO/BI
E2            1     ACETOMIDOPHENYL/BI
E3            0 --> ACETOMINOPHEN/BI
E4            2     ACETOMONO/BI
E5            1     ACETOMONOLAUR/BI
E6            1     ACETOMONOLAURIN/BI
E7            1     ACETOMORPHIN/BI
E8            1     ACETOMORPHINE/BI
E9            7     ACETOMORPHOL/BI
E10           1     ACETOMORPHOLI/BI
E11           6     ACETOMORPHOLIDE/BI
E12           1     ACETOMORPHOLIDI/BI

=> e acetaminophen
E1            1     ACETAMINOMETHYLBENZENESULFON/BI
E2            1     ACETAMINOMETHYLBENZENESULFONYL/BI
E3          130 --> ACETAMINOPHEN/BI
E4            1     ACETAMINOPHENACYL/BI
E5            1     ACETAMINOPHENACYLMETHYL/BI
E6           16     ACETAMINOPHENOL/BI
E7            1     ACETAMINOPHENOXAZIN/BI
E8           16     ACETAMINOPHENOXY/BI
E9            1     ACETAMINOPHENOXYACET/BI
E10           1     ACETAMINOPHENOXYACETAMIDE/BI
E11           1     ACETAMINOPHENOXYETHYL/BI
E12           3     ACETAMINOPHENOXYMETHYL/BI

=> s e3
L9          130 ACETAMINOPHEN/BI

=> file caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                               58.18      58.39

FILE 'CAPLUS' ENTERED AT 15:20:03 ON 15 SEP 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 15 Sep 2003  VOL 139 ISS 12
FILE LAST UPDATED: 14 Sep 2003  (20030914/ED)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.


=> d his

     (FILE 'HOME' ENTERED AT 15:07:02 ON 15 SEP 2003)
```

```
     FILE 'REGISTRY' ENTERED AT 15:07:15 ON 15 SEP 2003
                E ACETOMINOPHEN
                E ACETOMINOPHEN
                E ACETOMINOPHEN
                E NSAID
L1            9 S E3
                E ASPIRIN
L2           52 S E3
                E INDOMETHACIN
L3           52 S E3
                E KETOPROFIN
                E KETOPROFEN
L4           50 S E3
                E TRILISATR
                E TRILISATE
L5            1 S E3
L6         1158 S SALICYLAMIDE
L7           30 S SODIUM SALICYLATE
L8         6694 S SALICYLIC ACID
                E ACETOMINOPHEN
                E ACETAMINOPHEN
L9          130 S E3

     FILE 'CAPLUS' ENTERED AT 15:20:03 ON 15 SEP 2003

=> s l2
L10      17725 L2

=> s cns
L11      28561 CNS

=> d l10 and l11
L11 IS NOT VALID HERE
For an explanation, enter "HELP DISPLAY".

=> s l10 and l11
L12         28 L10 AND L11

=> d l12 10-28

L12  ANSWER 10 OF 28  CAPLUS  COPYRIGHT 2003 ACS on STN
AN   1998:780621  CAPLUS
DN   130:232124
TI   Peripheral administration of novel anti-inflammatories can attenuate the
     effects of chronic inflammation within the CNS [central nervous
     system]
AU   Hauss-Wegrzyniak, Beatrice; Willard, Lauren B.; Del Soldato, Piero; Pepeu,
     Giancarlo; Wenk, Gary L.
CS   Memory and Aging, Division of Neural Systems, Arizona Research
     Laboratories, University of Arizona, Tucson, AZ, 85724, USA
SO   Brain Research (1999), 815(1), 36-43
     CODEN: BRREAP; ISSN: 0006-8993
PB   Elsevier Science B.V.
DT   Journal
LA   English
RE.CNT  37    THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12  ANSWER 11 OF 28  CAPLUS  COPYRIGHT 2003 ACS on STN
AN   1998:43243  CAPLUS
DN   128:149902
```

TI Modulation of Brewer's yeast-induced peripheral inflammation and nociception in rats by centrally administered prostaglandins and their inhibitors
AU Hore, S. K.; Dumka, V. K.; Tandan, S. K.; Tripathi, H. C.; Kumar, Dinesh
CS Division of Pharmacology and Toxicology, Indian Veterinary Research Institute, Izatnagar, 243 122, India
SO Indian Journal of Pharmacology (1997), 29(6), 416-419
CODEN: INJPD2; ISSN: 0253-7613
PB Indian Pharmacological Society
DT Journal
LA English
RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 12 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1996:646511 CAPLUS
DN 125:276575
TI Preparation of arginine analogs having nitric oxide synthase inhibitor activity
IN Broquet, Colette; Chabrier, De Lassauniere, Pierre-Etienne
PA Societe De Conseils De Recherches Et D'application, Fr.
SO PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9627593	A1	19960912	WO 1996-FR337	19960304
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN				
	CA 2215476	AA	19960912	CA 1996-2215476	19960304
	AU 9649479	A1	19960923	AU 1996-49479	19960304
	AU 700871	B2	19990114		
	EP 813529	A1	19971229	EP 1996-905907	19960304
	EP 813529	B1	20020911		
	R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE, IE, SI, LT, LV, FI				
	CN 1179774	A	19980422	CN 1996-192885	19960304
	CN 1071328	B	20010919		
	JP 11501043	T2	19990126	JP 1996-526657	19960304
	RU 2168493	C2	20010610	RU 1997-116496	19960304
	AT 223907	E	20020915	AT 1996-905907	19960304
	CZ 290747	B6	20021016	CZ 1997-2687	19960304
	SK 282664	B6	20021106	SK 1997-1121	19960304
	ES 2182964	T3	20030316	ES 1996-905907	19960304
	US 5972940	A	19991026	US 1997-913455	19970910
	HK 1013777	A1	20020705	HK 1998-110921	19980924
PRAI	GB 1995-4350	A	19950304		
	WO 1996-FR337	W	19960304		

OS MARPAT 125:276575

L12 ANSWER 13 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1996:245721 CAPLUS
DN 125:48415
TI Effect of NM441 and its active form on GABA receptor binding
AU Hori, Seiji; Shimada, Jingoro
CS Div. Clin. Pharmacol. Inst. Med. Sci., St. Marianna Univ. Sch. Med., Kawasaki, 216, Japan

SO Nippon Kagaku Ryoho Gakkai Zasshi (1996), 44(Suppl. 1), 97-101
CODEN: NKRZE5; ISSN: 1340-7007
DT Journal
LA Japanese

L12 ANSWER 14 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1995:365390 CAPLUS
DN 122:204992
TI Neuronal expression of FOS protein in the nucleus tractus solitarii and the dorsal motor nucleus of the vagus nerve after i.p. injection of ulcerogenic aspirin
AU Takahashi, Akio; Miura, Mitsuhiko
CS Department of Physiology 1st Division, Gunma University School of Medicine, 3-39-22 Showa-machi, Maebashi-shi, 371, Japan
SO Neuroscience Letters (1995), 185(3), 214-16
CODEN: NELED5; ISSN: 0304-3940
PB Elsevier
DT Journal
LA English

L12 ANSWER 15 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1994:499126 CAPLUS
DN 121:99126
TI Mechanism of quinolone-induced convulsion and anticonvulsant effect of barbiturate for this seizure
AU Kanemitsu, Keiji
CS Dep. Intern. Med. and Lab. Med., St. Marianna Univ. Sch. Med., Kawasaki, 216, Japan
SO Sei Marianna Ika Daigaku Zasshi (1993), 21(6), 1177-85
CODEN: SMIZDS; ISSN: 0387-2289
DT Journal
LA Japanese

L12 ANSWER 16 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1993:573380 CAPLUS
DN 119:173380
TI Acetylsalicylic acid and related compounds depress nociceptive activity in the thalamus by a central action: indications for the involvement of prostaglandins
AU Jurna, I.
CS Inst. Pharmakol. Toxikol., Univ. Saarlandes, Homburg/Saar, D-6650, Germany
SO Progress in Pharmacology and Clinical Pharmacology (1993), 10(1), 51-68
CODEN: PPCPEP; ISSN: 0934-9545
DT Journal; General Review
LA English

L12 ANSWER 17 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1992:676 CAPLUS
DN 116:676
TI Central analgesic effects of acetylsalicylic acid in healthy men
AU Bromm, B.; Rundshagen, I.; Scharein, E.
CS Inst. Physiol., Univ. Hosp. Eppendorf, Hamburg, W-2000/20, Germany
SO Arzneimittel-Forschung (1991), 41(11), 1123-9
CODEN: ARZNAD; ISSN: 0004-4172
DT Journal
LA English

L12 ANSWER 18 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1990:91116 CAPLUS
DN 112:91116
TI Effects of pentazocine and acetylsalicylic acid on pain-rating, pain-related evoked potentials and vigilance in relationship to

pharmacokinetic parameters
AU Kobal, G.; Hummel, C.; Nuernberg, B.; Brune, K.
CS Inst. Pharmakol. Toxikol., Univ. Erlangen-Nuernberg, Erlangen, D-8520, Germany
SO Agents and Actions (1990), 29(3-4), 342-59
CODEN: AGACBH; ISSN: 0065-4299
DT Journal
LA English

L12 ANSWER 19 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1987:60703 CAPLUS
DN 106:60703
TI In vitro metabolism of teratogens by differentiating rat embryo cells
AU Brown, L. P.; Flint, O. P.; Orton, T. C.; Gibson, G. G.
CS Biochem. Dep., Univ. Surrey, Guildford/Surrey, GU2 5XH, UK
SO Food and Chemical Toxicology (1986), 24(6-7), 737-42
CODEN: FCTOD7; ISSN: 0278-6915
DT Journal
LA English

L12 ANSWER 20 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1985:73624 CAPLUS
DN 102:73624
TI An in vitro assay for teratogens with cultures of rat embryo midbrain and limb bud cells
AU Flint, O. P.; Orton, T. C.
CS Saf. Med. Dep., Imp. Chem. Ind. PLC, Macclesfield/Cheshire, SK10 4TG, UK
SO Toxicology and Applied Pharmacology (1984), 76(2), 383-95
CODEN: TXAPA9; ISSN: 0041-008X
DT Journal
LA English

L12 ANSWER 21 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1981:114385 CAPLUS
DN 94:114385
TI The antipyretic effects of aminopyrine and sodium acetylsalicylate on endotoxin-induced fever in rabbits
AU Nishio, Akira; Kanoh, Seizaburo
CS Fac. Agric., Kagoshima Univ., Kagoshima, 890, Japan
SO Nippon Yakurigaku Zasshi (1981), 77(1), 9-13
CODEN: NYKZAU; ISSN: 0015-5691
DT Journal
LA Japanese

L12 ANSWER 22 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1979:535333 CAPLUS
DN 91:135333
TI Prostaglandin synthetase inhibitors antagonize the depressant effects of ethanol
AU George, Frank R.; Collins, Allan C.
CS Inst. Behav. Genet., Univ. Colorado, Boulder, CO, 80309, USA
SO Pharmacology, Biochemistry and Behavior (1979), 10(6), 865-9
CODEN: PBBHAU; ISSN: 0091-3057
DT Journal
LA English

L12 ANSWER 23 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1978:499779 CAPLUS
DN 89:99779
TI Pharmacological characterization of benzodiazepine receptors in the brain
AU Braestrup, Claus; Squires, Richard F.
CS Res. Lab., A/S Ferrosan, Soeborg, Den.

SO European Journal of Pharmacology (1978), 48(3), 263-70
CODEN: EJPHAZ; ISSN: 0014-2999
DT Journal
LA English

L12 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1975:601968 CAPLUS
DN 83:201968
TI Mechanism of the synaptic effects of morphine, indomethacin, and prostaglandins
AU Ehrenpreis, Seymour; Greenberg, Joel
CS New York State Res. Inst. Neurochem. Drug Addict., New York, NY, USA
SO Clin. Pharmacol. Psychoact. Drugs, [Proc. Int. Symp. Alcohol Drug Res.] (1975), Meeting Date 1973, 171-82. Editor(s): Sellers, E. M. Publisher: Alcohol. Drug Addit. Res. Found., Toronto, Can.
CODEN: 31QKAO
DT Conference
LA English

L12 ANSWER 25 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1972:107738 CAPLUS
DN 76:107738
TI Drug interactions. **CNS** [central nervous system] drugs analgesics and antipyretics
AU Hartshorn, Edward A.
CS Pharm. Serv., Evanston Hosp., Evanston, IL, USA
SO Drug Intelligence (1971), 5(11), 356-60
CODEN: DRUIA6; ISSN: 0012-6578
DT Journal; General Review
LA English

L12 ANSWER 26 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1969:113689 CAPLUS
DN 70:113689
TI N-Aralkylanthranilic acid derivatives as **CNS** [central nervous system] depressants
AU Sisodia, P.; Rao, G. S. Rama; Sidhu, Gurbachan S.; Sattur, Prolhad B.; Hashim, Riaz
CS Gandhi Med. Coll., Hyderabad, India
SO CNS (Cent. Nerv. Syst.) Drugs, Symp. (1966), 238-48 Publisher: Counc. Sci. and Ind. Res., New Delhi, India.
CODEN: 20REAT
DT Conference
LA English

L12 ANSWER 27 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1968:113200 CAPLUS
DN 68:113200
TI Drug effects on electrically induced extensor seizures and clinical implications
AU Chen, Graham; Ensor, Charles R.; Bohner, Barbara
CS Parke, Davis and Co., Ann Arbor, MI, USA
SO Archives Internationales de Pharmacodynamie et de Therapie (1968), 172(1), 183-218
CODEN: AIPTAK; ISSN: 0003-9780
DT Journal
LA English

L12 ANSWER 28 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1962:15164 CAPLUS
DN 56:15164
OREF 56:2857g-i,2858a

TI Classification of **CNS** drugs by a mouse screening battery
AU Bastian, J. W.
CS Armour Pharmaceutical Co., Kankakee, IL
SO Archives Internationales de Pharmacodynamie et de Therapie (1961), 133, 347-64
    CODEN: AIPTAK; ISSN: 0003-9780
DT Journal
LA Unavailable

=> e trauma
E1   1   TRAULVETTERI/BI
E2   2   TRAUM/BI
E3   11866 --> TRAUMA/BI
E4   6   TRAUMACEL/BI
E5   1   TRAUMAFLID/BI
E6   1   TRAUMAFUSIN/BI
E7   1   TRAUMAHEMORRHAGE/BI
E8   1   TRAUMAINDUCED/BI
E9   1   TRAUMAN/BI
E10   1   TRAUMANET/BI
E11   13   TRAUMANN/BI
E12   1   TRAUMAPLAST/BI

=> s e3
L13   11866 TRAUMA/BI

=> s l13 and l10
L14   68 L13 AND L10

=> e head
E1   2   HEACY/BI
E2   1   HEACYCLEN/BI
E3   94345 --> HEAD/BI
E4   1   HEAD00/BI
E5   3   HEAD1/BI
E6   1   HEAD103A/BI
E7   1   HEAD107/BI
E8   1   HEAD12/BI
E9   1   HEAD12HAVING/BI
E10   1   HEAD12OF/BI
E11   1   HEAD13/BI
E12   1   HEAD1ALONG/BI

=> s e3
L15   94345 HEAD/BI

=> s l14 and l15
L16   12 L14 AND L15

=> d l16 1-12

L16 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2003 ACS on STN
AN   2002:883043 CAPLUS
DN   137:345844
TI   Intracranial complications of preinjury anticoagulation in **trauma** patients with **head** injury
AU   Mina, Alfred A.; Knipfer, John F.; Park, David Y.; Bair, Holly A.; Howells, Greg A.; Bendick, Phillip J.
CS   Division of Trauma Surgery and the Department of Surgery, William Beaumont Hospital, Royal Oak, MI, 48073, USA
SO   Journal of Trauma: Injury, Infection, and Critical Care (2002), 53(4),

668-672
CODEN: JOTRFA; ISSN: 1079-6061
PB Lippincott Williams & Wilkins
DT Journal
LA English
RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:588980 CAPLUS
DN 137:135080
TI Modification of NSAIDs by sulfur-containing functional groups
IN Lai, Ching-San; Wang, Tingmin
PA Medinox, Inc., USA
SO U.S., 27 pp., Cont.-in-part of U.S. Ser. No. 602,688.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6429223	B1	20020806	US 2000-715767	20001117
	US 6355666	B1	20020312	US 2000-602688	20000623
	WO 2002000167	A2	20020103	WO 2001-US19750	20010619
	WO 2002000167	A3	20020404		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2001070010	A5	20020108	AU 2001-70010	20010619
	EP 1296929	A2	20030402	EP 2001-948537	20010619
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2003088111	A1	20030508	US 2002-97197	20020312
PRAI	US 2000-602688	A2	20000623		
	US 2000-715767	A1	20001117		
	WO 2001-US19750	W	20010619		

RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:488246 CAPLUS
DN 137:57576
TI Methods and compositions using ion-dependent cotransporter modulators for treating conditions of the central and peripheral nervous systems using non-synaptic mechanisms
IN Hochman, Daryl W.
PA Cytoscan Sciences L.L.C., USA
SO U.S. Pat. Appl. Publ., 29 pp., Cont.-in-part of U.S. Ser. No. 470,637.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002082252	A1	20020627	US 2002-56528	20020123
	US 6495601	B1	20021217	US 1999-470637	19991222

PRAI US 1998-113620P P 19981223
US 1999-470637 A2 19991222
US 2001-263830P P 20010123

L16 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:438743 CAPLUS
DN 137:41504
TI Antiplatelet therapy: an alternative to heparin for blunt carotid injury
AU Wahl, Wendy L.; Brandt, Mary-Margaret; Thompson, B. Gregory; Taheri, Paul A.; Greenfield, Lazar J.
CS Division of Trauma Burn and Emergency Surgery, University of Michigan Health System, Ann Arbor, MI, 48109-0033, USA
SO Journal of Trauma: Injury, Infection, and Critical Care (2002), 52(5), 896-901
CODEN: JOTRFA; ISSN: 1079-6061
PB Lippincott Williams & Wilkins
DT Journal
LA English
RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:772458 CAPLUS
DN 133:317566
TI A composition and method for treatment of cerebral ischemia using caffeine and alcohol
IN Grotta, James C.; Strong, Roger A.; Aronowski, Jaroslaw Adam
PA Board of Regents, the University of Texas System, USA
SO PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000064448	A1	20001102	WO 2000-US10692	20000420

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI US 1999-131166P P 19990427
RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1999:556279 CAPLUS
DN 132:48501
TI Brain TXA2 and PGI2 levels related to diffuse brain injury with secondary insults
AU Zhou, Fei; Xiang, Zhang; Yu, Yi Sheng; Jun, Song Shao; Piper, I. R.; Thomson, D.; Miller, J. D.
CS Department of Neurosurgery, Xijing Hospital, Xian, 710032, Peop. Rep. China
SO Journal of Clinical Neuroscience (1999), 6(4), 306-308
CODEN: JCNUE6; ISSN: 0967-5868
PB Churchill Livingstone
DT Journal

LA English
RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:705957 CAPLUS
DN 129:298400
TI Method using citicoline for protecting brain tissue from cerebral infarction subsequent to ischemia
IN Sandage, Bobby W., Jr.; Fisher, Marc; Locke, Kenneth W.
PA Interneuron Pharmaceuticals, Inc., USA
SO U.S., 12 pp., Cont.-in-part of U.S. Ser. No. 603,102.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5827832	A	19981027	US 1996-609448	19960301
	US 5872108	A	19990216	US 1996-603102	19960220
	CA 2213000	AA	19960912	CA 1996-2213000	19960306
	WO 9627380	A1	19960912	WO 1996-US3159	19960306
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML				
	AU 9653047	A1	19960923	AU 1996-53047	19960306
	BR 9607206	A	19971111	BR 1996-7206	19960306
	EP 813416	A1	19971229	EP 1996-909616	19960306
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	CN 1181015	A	19980506	CN 1996-193176	19960306
	JP 11511732	T2	19991012	JP 1996-527057	19960306
	NZ 337305	A	20010427	NZ 1996-337305	19960306
	PL 185124	B1	20030228	PL 1996-322061	19960306
	NO 9704076	A	19971028	NO 1997-4076	19970904
PRAI	US 1995-399262	B2	19950306		
	US 1996-603102	A2	19960220		
	US 1996-609448	A	19960301		
	NZ 1996-305114	A1	19960306		
	WO 1996-US3159	W	19960306		

RE.CNT 69 THERE ARE 69 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:527193 CAPLUS
DN 129:166193
TI Therapeutic treatment and prevention of infections with a bioactive material encapsulated within a biodegradable-biocompatible polymeric matrix
IN Setterstrom, Jean A.; Van Hamont, John E.; Reid, Robert H.; Jacob, Elliot; Jeyanthi, Ramasubbu; Boedeker, Edgar C.; McQueen, Charles E.; Tice, Thomas R.; Roberts, F. Donald; Friden, Phil
PA United States Dept. of the Army, USA; Van Hamont, John E.; et al.
SO PCT Int. Appl., 363 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 15

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI	WO 9832427	A1	19980730	WO 1998-US1556	19980127
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 6309669	B1	20011030	US 1997-789734	19970127
	AU 9863175	A1	19980818	AU 1998-63175	19980127
PRAI	US 1997-789734	A	19970127		
	US 1984-590308	B1	19840316		
	US 1992-867301	A2	19920410		
	US 1995-446148	A2	19950522		
	US 1995-446149	B2	19950522		
	US 1996-590973	B2	19960124		
	WO 1998-US1556	W	19980127		

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1997:47183 CAPLUS
DN 126:99089
TI Effect of hemodilution with diaspirin cross-linked hemoglobin on intracranial pressure, cerebral perfusion pressure, and fluid requirements after **head** injury and shock
AU Chappell, James E.; Shackford, Steven R.; McBride, Whitney J.
CS College Medicine, University Vermont, Burlington, VT, USA
SO Journal of Neurosurgery (1997), 86(1), 131-138
CODEN: JONSAC; ISSN: 0022-3085
PB American Association of Neurological Surgeons
DT Journal
LA English

L16 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1996:735900 CAPLUS
DN 126:14735
TI Diaspirin cross-linked hemoglobin resuscitation improves cerebral perfusion after **head** injury and shock
AU Chappell, James E.; McBride, Whitney J.; Shackford, Steven R.
CS Department Surgery, University Vermont, Burlington, VT, 05401, USA
SO Journal of Trauma: Injury, Infection, and Critical Care (1996), 41(5), 781-788
CODEN: JOTRFA; ISSN: 1079-6061
PB Williams & Wilkins
DT Journal
LA English

L16 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1996:660964 CAPLUS
DN 125:293028
TI Reduction of infarct volume using citicoline
IN Sandage, Bobby Winston; Fisher, Marc; Locke, Kenneth W.
PA Interneuron Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI	WO 9627380	A1	19960912	WO 1996-US3159	19960306
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML				
	US 5872108	A	19990216	US 1996-603102	19960220
	US 5827832	A	19981027	US 1996-609448	19960301
	AU 9653047	A1	19960923	AU 1996-53047	19960306
	BR 9607206	A	19971111	BR 1996-7206	19960306
	EP 813416	A1	19971229	EP 1996-909616	19960306
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 11511732	T2	19991012	JP 1996-527057	19960306
	PL 185124	B1	20030228	PL 1996-322061	19960306
	NO 9704076	A	19971028	NO 1997-4076	19970904
PRAI	US 1995-399262	A	19950306		
	US 1996-603102	A	19960220		
	US 1996-609448	A	19960301		
	WO 1996-US3159	W	19960306		

L16 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1974:514759 CAPLUS
DN 81:114759
TI Effect of aspirin on bleeding time and survival of rats after **head trauma**
AU Davis, James W.; Phillips, Phyllis E.; Ellison, June M.; Lucas, Shannon R.
CS Hematol. Res. Lab., VA Hosp., Kansas City, MO, USA
SO Journal of Medicine (Westbury, NY, United States) (1974), 5(5), 229-33
CODEN: JNMDBO; ISSN: 0025-7850
DT Journal
LA English

=> d l16 10 all

L16 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1996:735900 CAPLUS
DN 126:14735
TI Diaspirin cross-linked hemoglobin resuscitation improves cerebral perfusion after **head** injury and shock
AU Chappell, James E.; McBride, Whitney J.; Shackford, Steven R.
CS Department Surgery, University Vermont, Burlington, VT, 05401, USA
SO Journal of Trauma: Injury, Infection, and Critical Care (1996), 41(5), 781-788
CODEN: JOTRFA; ISSN: 1079-6061
PB Williams & Wilkins
DT Journal
LA English
CC 1-12 (Pharmacology)
AB Shock assocd. with traumatic brain injury (TBI) doubles the mortality of TBI alone by inducing a secondary ischemic injury. Rapid correction of cerebral perfusion pressure (CPP) is thought to be essential to improving outcome. Diaspirin cross-linked Hb (DCLHb) has been shown to improve cerebral blood flow, increase mean arterial pressure (MAP), and reduce lesion size in models of occlusive cerebral ischemia but has not been evaluated in a model of TBI combined with hemorrhagic shock. The authors studied the effects of DCLHb resuscitation in a porcine model of cryogenic TBI and hemorrhagic shock (MAP = 50 mmHg). After combined insults, animals were randomized to receive a bolus of 4 mL/kg of either lactated

Ringer's soln. or DCLHb. Lactated Ringer's soln. was then infused in both groups to maintain MAP at baseline. Shed blood was returned 1 h after the initiation of resuscitation (R1). Animals were studied for 24 h. DCLHb infusion resulted in a significantly greater MAP at R1 and R24 (95 vs. 82 and 99 vs. 85 mm Hg, resp.) and a significantly greater CPP at R1 and R24 (83 vs. 68 and 89 vs. 71 mm Hg, resp.). Intracranial pressure was lower in the DCLHb group, but this difference was not significant. There was no significant difference between the groups in cerebral oxygen delivery. DCLHb animals required less fluid to maintain MAP (12,094 vs. 15,542 mL). These data suggest that DCLHb is beneficial in the early resuscitation of **head** injury and shock and that further investigation is warranted.

ST diaspirin crosslinked Hb brain **trauma** shock; resuscitation hemorrhagic shock diaspirin crosslinked Hb

IT Hemoglobins
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(crosslinked, with diaspirin; diaspirin cross-linked Hb resuscitation improves cerebral perfusion after **head** injury and shock)

IT Shock (circulatory collapse)
(hemorrhagic; diaspirin cross-linked Hb resuscitation improves cerebral perfusion after **head** injury and shock)

IT Respiration, animal
Respiration, animal
Therapy
Therapy
(resuscitation; diaspirin cross-linked Hb resuscitation improves cerebral perfusion after **head** injury and shock)

IT Brain, disease
(**trauma**; diaspirin cross-linked Hb resuscitation improves cerebral perfusion after **head** injury and shock)

IT **578-19-8D**, Diaspirin, Hb cross-linked derivs.
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(diaspirin cross-linked Hb resuscitation improves cerebral perfusion after **head** injury and shock)

=> d l16 9 all

L16 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1997:47183 CAPLUS
DN 126:99089
TI Effect of hemodilution with diaspirin cross-linked hemoglobin on intracranial pressure, cerebral perfusion pressure, and fluid requirements after **head** injury and shock
AU Chappell, James E.; Shackford, Steven R.; McBride, Whitney J.
CS College Medicine, University Vermont, Burlington, VT, USA
SO Journal of Neurosurgery (1997), 86(1), 131-138
CODEN: JONSAC; ISSN: 0022-3085
PB American Association of Neurological Surgeons
DT Journal
LA English
CC 1-8 (Pharmacology)
AB Hemodilution has been shown to increase cerebral blood flow (CBF) and reduce lesion vol. in models of occlusive cerebral ischemia, but it has not been evaluated in the setting of **head trauma** and shock in which ischemia is thought to play a role in the evolution of secondary injury. In a porcine model of brain injury and shock the authors compared hemodilution with diaspirin cross-linked Hb (DCLHb) to a std. resuscitation regimen using Ringer's lactate soln. and shed blood.

After creation of a cryogenic brain injury followed by hemorrhage, the animals received a bolus of either 4 mL/kg of Ringer's lactate soln. (Group 1, six animals) or DCLHb (Group 2, six animals), followed by infusion of Ringer's lactate soln. to restore mean arterial pressure (MAP) to baseline. Group 1 received shed blood 1 h after hemorrhage (R1) in the form of packed red blood cells. Group 2 received shed blood only for an Hb count of less than 5 g/dL. The animals were monitored for 24 h. At R1, Group 2 had a significantly greater cerebral perfusion pressure ([CPP] 88 .+-. 5.7 vs. 68 .+-. 2.4 mm Hg, $p < 0.05$). By 3 h after hemorrhage (R3) Group 2 had a significantly lower Hb concn. (8.5 .+-. 0.4 vs. 12.1 .+-. 0.3 g/dL, $p < 0.05$) and a significantly lower intracranial pressure ([ICP] 9 .+-. 0.8 vs. 14 .+-. 0.6 mm Hg, $p < 0.05$). The total 24-h fluid requirement was significantly less in Group 2 (10,654 .+-. 505 mL vs. 15,542 .+-. 1094 mL, $p < 0.05$) There was no difference between the groups regarding levels of regional CBF in the injured hemisphere. Cerebral O2 delivery was not significantly different between groups at any time. Lesion vol. as detd. at postmortem examn. was not significantly different between the groups. The increased MAP and CPP and lower ICP obsd. in the Group 2 animals indicate that hemodilution with DCLHb may be beneficial in the treatment of **head** injury and shock.

ST hemodilution diaspirin crosslinked Hb cerebral circulation; **head** injury shock hemodilution diaspirin Hb; cerebral ischemia shock hemodilution diaspirin Hb

IT Circulation
(cerebral; hemodilution with diaspirin cross-linked Hb effect on intracranial pressure, cerebral perfusion pressure, and fluid requirements after **head** injury and shock)

IT Hemoglobins
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(diaspirin cross-linked; hemodilution with diaspirin cross-linked Hb effect on intracranial pressure, cerebral perfusion pressure, and fluid requirements after **head** injury and shock)

IT Blood
(diln.; hemodilution with diaspirin cross-linked Hb effect on intracranial pressure, cerebral perfusion pressure, and fluid requirements after **head** injury and shock)

IT Shock (circulatory collapse)
(hemodilution with diaspirin cross-linked Hb effect on intracranial pressure, cerebral perfusion pressure, and fluid requirements after **head** injury and shock)

IT **Head**
(injury; hemodilution with diaspirin cross-linked Hb effect on intracranial pressure, cerebral perfusion pressure, and fluid requirements after **head** injury and shock)

IT Brain, disease
(ischemia; hemodilution with diaspirin cross-linked Hb effect on intracranial pressure, cerebral perfusion pressure, and fluid requirements after **head** injury and shock)

IT **578-19-8**, Diaspirin
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cross-linked Hb; hemodilution with diaspirin cross-linked Hb effect on intracranial pressure, cerebral perfusion pressure, and fluid requirements after **head** injury and shock)

=> d l16 7 all

L16 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1998:705957 CAPLUS
DN 129:298400
TI Method using citicoline for protecting brain tissue from cerebral infarction subsequent to ischemia
IN Sandage, Bobby W., Jr.; Fisher, Marc; Locke, Kenneth W.
PA Interneuron Pharmaceuticals, Inc., USA
SO U.S., 12 pp., Cont.-in-part of U.S. Ser. No. 603,102.
CODEN: USXXAM
DT Patent
LA English
IC ICM A61K031-70
NCL 514049000
CC 1-11 (Pharmacology)
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5827832	A	19981027	US 1996-609448	19960301
	US 5872108	A	19990216	US 1996-603102	19960220
	CA 2213000	AA	19960912	CA 1996-2213000	19960306
	WO 9627380	A1	19960912	WO 1996-US3159	19960306
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML				
	AU 9653047	A1	19960923	AU 1996-53047	19960306
	BR 9607206	A	19971111	BR 1996-7206	19960306
	EP 813416	A1	19971229	EP 1996-909616	19960306
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	CN 1181015	A	19980506	CN 1996-193176	19960306
	JP 11511732	T2	19991012	JP 1996-527057	19960306
	NZ 337305	A	20010427	NZ 1996-337305	19960306
	PL 185124	B1	20030228	PL 1996-322061	19960306
	NO 9704076	A	19971028	NO 1997-4076	19970904
PRAI	US 1995-399262	B2	19950306		
	US 1996-603102	A2	19960220		
	US 1996-609448	A	19960301		
	NZ 1996-305114	A1	19960306		
	WO 1996-US3159	W	19960306		

AB The invention is directed to a method of reducing the extent of infarction, particularly cerebral infarction subsequent to cerebral ischemia, by the administration of citicoline shortly after an ischemic episode and continuing daily treatment for up to about 30 days, preferably for at least about 6 wk. The method is useful in the treatment of stroke and severe **head trauma** patients and maximizes the chances for a full or substantially full recovery of the patient. Combination treatment regimens are also disclosed along with compns. for use therewith.

ST postischemic cerebral infarction citicoline
IT Anti-ischemic agents
Ischemia
(citicoline for protecting brain tissue from cerebral infarction subsequent to ischemia)
IT Brain, disease
(infarction; citicoline for protecting brain tissue from cerebral infarction subsequent to ischemia)
IT Brain, disease
(ischemia; citicoline for protecting brain tissue from cerebral infarction subsequent to ischemia)
IT Brain, disease

(stroke; citicoline for protecting brain tissue from cerebral infarction subsequent to ischemia)

IT **Head**
(**trauma**; citicoline for protecting brain tissue from cerebral infarction subsequent to ischemia)

IT **50-78-2**, Aspirin 58-32-2, Dipyridamole 9002-01-1, Streptokinase 9039-53-6, Urokinase 139639-23-9, Tissue plasminogen activator
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(citicoline and second agent for protecting brain tissue from cerebral infarction subsequent to ischemia)

IT 987-78-0, Citicoline
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(citicoline for protecting brain tissue from cerebral infarction subsequent to ischemia)

RE.CNT 69 THERE ARE 69 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Aguilar; Arzneimittel Forschung-Drug Research 1983, V33(II), P1051
(2) Agut; Arzneimittel Forschung-Drug Research 1983, V33(II), P1016
(3) Agut; Arzneimittel Forschung-Drug Research 1983, V33(II), P1029
(4) Agut; Arzneimittel Forschung-Drug Research 1983, V33(II), P1045
(5) Agut; Arzneimittel Forschung-Drug Research 1983, V33(II), P1048
(6) Algate; Arzneimittel Forschung-Drug Research 1983, V33(II), P1013
(7) Altman, R; British Medical Journal 1994, V308, P81
(8) Arrannz; Arzneimittel Forschung-Drug Research 1983, V33(II), P1071
(9) Barinaga; Science 1996, V272, P664 CAPLUS
(10) Bell, R; Stroke 1991, V22, P80 MEDLINE
(11) Braso; Arzneimittel Forschung-Drug Research 1983, V33(II), P1043
(12) Budavari; The Merck Index (11th Ed) 1989, P361
(13) Buyukuysal, R; Journal of Neurochemistry 1990, V54(4), P1302 CAPLUS
(14) de Medio, G; Journal of Neuroscience Research 1984, V11, P49 CAPLUS
(15) Del Zoppo, G; Seminars in Neurology 1991, V11(4), P368 MEDLINE
(16) Demeurisse, G; Stroke 1983, V14(1), P77 MEDLINE
(17) Diener, H; Stroke 1995, V26, P30
(18) Dinsdale; Arzneimittel Forschung-Drug Research 1983, V33(II), P1061
(19) Dinsdale; Arzneimittel Forschung-Drug Research 1983, V33(II), P1066
(20) D'Orlando, K; Neurological Research 1995, V17, P281 CAPLUS
(21) Fernandez; Arzneimittel Forschung-Drug Research 1983, V33(II), P1073
(22) Fukunaga; Anesthesia and Analgesia 1982, V61(3), P273 CAPLUS
(23) Gannaro; Remmington's Pharmaceutical Sciences, 18th ed 1990, P867
(24) Grau; Arzneimittel Forschung-Drug Research 1983, V33(II), P1025
(25) Grau; Arzneimittel Forschung-Drug Research 1983, V33(II), P1033
(26) Grosset, D; Journal of Cardiovascular Pharmacology 1995, V25(5), P705 CAPLUS
(27) Grotta, J; Stroke 1987, V18(1), P264 MEDLINE
(28) Hacke, W; Stroke 1995, V26, P167
(29) Horrocks; US 4386078 1983 CAPLUS
(30) Johannes, W; European Stroke Conference 1995
(31) Kakihana; CAPLUS 1988:143195 1988
(32) Kaste, M; Stroke 1994, V25, P1348 MEDLINE
(33) Kinouchi, H; Proc Natl Acad Sci USA 1991, V88, P11158 CAPLUS
(34) Kogure, K; Annals of Neurology 1980, V8(3), P278 CAPLUS
(35) Kottler, P; Physiology and Behavior 1992, V8, P291
(36) Lo, E; Neuroscience Letters 1991, V131, P17 CAPLUS
(37) Longa, Z; Stroke 1989, V20, P84
(38) Makishima; Arzeneimittel Forsch Dtsh 1971, V21(9), P1343 MEDLINE
(39) McCulloch, J; Acta Neurochir 1993, V57(Suppl), P73
(40) Minematsu, K; Cerebrovasc Dis 1993, V3, P99

(41) Nilsson; Clin Pharmacol Drug Epidemiol 1979, V2, P273 CAPLUS
(42) Ochiai, C; Stroke 1982, V13(6), P788 CAPLUS
(43) Olney, J; Science 1991, V254, P1515 CAPLUS
(44) Ortiz, J; Arzneimittel Forschung-Drug Research 1983, V33(II), P1009
(45) Petkov, V; Effects of Cytidine Diphosphate Choline on Rats with Memory Deficits
(46) Phuong; Bull Soc Chim Fr Pt II 1979, 9-10, P518
(47) Romero; Arzneimittel Forschung-Drug Research 1983, V33(II), P1035
(48) Romero; Arzneimittel Forschung-Drug Research 1983, V33(II), P1038
(49) Romero; Arzneimittel Forschung-Drug Research 1983, V33(II), P1054
(50) Romero; Arzneimittel Forschung-Drug Research 1983, V33(II), P1056
(51) Romero; Arzneimittel Forschung-Drug Research 1983, V33(II), P1058
(52) Rossi, M; No publication given 1993
(53) Sanchez; Arzneimittel Forschung-Drug Research 1983, V33(II), P1011
(54) Savci, V; Journal of Neurochemistry 1995, V64(1), P378 CAPLUS
(55) Schabitz, W; Journal of the Neurological Sciences 1996, V138, P21 CAPLUS
(56) The Ancrod Stroke Study Investigators; Stroke 1994, V25, P1755
(57) The Ancrod Study Investigators; Stroke 1994, V25, P1755
(58) The Canadian Cooperative Study Group; New England Journal of Medicine 1978, V299, P53
(59) The Esps Group; Stroke 1990, V21, P1122
(60) Tornos; Arzneimittel Forschung-Drug Research 1983, V33(II), P1018
(61) Tornos; Arzneimittel Forschung-Drug Research 1983, V33(II), P1022
(62) Tornos; Arzneimittel Forschung-Drug Research 1983, V33(II), P1026
(63) Trovarelli, G; Neurochemical Research 1982, V7(10), P1199 CAPLUS
(64) Trovarelli, G; Neurochemical Research 1984, V9(1), P73 CAPLUS
(65) Trovarelli, G; Neurochemical Research 1987, V12(3), P227 CAPLUS
(66) Tuor, U; Stroke 1993, V24(3), P452 CAPLUS
(67) Ulus, I; Brain Research 1989, V484, P217 CAPLUS
(68) Windholtz; The Merck Index, 19th Ed 1983, P329
(69) Wurtman, R; The ` Autocannibalism' of Choline-Containing Membrane Phospholipids in the Pathogenesis of Alzheimer's Disease

```
=> e ischema
E1            6     ISCHELIUM/BI
E2          142     ISCHEM/BI
E3            9 --> ISCHEMA/BI
E4            1     ISCHEMAI/BI
E5            1     ISCHEMATIC/BI
E6            1     ISCHEME/BI
E7            2     ISCHEMI/BI
E8        53068     ISCHEMIA/BI
E9            2     ISCHEMIAC/BI
E10           1     ISCHEMIAIN/BI
E11           1     ISCHEMIAINDUCED/BI
E12           3     ISCHEMIAL/BI

=> s e5-e8
              1 ISCHEMATIC/BI
              1 ISCHEME/BI
              2 ISCHEMI/BI
          53068 ISCHEMIA/BI
L17       53069 (ISCHEMATIC/BI OR ISCHEME/BI OR ISCHEMI/BI OR ISCHEMIA/BI)

=> s l17 and l10
L18         356 L17 AND L10

=> sd his
SD IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
```

```
"HELP COMMANDS" at an arrow prompt (=>).

=> d his

     (FILE 'HOME' ENTERED AT 15:07:02 ON 15 SEP 2003)

     FILE 'REGISTRY' ENTERED AT 15:07:15 ON 15 SEP 2003
                E ACETOMINOPHEN
                E ACETOMINOPHEN
                E ACETOMINOPHEN
                E NSAID
L1             9 S E3
                E ASPIRIN
L2            52 S E3
                E INDOMETHACIN
L3            52 S E3
                E KETOPROFIN
                E KETOPROFEN
L4            50 S E3
                E TRILISATR
                E TRILISATE
L5             1 S E3
L6          1158 S SALICYLAMIDE
L7            30 S SODIUM SALICYLATE
L8          6694 S SALICYLIC ACID
                E ACETOMINOPHEN
                E ACETAMINOPHEN
L9           130 S E3

     FILE 'CAPLUS' ENTERED AT 15:20:03 ON 15 SEP 2003
L10        17725 S L2
L11        28561 S CNS
L12           28 S L10 AND L11
                E TRAUMA
L13        11866 S E3
L14           68 S L13 AND L10
                E HEAD
L15        94345 S E3
L16           12 S L14 AND L15
                E ISCHEMA
L17        53069 S E5-E8
L18          356 S L17 AND L10

=> e cerebral
E1             1     CEREBRACIDE/BI
E2             1     CEREBRAE/BI
E3         78138 --> CEREBRAL/BI
E4             1     CEREBRALCRAST/BI
E5             1     CEREBRALCYST/BI
E6             5     CEREBRALE/BI
E7             4     CEREBRALECTOMIZED/BI
E8             2     CEREBRALEN/BI
E9             3     CEREBRALES/BI
E10            1     CEREBRALHEMISPHERES/BI
E11           29     CEREBRALIS/BI
E12            2     CEREBRALIZATION/BI

=> s e3
L19        78138 CEREBRAL/BI

=> s l18 and 19
          407853 19
```

L20 14 L18 AND 19

=> s l18 and l19
L21 66 L18 AND L19

=> d 121 40-66

L21 ANSWER 40 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:705957 CAPLUS
DN 129:298400
TI Method using citicoline for protecting brain tissue from **cerebral** infarction subsequent to **ischemia**
IN Sandage, Bobby W., Jr.; Fisher, Marc; Locke, Kenneth W.
PA Interneuron Pharmaceuticals, Inc., USA
SO U.S., 12 pp., Cont.-in-part of U.S. Ser. No. 603,102.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5827832	A	19981027	US 1996-609448	19960301
	US 5872108	A	19990216	US 1996-603102	19960220
	CA 2213000	AA	19960912	CA 1996-2213000	19960306
	WO 9627380	A1	19960912	WO 1996-US3159	19960306
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML				
	AU 9653047	A1	19960923	AU 1996-53047	19960306
	BR 9607206	A	19971111	BR 1996-7206	19960306
	EP 813416	A1	19971229	EP 1996-909616	19960306
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	CN 1181015	A	19980506	CN 1996-193176	19960306
	JP 11511732	T2	19991012	JP 1996-527057	19960306
	NZ 337305	A	20010427	NZ 1996-337305	19960306
	PL 185124	B1	20030228	PL 1996-322061	19960306
	NO 9704076	A	19971028	NO 1997-4076	19970904
PRAI	US 1995-399262	B2	19950306		
	US 1996-603102	A2	19960220		
	US 1996-609448	A	19960301		
	NZ 1996-305114	A1	19960306		
	WO 1996-US3159	W	19960306		

RE.CNT 69 THERE ARE 69 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 41 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:605885 CAPLUS
DN 129:339797
TI Influence of aspirin on nerve injury of experimental **cerebral ischemia** in rabbits
AU Liu, Shi-Xiang; Hou, Jing-Bian; Yang, Qing-Zhou; Zhang, Jia-Lin; Huang, Li-Chun; Liang, Yan
CS Dep. Neurol., Kunming Gen. Hosp., Kumming, 650032, Peop. Rep. China
SO Zhongguo Bingli Shengli Zazhi (1997), 13(2), 162-164
CODEN: ZBSZEB; ISSN: 1000-4718
PB Jinan Daxue
DT Journal
LA Chinese

L21 ANSWER 42 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:605876 CAPLUS
DN 129:339796
TI Effects of acetylsalicylic acid on **cerebral** and cardiac function during thrombotic **cerebral ischemia**
AU Li, Shu Qing; Zou, Lian-Fang
CS Dep. Pathophysiology, Kunming Med. Coll., Kunming, 650031, Peop. Rep. China
SO Zhongguo Bingli Shengli Zazhi (1997), 13(2), 158-161
CODEN: ZBSZEB; ISSN: 1000-4718
PB Jinan Daxue
DT Journal
LA Chinese

L21 ANSWER 43 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:523321 CAPLUS
DN 129:239678
TI Potential application of copper aspirinate in preventing and treating thromboembolic diseases
AU Liu, Weiping; Xiong, Huizhou; Yang, Yikun; Li, Ling; Shen, Zhiqiang; Chen, Zhihe
CS Institute of Precious Metals, Kunming, 650221, Peop. Rep. China
SO Metal-Based Drugs (1998), 5(3), 123-126
CODEN: MBADEI; ISSN: 0793-0291
PB Freund Publishing House Ltd.
DT Journal
LA English
RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 44 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:137657 CAPLUS
DN 128:278783
TI Risk factors and antiplatelet therapy in TIA and stroke patients
AU Puranen, Juha; Laakso, Markku; Riekkinen, Paavo; Sivenius, Juhani
CS Department of Neurology, Kuopio University, Kuopio, Finland
SO Journal of the Neurological Sciences (1998), 154(2), 200-204
CODEN: JNSCAG; ISSN: 0022-510X
PB Elsevier Science B.V.
DT Journal
LA English
RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 45 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:97670 CAPLUS
DN 128:212696
TI Intravenously administered acetylsalicylic acid in combination with low-dose heparin in acute ischemic stroke: a safety analysis
AU Buttner, Th.; Hellwig, K.; Muller, Th.; Kuhn, W.
CS Department of Neurology, St. Josef-Hospital Bochum, Ruhr-University, Bochum, D-44791, Germany
SO Clinical Neuropharmacology (1998), 21(1), 48-51
CODEN: CLNEDB; ISSN: 0362-5664
PB Lippincott-Raven Publishers
DT Journal
LA English
RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 46 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1998:14862 CAPLUS
DN 128:136304
TI A randomized trial of anticoagulants versus aspirin after **cerebral ischemia** of presumed arterial origin
CS Stroke Prevention in Reversible Ischemia trial (SPIRIT) Study Group, Neth.
SO Annals of Neurology (1997), 42(6), 857-865
CODEN: ANNED3; ISSN: 0364-5134
PB Lippincott-Raven Publishers
DT Journal
LA English
RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 47 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:7118 CAPLUS
DN 128:110606
TI Experimental subarachnoid hemorrhage in rats: effect of intravenous .alpha.-.alpha. diaspirin crosslinked hemoglobin on hypoperfusion and neuronal death
AU Cole, Daniel J.; Nary, Jeffrey C.; Reynolds, Lowell W.; Patel, Piyush M.; Drummond, John C.
CS Departments of Anesthesiology, Loma Linda University, Loma Linda, CA, USA
SO Anesthesiology (1997), 87(6), 1486-1493
CODEN: ANESAV; ISSN: 0003-3022
PB Lippincott-Raven Publishers
DT Journal
LA English
RE.CNT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 48 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1997:413643 CAPLUS
DN 127:144994
TI Prevention of thromboembolic events in atrial fibrillation
AU Gade Koefoed, Birgitte; Lemche Gullov, Annette; Petersen, Palle
CS AFASAK 2 Study Center, Copenhagen, DK-1112, Den.
SO Thrombosis and Haemostasis (1997), 78(1), 377-381
CODEN: THHADQ; ISSN: 0340-6245
PB Schattauer
DT Journal
LA English

L21 ANSWER 49 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1997:266014 CAPLUS
DN 126:301593
TI .alpha.-.alpha. Diaspirin crosslinked hemoglobin, nitric oxide, and **cerebral** ischemic injury in rats
AU Cole, D. J.; Nary, J. C.; Drummond, J. C.; Patel, P. M.; Jacobsen, W. K.
CS Sch. Med., Loma Linda Univ., Loma Linda, CA, 92354, USA
SO Artificial Cells, Blood Substitutes, and Immobilization Biotechnology (1997), 25(1 & 2), 141-152
CODEN: ABSBE4; ISSN: 1073-1199
PB Dekker
DT Journal
LA English

L21 ANSWER 50 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1997:47183 CAPLUS
DN 126:99089
TI Effect of hemodilution with diaspirin cross-linked hemoglobin on intracranial pressure, **cerebral** perfusion pressure, and fluid requirements after head injury and shock

AU Chappell, James E.; Shackford, Steven R.; McBride, Whitney J.
CS College Medicine, University Vermont, Burlington, VT, USA
SO Journal of Neurosurgery (1997), 86(1), 131-138
CODEN: JONSAC; ISSN: 0022-3085
PB American Association of Neurological Surgeons
DT Journal
LA English

L21 ANSWER 51 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1996:735900 CAPLUS
DN 126:14735
TI Diaspirin cross-linked hemoglobin resuscitation improves **cerebral** perfusion after head injury and shock
AU Chappell, James E.; McBride, Whitney J.; Shackford, Steven R.
CS Department Surgery, University Vermont, Burlington, VT, 05401, USA
SO Journal of Trauma: Injury, Infection, and Critical Care (1996), 41(5), 781-788
CODEN: JOTRFA; ISSN: 1079-6061
PB Williams & Wilkins
DT Journal
LA English

L21 ANSWER 52 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1996:660964 CAPLUS
DN 125:293028
TI Reduction of infarct volume using citicoline
IN Sandage, Bobby Winston; Fisher, Marc; Locke, Kenneth W.
PA Interneuron Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9627380	A1	19960912	WO 1996-US3159	19960306
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML				
	US 5872108	A	19990216	US 1996-603102	19960220
	US 5827832	A	19981027	US 1996-609448	19960301
	AU 9653047	A1	19960923	AU 1996-53047	19960306
	BR 9607206	A	19971111	BR 1996-7206	19960306
	EP 813416	A1	19971229	EP 1996-909616	19960306
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 11511732	T2	19991012	JP 1996-527057	19960306
	PL 185124	B1	20030228	PL 1996-322061	19960306
	NO 9704076	A	19971028	NO 1997-4076	19970904
PRAI	US 1995-399262	A	19950306		
	US 1996-603102	A	19960220		
	US 1996-609448	A	19960301		
	WO 1996-US3159	W	19960306		

L21 ANSWER 53 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1996:520215 CAPLUS
DN 125:212206
TI Effect of oncotic pressure of diaspirin cross-linked hemoglobin (DCLHb) on brain injury after temporary focal **cerebral ischemia**

in rats
AU Cole, Daniel J.; Drummond, John C.; Patel, Piyush M.; Nary, Jeffrey C.; Applegate, Richard L. II
CS Departments Anesthesiology, Loma Linda University, Loma Linda, CA, 92354, USA
SO Anesthesia & Analgesia (Baltimore) (1996), 83(2), 342-347
CODEN: AACRAT; ISSN: 0003-2999
PB Williams & Wilkins
DT Journal
LA English

L21 ANSWER 54 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1996:72079 CAPLUS
DN 124:164820
TI A rat middle **cerebral** artery thrombosis model for evaluation of thrombolytic and antithrombotic agents
AU Liu, X. G.; Xu, L. N.
CS Inst. Materia Medica, Chin. Acad. Med. Sci., Beijing, 100050, Peop. Rep. China
SO Yaoxue Xuebao (1995), 30(9), 662-7
CODEN: YHHPAL; ISSN: 0513-4870
PB Chinese Academy of Medical Sciences, Institute of Materia Media
DT Journal
LA Chinese

L21 ANSWER 55 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1995:867995 CAPLUS
DN 123:274896
TI The efficacy of aspirin administration on ischemic cerebrovascular disease
AU Hamano, Hitoshi; Shinohara, Yukito
CS Sch. Med., Tokai Univ., Isehara, 259-11, Japan
SO Sogo Rinsho (1995), 44(10), 2397-401
CODEN: SORIAX; ISSN: 0371-1900
DT Journal; General Review
LA Japanese

L21 ANSWER 56 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1994:645651 CAPLUS
DN 121:245651
TI Diaspirin crosslinked hemoglobin (DCLHb): effect of hemodilution during focal **cerebral ischemia** in rats
AU Cole, D.J.; Schell, R.M.; Drummond, J.C.
CS Department of Anesthesiology, Loma Linda University, Loma Linda, CA, 92354, USA
SO Artificial Cells, Blood Substitutes, and Immobilization Biotechnology (1994), 22(3), 813-18
CODEN: ABSBE4; ISSN: 1073-1199
DT Journal
LA English

L21 ANSWER 57 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1993:662355 CAPLUS
DN 119:262355
TI Effect of policosanol on **cerebral ischemia** in Mongolian gerbils: role of prostacyclin and thromboxane A2
AU Arruzazabala, M. L.; Molina, V.; Carbajal, D.; Valdes, S.; Mas, R.
CS Cent. Nat. Prod., CNIC, Havana, Cuba
SO Prostaglandins, Leukotrienes and Essential Fatty Acids (1993), 49(2), 695-7
CODEN: PLEAEU; ISSN: 0952-3278
DT Journal
LA English

L21 ANSWER 58 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1993:139579 CAPLUS
DN 118:139579
TI Focal **cerebral ischemia** in rats: effect of hypervolemic hemodilution with diaspirin cross-linked hemoglobin versus albumin on brain injury and edema
AU Cole, Daniel J.; Schell, Randall M.; Drummond, John C.; Reynolds, Lowell
CS Dep. Anesthesiol., Loma Linda Univ., Loma Linda, CA, USA
SO Anesthesiology (1993), 78(2), 335-42
CODEN: ANESAV; ISSN: 0003-3022
DT Journal
LA English

L21 ANSWER 59 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1992:584681 CAPLUS
DN 117:184681
TI EEG and higher nervous activity alterations in rats during anti-ischemic brain protection with atselizin
AU Tel'pukhov, V. I.; Bilenko, M. V.; Khokhlov, A. V.; Komarov, P. G.
CS All-Union Sci. Surg. Cent., Russia
SO Byulleten Eksperimental'noi Biologii i Meditsiny (1992), 113(3), 245-7
CODEN: BEBMAE; ISSN: 0365-9615
DT Journal
LA Russian

L21 ANSWER 60 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1991:505705 CAPLUS
DN 115:105705
TI Effects of triflusal and acetylsalicyclic acid on microthrombi formation in experimental brain **ischemia**
AU Heye, N.; Campos, A.; Kannuki, S.; Cervos-Navarro, J.
CS Inst. Neuropathol., Free Univ., Berlin, W-1000/45, Germany
SO Experimental Pathology (1981) (1991), 41(1), 31-6
CODEN: EXPADD; ISSN: 0232-1513
DT Journal
LA English

L21 ANSWER 61 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1986:491040 CAPLUS
DN 105:91040
TI Effect of cilostazol on experimental **cerebral** infarction in rabbits
AU Watanabe, K.; Nakase, H.; Kimura, Y.
CS Tokushima Res. Inst., Otsuka Pharm. Co., Ltd., Tokushima, Japan
SO Arzneimittel-Forschung (1986), 36(7), 1022-4
CODEN: ARZNAD; ISSN: 0004-4172
DT Journal
LA English

L21 ANSWER 62 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1985:55873 CAPLUS
DN 102:55873
TI Central and peripheral hemodynamic effects of non-steroidal anti-inflammatory drugs in man
AU Wennmalm, A.; Carlsson, I.; Edlund, A.; Eriksson, S.; Kaijser, L.; Nowak, J.
CS Dep. Clin. Physiol., Karolinska Inst., Stockholm, 104 01, Swed.
SO Archives of Toxicology, Supplement (1984), 7(Dis. Metab. Reprod. Toxic Response Drugs Other Chem.), 350-9
CODEN: ATSUDG; ISSN: 0171-9750
DT Journal

LA English

L21 ANSWER 63 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1983:173886 CAPLUS
DN 98:173886
TI Measurement of plasma thromboxane B2 in ischemic cerebrovascular diseases
AU Shimada, Yukihiko; Sakurai, Heiichiro
CS Med. Sch., Tokyo Univ., Tokyo, Japan
SO Rinsho Kagaku Shinpojumu (1981), 21, 63-7
CODEN: RKASDA; ISSN: 0386-3417
DT Journal
LA Japanese

L21 ANSWER 64 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1979:413741 CAPLUS
DN 91:13741
TI Platelet emboli and **ischemia** in rabbit's brain caused by ADP or arachidonic acid and the protective effect of ASA and dipyridamole
AU Fieschi, C.; Volante, F.
CS Clin. Malattie Nerv. Ment., Univ. Siena, Siena, Italy
SO Biochemistry and Experimental Biology (1977), 13(3), 315-19
CODEN: BEXBBO; ISSN: 0366-0060
DT Journal
LA English

L21 ANSWER 65 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1979:115447 CAPLUS
DN 90:115447
TI Acetylsalicylic Acid in **Cerebral Ischemia** and Coronary Heart Disease. [Proceedings of the 5th Colfarit Symposium, Berlin, 1977]
AU Breddin, Klaus; Dorndorf, W.; Loew, D.; Marx, R.; Editors
CS Fed. Rep. Ger.
SO (1978) Publisher: (F. K. Schattauer Verlag, Stuttgart, Ger.), 176 pp.
DT Book
LA English

L21 ANSWER 66 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1978:44925 CAPLUS
DN 88:44925
TI Experimental observations on platelet emboli in focal brain **ischemia**
AU Fieschi, C.; Volante, F.; Battistini, N.; Zanette, E.
CS Dep. Neurol. Psychiatry, Univ. Siena, Siena, Italy
SO Platelet Aggregation Pathog. Cerebrovasc. Disord., Proc. Round Table Conf. (1977), Meeting Date 1974, 87-92. Editor(s): Agnoli, Alessandro; Fazio, Cornelio. Publisher: Springer, Berlin, Ger.
CODEN: 36WKAL
DT Conference
LA English

=>
=> d l21 30-39

L21 ANSWER 30 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:306966 CAPLUS
DN 132:317825
TI Low molecular-weight heparin versus aspirin in patients with acute ischemic stroke and atrial fibrillation: a double-blind randomized study
AU Berge, E.; Abdelnoor, M.; Nakstad, P. H.; Sandset, P. M.; Abdelnoor, M.; Abildgaard, U.; Indredavik, B.; Nakstad, P. H.; Russell, D.; Smith, G.; Pedersen, T. R.; Arnesen, H.; Dahl, T.; Nordal, H.; Nakstad, P. H.;

Johnsen, U.; Smith, G.; Gjestvang, F. T.; Bjornstad, K.; Holo, L.; Solhoff, R.; Jorgensen, E. B.; Lofsnes, I. L.; Svendsen, T. J.; Naess, H.; Ofstad, R.; Kvambe, V.; Urnes, S.; Heggdal, H.; Hareide, S.; Dahl-Eriksen, O.; Saggurthi, D.; Bergo, F.; Moen, F.; Eriksen, L.; Kildahl-Andersen, O.; Thomassen, L.; Graesdal, A.; Ellekjaer, E.; Vejle, A.; Berget, K.; Asak, T.; Brandt, E.; Omland, T.; Holm, B.; Olavsen, J.; Rian, U.; Rana; Nesje, P.; Johnsen, S. H.; Indredavik, B.; Pettersen, A. A.; Thoresen, L.; Krogseth, S. B.; Karlsson, A. G.; Skogen, O. R.; Bondevik, A.; Bergqvist, F.; Larssen-Aas, F.; Spenning, A. B.; Ronning, Y.; Andersen, A.; Berge, E.; Rygh, J.; Sjobrend, K.; Friis, P.; Skogen, P.

CS Department of Haematology, Haematological Research Laboratory, Ulleval University Hospital, Oslo, N-0407, Norway

SO Lancet (2000), 355(9211), 1205-1210
CODEN: LANCAO; ISSN: 0140-6736

PB Lancet Ltd.

DT Journal

LA English

RE.CNT 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 31 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2000:165906 CAPLUS

DN 132:202882

TI Randomized pilot trial of postoperative aspirin in subarachnoid hemorrhage

AU Hop, J. W.; Rinkel, G. J. E.; Algra, A.; Van Der Sprenkel, J. W. Berkelbach; Van Gijn, J.

CS University Department of Neurology, Utrecht, 3508 GA, Neth.

SO Neurology (2000), 54(4), 872-878
CODEN: NEURAI; ISSN: 0028-3878

PB Lippincott Williams & Wilkins

DT Journal

LA English

RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 32 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2000:144772 CAPLUS

DN 132:189689

TI Bioreductive conjugates for drug targeting

IN Adams, Ged; Blake, David; Naughton, Declan; Stratford, Ian

PA Theramark Limited, UK; Adams, Margaret

SO PCT Int. Appl., 48 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000010610	A2	20000302	WO 1999-GB2606	19990819
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9954296	A1	20000314	AU 1999-54296	19990819
PRAI	GB 1998-18027	A	19980819		
	GB 1998-18156	A	19980820		
	WO 1999-GB2606	W	19990819		

OS MARPAT 132:189689

L21 ANSWER 33 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1999:790325 CAPLUS
DN 132:303188
TI Protective effect of aspirin against local **cerebral ischemia** in rats and its mechanism of action
AU Lin, Chun; Zheng, Shuqiu; Chen, Chonghong; Yan, Guangmei
CS Dept of Pharmacology, Sun Yat-sen University of Medical Sciences, Canton, 510080, Peop. Rep. China
SO Zhongguo Yaolixue Tongbao (1999), 15(5), 418-421
CODEN: ZYTOE8; ISSN: 1001-1978
PB Anhui Yike Daxue Linchuan Yaoli Yanjiuso
DT Journal
LA Chinese

L21 ANSWER 34 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1999:685959 CAPLUS
DN 132:18712
TI Cyclooxygenase-2 selective inhibitors aggravate kainic acid induced seizure and neuronal cell death in the hippocampus
AU Baik, E. J.; Kim, E. J.; Lee, S. H.; Moon, C.-H.
CS School of Medicine, Department of Physiology, Ajou University, Suwon, S. Korea
SO Brain Research (1999), 843(1-2), 118-129
CODEN: BRREAP; ISSN: 0006-8993
PB Elsevier Science B.V.
DT Journal
LA English
RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 35 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1999:501659 CAPLUS
DN 131:138720
TI Aspirin and heparin in acute ischemic stroke in older patients
AU Gubitz, Gordon J.; Sandercock, Peter A. G.
CS Neurosciences Trials Unit, Department of Clinical Neurosciences, The University of Edinburgh, Edinburgh, UK
SO Drugs & Aging (1999), 15(1), 29-36
CODEN: DRAGE6; ISSN: 1170-229X
PB Adis International Ltd.
DT Journal; General Review
LA English
RE.CNT 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 36 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1999:406725 CAPLUS
DN 131:194178
TI Primary hypoxic tolerance and chemical preconditioning during estrus cycle in mice
AU Kasischke, Karl; Huber, Roman; Li, Hongge; Timmler, Melanie; Riepe, Matthias W.
CS Department of Neurology, University of Ulm, Ulm, Germany
SO Stroke (1999), 30(6), 1256-1262
CODEN: SJCCA7; ISSN: 0039-2499
PB Lippincott Williams & Wilkins
DT Journal
LA English
RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 37 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1999:373742 CAPLUS
DN 131:208862
TI Neuroprotective effects of acetylsalicylic acid in an animal model of focal brain **ischemia**
AU Khayyam, Naiyar; Thavendiranathan, Paaladinesh; Carmichael, F. J.; Kus, Bart; Jay, Venita; Burnham, W. McIntyre
CS Department of Pharmacology and Bloorview Epilepsy Program, University of Toronto, Toronto, ON, M5S 1A8, Can.
SO NeuroReport (1999), 10(2), 371-374
CODEN: NERPEZ; ISSN: 0959-4965
PB Lippincott Williams & Wilkins
DT Journal
LA English
RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 38 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1999:247624 CAPLUS
DN 130:305927
TI Antiplatelet therapy in acute **cerebral ischemia**
AU Bednar, Martin M.; Gross, Cordell E.
CS Divisions of Neurosurgery and Surgical Research and the Department of, University of Vermont, Burlington, VT, 05405, USA
SO Stroke (1999), 30(4), 887-893
CODEN: SJCCA7; ISSN: 0039-2499
PB Lippincott Williams & Wilkins
DT Journal; General Review
LA English
RE.CNT 99 THERE ARE 99 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 39 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1999:88971 CAPLUS
DN 131:521
TI Effects of butylphthalide on extracellular 6-keto-PGF1.alpha., TXB2 and 6-keto-PGF1.alpha./TXB2 ratio in cultured rat cortical neurons
AU Yan, Chaohua; Feng, Yipu
CS Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, Peop. Rep. China
SO Yaoxue Xuebao (1998), 33(12), 881-885
CODEN: YHHPAL; ISSN: 0513-4870
PB Chinese Academy of Medical Sciences, Institute of Materia Media
DT Journal
LA Chinese

=> d l21 60 all

L21 ANSWER 60 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1991:505705 CAPLUS
DN 115:105705
TI Effects of triflusal and acetylsalicyclic acid on microthrombi formation in experimental brain **ischemia**
AU Heye, N.; Campos, A.; Kannuki, S.; Cervos-Navarro, J.
CS Inst. Neuropathol., Free Univ., Berlin, W-1000/45, Germany
SO Experimental Pathology (1981) (1991), 41(1), 31-6
CODEN: EXPADD; ISSN: 0232-1513
DT Journal
LA English
CC 1-8 (Pharmacology)

AB Ischemic **cerebral** infarcts induce hypercoagulation and microthrombosis, thus leading to vessel occlusion and redn. of local **cerebral** blood flow. Antiaggregant therapy can reduce the formation of microthrombi. The authors tested the effect of acetylsalicylic acid (ASA) and triflusal (2-acetoxy-4-trifluoromethylbenzonic acid) on the formation of microthrombi after middle **cerebral** artery (MCA) occlusion. Six groups of rats, each consisting of six animals received either ASA or triflusal at dosages of 12.5, 25, or 50 mg/L 1000 g b.wt./day. One control group was sham-operated, in another control group MCA occlusion was performed; both groups received no therapy. The no. of microthrombi was counted 7 days after MCA occlusion on paraffin sections. The highest no. of microthrombi was found in the group with MCAO and without therapy (mean 28 microthrombi/animal). In treated groups a redn. of the no. of microthrombi could be stated. The strongest redn. was achieved in the group treated with 12.5 mg triflusal (mean 5.2). No difference in the no. of microthrombi was found between the groups treated with 12.5 mg triflusal and 50 mg ASA (mean 8.7) compared to sham-operated control animals (mean 4.3). Treatment with 12.5 mg triflusal was superior to 50 mg ASA in preventing microthrombi formation. These results indicate, that in exptl. brain **ischemia** the no. of microthrombi can be effectively reduced by application of antiaggregatory drugs.
ST triflusal acetylsalicyllate brain **ischemia** microthrombus
IT Brain, disease or disorder
(**ischemia**, brain microthrombi formation induced by, treatment of, with acetylsalicylate or triflusal)
IT Thrombus and Blood clot
(micro-, treatment of brain **ischemia**-induced, with acetylsalicylic or triflusal)
IT **50-78-2**, Acetylsalicylic acid 322-79-2, Triflusal
RL: BIOL (Biological study)
(brain **ischemia**-induced brain microthrombus treatment with)

=> d 121 51 all

L21 ANSWER 51 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1996:735900 CAPLUS
DN 126:14735
TI Diaspirin cross-linked hemoglobin resuscitation improves **cerebral** perfusion after head injury and shock
AU Chappell, James E.; McBride, Whitney J.; Shackford, Steven R.
CS Department Surgery, University Vermont, Burlington, VT, 05401, USA
SO Journal of Trauma: Injury, Infection, and Critical Care (1996), 41(5), 781-788
CODEN: JOTRFA; ISSN: 1079-6061
PB Williams & Wilkins
DT Journal
LA English
CC 1-12 (Pharmacology)
AB Shock assocd. with traumatic brain injury (TBI) doubles the mortality of TBI alone by inducing a secondary ischemic injury. Rapid correction of **cerebral** perfusion pressure (CPP) is thought to be essential to improving outcome. Diaspirin cross-linked Hb (DCLHb) has been shown to improve **cerebral** blood flow, increase mean arterial pressure (MAP), and reduce lesion size in models of occlusive **cerebral** **ischemia** but has not been evaluated in a model of TBI combined with hemorrhagic shock. The authors studied the effects of DCLHb resuscitation in a porcine model of cryogenic TBI and hemorrhagic shock (MAP = 50 mmHg). After combined insults, animals were randomized to receive a bolus of 4 mL/kg of either lactated Ringer's soln. or DCLHb. Lactated Ringer's soln. was then infused in both groups to maintain MAP at

baseline. Shed blood was returned 1 h after the initiation of resuscitation (R1). Animals were studied for 24 h. DCLHb infusion resulted in a significantly greater MAP at R1 and R24 (95 vs. 82 and 99 vs. 85 mm Hg, resp.) and a significantly greater CPP at R1 and R24 (83 vs. 68 and 89 vs. 71 mm Hg, resp.). Intracranial pressure was lower in the DCLHb group, but this difference was not significant. There was no significant difference between the groups in **cerebral** oxygen delivery. DCLHb animals required less fluid to maintain MAP (12,094 vs. 15,542 mL). These data suggest that DCLHb is beneficial in the early resuscitation of head injury and shock and that further investigation is warranted.

ST diaspirin crosslinked Hb brain trauma shock; resuscitation hemorrhagic shock diaspirin crosslinked Hb

IT Hemoglobins
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(crosslinked, with diaspirin; diaspirin cross-linked Hb resuscitation improves **cerebral** perfusion after head injury and shock)

IT Shock (circulatory collapse)
(hemorrhagic; diaspirin cross-linked Hb resuscitation improves **cerebral** perfusion after head injury and shock)

IT Respiration, animal
Respiration, animal
Therapy
Therapy
(resuscitation; diaspirin cross-linked Hb resuscitation improves **cerebral** perfusion after head injury and shock)

IT Brain, disease
(trauma; diaspirin cross-linked Hb resuscitation improves **cerebral** perfusion after head injury and shock)

IT **578-19-8D**, Diaspirin, Hb cross-linked derivs.
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(diaspirin cross-linked Hb resuscitation improves **cerebral** perfusion after head injury and shock)

=> d l21 41 all

L21 ANSWER 41 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:605885 CAPLUS
DN 129:339797
TI Influence of aspirin on nerve injury of experimental **cerebral ischemia** in rabbits
AU Liu, Shi-Xiang; Hou, Jing-Bian; Yang, Qing-Zhou; Zhang, Jia-Lin; Huang, Li-Chun; Liang, Yan
CS Dep. Neurol., Kunming Gen. Hosp., Kumming, 650032, Peop. Rep. China
SO Zhongguo Bingli Shengli Zazhi (1997), 13(2), 162-164
CODEN: ZBSZEB; ISSN: 1000-4718
PB Jinan Daxue
DT Journal
LA Chinese
CC 1-11 (Pharmacology)
AB Platelet play an important role in **cerebral** ischemial nerve injury. Aspirin (ASA) had been used to treat and prevent stroke in clinic. 30 Rabbits were randomly divided into A, B and C groups. In group A ASA was given orally at a daily dosage of 15 mg/kg per rabbit for 5 days before **cerebral ischemia**; group B **cerebral ischemia** without giving ASA, and group C was normal rabbits as controls. The **cerebral** ischemial model was

produced by occluding bilateral carotid arteries and bleeding from femoral artery. The results indicated that there was an obvious decrease of platelet aggregation and TXA2 and had no significance changes in free radicals increasing and Ca2+ rising from **cerebral** tissue in group A. The **cerebral** edema of group A was less severe than group B. It seemed that ASA had a protective effect on the nerve injury of **cerebral ischemia**. The derangement of ASA, platelet, free radicals and calcium ions interrelation and their significance on the nerve injury should be further studied.

ST aspirin nerve injury brain **ischemia** TXA2

IT Brain, disease
(**cerebral** cortex, **ischemia**; influence of aspirin on nerve injury of exptl. **cerebral ischemia** in rabbits)

IT Platelet aggregation inhibitors
(influence of aspirin on nerve injury of exptl. **cerebral ischemia** in rabbits)

IT Nerve, disease
(injury; influence of aspirin on nerve injury of exptl. **cerebral ischemia** in rabbits)

IT Cytoprotective agents
(neuroprotectants; influence of aspirin on nerve injury of exptl. **cerebral ischemia** in rabbits)

IT **50-78-2**, Aspirin
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(influence of aspirin on nerve injury of exptl. **cerebral ischemia** in rabbits)

IT 57576-52-0, Thromboxane A2
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(influence of aspirin on nerve injury of exptl. **cerebral ischemia** in rabbits)

=> d his

(FILE 'HOME' ENTERED AT 15:07:02 ON 15 SEP 2003)

FILE 'REGISTRY' ENTERED AT 15:07:15 ON 15 SEP 2003

		E	ACETOMINOPHEN
		E	ACETOMINOPHEN
		E	ACETOMINOPHEN
		E	NSAID
L1	9	S	E3
		E	ASPIRIN
L2	52	S	E3
		E	INDOMETHACIN
L3	52	S	E3
		E	KETOPROFIN
		E	KETOPROFEN
L4	50	S	E3
		E	TRILISATR
		E	TRILISATE
L5	1	S	E3
L6	1158	S	SALICYLAMIDE
L7	30	S	SODIUM SALICYLATE
L8	6694	S	SALICYLIC ACID
		E	ACETOMINOPHEN
		E	ACETAMINOPHEN
L9	130	S	E3

```
     FILE 'CAPLUS' ENTERED AT 15:20:03 ON 15 SEP 2003
L10        17725 S L2
L11        28561 S CNS
L12           28 S L10 AND L11
                 E TRAUMA
L13        11866 S E3
L14           68 S L13 AND L10
                 E HEAD
L15        94345 S E3
L16           12 S L14 AND L15
                 E ISCHEMA
L17        53069 S E5-E8
L18          356 S L17 AND L10
                 E CEREBRAL
L19        78138 S E3
L20           14 S L18 AND 19
L21           66 S L18 AND L19

=> s l19 and l12
L22            2 L19 AND L12

=> s l10 and l19
L23          211 L10 AND L19

=> s l23 and l17
L24           66 L23 AND L17

=> s l24 not l21
L25            0 L24 NOT L21

=> s l12 and l17
L26            2 L12 AND L17

=> d l26 1-2

L26  ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2003 ACS on STN
AN   2002:657907  CAPLUS
DN   137:195592
TI   Chimeric compounds co-inducing cholinergic up-regulation and inflammation
     down-regulation, and use for treatment and/or prevention of central
     nervous system diseases
IN   Amitai, Gabriel; Adani, Rachel; Rabinovitz, Ishai; Sod-Moriah, Gali;
     Meshulam, Haim
PA   Israel Institute for Biological Research, Israel
SO   PCT Int. Appl., 139 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.         KIND  DATE           APPLICATION NO.   DATE
     ---------------    ----  --------       ---------------   --------
PI   WO 2002065977       A2   20020829       WO 2002-IL122     20020217
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
             TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
             CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
```

```
            BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     US 2002160988     A1   20021031       US 2001-906952   20010716
PRAI US 2001-269343P   P    20010220
     US 2001-906952    A    20010716
OS   MARPAT 137:195592

L26  ANSWER 2 OF 2  CAPLUS  COPYRIGHT 2003 ACS on STN
AN   2002:488246  CAPLUS
DN   137:57576
TI   Methods and compositions using ion-dependent cotransporter modulators for
     treating conditions of the central and peripheral nervous systems using
     non-synaptic mechanisms
IN   Hochman, Daryl W.
PA   Cytoscan Sciences L.L.C., USA
SO   U.S. Pat. Appl. Publ., 29 pp., Cont.-in-part of U.S. Ser. No. 470,637.
     CODEN: USXXCO
DT   Patent
LA   English
FAN.CNT 2
     PATENT NO.        KIND  DATE           APPLICATION NO.  DATE
     ---------------   ----  --------       ---------------  --------
PI   US 2002082252      A1   20020627       US 2002-56528    20020123
     US 6495601         B1   20021217       US 1999-470637   19991222
PRAI US 1998-113620P    P    19981223
     US 1999-470637     A2   19991222
     US 2001-263830P    P    20010123


=> d l9
YOU HAVE REQUESTED DATA FROM FILE 'REGISTRY' - CONTINUE? (Y)/N:n

=> s l9
L27      10826 L9

=> s l5
L28          46 L5

=> d l28  20-46

L28  ANSWER 20 OF 46  CAPLUS  COPYRIGHT 2003 ACS on STN
AN   1996:367739  CAPLUS
DN   125:19043
TI   Bioadhesive-wound healing composition
IN   Leung, Sau-Hung S.; Martin, Alain
PA   Warner-Lambert Company, USA
SO   PCT Int. Appl., 159 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 28
     PATENT NO.        KIND  DATE           APPLICATION NO.  DATE
     ---------------   ----  --------       ---------------  --------
PI   WO 9606640         A1   19960307       WO 1995-US8568   19950707
         W:  AU, CA, JP, MX, NZ, SG
         RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
     US 5658956         A    19970819       US 1995-445824   19950522
     AU 9530045         A1   19960322       AU 1995-30045    19950707
     AU 707353          B2   19990708
     EP 779820          A1   19970625       EP 1995-926209   19950707
         R:  BE, CH, DE, DK, ES, FR, GB, GR, IT, LI
     JP 10505057        T2   19980519       JP 1996-508729   19950707
```

	ZA 9507245	A	19970630	ZA 1995-7245	19950829
PRAI	US 1994-298521	A	19940830		
	US 1995-445824	A	19950522		
	US 1991-663500	B1	19910301		
	US 1993-53922	B2	19930426		
	WO 1995-US8568	W	19950707		

L28 ANSWER 21 OF 46 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1996:318495 CAPLUS
DN 124:352761
TI Antifungal-wound healing compositions containing pyruvates and antioxidants and fatty acids
IN Martin, Alain
PA Warner-Lambert Company, USA
SO PCT Int. Appl., 114 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 28

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9603149	A1	19960208	WO 1995-US8551	19950707
	W: AU, CA, JP, MX, NZ, SG				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 5663208	A	19970902	US 1995-445831	19950522
	AU 9530042	A1	19960222	AU 1995-30042	19950707
	AU 701179	B2	19990121		
	EP 773795	A1	19970521	EP 1995-926203	19950707
	R: BE, CH, DE, DK, ES, FR, GB, GR, IT, LI				
	JP 10503200	T2	19980324	JP 1995-505755	19950707
	ZA 9506117	A	19970421	ZA 1995-6117	19950721
PRAI	US 1994-279462	A	19940722		
	US 1995-445831	A	19950522		
	US 1991-663500	B1	19910301		
	US 1993-53922	B2	19930426		
	WO 1995-US8551	W	19950707		

L28 ANSWER 22 OF 46 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1996:171907 CAPLUS
DN 124:212140
TI Anti-inflammatory wound healing compositions containing pyruvates and antioxidants and fatty acids
IN Martin, Alain
PA Warner-Lambert Co., USA
SO PCT Int. Appl., 113 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 28

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9600584	A1	19960111	WO 1995-US7942	19950622
	W: AU, CA, JP, MX, NZ, SG				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 5648380	A	19970715	US 1995-445845	19950522
	AU 9529080	A1	19960125	AU 1995-29080	19950622
	AU 701454	B2	19990128		
	EP 759783	A1	19970305	EP 1995-924660	19950622
	R: BE, CH, DE, DK, ES, FR, GB, GR, IT, LI				
	JP 10502345	T2	19980303	JP 1995-503323	19950622
	NZ 289287	A	20010223	NZ 1995-289287	19950622
	ZA 9505408	A	19970401	ZA 1995-5408	19950629

PRAI US 1994-268429 A 19940630
US 1995-445845 A 19950522
US 1991-663500 B1 19910301
US 1993-53922 B2 19930426
WO 1995-US7942 W 19950622

L28 ANSWER 23 OF 46 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1995:604005 CAPLUS
DN 123:970
TI Compositions and methods for inhibiting uterine contractility
IN Bockow, Barry I.; Erlitz, Marc D.
PA USA
SO U.S., 5 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 5409955	A	19950425	US 1993-62459	19930513
PRAI US 1993-62459		19930513		

OS MARPAT 123:970

L28 ANSWER 24 OF 46 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1994:38058 CAPLUS
DN 120:38058
TI choline magnesium trisalicylate tablets
AU Zhou, Jianping; Zhang, Junshou; Chen, Jidong
CS Div. Pharm., China Pharm. Univ., Nanjing, Peop. Rep. China
SO Zhongguo Yaoke Daxue Xuebao (1993), 24(5), 287-9
CODEN: ZHYXE9; ISSN: 1000-5048
DT Journal
LA Chinese

L28 ANSWER 25 OF 46 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1993:524839 CAPLUS
DN 119:124839
TI Compositions for regulating skin wrinkles and/or skin atrophy
IN Blank, Roy Lonnie; Doughty, Darell Gene; Linares, Carlos Gabriel
PA Richardson-Vicks, Inc., USA
SO PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9310755	A1	19930610	WO 1992-US9737	19921109
W: AU, BB, BG, BR, CA, CS, FI, HU, JP, KP, KR, LK, MG, MN, MW, NO, PL, RO, RU, SD				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG				
AU 9230736	A1	19930628	AU 1992-30736	19921109
EP 614353	A1	19940914	EP 1992-924418	19921109
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, SE				
CA 2122923	C	19990119	CA 1992-2122923	19921109
CN 1073859	A	19930707	CN 1992-111816	19921125
CN 1063627	B	20010328		
US 5605894	A	19970225	US 1994-342673	19941121
US 5776917	A	19980707	US 1996-768095	19961216
US 5776918	A	19980707	US 1996-771332	19961216
US 5811413	A	19980922	US 1996-768053	19961216

	US 5837697	A	19981117	US 1996-767551	19961216
	US 5780459	A	19980714	US 1997-921424	19970829
	US 5786345	A	19980728	US 1997-921422	19970829
	US 5789396	A	19980804	US 1997-921018	19970829
	US 5804572	A	19980908	US 1997-920641	19970829
	US 5869470	A	19990209	US 1997-920642	19970829
	US 5883085	A	19990316	US 1998-63480	19980420
PRAI	US 1991-796749	A	19911125		
	WO 1992-US9737	A	19921109		
	US 1993-47602	B1	19930414		
	US 1994-342673	A1	19941121		
	US 1996-767050	B1	19961216		
	US 1996-767533	B1	19961216		
	US 1996-767549	B1	19961216		
	US 1996-767552	B1	19961216		
	US 1996-768086	B1	19961216		
	US 1996-768095	A1	19961216		

L28 ANSWER 26 OF 46 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1993:247651 CAPLUS
DN 118:247651
TI Nonsteroidal anti-rheumatoid arthritic drugs in the treatment of dementia
IN McGeer, Patrick L.; Rogers, Joseph; Sibley, John; Mcgeer, Edith
PA Can.
SO U.S., 6 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5192753	A	19930309	US 1991-689499	19910423
	WO 9324115	A1	19931209	WO 1992-CA229	19920529
	W: JP				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
	EP 642336	A1	19950315	EP 1992-910600	19920529
	EP 642336	B1	19980114		
	R: DE, FR, GB, IT				
	JP 07506559	T2	19950720	JP 1992-509619	19920529
PRAI	US 1991-689499		19910423		
	WO 1992-CA229		19920529		

L28 ANSWER 27 OF 46 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1993:131920 CAPLUS
DN 118:131920
TI Bioequivalence evaluation of commercially available choline magnesium trisalicylate tablets in healthy volunteers
AU Park, Kyoung Ho; Shin, Hyun Taek; Lee, Min Hwa; Goh, Young Yul
CS Dep. Pharm., Seoul Natl. Univ. Hosp., Seoul, S. Korea
SO Yakche Hakhoechi (1992), 22(3), 229-36
CODEN: YAHAEX; ISSN: 0259-2347
DT Journal
LA English

L28 ANSWER 28 OF 46 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1993:66852 CAPLUS
DN 118:66852
TI Sucralfate-cyclodextrin complexes as gastroprotective agents
IN Koslo, Randy J.; Farina, Vincent J.
PA Bristol-Myers Co., USA
SO U.S., 4 pp.
CODEN: USXXAM

DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5164379	A	19921117	US 1991-734370	19910715
PRAI	US 1991-734370		19910715		

L28 ANSWER 29 OF 46 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1993:45816 CAPLUS
DN 118:45816
TI Stabilized solid dosage forms of choline salicylate
IN Oshlack, Benjamin; Pedi, Frank C., Jr.; Zirlis, Joseph
PA Euro-Celtique S.A., Luxembourg
SO Eur. Pat. Appl., 15 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 519371	A1	19921223	EP 1992-110049	19920615
	EP 519371	B1	19960828		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, PT, SE				
	US 5217965	A	19930608	US 1991-716547	19910617
	IN 173260	A	19940319	IN 1992-CA351	19920525
	AU 9217309	A1	19921224	AU 1992-17309	19920529
	AU 645205	B2	19940106		
	ZA 9204002	A	19930224	ZA 1992-4002	19920602
	CA 2071262	AA	19921218	CA 1992-2071262	19920615
	CA 2071262	C	19980203		
	AT 141795	E	19960915	AT 1992-110049	19920615
	ES 2093740	T3	19970101	ES 1992-110049	19920615
PRAI	US 1991-716547		19910617		

L28 ANSWER 30 OF 46 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1991:74872 CAPLUS
DN 114:74872
TI The effect of antirheumatic drugs on interleukin 1 (IL-1) activity and IL-1 and IL-1 inhibitor production by human monocytes
AU Chang, Deh Ming; Baptiste, Paul; Schur, Peter H.
CS Dep. Rheumatol./Immunol., Brigham and Women's Hosp., Boston, MA, 02115, USA
SO Journal of Rheumatology (1990), 17(9), 1148-57
CODEN: JRHUA9; ISSN: 0315-162X
DT Journal
LA English

L28 ANSWER 31 OF 46 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1989:13568 CAPLUS
DN 110:13568
TI Gastric-resistant liposomes containing nonsteroidal antiinflammatory agents and glycolipids
IN Weiner, Alan L.; Cullis, Pieter R.
PA Liposome Co., Inc., USA
SO Eur. Pat. Appl., 21 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 9

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI	EP 249561	A2	19871216	EP 1987-401327	19870612
	EP 249561	A3	19881026		
	EP 249561	B1	19920513		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	JP 09040550	A2	19970210	JP 1996-191707	19850411
	WO 8707506	A1	19871217	WO 1987-US1402	19870612
	W: AU, DK, FI, HU, JP, KR, NO				
	RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
	AU 8775438	A1	19880111	AU 1987-75438	19870612
	JP 01501622	T2	19890608	JP 1987-503771	19870612
	AT 75937	E	19920515	AT 1987-401327	19870612
	IL 82863	A1	19930221	IL 1987-82863	19870612
	IL 96284	A1	19930221	IL 1987-96284	19870612
	ES 2036593	T3	19930601	ES 1987-401327	19870612
	CA 1320130	A1	19930713	CA 1987-539517	19870612
	JP 07100367	A2	19950418	JP 1993-268664	19931027
	JP 2568034	B2	19961225		
PRAI	US 1986-873584	A	19860612		
	US 1986-934151	A	19861124		
	US 1987-61186	A	19870611		
	JP 1985-502090		19850411		
	JP 1993-268664	A3	19850411		
	EP 1987-401327	A	19870612		
	WO 1987-US1402	A	19870612		

L28 ANSWER 32 OF 46 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1987:432999 CAPLUS
DN 107:32999
TI Replacing the acetyl linkage in aspirin with choline and magnesium moieties reduces the occurrence of gastric mucosal injury
AU Danesh, B. J. Z.; Nelson, L. M.; Russell, R I.; Docherty, C.
CS Gastroenterol. Unit, R. Infirm., Glasgow, G31 2ER, UK
SO Alimentary Pharmacology and Therapeutics (1987), 1(1), 51-6
CODEN: APTHEN; ISSN: 0269-2813
DT Journal
LA English

L28 ANSWER 33 OF 46 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1985:220523 CAPLUS
DN 102:220523
TI Synthesis of choline magnesium trisalicylate
AU Li, Jie
CS Jilin Pharm. Co., Jilin, Peop. Rep. China
SO Yiyao Gongye (1985), 16(2), 79-80
CODEN: YIGODN; ISSN: 0255-7223
DT Journal
LA Chinese

L28 ANSWER 34 OF 46 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1984:465538 CAPLUS
DN 101:65538
TI Choline magnesium trisalicylate: comparative pharmacokinetic study of once-daily and twice-daily dosages
AU Levitt, Monte J.; Kann, Jules
CS Biodecision Lab., Inc., Pittsburgh, PA, 15213, USA
SO Journal of Pharmaceutical Sciences (1984), 73(7), 977-9
CODEN: JPMSAE; ISSN: 0022-3549
DT Journal
LA English

L28 ANSWER 35 OF 46 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1984:96605 CAPLUS

DN 100:96605
TI The effect of the non-steroidal anti-inflammatory drug choline magnesium trisalicylate on gastric mucosal cell exfoliation
AU Mitchell, K. G.; Hearns, J.; Crean, G. P.
CS Dep. Surg., Gartnavel Gen. Hosp., Glasgow, UK
SO British Journal of Clinical Pharmacology (1984), 17(1), 27-30
CODEN: BCPHBM; ISSN: 0306-5251
DT Journal
LA English

L28 ANSWER 36 OF 46 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1983:172771 CAPLUS
DN 98:172771
TI Effect of choline magnesium trisalicylate on prostacyclin production by isolated vascular tissue of the rat
AU Levy, Joseph V.
CS Pharmacol. Lab., Kuzell Inst. Arthritis Res., San Francisco, CA, 94115, USA
SO Thrombosis Research (1983), 29(2), 149-54
CODEN: THBRAA; ISSN: 0049-3848
DT Journal
LA English

L28 ANSWER 37 OF 46 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1983:132330 CAPLUS
DN 98:132330
TI Antiinflammatory compositions exhibiting minimized gastric damage
IN Paulson, Joy Lee; Feller, Martha Rosand
PA Procter and Gamble Co., USA
SO Eur. Pat. Appl., 28 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 66918	A1	19821215	EP 1982-200618	19820519
	R: BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	AU 8283791	A1	19821209	AU 1982-83791	19820518
	ES 512808	A1	19830801	ES 1982-512808	19820603
	JP 58041821	A2	19830311	JP 1982-96094	19820604
PRAI	US 1981-270283		19810604		

L28 ANSWER 38 OF 46 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1982:634 CAPLUS
DN 96:634
TI Salicylate prevents gallbladder stasis and cholesterol gallstones in the prairie dog
AU Kuckenbecker, Stephen L.; Doty, Jeffrey E.; Pitt, Henry A.; DenBesten, Lawrence
CS Surg. Res. Serv., VA Med. Cent., Sepulveda, CA, USA
SO Surgical Forum (1981), 32, 154-5
CODEN: SUFOAX; ISSN: 0071-8041
DT Journal
LA English

L28 ANSWER 39 OF 46 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1981:52798 CAPLUS
DN 94:52798
TI Comparative plasma salicylate and urine salicylurate levels following administration of aspirin, magnesium salicylate, and choline magnesium trisalicylate

AU Mason, William D.
CS Sch. Pharm., Univ. Missouri, Kansas City, MO, 64108, USA
SO Journal of Pharmaceutical Sciences (1980), 69(11), 1355-6
CODEN: JPMSAE; ISSN: 0022-3549
DT Journal
LA English

L28 ANSWER 40 OF 46 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1980:453898 CAPLUS
DN 93:53898
TI A comparison of two oral dosage forms of choline magnesium trisalicylate: a bioavailability/bioequivalence study
AU Cohen, Albert
CS Peninsular Testing Corp., Miami, FL, USA
SO Current Therapeutic Research (1980), 27(5), 692-8
CODEN: CTCEA9; ISSN: 0011-393X
DT Journal
LA English

L28 ANSWER 41 OF 46 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1979:468417 CAPLUS
DN 91:68417
TI Comparison of the effects of diflunisal and other salicylates on the intragastric electropotential
AU Torchiana, Mary Lou; Wiese, Sylvia R.; Westrick, Barbara L.
CS Merck Inst. Ther. Res., West Point, PA, USA
SO Journal of Pharmacy and Pharmacology (1979), 31(2), 112-13
CODEN: JPPMAB; ISSN: 0022-3573
DT Journal
LA English

L28 ANSWER 42 OF 46 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1979:432619 CAPLUS
DN 91:32619
TI Steady-state serum salicylate levels in hospitalized patients with rheumatoid arthritis. Comparison of two dosage schedules of choline magnesium trisalicylate
AU Cassell, Sidney; Furst, Daniel; Dromgoole, Sydney; Paulus, Harold
CS Sch. Med., Univ. California, Los Angeles, CA, USA
SO Arthritis & Rheumatism (1979), 22(4), 384-8
CODEN: ARHEAW; ISSN: 0004-3591
DT Journal
LA English

L28 ANSWER 43 OF 46 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1978:590696 CAPLUS
DN 89:190696
TI Serum concentration, safety and tolerance of oral doses of choline magnesium trisalicylate
AU Cohen, Albert; Thomas, G. B.; Cohen, E. B.
CS Peninsular Test. Corp., Miami, FL, USA
SO Current Therapeutic Research (1978), 23(3, Sect. 1), 358-64
CODEN: CTCEA9; ISSN: 0011-393X
DT Journal
LA English

L28 ANSWER 44 OF 46 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1978:573531 CAPLUS
DN 89:173531
TI Differential influences of salicylate compounds on platelet aggregation and serotonin release
AU Zucker, Marjorie B.; Rothwell, Kenneth G.

CS Dep. Pathol., New York Univ. Med. Cent., New York, NY, USA
SO Current Therapeutic Research (1978), 23(2, Sect. 1), 194-9
CODEN: CTCEA9; ISSN: 0011-393X
DT Journal
LA English

L28 ANSWER 45 OF 46 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1978:552647 CAPLUS
DN 89:152647
TI A comparative blood salicylate study of two salicylate tablet formulations utilizing normal volunteers
AU Cohen, Albert
CS Peninsular Test. Corp., Miami, FL, USA
SO Current Therapeutic Research (1978), 23(6), 772-8
CODEN: CTCEA9; ISSN: 0011-393X
DT Journal
LA English

L28 ANSWER 46 OF 46 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1978:183166 CAPLUS
DN 88:183166
TI Comparison of choline magnesium trisalicylate and acetylsalicylic acid in relation to fecal blood loss
AU Cohen, Albert; Garber, Harold E.
CS Peninsular Test. Corp., Miami, FL, USA
SO Current Therapeutic Research (1978), 23(2, Sect. 1), 187-93
CODEN: CTCEA9; ISSN: 0011-393X
DT Journal
LA English

=> s l12 and l10
L29 28 L12 AND L10

=> d l29 1-28

L29 ANSWER 1 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2003:280985 CAPLUS
DN 139:143565
TI Paracetamol effectively reduces prostaglandin E2 synthesis in brain macrophages by inhibiting enzymatic activity of cyclooxygenase but not phospholipase and prostaglandin E synthase
AU Greco, Anita; Ajmone-Cat, Maria Antonietta; Nicolini, Alessia; Sciulli, Maria Gina; Minghetti, Luisa
CS Laboratory of Pathophysiology, Istituto Superiore di Sanita, Rome, 299-00161, Italy
SO Journal of Neuroscience Research (2003), 71(6), 844-852
CODEN: JNREDK; ISSN: 0360-4012
PB Wiley-Liss, Inc.
DT Journal
LA English
RE.CNT 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 2 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2003:242167 CAPLUS
DN 138:248536
TI Methods using cholinesterase inhibitors for treating and preventing migraine
IN Pratt, Raymond
PA Eisai Co., Ltd., Japan
SO PCT Int. Appl., 30 pp.

CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003024456	A1	20030327	WO 2002-US29734	20020920

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2001-323310P P 20010920
US 2002-349244P P 20020118
OS MARPAT 138:248536
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 3 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:657907 CAPLUS
DN 137:195592
TI Chimeric compounds co-inducing cholinergic up-regulation and inflammation down-regulation, and use for treatment and/or prevention of central nervous system diseases
IN Amitai, Gabriel; Adani, Rachel; Rabinovitz, Ishai; Sod-Moriah, Gali; Meshulam, Haim
PA Israel Institute for Biological Research, Israel
SO PCT Int. Appl., 139 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002065977	A2	20020829	WO 2002-IL122	20020217

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2002160988 A1 20021031 US 2001-906952 20010716
PRAI US 2001-269343P P 20010220
US 2001-906952 A 20010716
OS MARPAT 137:195592

L29 ANSWER 4 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:488246 CAPLUS
DN 137:57576
TI Methods and compositions using ion-dependent cotransporter modulators for treating conditions of the central and peripheral nervous systems using non-synaptic mechanisms

IN Hochman, Daryl W.
PA Cytoscan Sciences L.L.C., USA
SO U.S. Pat. Appl. Publ., 29 pp., Cont.-in-part of U.S. Ser. No. 470,637.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002082252	A1	20020627	US 2002-56528	20020123
	US 6495601	B1	20021217	US 1999-470637	19991222
PRAI	US 1998-113620P	P	19981223		
	US 1999-470637	A2	19991222		
	US 2001-263830P	P	20010123		

L29 ANSWER 5 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:856855 CAPLUS
DN 136:194095
TI Antinociceptive profiles of aspirin and acetaminophen in formalin, substance P and glutamate pain models
AU Choi, Seong-Soo; Lee, Jin-Koo; Suh, Hong-Won
CS Department of Pharmacology, Hallym University, College of Medicine, and Institute of Natural Medicine, Kangwon-Do, Chunchon, 200-702, S. Korea
SO Brain Research (2001), 921(1,2), 233-239
CODEN: BRREAP; ISSN: 0006-8993
PB Elsevier Science B.V.
DT Journal
LA English
RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 6 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:797561 CAPLUS
DN 137:103455
TI Paradoxical effect of aspirin on the growth of C6 rat glioma and on time of development of ENU-induced tumors of the nervous system
AU Arrieta, Oscar; Guevara, Patricia; Reyes, Sandra; Palencia, Guadalupe; Rivera, Erika; Sotelo, Julio
CS Neuroimmunology Unit, Instituto Nacional de Neurologia y Neurocirugia and Instituto de Investigaciones Biomedicas, Mexico City, 14269, Mex.
SO Journal of Cancer Research and Clinical Oncology (2001), 127(11), 681-686
CODEN: JCROD7; ISSN: 0171-5216
PB Springer-Verlag
DT Journal
LA English
RE.CNT 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 7 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:704905 CAPLUS
DN 134:51168
TI NSAID Treatment Suppresses VSV Propagation in Mouse **CNS**
AU Chen, Nannan; Warner, Jennifer L.; Reiss, Carol Shoshkes
CS Department of Biology, New York University, New York, NY, 10003, USA
SO Virology (2000), 276(1), 44-51
CODEN: VIRLAX; ISSN: 0042-6822
PB Academic Press
DT Journal
LA English
RE.CNT 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 8 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:598508 CAPLUS
DN 134:114081
TI Incidence, clinical features and outcome of essential thrombocythemia in a well defined geographical area
AU Jensen, Morten Krogh; De Nully Brown, Peter; Nielsen, Ove Juul; Hasselbalch, Hans Carl
CS Department of Haematology, Herlev Hospital, University Hospital of Copenhagen, Copenhagen, Den.
SO European Journal of Haematology (2000), 65(2), 132-139
CODEN: EJHAEC; ISSN: 0902-4441
PB Munksgaard International Publishers Ltd.
DT Journal
LA English
RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 9 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1999:576796 CAPLUS
DN 131:204626
TI Compositions comprising valerian extracts, isovaleric acid or derivatives thereof with a NSAID
IN Artman, Linda D.; Balandrin, Manuel F.
PA NPS Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9944623	A1	19990910	WO 1999-US4786	19990304
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2321737	AA	19990910	CA 1999-2321737	19990304
	AU 9928945	A1	19990920	AU 1999-28945	19990304
	EP 1059930	A1	20001220	EP 1999-909827	19990304
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2002505296	T2	20020219	JP 2000-534224	19990304
	US 6383527	B1	20020507	US 2001-623384	20010222
PRAI	US 1998-76737P	A2	19980304		
	WO 1999-US4786	W	19990304		

OS MARPAT 131:204626
RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 10 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:780621 CAPLUS
DN 130:232124
TI Peripheral administration of novel anti-inflammatories can attenuate the effects of chronic inflammation within the **CNS** [central nervous system]
AU Hauss-Wegrzyniak, Beatrice; Willard, Lauren B.; Del Soldato, Piero; Pepeu, Giancarlo; Wenk, Gary L.

CS Memory and Aging, Division of Neural Systems, Arizona Research Laboratories, University of Arizona, Tucson, AZ, 85724, USA
SO Brain Research (1999), 815(1), 36-43
CODEN: BRREAP; ISSN: 0006-8993
PB Elsevier Science B.V.
DT Journal
LA English
RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 11 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:43243 CAPLUS
DN 128:149902
TI Modulation of Brewer's yeast-induced peripheral inflammation and nociception in rats by centrally administered prostaglandins and their inhibitors
AU Hore, S. K.; Dumka, V. K.; Tandan, S. K.; Tripathi, H. C.; Kumar, Dinesh
CS Division of Pharmacology and Toxicology, Indian Veterinary Research Institute, Izatnagar, 243 122, India
SO Indian Journal of Pharmacology (1997), 29(6), 416-419
CODEN: INJPD2; ISSN: 0253-7613
PB Indian Pharmacological Society
DT Journal
LA English
RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 12 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1996:646511 CAPLUS
DN 125:276575
TI Preparation of arginine analogs having nitric oxide synthase inhibitor activity
IN Broquet, Colette; Chabrier, De Lassauniere, Pierre-Etienne
PA Societe De Conseils De Recherches Et D'application, Fr.
SO PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9627593	A1	19960912	WO 1996-FR337	19960304
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN				
	CA 2215476	AA	19960912	CA 1996-2215476	19960304
	AU 9649479	A1	19960923	AU 1996-49479	19960304
	AU 700871	B2	19990114		
	EP 813529	A1	19971229	EP 1996-905907	19960304
	EP 813529	B1	20020911		
	R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE, IE, SI, LT, LV, FI				
	CN 1179774	A	19980422	CN 1996-192885	19960304
	CN 1071328	B	20010919		
	JP 11501043	T2	19990126	JP 1996-526657	19960304
	RU 2168493	C2	20010610	RU 1997-116496	19960304
	AT 223907	E	20020915	AT 1996-905907	19960304
	CZ 290747	B6	20021016	CZ 1997-2687	19960304
	SK 282664	B6	20021106	SK 1997-1121	19960304
	ES 2182964	T3	20030316	ES 1996-905907	19960304

	US 5972940	A	19991026	US 1997-913455	19970910
	HK 1013777	A1	20020705	HK 1998-110921	19980924
PRAI	GB 1995-4350	A	19950304		
	WO 1996-FR337	W	19960304		

OS MARPAT 125:276575

L29 ANSWER 13 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1996:245721 CAPLUS
DN 125:48415
TI Effect of NM441 and its active form on GABA receptor binding
AU Hori, Seiji; Shimada, Jingoro
CS Div. Clin. Pharmacol. Inst. Med. Sci., St. Marianna Univ. Sch. Med., Kawasaki, 216, Japan
SO Nippon Kagaku Ryoho Gakkai Zasshi (1996), 44(Suppl. 1), 97-101
CODEN: NKRZE5; ISSN: 1340-7007
DT Journal
LA Japanese

L29 ANSWER 14 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1995:365390 CAPLUS
DN 122:204992
TI Neuronal expression of FOS protein in the nucleus tractus solitarii and the dorsal motor nucleus of the vagus nerve after i.p. injection of ulcerogenic aspirin
AU Takahashi, Akio; Miura, Mitsuhiko
CS Department of Physiology 1st Division, Gunma University School of Medicine, 3-39-22 Showa-machi, Maebashi-shi, 371, Japan
SO Neuroscience Letters (1995), 185(3), 214-16
CODEN: NELED5; ISSN: 0304-3940
PB Elsevier
DT Journal
LA English

L29 ANSWER 15 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1994:499126 CAPLUS
DN 121:99126
TI Mechanism of quinolone-induced convulsion and anticonvulsant effect of barbiturate for this seizure
AU Kanemitsu, Keiji
CS Dep. Intern. Med. and Lab. Med., St. Marianna Univ. Sch. Med., Kawasaki, 216, Japan
SO Sei Marianna Ika Daigaku Zasshi (1993), 21(6), 1177-85
CODEN: SMIZDS; ISSN: 0387-2289
DT Journal
LA Japanese

L29 ANSWER 16 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1993:573380 CAPLUS
DN 119:173380
TI Acetylsalicylic acid and related compounds depress nociceptive activity in the thalamus by a central action: indications for the involvement of prostaglandins
AU Jurna, I.
CS Inst. Pharmakol. Toxikol., Univ. Saarlandes, Homburg/Saar, D-6650, Germany
SO Progress in Pharmacology and Clinical Pharmacology (1993), 10(1), 51-68
CODEN: PPCPEP; ISSN: 0934-9545
DT Journal; General Review
LA English

L29 ANSWER 17 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1992:676 CAPLUS
DN 116:676

TI Central analgesic effects of acetylsalicylic acid in healthy men
AU Bromm, B.; Rundshagen, I.; Scharein, E.
CS Inst. Physiol., Univ. Hosp. Eppendorf, Hamburg, W-2000/20, Germany
SO Arzneimittel-Forschung (1991), 41(11), 1123-9
CODEN: ARZNAD; ISSN: 0004-4172
DT Journal
LA English

L29 ANSWER 18 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1990:91116 CAPLUS
DN 112:91116
TI Effects of pentazocine and acetylsalicylic acid on pain-rating, pain-related evoked potentials and vigilance in relationship to pharmacokinetic parameters
AU Kobal, G.; Hummel, C.; Nuernberg, B.; Brune, K.
CS Inst. Pharmakol. Toxikol., Univ. Erlangen-Nuernberg, Erlangen, D-8520, Germany
SO Agents and Actions (1990), 29(3-4), 342-59
CODEN: AGACBH; ISSN: 0065-4299
DT Journal
LA English

L29 ANSWER 19 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1987:60703 CAPLUS
DN 106:60703
TI In vitro metabolism of teratogens by differentiating rat embryo cells
AU Brown, L. P.; Flint, O. P.; Orton, T. C.; Gibson, G. G.
CS Biochem. Dep., Univ. Surrey, Guildford/Surrey, GU2 5XH, UK
SO Food and Chemical Toxicology (1986), 24(6-7), 737-42
CODEN: FCTOD7; ISSN: 0278-6915
DT Journal
LA English

L29 ANSWER 20 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1985:73624 CAPLUS
DN 102:73624
TI An in vitro assay for teratogens with cultures of rat embryo midbrain and limb bud cells
AU Flint, O. P.; Orton, T. C.
CS Saf. Med. Dep., Imp. Chem. Ind. PLC, Macclesfield/Cheshire, SK10 4TG, UK
SO Toxicology and Applied Pharmacology (1984), 76(2), 383-95
CODEN: TXAPA9; ISSN: 0041-008X
DT Journal
LA English

L29 ANSWER 21 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1981:114385 CAPLUS
DN 94:114385
TI The antipyretic effects of aminopyrine and sodium acetylsalicylate on endotoxin-induced fever in rabbits
AU Nishio, Akira; Kanoh, Seizaburo
CS Fac. Agric., Kagoshima Univ., Kagoshima, 890, Japan
SO Nippon Yakurigaku Zasshi (1981), 77(1), 9-13
CODEN: NYKZAU; ISSN: 0015-5691
DT Journal
LA Japanese

L29 ANSWER 22 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1979:535333 CAPLUS
DN 91:135333
TI Prostaglandin synthetase inhibitors antagonize the depressant effects of ethanol

AU George, Frank R.; Collins, Allan C.
CS Inst. Behav. Genet., Univ. Colorado, Boulder, CO, 80309, USA
SO Pharmacology, Biochemistry and Behavior (1979), 10(6), 865-9
CODEN: PBBHAU; ISSN: 0091-3057
DT Journal
LA English

L29 ANSWER 23 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1978:499779 CAPLUS
DN 89:99779
TI Pharmacological characterization of benzodiazepine receptors in the brain
AU Braestrup, Claus; Squires, Richard F.
CS Res. Lab., A/S Ferrosan, Soeborg, Den.
SO European Journal of Pharmacology (1978), 48(3), 263-70
CODEN: EJPHAZ; ISSN: 0014-2999
DT Journal
LA English

L29 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1975:601968 CAPLUS
DN 83:201968
TI Mechanism of the synaptic effects of morphine, indomethacin, and prostaglandins
AU Ehrenpreis, Seymour; Greenberg, Joel
CS New York State Res. Inst. Neurochem. Drug Addict., New York, NY, USA
SO Clin. Pharmacol. Psychoact. Drugs, [Proc. Int. Symp. Alcohol Drug Res.] (1975), Meeting Date 1973, 171-82. Editor(s): Sellers, E. M. Publisher: Alcohol. Drug Addit. Res. Found., Toronto, Can.
CODEN: 31QKAO
DT Conference
LA English

L29 ANSWER 25 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1972:107738 CAPLUS
DN 76:107738
TI Drug interactions. **CNS** [central nervous system] drugs analgesics and antipyretics
AU Hartshorn, Edward A.
CS Pharm. Serv., Evanston Hosp., Evanston, IL, USA
SO Drug Intelligence (1971), 5(11), 356-60
CODEN: DRUIA6; ISSN: 0012-6578
DT Journal; General Review
LA English

L29 ANSWER 26 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1969:113689 CAPLUS
DN 70:113689
TI N-Aralkylanthranilic acid derivatives as **CNS** [central nervous system] depressants
AU Sisodia, P.; Rao, G. S. Rama; Sidhu, Gurbachan S.; Sattur, Prolhad B.; Hashim, Riaz
CS Gandhi Med. Coll., Hyderabad, India
SO CNS (Cent. Nerv. Syst.) Drugs, Symp. (1966), 238-48 Publisher: Counc. Sci. and Ind. Res., New Delhi, India.
CODEN: 20REAT
DT Conference
LA English

L29 ANSWER 27 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1968:113200 CAPLUS
DN 68:113200
TI Drug effects on electrically induced extensor seizures and clinical

implications
AU Chen, Graham; Ensor, Charles R.; Bohner, Barbara
CS Parke, Davis and Co., Ann Arbor, MI, USA
SO Archives Internationales de Pharmacodynamie et de Therapie (1968), 172(1), 183-218
CODEN: AIPTAK; ISSN: 0003-9780
DT Journal
LA English

L29 ANSWER 28 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1962:15164 CAPLUS
DN 56:15164
OREF 56:2857g-i,2858a
TI Classification of **CNS** drugs by a mouse screening battery
AU Bastian, J. W.
CS Armour Pharmaceutical Co., Kankakee, IL
SO Archives Internationales de Pharmacodynamie et de Therapie (1961), 133, 347-64
CODEN: AIPTAK; ISSN: 0003-9780
DT Journal
LA Unavailable

=> d l29 27 all

L29 ANSWER 27 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1968:113200 CAPLUS
DN 68:113200
TI Drug effects on electrically induced extensor seizures and clinical implications
AU Chen, Graham; Ensor, Charles R.; Bohner, Barbara
CS Parke, Davis and Co., Ann Arbor, MI, USA
SO Archives Internationales de Pharmacodynamie et de Therapie (1968), 172(1), 183-218
CODEN: AIPTAK; ISSN: 0003-9780
DT Journal
LA English
CC 15 (Pharmacodynamics)
AB The central nervous system depressants (**CNS** depressants) produce an elevation of the extensor-seizure threshold (ExST) in mice to electroshock. The ExST raising action at non-neurotoxic doses is an essential property of drugs for grand mal epilepsy. The different types of **CNS** depressants caused a maximal increase in ExST of mice at doses that produced different degrees of central depression. The relation between ExST and the degree of depression may be taken for the characterization of the various types of **CNS** depressants. The excitants and those drugs having both a central stimulating and depressant action also produced an increase of ExST. On the other hand, the convulsants which do not possess a depressant component lowered the ExST at subconvulsive doses. A lowering of ExST was obtained with some other **CNS** depressants. Reserpine and tetrabenazine were the most active; their effect was dose dependent. Chlorpromazine, haloperidol, and a no. of other major tranquilizers produced a slight lowering of the ExST at low doses but an elevation of ExST at higher doses. The ExST lowering effect of the major tranquilizers may be related to the extrapyramidal syndrome seen in subjects under therapy with these drugs. The effect on ExST of reserpine or tetrabenazine was a useful indicator for testing the activity of monoamine oxidase inhibitors and for investigating the pharmacology of the biogenic amines in the central nervous system. A dichotomy was observed between the sympathetic drugs and the parasympathetic drugs in their effects on elec. induced extensor seizure (ExS) in mice: the sympathomimetics and the anticholinergics caused an

increase in ExST while the parasympathetics and the adrenergic blockers lowered it. Different mechanisms were involved in the elevation of ExST by the various drugs. In reserpinized mice, diphenylhydantoin, amphetamine, hyoscine, and some other drugs were still effective in producing an increase in ExST, while acetazolamide, methazolamide, and oxotremorine were ineffective. Quant. studies of the combined effects of DPHD (diphenylhydantoin) and of amphetamine or hyoscine on extensor seizure showed that these drugs affect the ExST by diverse actions. 45 references.

ST ANTIEPILEPTIC DRUGS; ANTICONVULSANT DRUGS; DIPHENYLHYDANTOIN SEIZURES; DRUGS ANTIEPILEPTIC; RESERPINE SEIZURES; NERVES DEPRESSANTS

IT Convulsions
(psychotropic agents effect on)

IT 50-13-5 50-35-1 50-48-6 50-49-7 50-53-3, biological studies 50-55-5, biological studies 50-67-9, biological studies **50-78-2**, biological studies 51-34-3 52-86-8 54-92-2 54-95-5 57-30-7 57-33-0 57-53-4 58-08-2, biological studies 58-25-3 58-39-9 58-40-2 58-46-8 60-45-7 63-84-3 64-31-3 66-05-7 66-32-0 77-10-1 77-65-6 77-67-8 113-45-1 117-89-5 127-48-0 144-02-5 146-54-3 300-62-9, biological studies 302-17-0, biological studies 305-96-4 439-14-5 467-60-7 555-30-6 555-57-7 630-93-3 658-48-0 1421-14-3 1867-66-9 3721-28-6 7632-10-2
RL: BIOL (Biological study)
(convulsion threshold response to)

=> d 129 28 all

L29 ANSWER 28 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1962:15164 CAPLUS
DN 56:15164
OREF 56:2857g-i,2858a
TI Classification of **CNS** drugs by a mouse screening battery
AU Bastian, J. W.
CS Armour Pharmaceutical Co., Kankakee, IL
SO Archives Internationales de Pharmacodynamie et de Therapie (1961), 133, 347-64
CODEN: AIPTAK; ISSN: 0003-9780
DT Journal
LA Unavailable
CC 73 (Pharmacodynamics)
AB Forty-two central nervous system (**CNS**) drugs and 16 nonCNS drugs were studied on a battery of mouse screening tests. The following end-points were measured in each animal: motor activity; ataxia; body temp.; metrazole threshold as described by Bastian, et al. (CA 54, 671h); block of Metrazole-induced extensor tonus; and time to Metrazole death. Twenty-four of the **CNS** drugs were found to raise Metrazole threshold. This group, made up of **CNS** depressants, included mainly hypnotics, antiepileptic drugs, and antineurotic tranquilizers. The remaining group of **CNS** drugs, which included depressants as well as stimulants, failed to cause an appreciable elevation of Metrazole threshold. Some of the stimulants lowered the threshold. None of the 16 non-**CNS** drugs had any marked effect on this endpoint. Most drugs which elevated Metrazole threshold also caused increased motor activity. Most **CNS** depressants which did not elevate Metrazole threshold were found to lower body temp. Normal or elevated levels of motor activity were assocd. with body temps. of 99.degree.F. or higher, whereas low body temps. were always assocd. with low motor activities. This was true for drugs with a variety of types of pharmacol. effects.

IT Polyoxymethylenes
(nervous system response to)

IT Pharmacology

(of central nervous system drugs)
IT Nervous system
(pharmaceuticals affecting central, classification of)
IT 5H-Tetrazoloazepine, 6,7,8,9-tetrahydro-
Ammonium, hexamethylenebis[trimethyl-, chloride
Benzoxazole, 2-acetamnido-5-chloro-
Benzyl alcohol, .alpha.-[(2-pyridylamino)methyl]-, (-)-
Carbamic acid (aminoformic acid), 1-ethynylcyclohexyl ester
Carbamic acid (aminoformic acid), 2-hydroxy-3-(o-methoxyphenoxy)propyl ester
Carbamic acid (aminoformic acid), 2-methyl-2-propyltrimethylene ester meprobamate
Carbamic acid (aminoformic acid), .alpha.,.beta.-diethyl-.beta.-hydroxyphenethyl ester
Carbamic acid (aminoformic acid), .beta.-ethyl-.beta.-hydroxyphenethyl ester
Carbamic acid (aminoformic acid), .beta.-hydroxyphenethyl ester
Lysergamide, N,N-diethyl-
(nervous system response to)
IT 50-33-9, 3,5-Pyrazolidinedione, 4-butyl-1,2-diphenyl- 50-49-7, 5H-Dibenz[b,f]azepine, 5-[3-(dimethylamino)propyl]-10,11-dihydro- 50-53-3, Phenothiazine, 2-chloro-10-[3-(dimethylamino)propyl]- 50-55-5, Reserpine 50-67-9, Indol-5-ol, 3-(2-aminoethyl) **50-78-2**, Acetylsalicylic acid 51-45-6, Histamine 51-55-8, Atropine 51-79-6, Ethyl carbamate 54-11-5, Nicotine 57-24-9, Strychnine 57-41-0, Hydantoin, 5,5-diphenyl- 57-44-3, Barbituric acid, 5,5-diethyl- 57-47-6, Physostigmine 58-08-2, Caffeine 58-25-3, 3H-1,4-Benzodiazepine, 7-chloro-2-(methylamino)-5-phenyl-, 4-oxide 58-73-1, Ethylamine, 2-(diphenylmethoxy)-N,N-dimethyl- 59-47-2, 1,2-Propanediol, 3-(o-tolyloxy)- 59-67-6, Nicotinic acid 60-40-2, 2-Norbornanamine, N,2,3,3-tetramethyl- 62-44-2, p-Acetophenetidide 64-17-5, Ethyl alcohol 64-95-9, Acetic acid, diphenyl-, 2-(diethylamino)ethyl ester) 66-40-0, Ammonium, tetraethyl 75-87-6, Chloral 76-74-4, Barbituric acid, 5-ethyl-5-(1-methylbutyl)- 77-38-3, Ethylamine, 2-[(p-chloro-.alpha.-methyl-.alpha.-phenylbenzyl)oxy]-N,N-dimethyl- 80-77-3, 4H-1,3-Thiazin-4-one, 2-(p-chlorophenyl)tetrahydro-3-methyl-, 1,1-dioxide 83-98-7, Ethylamine, N,N-dimethyl-2-[(o-methyl-.alpha.-phenylbenzyl)oxy]- 90-49-3, Urea, (2-phenylbutyryl)- 92-12-6, Ethylamine, N,N-dimethyl-2-[(.alpha.-phenyl-o-tolyl)oxy] 95-25-0, 2-Benzoxazolinone, 5-chloro- 113-18-8, 1-Penten-4-yn-3-ol, 1-chloro-3-ethyl- 113-45-1, 2-Piperidineacetic acid, .alpha.-phenyl-, methyl ester 115-76-4, 1,3-Propanediol, 2,2-diethyl- 125-64-4, 2,4-Piperidinedione, 3,3-diethyl-5-methyl- 127-48-0, 2,4-Oxazolidinedione, 3,5,5-trimethyl- 300-62-9, Phenethylamine, .alpha.-methyl- 631-07-2, Hydantoin, 5-ethyl-5-phenyl- 7647-15-6, Sodium bromide 13454-23-4, Carbamic acid, dimethyl-, 2-hydroxy-2,2-diphenylethyl ester 90871-96-8, Urea, [(2-phenylacetamido)methyl]-
(nervous system response to)
IT 77-41-8, Succinimide, N,2-dimethyl-2-phenyl- 5586-60-7, 3,4-Hexanediol, 3-phenyl-, 4-carbamate
(nervous-system response to)

=> d 129 17 all

L29 ANSWER 17 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1992:676 CAPLUS
DN 116:676
TI Central analgesic effects of acetylsalicylic acid in healthy men
AU Bromm, B.; Rundshagen, I.; Scharein, E.
CS Inst. Physiol., Univ. Hosp. Eppendorf, Hamburg, W-2000/20, Germany

SO Arzneimittel-Forschung (1991), 41(11), 1123-9
CODEN: ARZNAD; ISSN: 0004-4172
DT Journal
LA English
CC 1-11 (Pharmacology)
AB Acetylsalicylic acid (1000 mg orally) was investigated in a non-inflammatory exptl. pain model in healthy men. Phasic pain was induced by intracutaneously applied elec. pulses of const. current. The nociceptive responses measured were pain ratings, cerebral potentials, and EEG delta powers in response to stimuli. Spontaneous EEG, auditory evoked potentials, and reaction times were evaluated to det. effects on the vigilance system. Acetylsalicylic acid produced clear analgesic effects in all pain relevant target variables. The effects increased with postmediation time, becoming different from placebo 90 min after medication. At this time the pain ratings were reduced by 4%, the pain related cerebral potentials by 15%, and the stimulus-induced delta power of EEG by 20%. The findings suggest a central action of acetylsalicylic acid by attenuation of exptl. induced nociceptive activity. No influences could be obsd. on auditory evoked potentials, spontaneous EEG, and reaction times. Acetylsalicylic acid did not change vigilance by unspecific alterations of the **CNS**. The plasma concn. of acetylsalicylic acid reached mean values of 2.5 .mu.g/mL within 25 min after medication and remained const. during the entire post-medication period of 105 min. The concn. of the metabolite salicylic acid increased steadily, reaching mean values of 32.0 .mu.g/mL at the end of the investigated period. Although both the analgesic efficacy and the concn. of salicylate increased with post-medication time, no correlations were found between individual plasma level and effects.
ST aspirin analgesia central vigilance pharmacokinetics
IT Analgesia
(central, from aspirin, vigilance and pharmacokinetics in, in humans)
IT Mental activity
(vigilance, aspirin-induced central analgesia effects on, in humans)
IT **50-78-2**, Aspirin
RL: BIOL (Biological study)
(central analgesia from, vigilance and pharmacokinetics in, in humans)
IT 69-72-7, Salicylic acid, biological studies
RL: BIOL (Biological study)
(of blood plasma, as aspirin metabolite, central analgesia in relation to, in human)

=> d 129 10 all

L29 ANSWER 10 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:780621 CAPLUS
DN 130:232124
TI Peripheral administration of novel anti-inflammatories can attenuate the effects of chronic inflammation within the **CNS** [central nervous system]
AU Hauss-Wegrzyniak, Beatrice; Willard, Lauren B.; Del Soldato, Piero; Pepeu, Giancarlo; Wenk, Gary L.
CS Memory and Aging, Division of Neural Systems, Arizona Research Laboratories, University of Arizona, Tucson, AZ, 85724, USA
SO Brain Research (1999), 815(1), 36-43
CODEN: BRREAP; ISSN: 0006-8993
PB Elsevier Science B.V.
DT Journal
LA English
CC 1-7 (Pharmacology)
AB This study investigated whether nitroflurbiprofen (NFP) or nitro-aspirin can reduce the inflammatory response induced by continuous infusion of

lipopolysaccharide (LPS) into the 4th ventricular space of the rat brain for 30 days. The chronic LPS infusion produced an extensive inflammation that was particularly evident in the hippocampus, subiculum and entorhinal and piriform cortices. Daily peripheral administration of NFP dose-dependently attenuated the brain inflammation, as indicated by the decreased d. and reactive state of microglial cells. Daily peripheral administration of nitro-aspirin also attenuated the brain inflammation, but to a much lesser degree than NFP. The results demonstrated that nonsteroidal anti-inflammatory drugs can reduce brain inflammation and that NFP is an effective anti-inflammatory agent.

ST brain inflammation inhibition nitroflurbiprofen nitroaspirin; nonsteroidal antiinflammatory drug brain inflammation

IT Encephalitis
(nitroflurbiprofen and nitroaspirin inhibition of)

IT Alzheimer's disease
(nitroflurbiprofen and nitroaspirin inhibition of brain inflammation in relation to)

IT Anti-inflammatory agents
(nonsteroidal; brain inflammation inhibition by nitroflurbiprofen and nitroaspirin as)

IT **17336-14-0** 158836-71-6, Nitroflurbiprofen
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(brain inflammation inhibition by)

RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Aisen, P; Am J Psychiatr 1994, V151, P1105 MEDLINE
(2) Allison, M; N Engl J Med 1992, V327, P749 MEDLINE
(3) Altstiel, L; Prog Neuropsycho-Pharmacol Biol Psychiatr 1991, V15, P481 CAPLUS
(4) Banati, R; Glia 1993, V7, P111 MEDLINE
(5) Bannwarth, B; Therapie 1986, V41, P409 CAPLUS
(6) Breder, C; Brain Res 1996, V713, P64 CAPLUS
(7) Breitner, J; Neurobiol Aging 1996, V17, P789 MEDLINE
(8) Burrel, R; Crit Rev Microbiol 1990, V17, P188
(9) Cacabelos, R; Meth Find Exp Clin Pharmacol 1994, V16, P141 MEDLINE
(10) Chiang, C; Dev Neurosci 1994, V16, P212 CAPLUS
(11) Das, S; Neuron 1995, V14, P447 CAPLUS
(12) Eikelenboom, P; Virchows Arch B Cell Pathol 1989, V56, P259 MEDLINE
(13) Elmquist, J; J Comp Neurol 1997, V381, P119 CAPLUS
(14) Greenblatt, D; Arzneimittel-Forschung 1983, V33, P1671 CAPLUS
(15) Griffin, W; Proc Natl Acad Sci USA 1989, V86, P7611 MEDLINE
(16) Hauss-Wegrzyniak, B; Brain Res 1998, V794, P211 CAPLUS
(17) Hauss-Wegrzyniak, B; Brain Res 1998, V780, P294 CAPLUS
(18) Jenkinson, M; Br J Rheumatol 1989, V28, P86 MEDLINE
(19) Kitagawa, H; J Pharmacol Exp Therap 1990, V253, P1133 CAPLUS
(20) Macnaughton, W; Life Sci 1989, V45, P1869 CAPLUS
(21) McGeer, P; Brain Res Rev 1995, V21, P195 MEDLINE
(22) McGeer, P; Lancet 1990, V335, P1037 MEDLINE
(23) McGeer, P; Neurosci Lett 1988, V79, P195
(24) McGeer, P; Neurosci Lett 1989, V107, P341 MEDLINE
(25) Mrak, R; Human Pathol 1995, V26, P816 MEDLINE
(26) Myllykangas-Luosujarvi, R; Br J Rheumatol 1994, V33, P501 MEDLINE
(27) Rogers, J; Drug Res 1995, V45, P439 CAPLUS
(28) Rogers, J; Neurobiol Aging 1996, V17, P681 MEDLINE
(29) Rogers, J; Neurology 1993, V43, P1609 MEDLINE
(30) Roth, S; Ann Intern Med 1988, V109, P353 MEDLINE
(31) Santini, G; Eur J Pharmacol 1996, V316, P65 CAPLUS
(32) Sheng, J; Neurobiol Aging 1996, V17, P761 CAPLUS
(33) Strauss, S; Lab Invest 1992, V66, P223 MEDLINE
(34) Vandenabeele, P; Immunol Today 1991, V12, P217 CAPLUS

(35) Wallace, J; Gastroenterology 1994, V107, P173 CAPLUS
(36) Wallace, J; Trends Pharmacol Sci 1992, V13, P129 MEDLINE
(37) Watson; Paxinos 1986

```
=>  e lupus
E1            1     LUPUR/BI
E2            1     LUPURENE/BI
E3        11819 --> LUPUS/BI
E4           13     LUPUSLIKE/BI
E5            1     LUPUSS/BI
E6            2     LUPUTRIONE/BI
E7            2     LUPUTRIONES/BI
E8           15     LUQ/BI
E9            1     LUQ1/BI
E10           1     LUQ3/BI
E11           4     LUQAS/BI
E12           1     LUQB/BI

=> s e3
L30       11819 LUPUS/BI

=> s l30 and l10
L31          53 L30 AND L10

=> d l31 30-53

L31  ANSWER 30 OF 53  CAPLUS  COPYRIGHT 2003 ACS on STN
AN   1999:282073  CAPLUS
DN   130:320863
TI   Use of inhaled nitric oxide for lessening or preventing non-pulmonary
     ischemia-reperfusion injury or inflammation
IN   Zapol, Warren M.; Bloch, Kenneth D.; Rosenzweig, Anthony
PA   The General Hospital Corporation, USA
SO   PCT Int. Appl., 19 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.         KIND  DATE          APPLICATION NO.  DATE
     ---------------    ----  --------      ---------------  --------
PI   WO 9920251          A1   19990429      WO 1998-US22044  19981019
         W:  AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
             DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG,
             KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX,
             NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,
             UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
             FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
             CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     CA 2309038          AA   19990429      CA 1998-2309038  19981019
     AU 9911012          A1   19990510      AU 1999-11012    19981019
     AU 751853           B2   20020829
     EP 1073416          A1   20010207      EP 1998-953702   19981019
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, FI
     ZA 9809550          A    19990721      ZA 1998-9550     19981020
PRAI US 1997-62926P      P    19971021
     US 1997-971003      A    19971114
     WO 1998-US22044     W    19981019
RE.CNT  4     THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT
```

L31 ANSWER 31 OF 53 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:806633 CAPLUS
DN 130:57211
TI Preparation of conjugates of dithiocarbamates with drugs
IN Lai, Ching-san
PA Medinox, Inc., USA
SO PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9855453	A1	19981210	WO 1998-US10295	19980519
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5916910	A	19990629	US 1997-869158	19970604
	AU 9875828	A1	19981221	AU 1998-75828	19980519
	AU 743205	B2	20020124		
	EP 1001932	A1	20000524	EP 1998-923563	19980519
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2002511858	T2	20020416	JP 1999-502493	19980519
	US 6407135	B1	20020618	US 1999-453608	19991203
	US 2003087840	A1	20030508	US 2002-176396	20020618
PRAI	US 1997-869158	A1	19970604		
	WO 1998-US10295	W	19980519		
	US 1999-453608	A3	19991203		

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 32 OF 53 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:766188 CAPLUS
DN 130:166818
TI Anti-phospholipid syndrome: from patient's bedside to experimental animal models and back to the patient's bedside
AU Ziporen, L.; Shoenfeld, Y.
CS Research Unit. of Autoimmune Diseases, Department of Medicine B, Sheba Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Israel
SO Hematology and Cell Therapy (1998), 40(5), 175-182
CODEN: HCTHFA; ISSN: 1430-2772
PB Springer-Verlag France
DT Journal; General Review
LA English
RE.CNT 70 THERE ARE 70 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 33 OF 53 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:708808 CAPLUS
DN 129:310911
TI TGF-.beta.-elevating compounds and therapies for the prevention of vascular and non-vascular pathologies, and diagnostic methods
IN Grainger, David J.; Metcalfe, James C.; Kasina, Sudhakar
PA Neorx Corp., USA
SO PCT Int. Appl., 153 pp.

CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9846588	A2	19981022	WO 1998-US7063	19980409
	WO 9846588	A3	19990107		

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

	AU 9869598	A1	19981111	AU 1998-69598	19980409
	US 6117911	A	20000912	US 1998-57323	19980409
	US 6410587	B1	20020625	US 2000-567558	20000505
	US 2003064970	A1	20030403	US 2002-170971	20020613
PRAI	US 1997-43852P	P	19970411		
	US 1998-57323	A1	19980409		
	WO 1998-US7063	W	19980409		
	US 2000-567558	A3	20000505		

OS MARPAT 129:310911

L31 ANSWER 34 OF 53 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:584280 CAPLUS
DN 129:342593
TI Recurrent abortion and moderate or strong antiphospholipid antibody production
AU Ogasawara, M.; Sasa, H.; Katano, K.; Aoyama, T.; Aoki, K.; Suzumori, K.
CS Department of Obstetrics and Gynecology, Nagoya City University Medical School, Nagoya, Japan
SO International Journal of Gynecology & Obstetrics (1998), 62(2), 183-188
CODEN: IJGOAL; ISSN: 0020-7292
PB Elsevier Science Ireland Ltd.
DT Journal
LA English
RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 35 OF 53 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:341491 CAPLUS
DN 129:12742
TI Methods and compositions using thalidomide or other angiogenesis-inhibitory compound and anti-inflammatory agent for inhibition of angiogenesis
IN D'Amato, Robert J.
PA Children's Medical Center, USA
SO PCT Int. Appl., 63 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9819649	A2	19980514	WO 1997-US20116	19971104
	WO 9819649	A3	19980625		

W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT,

RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

	AU 9851973	A1	19980529	AU 1998-51973	19971104
	AU 746713	B2	20020502		
	EP 963200	A2	19991215	EP 1997-946884	19971104
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	NZ 336035	A	20020328	NZ 1997-336035	19971104
	JP 2002513391	T2	20020508	JP 1998-521728	19971104
PRAI	US 1996-28708P	P	19961105		
	US 1997-963058	A	19971103		
	WO 1997-US20116	W	19971104		

OS MARPAT 129:12742

L31 ANSWER 36 OF 53 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:167985 CAPLUS
DN 128:293600
TI The effect of sera from women with systemic **lupus** erythematosus and/or antiphospholipid syndrome on rat embryos in culture
AU Ornoy, A.; Yacobi, S.; Avraham, S.; Blumenfeld, Z.
CS Laboratory of Teratology, Department of Anatomy & Cell Biology, Hebrew University Hadassah Medical School, Jerusalem, 91120, Israel
SO Reproductive Toxicology (1998), 12(2), 185-191
CODEN: REPTED; ISSN: 0890-6238
PB Elsevier Science Inc.
DT Journal
LA English
RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 37 OF 53 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1997:804013 CAPLUS
DN 128:60525
TI Coagulation and fibrinolysis in pregnant women with antiphospholipid antibodies
AU Amemiya, Teruko; Nakabayashi, Masao; Adachi, Tomoko; Takeda, Yoshihiko
CS Dep. Obstet. Gynecol., Tokyo Women's Med. Coll., Tokyo, 162, Japan
SO Tokyo Joshi Ika Daigaku Zasshi (1997), 67(11), 892-901
CODEN: TJIZAF; ISSN: 0040-9022
PB Tokyo Joshi Ika Daigaku Gakkai
DT Journal
LA Japanese

L31 ANSWER 38 OF 53 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1997:746178 CAPLUS
DN 128:21484
TI Classification of asthma patients using polymorphisms in the 5-lipoxygenase gene
IN Drazen, Jeffrey M.; In, Kwang-Ho; Asano, Koichiro; Beier, David; Grobholz, James
PA Brigham and Women's Hospital, USA
SO PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9742347	A2	19971113	WO 1997-US7137	19970429

	WO 9742347	A3	19980108		
	W: AU, BR, CA, CN, CZ, HU, IL, JP, KR, MX, NZ				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 6090547	A	20000718	US 1997-846020	19970425
	AU 9729277	A1	19971126	AU 1997-29277	19970429
	EP 896633	A2	19990217	EP 1997-923486	19970429
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	ZA 9703849	A	19980204	ZA 1997-3849	19970505
	US 6355434	B1	20020312	US 2000-617871	20000717
PRAI	US 1996-16890P	P	19960506		
	US 1997-846020	A	19970425		
	WO 1997-US7137	W	19970429		

L31 ANSWER 39 OF 53 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1997:520584 CAPLUS
DN 127:171563
TI Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss
AU Laskin, Carl A.; Bombardier, Claire; Hannah, Mary E.; Mandel, Fred P.; Ritchie, J.W. Knox; Farewell, Vern; Farine, Dan; Spitzer, Karen; Fielding, Lynda; Soloninka, Christine A.; Yeung, Maria
CS Department of Medicine, Division of Rheumatology, University of Toronto, Toronto, Can.
SO New England Journal of Medicine (1997), 337(3), 148-153
CODEN: NEJMAG; ISSN: 0028-4793
PB Massachusetts Medical Society
DT Journal
LA English

L31 ANSWER 40 OF 53 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1997:498354 CAPLUS
DN 127:160341
TI Effect of antiphospholipid antibodies in women undergoing in-vitro fertilization: role of heparin and aspirin
AU Kutteh, William H.; Yetman, Deborah L.; Chantilis, Samuel J.; Crain, Jack
CS Memphis Health Science Center, The University of Tennessee, Memphis, TN, USA
SO Human Reproduction (1997), 12(6), 1171-1175
CODEN: HUREEE; ISSN: 0268-1161
PB Oxford University Press
DT Journal
LA English

L31 ANSWER 41 OF 53 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1997:343267 CAPLUS
DN 127:13431
TI Antiphospholipid antibodies in pregnant patients
AU Caruso, A.; De Carolis, S.; Ferrazzani, S.; De Santis, L.; Carducci, B.; Trivellinil, C.; Mancuso, S.
CS Department Obstetrics Gynecology, Catholic University Rome, Rome, 00168, Italy
SO International Journal of Immunopathology and Pharmacology (1997), 10(2, Suppl.), 137-138
CODEN: IJIPE4; ISSN: 0394-6320
PB Biomedical Research Press
DT Journal
LA English

L31 ANSWER 42 OF 53 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1996:68836 CAPLUS
DN 124:193785

TI The effect of aspirin and indomethacin on prostacyclin and thromboxane production by placental tissue incubated with immunoglobulin G fractions from patients with **lupus** anticoagulant
AU Peaceman, Alan M.; Rehnberg, Karen A.
CS Medical School, Northwestern University, Chicago, IL, 60611, USA
SO American Journal of Obstetrics and Gynecology (1995), 173(5), 1391-6
CODEN: AJOGAH; ISSN: 0002-9378
PB Mosby-Year Book
DT Journal
LA English

L31 ANSWER 43 OF 53 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1993:400486 CAPLUS
DN 119:486
TI Production of prostacyclin and thromboxane in **lupus** pregnancies: effect of small dose of aspirin
AU Kaaja, Risto; Julkunen, Heikki; Viinikka, Lasse; Ylikorkala, Olavi
CS Dep. I II Obstetr. Gynceol., Univ. Cent. Hosp. Helsinki, Helsinki, Finland
SO Obstetrics & Gynecology (New York, NY, United States) (1993), 81(3), 327-31
CODEN: OBGNAS; ISSN: 0029-7844
DT Journal
LA English

L31 ANSWER 44 OF 53 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1991:400390 CAPLUS
DN 115:390
TI Selective inhibition of platelet-derived thromboxane A2 in patients with **lupus** anticoagulant using low doses aspirin as assessed by enzyme immunoassay
AU Lellouche, Franck; Falcon, , Cristina; Carreras, Luis; Maclouf, Jacques
CS Hop. Lariboisiere, Paris, 75475, Fr.
SO Advances in Prostaglandin, Thromboxane, and Leukotriene Research (1990), 21B(Prostaglandins Relat. Compd.), 611-14
CODEN: ATLRD6; ISSN: 0732-8141
DT Journal
LA English

L31 ANSWER 45 OF 53 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1991:22375 CAPLUS
DN 114:22375
TI Interleukin-4 (IL-4) in method and compositions for degradation and prevention of fibrin deposits associated with pathological conditions
IN Hamilton, John Allan; Hart, Prudence Hamilton
PA University of Melbourne, Australia
SO PCT Int. Appl., 23 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9007932	A1	19900726	WO 1990-AU13	19900119
	W: AU, CA, JP, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, IT, LU, NL, SE				
	CA 2045574	AA	19900721	CA 1990-2045574	19900119
	AU 9049645	A1	19900813	AU 1990-49645	19900119
	AU 639903	B2	19930812		
	EP 454736	A1	19911106	EP 1990-902120	19900119
	R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE				
	JP 04503062	T2	19920604	JP 1990-502488	19900119
	JP 06011706	B4	19940216		

US 5236705 A 19930817 US 1991-720868 19910918
PRAI AU 1989-2356 19890120
WO 1990-AU13 19900119

L31 ANSWER 46 OF 53 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1991:564 CAPLUS
DN 114:564
TI Scavengers of free radical oxygen affect the generation of low molecular weight DNA in stimulated lymphocytes from patients with systemic **lupus** erythematosus
AU Benke, Paul J.; Levcovitz, Henrique; Paupe, Jean; Tozman, Elaine
CS Sch. Med., Univ. Miami, Miami, FL, USA
SO Metabolism, Clinical and Experimental (1990), 39(12), 1278-84
CODEN: METAAJ; ISSN: 0026-0495
DT Journal
LA English

L31 ANSWER 47 OF 53 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1987:188817 CAPLUS
DN 106:188817
TI Assessment of kininases in rheumatic diseases and the effect of therapeutic agents
AU Sheikh, Iftikhar A.; Kaplan, Allen P.
CS Dep. Med., SUNY, Stony Brook, NY, USA
SO Arthritis & Rheumatism (1987), 30(2), 138-45
CODEN: ARHEAW; ISSN: 0004-3591
DT Journal
LA English

L31 ANSWER 48 OF 53 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1984:504080 CAPLUS
DN 101:104080
TI Effects of oral aspirin and oxaprozin on the development of **lupus** -like disease in MRL/1 mice
AU Carlson, Richard P.; Gilman, Steven C.; Hodge, Thomas G.; O'Neill-Davis, Lynn; Blazek, Eileen M.; Lewis, Alan J.
CS Dep. Exp. Ther., Wyeth Lab., Inc., Philadelphia, PA, 19101, USA
SO Journal of Immunopharmacology (1984), 6(1-2), 69-78
CODEN: JOIMD6; ISSN: 0163-0571
DT Journal
LA English

L31 ANSWER 49 OF 53 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1979:197800 CAPLUS
DN 90:197800
TI Salicylate hepatotoxicity in systemic **lupus** erythematosus: a common occurrence?
AU Travers, R. L.; Hughes, G. R. V.
CS R. Postgrad. Med. Sch., Hammersmith Hosp., London, UK
SO British Medical Journal (1978), 2(6151), 1532-3
CODEN: BMJOAE; ISSN: 0007-1447
DT Journal
LA English

L31 ANSWER 50 OF 53 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1978:609248 CAPLUS
DN 89:209248
TI Elevated urinary prostaglandins and the effects of aspirin on renal function in **lupus** erythematosus
AU Kimberly, Robert P.; Gill, John R., Jr.; Bowden, Robert E.; Keiser, Harry R.; Plotz, Paul H.
CS Natl. Inst. Arthritis, Metab. Dig. Dis., NIH, Bethesda, MD, USA

SO Annals of Internal Medicine (1978), 89(3), 336-41
CODEN: AIMEAS; ISSN: 0003-4819
DT Journal
LA English

L31 ANSWER 51 OF 53 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1978:45148 CAPLUS
DN 88:45148
TI Aspirin and renal function
AU Spooner, J. B.; Cleaver, G. J.
CS Winthrop Lab., Surbiton-upon-Thames/Surrey, UK
SO Lancet (1977), 8028, 88
CODEN: LANCAO; ISSN: 0140-6736
DT Journal
LA English

L31 ANSWER 52 OF 53 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1973:37784 CAPLUS
DN 78:37784
TI Spectrum of drug-induced pulmonary disease
AU Rosenow, E. C. III
CS Mayo Clin. and Mayo Found., Rochester, MN, USA
SO Annals of Internal Medicine (1972), 77(6), 977-91
CODEN: AIMEAS; ISSN: 0003-4819
DT Journal; General Review
LA English

L31 ANSWER 53 OF 53 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1963:484674 CAPLUS
DN 59:84674
OREF 59:15746a-b
TI Impairments of aromatic amino acid metabolism in collagenoses; their contribution to the conception of systemic **lupus**
AU Grupper, Ch.; Legrand, J. C.; Gonnard, P.
CS Hop. St. Louis, Paris
SO Semaine des Hopitaux (1962), 38, 70-6
CODEN: SHPAAI; ISSN: 0037-1777
DT Journal
LA Unavailable

=> e alzheimers
E1 1 ALZHEIMERISTS/BI
E2 1 ALZHEIMERLIKE/BI
E3 1977 --> ALZHEIMERS/BI
E4 2 ALZHEIMERSDISEASE/BI
E5 1 ALZHEIMR/BI
E6 1 ALZHEINER/BI
E7 1 ALZHEINIER/BI
E8 1 ALZHEMER/BI
E9 3 ALZHEMIER/BI
E10 1 ALZHEMIERS/BI
E11 1 ALZHEMIMER/BI
E12 1 ALZHIEMER/BI

=> s e3
L32 1977 ALZHEIMERS/BI

=> s l10 and l32
L33 8 L10 AND L32

=> d l33 1-8

L33 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2003:633484 CAPLUS
DN 139:173796
TI Method for treating a mammal by administration of a compound having the ability to release CO, compounds having the ability to release CO and pharmaceutical compositions thereof
IN Haas, Werner; Romao, Carlos; Royo, Beatriz; Fernandes, Ana Cristina; Goncalves, Isabel
PA Port.
SO PCT Int. Appl., 76 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003066067	A2	20030814	WO 2003-IB932	20030203

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2002-353233P P 20020204

L33 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:262912 CAPLUS
DN 136:363747
TI An open-label study to evaluate the safety, tolerability and efficacy of rivastigmine in patients with mild to moderate probable Alzheimer's disease in the community setting
AU Bilikiewicz, Adam; Opala, Grzegorz; Podemski, Ryszard; Puzynski, Stanislaw; Lapin, Joanna; Soltys, Krzysztof; Ochudlo, Stanislaw; Barcikowska, Maria; Pfeffer, Anna; Bilinska, Malgorzata; Paradowski, Boguslaw; Parnowski, Tadeusz; Gabryelewicz, Tomasz
CS 2nd Clinic of Mental Diseases, Medical University of Gdansk, Gdansk, 80-282, Pol.
SO Medical Science Monitor (2002), 8(2), PI9-PI15
CODEN: MSMOFR; ISSN: 1234-1010
PB Medical Science International Publishing Co., Ltd.
DT Journal
LA English
RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:597824 CAPLUS
DN 135:175406
TI Methods and compositions for treatment of Alzheimer's disease by enhancing plasmin or plasmin-like activity
IN Dotti, Carlos G.; Ledesma, Maria D.
PA The European Molecular Biology Laboratory, Germany
SO PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001058476	A2	20010816	WO 2001-EP1517	20010212
	WO 2001058476	A3	20020328		
	W: AU, CA, JP, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
PRAI	US 2000-502448	A	20000211		
	US 2000-714928	A	20001117		

L33 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:83218 CAPLUS
DN 135:102424
TI Regulation of APP synthesis and secretion by neuroimmunophilin ligands and cyclooxygenase inhibitors
AU Lee, Robert K. K.; Wurtman, Richard J.
CS Division of Health Sciences and Technology, Harvard University-Massachusetts Institute of Technology, Cambridge, MA, 02139, USA
SO Annals of the New York Academy of Sciences (2000), 920(Molecular Basis of Dementia), 261-268
CODEN: ANYAA9; ISSN: 0077-8923
PB New York Academy of Sciences
DT Journal
LA English
RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:445101 CAPLUS
DN 133:68575
TI Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists: the Cache County Study
AU Anthony, J. C.; Breitner, J. C. S.; Zandi, P. P.; Meyer, M. R.; Jurasova, I.; Norton, M. C.; Stone, S. V.; Burke, James; Calvert, Tony; Gau, Barbara; Helms, Michael; Khachaturian, Ara; Leslie, Carole; Newman, Tiffany; Plassman, Brenda; Steffens, David C.; Steinberg, Martin; Tschanz, JoAnn T.; Welsh-Bohmer, Kathleen A.; West, Nancy; Wyse, Bonita
CS Cache County Memory Study Group, Department of Mental Hygiene, School of Hygiene and Public Health, Johns Hopkins University, Baltimore, MD, USA
SO Neurology (2000), 54(11), 2066-2071
CODEN: NEURAI; ISSN: 0028-3878
PB Lippincott Williams & Wilkins
DT Journal
LA English
RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1999:438032 CAPLUS
DN 131:193920
TI Toxicity of human THP-1 monocytic cells towards neuron-like cells is reduced by non-steroidal anti-inflammatory drugs (NSAIDs)
AU Klegeris, A.; Walker, D. G.; McGeer, P. L.
CS Kinsmen Laboratory of Neurological Research, University of British Columbia, Vancouver, BC, V6T 1Z3, Can.
SO Neuropharmacology (1999), 38(7), 1017-1025
CODEN: NEPHBW; ISSN: 0028-3908
PB Elsevier Science Ltd.
DT Journal
LA English
RE.CNT 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1996:97266 CAPLUS
DN 124:135727
TI Method and use of agents to inhibit protein polymerization, methods of identifying these agents, and use of the agents as antithrombotics and for the treatment of Alzheimer's disease
IN Bjornsson, Thorir D.
PA Thomas Jefferson University, USA
SO PCT Int. Appl., 18 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9531192	A1	19951123	WO 1995-US6383	19950515
	W: CA, JP, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
PRAI	US 1994-243114		19940516		

OS MARPAT 124:135727

L33 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1989:206625 CAPLUS
DN 110:206625
TI Hormone treatment for central nervous system diseases such as **Alzheimers** disease and Parkinsons disease
IN Aroonsakul, Chaovanee
PA USA
SO U.S., 4 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4791099	A	19881213	US 1984-666254	19841029
	EP 324037	A1	19890719	EP 1988-100233	19880111
	EP 324037	B1	19970903		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	AT 157546	E	19970915	AT 1988-100233	19880111
	ES 2109914	T3	19980201	ES 1988-100233	19880111
	US 4898856	A	19900206	US 1988-156242	19880216
	JP 01216940	A2	19890830	JP 1988-39323	19880222
	JP 09216837	A2	19970819	JP 1997-38275	19880222
	US 4897389	A	19900130	US 1989-293134	19890103
	US 4902680	A	19900220	US 1989-293017	19890103
	US 4898857	A	19900206	US 1989-293132	19890203
PRAI	US 1984-666254		19841029		
	US 1986-852645		19860416		
	EP 1988-100233		19880111		
	US 1988-156242		19880216		
	JP 1988-39323		19880222		

=> e nsaids

E1	1	NSAID5/BI
E2	1	NSAIDH/BI
E3	3367	--> NSAIDS/BI
E4	3	NSAIDSS/BI
E5	1	NSAIFA/BI

```
E6            1     NSAIFD/BI
E7            2     NSAIIDS/BI
E8            1     NSAIO/BI
E9            6     NSAIS/BI
E10           1     NSAISS/BI
E11           2     NSAIW/BI
E12           1     NSAJDS/BI

=> s e3
L34       3367 NSAIDS/BI

=> s l34 and l17
L35         36 L34 AND L17

=> d l35 20-36

L35  ANSWER 20 OF 36  CAPLUS  COPYRIGHT 2003 ACS on STN
AN   2000:368364  CAPLUS
DN   133:12744
TI   Phospholipid derivatives of nonsteroidal antiinflammatory drugs
IN   Kozak, Alexander; Shapiro, Israel
PA   D-Pharm Ltd., Israel
SO   PCT Int. Appl., 76 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.        KIND  DATE          APPLICATION NO.  DATE
     ---------------   ----  --------      ---------------  --------
PI   WO 2000031083      A1   20000602      WO 1999-IL623    19991118
         W:  AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
             CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
             IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
             MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
             SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
             DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
             CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     CA 2346869        AA   20000602      CA 1999-2346869  19991118
     EP 1131326        A1   20010912      EP 1999-956297   19991118
     EP 1131326        B1   20030507
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO
     JP 2002530410     T2   20020917      JP 2000-583911   19991118
     NZ 510938         A    20021126      NZ 1999-510938   19991118
     AT 239739         E    20030515      AT 1999-956297   19991118
PRAI IL 1998-127143    A    19981119
     WO 1999-IL623     W    19991118
OS   MARPAT 133:12744
RE.CNT  2     THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35  ANSWER 21 OF 36  CAPLUS  COPYRIGHT 2003 ACS on STN
AN   2000:176859  CAPLUS
DN   132:303172
TI   Glutamate and kynurenate in the rat central nervous system following
     treatments with tail ischemia or diclofenac
AU   Edwards, Stephen R.; Mather, Laurence E.; Lin, Yiguang; Power, Ian;
     Cousins, Michael J.
CS   Department of Anaesthesia and Pain Management, University of Sydney at
     Royal North Shore Hospital, St Leonards, 2065, Australia
```

SO Journal of Pharmacy and Pharmacology (2000), 52(1), 59-66
CODEN: JPPMAB; ISSN: 0022-3573
PB Royal Pharmaceutical Society of Great Britain
DT Journal
LA English
RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 22 OF 36 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1999:399998 CAPLUS
DN 131:164908
TI Antirheumatic agents and leukocyte recruitment: new light on the mechanism of action of oxaceprol
AU Parnham, Michael J.
CS Pharmacological Institute for the Life Sciences, J. W. Goethe University, Frankfurt am Main, D-60439, Germany
SO Biochemical Pharmacology (1999), 58(2), 209-215
CODEN: BCPCA6; ISSN: 0006-2952
PB Elsevier Science Inc.
DT Journal; General Review
LA English
RE.CNT 58 THERE ARE 58 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 23 OF 36 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1999:396786 CAPLUS
DN 131:208462
TI Renal side effects of **NSAIDs**: role of COX-1 and COX-2
AU Frolich, J. C.; Stichtenoth, D. O.
CS Institute of Clinical Pharmacology, Hannover Medical School, Hannover, 30623, Germany
SO Selective COX-2 Inhibitors: Pharmacology, Clinical Effects and Therapeutic Potential, Proceedings of a Conference, Cannes, Fr., Mar. 20-21, 1997 (1998), Meeting Date 1997, 87-98. Editor(s): Vane, John R.; Botting, Jack H. Publisher: Kluwer, Dordrecht, Neth.
CODEN: 67UBAO
DT Conference; General Review
LA English
RE.CNT 79 THERE ARE 79 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 24 OF 36 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1999:316752 CAPLUS
DN 131:129302
TI Short-term vitamin E supplementation before marathon running: a placebo-controlled trial
AU Buchman, Alan L.; Killip, Donna; Ou, Ching-Nan; Rognerud, Cheryl L.; Pownall, Henry; Dennis, Kenneth; Dunn, J. Kay
CS Division of Gastroenterology, University of Texas Houston Health Science Center, Houston, TX, 77030, USA
SO Nutrition (New York) (1999), 15(4), 278-283
CODEN: NUTRER; ISSN: 0899-9007
PB Elsevier Science Inc.
DT Journal
LA English
RE.CNT 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 25 OF 36 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:744944 CAPLUS
DN 130:10625
TI COX-2-selective carprofen and related compounds for treating pain and

inflammation in dogs
IN Lundy, Kristin Marie; Ricketts, Anthony Paul
PA Pfizer Inc., USA
SO PCT Int. Appl., 83 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9850033	A1	19981112	WO 1998-IB662	19980501
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9869321	A1	19981127	AU 1998-69321	19980501
	EP 988034	A1	20000329	EP 1998-915041	19980501
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
	BR 9808720	A	20000711	BR 1998-8720	19980501
	JP 2000513020	T2	20001003	JP 1998-547869	19980501
	NZ 500183	A	20020426	NZ 1998-500183	19980501
	ZA 9803722	A	19991104	ZA 1998-3722	19980504
	MX 9910148	A	20000228	MX 1999-10148	19991104
PRAI	US 1997-45635P	P	19970505		
	WO 1998-IB662	W	19980501		

OS MARPAT 130:10625
RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 26 OF 36 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:700744 CAPLUS
DN 130:60774
TI Nonsteroidal anti-inflammatory drugs increase tumor necrosis factor production in the periphery but not in the central nervous system in mice and rats
AU Sacco, Silvano; Agnello, Davide; Sottocorno, Marcello; Lozza, Gianluca; Monopoli, Angela; Villa, Pia; Ghezzi, Pietro
CS Laboratory of Neuroimmunology, "Mario Negri" Institute for Pharmacological Research, Milan, 20157, Italy
SO Journal of Neurochemistry (1998), 71(5), 2063-2070
CODEN: JONRA9; ISSN: 0022-3042
PB Lippincott-Raven Publishers
DT Journal
LA English
RE.CNT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 27 OF 36 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:92958 CAPLUS
DN 128:212888
TI The effect of prednisolone and non-steroidal anti-inflammatory agents on the normal and noise-damaged guinea pig inner ear
AU Lamm, Kerstin; Arnold, Wolfgang
CS Department of Otolaryngology, Head and Neck Surgery, Klinikum rechts der Isar, Technical University of Munich, Munich, D-81675, Germany
SO Hearing Research (1998), 115(1-2), 149-161
CODEN: HERED3; ISSN: 0378-5955

PB Elsevier Science B.V.
DT Journal
LA English
RE.CNT 61 THERE ARE 61 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 28 OF 36 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1997:255183 CAPLUS
DN 126:288084
TI Protective effect of taurine on indomethacin-induced gastric mucosal injury
AU Son, Miwon; Kim, Hee Kee; Kim, Won Bae; Yang, Junnick; Kim, Byong Kak
CS Research Laboratories of Dong-A Pharmaceutical Co., Ltd., Kyungki, 449-900, S. Korea
SO Advances in Experimental Medicine and Biology (1996), 403(Taurine 2), 147-155
CODEN: AEMBAP; ISSN: 0065-2598
PB Plenum
DT Journal
LA English

L35 ANSWER 29 OF 36 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1996:659613 CAPLUS
DN 125:292562
TI Superior mesenteric artery blood flow and indomethacin-induced intestinal injury and inflammation
AU Battarbee, Harold D.; Grisham, Matthew B.; Johnson, Glenda G.; Zavecz, James H.
CS Dep. Physiology Pharmacology, Louisiana State Univ. Med. Center, Shreveport, LA, 71130-3932, USA
SO American Journal of Physiology (1996), 271(4, Pt. 1), G605-G612
CODEN: AJPHAP; ISSN: 0002-9513
PB American Physiological Society
DT Journal
LA English

L35 ANSWER 30 OF 36 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1996:629649 CAPLUS
DN 125:265970
TI Omeprazole attenuates oxygen-derived free radical production from human neutrophils
AU Suzuki, Masayuki; Mori, Mikiji; Miura, Soichiro; Suematsu, Makoto; Fukumura, Dai; Kimura, Hiroyuki; Ishii, Hiromasa
CS School of Medicine, Keio Univ., Tokyo, Japan
SO Free Radical Biology & Medicine (1996), 21(5), 727-731
CODEN: FRBMEH; ISSN: 0891-5849
PB Elsevier
DT Journal
LA English

L35 ANSWER 31 OF 36 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1996:302882 CAPLUS
DN 125:794
TI Protective effect of taurine on indomethacin-induced gastric mucosal injury
AU Son, Miwon; Kim, Hee Kee; Kim, Won Bae; Yang, Junnick; Kim, Byong Kak
CS Res. Lab. Dong-A Pharm. Co. Ltd., Kyungki-DO, 449-900, S. Korea
SO Archives of Pharmacal Research (1996), 19(2), 85-90
CODEN: APHRDQ; ISSN: 0253-6269
PB Pharmaceutical Society of Korea
DT Journal
LA English

L35 ANSWER 32 OF 36 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1995:480859 CAPLUS
DN 122:262793
TI Prostanoid synthesis in the spinal cord enhances excitability of dorsal horn convergent neurons during reperfusion of ischemic receptive fields on the rat's tail
AU Gelgor, L.; Mitchell, D.
CS Department Physiology, University the Witwatersrand Medical School, Johannesburg, 2193, S. Afr.
SO Pain (1995), 60(2), 181-7
CODEN: PAINDB; ISSN: 0304-3959
DT Journal
LA English

L35 ANSWER 33 OF 36 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1994:508239 CAPLUS
DN 121:108239
TI Nitric ester derivatives of nonsteroidal antiinflammatories and process for their preparation
IN Arena, Barbara
PA HCT-Health Care Trading Ltd., Ire.
SO PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9412463	A1	19940609	WO 1993-EP3193	19931115
	W: AU, BR, CA, CZ, FI, HU, JP, KP, KR, NO, NZ, PL, RO, RU, SK, UA, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2150229	AA	19940609	CA 1993-2150229	19931115
	AU 9456241	A1	19940622	AU 1994-56241	19931115
	AU 676527	B2	19970313		
	EP 670825	A1	19950913	EP 1994-901797	19931115
	EP 670825	B1	19970423		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, NL, PT, SE				
	JP 08504191	T2	19960507	JP 1993-512701	19931115
	HU 73773	A2	19960930	HU 1995-1531	19931115
	HU 215437	B	20001228		
	AT 152092	E	19970515	AT 1994-901797	19931115
	ES 2103563	T3	19970916	ES 1994-901797	19931115
	RU 2127723	C1	19990320	RU 1995-114376	19931115
	BR 9307530	A	19990525	BR 1993-7530	19931115
	JP 3231043	B2	20011119	JP 1994-512701	19931115
	US 5621000	A	19970415	US 1995-446624	19950526
PRAI	IT 1992-MI2699	A	19921126		
	WO 1993-EP3193	W	19931115		

OS MARPAT 121:108239

L35 ANSWER 34 OF 36 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1992:165941 CAPLUS
DN 116:165941
TI Effects of systemic nonsteroidal antiinflammatory drugs on nociception during tail **ischemia** and on reperfusion hyperalgesia in rats
AU Gelgor, Linda; Butkow, Neil; Mitchell, Duncan
CS Med. Sch., Univ. Witwatersrand, Johannesburg, 2193, S. Afr.
SO British Journal of Pharmacology (1992), 105(2), 412-16
CODEN: BJPCBM; ISSN: 0007-1188
DT Journal
LA English

L35 ANSWER 35 OF 36 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1992:165595 CAPLUS
DN 116:165595
TI Progress of active oxygen research in inflammation
AU Oyanagui, Yoshihiko
CS Prod. Dev. Res. Lab., Fujisawa Pharm. Co., Japan
SO Ensho (1992), 12(1), 9-18
CODEN: ENSHEE; ISSN: 0389-4290
DT Journal; General Review
LA Japanese

L35 ANSWER 36 OF 36 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1987:114179 CAPLUS
DN 106:114179
TI Inhibition of prostaglandin synthesis in rat kidney perfused with and without erythrocytes: implication for analgesic nephropathy
AU Brezis, Mayer; Rosen, Seymour; Stoff, Jeffrey S.; Spokes, Katherine; Silva, Patricio; Epstein, Franklin H.
CS Dep. Med., Hadassah Univ. Hosp., Jerusalem, Israel
SO Mineral and Electrolyte Metabolism (1987), Volume Date 1986, 12(5-6), 326-32
CODEN: MELMDI; ISSN: 0378-0392
DT Journal
LA English

=> d l35 34 all

L35 ANSWER 34 OF 36 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1992:165941 CAPLUS
DN 116:165941
TI Effects of systemic nonsteroidal antiinflammatory drugs on nociception during tail **ischemia** and on reperfusion hyperalgesia in rats
AU Gelgor, Linda; Butkow, Neil; Mitchell, Duncan
CS Med. Sch., Univ. Witwatersrand, Johannesburg, 2193, S. Afr.
SO British Journal of Pharmacology (1992), 105(2), 412-16
CODEN: BJPCBM; ISSN: 0007-1188
DT Journal
LA English
CC 1-7 (Pharmacology)
AB The authors have investigated the effects of five non-steroidal antiinflammatory drugs (**NSAIDs**) on nociception during **ischemia** and on reperfusion hyperalgesia in rats. Tail **ischemia** was induced in conscious rats by applying a tourniquet at the base of the tail until the rats exhibited co-ordinated escape behavior when the tourniquet was released. Hyperalgesia was assessed by measuring the tail flick latency following tail immersion in water at 49.degree., before applying and immediately after releasing the tourniquet, and then at 30 min intervals for 2 h. I.p. injection of **NSAIDs** prior to applying the tourniquet had no effect on the coordinated escape behavior during **ischemia**, nor on tail flick latency in the absence of prior **ischemia**. However all the drugs attenuated reperfusion hyperalgesia in a log dose-dependent manner. Doses required to abolish hyperalgesia, were indomethacin 5 mg/kg, diclofenac sodium 42 mg/kg, ibuprofen 54 mg/kg, dipyrone 168 mg/kg and paracetamol 170 mg/kg. The authors conclude that the mechanisms underlying nociception during **ischemia** are not the same as those underlying reperfusion hyperalgesia. Moreover this procedure provides a rapid and more humane method for measuring the antinociceptive potency of **NSAIDs**.
ST **ischemia** reperfusion hyperalgesia nonsteroidal antiinflammatory analgesia

IT **Ischemia**
(nociception during, nonsteroidal antiinflammatory drugs effect on)
IT Analgesics
(nonsteroidal antiinflammatory drugs, effects on nociception during **ischemia** and reperfusion hyperalgesia)
IT Inflammation inhibitors
(nonsteroidal, nociception during **ischemia** and reperfusion hyperalgesia inhibition by)
IT Pain
(hyperalgesia, from reperfusion after **ischemia**, nonsteroidal antiinflammatory drugs effect on)
IT 53-86-1, Indomethacin 68-89-3, Dipyrone 103-90-2, Paracetamol 15307-86-5, Diclofenac 15687-27-1, Ibuprofen
RL: BIOL (Biological study)
(nociception during **ischemia** and reperfusion hyperalgesia inhibition by)

=> d l35 35 all

L35 ANSWER 35 OF 36 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1992:165595 CAPLUS
DN 116:165595
TI Progress of active oxygen research in inflammation
AU Oyanagui, Yoshihiko
CS Prod. Dev. Res. Lab., Fujisawa Pharm. Co., Japan
SO Ensho (1992), 12(1), 9-18
CODEN: ENSHEE; ISSN: 0389-4290
DT Journal; General Review
LA Japanese
CC 1-0 (Pharmacology)
Section cross-reference(s): 14
AB A review with 27 refs. Active oxygens (O2-, H2O2, .cntdot.OH, OCl-, 1O2, LOO.cntdot., LO.cntdot.) are involved in various inflammatory processes. Leukocytes generate O2- and H2O2 to attack the invaded bacteria and xenobiotics, but excess prodn. results in inflammation. Antigen-antibody complex, cytokines etc. also generate active oxygens. Clin. using non-steroidal antiinflammatory drugs (**NSAIDs**, diclofenac sodium, indomethacin etc.) inhibit leukocyte O2- prodn. Immune diseases, **ischemia** and atherosclerosis develop organ inflammation via formation of active oxygens. Vascular tone-regulating EDRF (NO.cntdot.) is decompd. by O2- and proteinases may react to the proteins which were degenerated by active oxygens. Free and modified SODs are under animal and clin. trails as well as antioxidant derivs.
ST review active oxygen inflammation antiinflammatory drug; antioxidant drug inflammation review
IT Inflammation
(active oxygens in pathophysiol. of)
IT Inflammation inhibitors
(as antioxidants)
IT Reactive oxygen species
RL: BIOL (Biological study)
(in inflammation)
IT Antioxidants
(inflammation inhibitors as)

=> d l35 27 all

L35 ANSWER 27 OF 36 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:92958 CAPLUS
DN 128:212888

TI The effect of prednisolone and non-steroidal anti-inflammatory agents on the normal and noise-damaged guinea pig inner ear

AU Lamm, Kerstin; Arnold, Wolfgang
CS Department of Otolaryngology, Head and Neck Surgery, Klinikum rechts der Isar, Technical University of Munich, Munich, D-81675, Germany

SO Hearing Research (1998), 115(1-2), 149-161
CODEN: HERED3; ISSN: 0378-5955
PB Elsevier Science B.V.
DT Journal
LA English
CC 1-7 (Pharmacology)
Section cross-reference(s): 2

AB The effect of anti-inflammatory agents, such as the synthetic glucocorticoid prednisolone, diclofenac sodium, and histamine H1-receptor antagonist, was studied in unexposed and noise-exposed (broad-band noise, bandwidth 1-12 kHz, 106 dB SPL, 30 min) guinea pigs. The results were compared with the results obtained from no treatment and with isotonic saline (placebo) therapy. The cochlear blood flow (CoBF) and the partial oxygen pressure in the perilymph (PL-pO2) were continuously and simultaneously recorded over a period of 210 min. In addn., cochlear microphonics (CMs), compd. action potentials of the auditory nerve (CAPs), and auditory brain stem responses (ABRs) were registered. Noise-induced hearing loss paralleled a decrease of PL-pO2. Both were found to occur before evidence of reduced CoBF. PL-pO2 and CoBF progressively declined post-exposure, while CMs, CAPs, and ABRs did not further deteriorate nor showed signs of recovery up to 180 min after cessation of noise. Treatment started 60 min post-exposure, or after 90 min without manipulation and was then further studied for 120 min. In the unexposed animals, diclofenac sodium and prednisolone induced a significant decline of PL-pO2, while CoBF, CMs, CAPs, and ABRs revealed no change. Isotonic saline did not influence the measured parameters. After infusion of the histamine H1-receptor antagonist, a significant decrease of CoBF together with blood pressure and CMs was obsd., while PL-pO2, CAPs, and ABRs showed no change. In the noise-exposed animals, diclofenac sodium induced partial restoration of CM and CAP amplitudes and full restoration of ABRs. Following a high dose of prednisolone (25 mg), partial restoration of CMs and full restoration of CAPs and ABRs were registered. This effect was significantly less pronounced following a low dose of prednisolone (2.5 mg). Restoration of CMs, CAPs, and ABRs was immediate (i.e. 50 min after infusion) and remained stable for another 60 min until the end of the recording period. The histamine H1-receptor antagonist and isotonic saline did not influence CMs, CAPs, and ABRs. None of the applied drugs resulted in relief of progressive noise-induced cochlear hypoxia and post-traumatic **ischemia**. These findings indicate direct cellular effects of prednisolone and diclofenac sodium in the cochlea taking into account no blood flow and oxygenation. The possible mechanisms involved are discussed.

ST glucocorticoid NSAID hearing loss noise

IT Antihistamines
(H1; effect of glucocorticoid and **NSAIDs** on normal and noise-damaged guinea pig inner ear)

IT Nerve
(auditory; effect of glucocorticoid and **NSAIDs** on normal and noise-damaged guinea pig inner ear)

IT Ear
(cochlea, hypoxia and **ischemia**; effect of glucocorticoid and **NSAIDs** on normal and noise-damaged guinea pig inner ear)

IT Hypoxia, animal
Ischemia
(cochlear; effect of glucocorticoid and **NSAIDs** on normal and noise-damaged guinea pig inner ear)

IT Ear

(disease, noise-induced; effect of glucocorticoid and **NSAIDs** on normal and noise-damaged guinea pig inner ear)
IT Acoustic noise
(effect of glucocorticoid and **NSAIDs** on normal and noise-damaged guinea pig inner ear)
IT Glucocorticoids
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(effect of glucocorticoid and **NSAIDs** on normal and noise-damaged guinea pig inner ear)
IT Anti-inflammatory agents
(nonsteroidal; effect of glucocorticoid and **NSAIDs** on normal and noise-damaged guinea pig inner ear)
IT Brain
(stem, auditory system; effect of glucocorticoid and **NSAIDs** on normal and noise-damaged guinea pig inner ear)
IT 3614-69-5, Fenistil
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(effect of glucocorticoid and **NSAIDs** on normal and noise-damaged guinea pig inner ear)
IT 50-24-8, Prednisolone 15307-86-5, Diclofenac
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(effect of glucocorticoid and **NSAIDs** on normal and noise-damaged guinea pig inner ear)
RE.CNT 61 THERE ARE 61 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Axelsson, A; Hear Res 1987, V31, P183 MEDLINE
(2) Axelsson, A; New Perspectives on Noise-induced Hearing Loss 1982, P49
(3) Barnes, P; Trends Pharmacol Ssci 1993, V14, P436 CAPLUS
(4) Baulieu, E; Endocrinology 1989, P16
(5) Borg, E; Scand Audiol Suppl 1995, V40, P1 MEDLINE
(6) Brooks, P; New Engl J Med 1991, V324, P1716 MEDLINE
(7) Brown, J; Am J Physiol 1994, V266, PH458 MEDLINE
(8) Campbell, W; Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th edn 1990, P600
(9) Dengerink, H; Acta Otolaryngol (Stockh) 1985, V100, P19 MEDLINE
(10) Erichsen, S; Acta Otolaryngol (Stockh) 1996, V116, P721 MEDLINE
(11) Erichsen, S; Hear Res 1996, V100, P143 CAPLUS
(12) Furuta, H; Hear Res 1994, V78, P175 CAPLUS
(13) Garrison, J; Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th edn 1990, P575
(14) Hawkins, J; Ann Otol Rhinol Laryngol 1971, V80, P903
(15) Hawkins, J; Arch Otorhinolaryngol 1976, V212, P241
(16) Hawkins, J; Laryngoscope 1972, V82, P1091
(17) Haynes, R; Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th edn 1990, P1431
(18) Insel, P; Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th edn 1990, P638
(19) Kanzaki, J; Acta Otolaryngol Suppl 1983, V393, P77 MEDLINE
(20) Kanzaki, J; Arch Otorhinolaryngol 1981, V230, P5 MEDLINE
(21) Kanzaki, J; Oto-Rhino-Laryngology 1993, V55, P24 MEDLINE
(22) Kunihiro, T; Oto-Rhino-Laryngology 1990, V52, P86 MEDLINE
(23) Lamm, H; Otorhinolaryngol Nova 1995, V5, P161
(24) Lamm, K; Adv Oto-Rhino Laryngol, in press 1997, V54
(25) Lamm, K; Adv Oto-Rhino-Laryngol, in press 1997, V54
(26) Lamm, K; Audiol Neurootol 1996, V1, P148 MEDLINE
(27) Lamm, K; Otorhinolaryngol Nova 1993, V3, P285
(28) Lamm, K; Otorhinolaryngol Nova 1995, V5, P153

(29) Lamm, K; Wien Med Wschr 1992, V20/21, P455
(30) Lipscomb, D; Acta Otolaryngol (Stockh) 1977, V84, P44 MEDLINE
(31) Lipscomb, D; Laryngoscope 1973, V83, P259 MEDLINE
(32) Mattox, D; Ann Otol 1977, V86, P463 MEDLINE
(33) McMahon, M; Diabetes Metab Rev 1988, V4, P17 CAPLUS
(34) Michel, O; Otorhinolaryngol Nova 1993, V3, P292
(35) Miller, J; Am J Otolaryngol 1988, V9, P302 MEDLINE
(36) Miller, J; Laser-Doppler Blood Flowmetry 1990, P319 CAPLUS
(37) Miller, J; Otolaryngol Head Neck Surg 1995, V112, P101 MEDLINE
(38) Moskowitz, D; Laryngoscope 1984, V94, P664 MEDLINE
(39) Munck, A; Am Rev Respir Dis 1990, V141, PS2 CAPLUS
(40) Pitovski, D; Acta Otolarygol (Stockh) 1996, V116, P737 MEDLINE
(41) Pitovski, D; Brain Res 1993, V601, P273 CAPLUS
(42) Pitovski, D; Hear Res 1993, V69, P10 CAPLUS
(43) Pitovski, D; Hear Res 1994, V77, P216 CAPLUS
(44) Quirk, W; Hear Res 1991, V52, P217 MEDLINE
(45) Quirk, W; Hear Res 1992, V63, P102 MEDLINE
(46) Rarey, K; Hear Res 1989, V41, P217 CAPLUS
(47) Rarey, K; Hear Res 1993, V64, P205 CAPLUS
(48) Rarey, K; Hear Res 1995, V82, P135 CAPLUS
(49) Saunders, J; J Acoust Soc Am 1991, V90, P136 MEDLINE
(50) Ten Cate, W; Am J Physiol 1994, V266, PE269 CAPLUS
(51) Ten Cate, W; Hear Res 1992, V60, P199 CAPLUS
(52) Ten Cate, W; Hear Res 1994, V75, P151 MEDLINE
(53) Ten Cate, W; Laryngoscope 1993, V103, P865 CAPLUS
(54) Todd, P; Drugs 1988, V35, P244 CAPLUS
(55) Veldman, J; Acta Otolaryngol (Stockh) 1993, V113, P303 MEDLINE
(56) Vertes, D; Acta Otolaryngol (Stockh) 1979, V88, P47 MEDLINE
(57) Vertes, D; Arch Otorhinolaryngol 1981, V230, P285 MEDLINE
(58) Vischer, M; Otorhinolaryngol Nova 1991, V1, P75
(59) Wilson, W; Arch Otolaryngol 1980, V106, P772 MEDLINE
(60) Zuo, J; Acta Otolaryngol (Stockh) 1995, V115, P497 MEDLINE
(61) Zuo, J; Hear Res 1995, V87, P220 CAPLUS

=> d l35 26 all

L35 ANSWER 26 OF 36 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:700744 CAPLUS
DN 130:60774
TI Nonsteroidal anti-inflammatory drugs increase tumor necrosis factor production in the periphery but not in the central nervous system in mice and rats
AU Sacco, Silvano; Agnello, Davide; Sottocorno, Marcello; Lozza, Gianluca; Monopoli, Angela; Villa, Pia; Ghezzi, Pietro
CS Laboratory of Neuroimmunology, "Mario Negri" Institute for Pharmacological Research, Milan, 20157, Italy
SO Journal of Neurochemistry (1998), 71(5), 2063-2070
CODEN: JONRA9; ISSN: 0022-3042
PB Lippincott-Raven Publishers
DT Journal
LA English
CC 1-7 (Pharmacology)
AB Nonsteroidal anti-inflammatory drugs (**NSAIDs**), which inhibit prostaglandin (PG) synthesis, augment prodn. of tumor necrosis factor (TNF) in most exptl. models. We investigated the effect of two **NSAIDs**, indomethacin and ibuprofen, on the prodn. of TNF in the CNS induced by intracerebroventricular injection of lipopolysaccharide (LPS). Indomethacin and ibuprofen, administered i.p., augmented (three- to ninefold) the levels of TNF in serum and peripheral organs of mice injected i.p. with LPS and in rats with adjuvant arthritis (up to a sevenfold increase). However, **NSAIDs** (i.p. or

intracerebroventricularly) did not increase brain TNF prodn. induced by i.v. LPS. In fact, indomethacin decreased (1.4-1.8-fold) TNF levels in the spinal cord of rats with exptl. autoimmune encephalomyelitis and in the cortex of rats with focal cerebral **ischemia**. Systemic administration of iloprost inhibited serum TNF levels after i.p. LPS, whereas intracerebroventricular injection of iloprost or PGE2 did not inhibit brain TNF induced by intracerebroventricular LPS. Both peripheral and central TNF productions were inhibited by cAMP level-elevating agents or dexamethasone. Thus, a PG-driven neg. feedback controls TNF prodn. in the periphery but not in the CNS.

ST antiinflammatory **NSAIDs** TNF peripheral central nervous system

IT Anti-inflammatory agents
Brain
(**NSAIDs** increase TNF prodn. in peripheral but not central nervous system in mice and rats)

IT Tumor necrosis factors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(**NSAIDs** increase TNF prodn. in peripheral but not central nervous system in mice and rats)

IT Encephalomyelitis
(autoimmune; **NSAIDs** increase TNF prodn. in peripheral but not central nervous system in mice and rats)

IT Nervous system
(central; **NSAIDs** increase TNF prodn. in peripheral but not central nervous system in mice and rats)

IT Brain, disease
(**ischemia**; **NSAIDs** increase TNF prodn. in peripheral but not central nervous system in mice and rats)

IT Anti-inflammatory agents
(nonsteroidal; **NSAIDs** increase TNF prodn. in peripheral but not central nervous system in mice and rats)

IT Nervous system
(peripheral; **NSAIDs** increase TNF prodn. in peripheral but not central nervous system in mice and rats)

IT 53-86-1, Indomethacin 15687-27-1, Ibuprofen
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**NSAIDs** increase TNF prodn. in peripheral but not central nervous system in mice and rats)

IT 60-92-4, CAMP
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(**NSAIDs** increase TNF prodn. in peripheral but not central nervous system in mice and rats)

RE.CNT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Aggarwal, B; J Biol Chem 1985, V260, P2345 CAPLUS
(2) Asanuma, M; Neurosci Lett 1997, V225, P109 CAPLUS
(3) Bagby, G; J Appl Physiol 1994, V77, P1542 CAPLUS
(4) Benigni, F; Mol Med 1995, V1, P568 CAPLUS
(5) Breder, C; J Comp Neurol 1993, V337, P543 CAPLUS
(6) Breitner, J; Annu Rev Med 1996, V47, P401 CAPLUS
(7) Brosnan, C; Neurology 1995, V45(Suppl 6), PS16
(8) Bruce, A; Nature Med 1996, V2, P788 CAPLUS
(9) Di Santo, E; Cytokine 1997, V9, P300 CAPLUS
(10) Di Santo, E; Eur J Pharmacol 1997, V336, P197 CAPLUS
(11) Di Santo, E; Neuroimmunomodulation 1995, V2, P149 CAPLUS
(12) Dickson, D; Glia 1993, V7, P75 MEDLINE
(13) Dinarello, C; Am J Med 1982, V72, P799 CAPLUS
(14) Dinarello, C; Rev Infect Dis 1988, V10, P168 CAPLUS
(15) Faggioni, R; Infect Immun 1995, V63, P1473 CAPLUS

(16) Fattori, E; J Exp Med 1994, V180, P1243 CAPLUS
(17) Gahring, L; Neuroimmunomodulation 1996, V3, P289 CAPLUS
(18) Grundmann, H; J Infect Dis 1992, V165, P501 CAPLUS
(19) Haley, T; Br J Pharmacol 1957, V12, P12 CAPLUS
(20) Honda, A; J Biol Chem 1993, V268, P7759 CAPLUS
(21) Irani, D; J Immunol 1997, V158, P2318 CAPLUS
(22) Knudsen, P; J Immunol 1986, V137, P3189 CAPLUS
(23) Lipton, J; Peptides 1991, V12, P795 CAPLUS
(24) Liu, T; Stroke 1994, V25, P1481 CAPLUS
(25) Martich, G; J Exp Med 1991, V173, P1021 CAPLUS
(26) Meistrell, M; Shock 1997, V8, P341
(27) Mengozzi, M; Immunology 1994, V82, P207 CAPLUS
(28) Mustafa, M; Am J Dis Child 1990, V144, P883 MEDLINE
(29) Mustafa, M; J Clin Invest 1989, V84, P1253 CAPLUS
(30) Nataf, S; Acta Neurol Scand 1993, V88, P97 CAPLUS
(31) Noel, P; Life Sci 1990, V47, P1023 CAPLUS
(32) Olsson, T; Neurology 1995, V45(Suppl 6), PS11
(33) Reder, A; J Neuroimmunol 1994, V54, P117 CAPLUS
(34) Renz, H; J Immunol 1988, V141, P2388 CAPLUS
(35) Ruddle, N; J Exp Med 1990, V172, P1193 CAPLUS
(36) Saez-Llorens, X; Animicrob Agents Chemother 1990, V34, P837 CAPLUS
(37) Saukkonen, K; J Exp Med 1990, V171, P439 CAPLUS
(38) Schooltink, H; FEBS Lett 1992, V314, P280 CAPLUS
(39) Selmaj, K; Neurology 1995, V45(Suppl 6), PS44
(40) Shigeno, T; Surg Neurol 1985, V24, P47 MEDLINE
(41) Sironi, M; Int J Immunopharmacol 1992, V14, P1045 CAPLUS
(42) Sommer, N; Nature Med 1995, V1, P244 CAPLUS
(43) Spengler, R; Infect Immun 1989, V57, P2837 CAPLUS
(44) Stewart, W; Neurology 1997, V48, P626 MEDLINE
(45) Sugimoto, Y; J Biol Chem 1992, V267, P6463 CAPLUS
(46) Sugimoto, Y; Neuroscience 1994, V62, P919 CAPLUS
(47) van der Poll, T; J Immunol 1995, V155, P5397 CAPLUS
(48) Watabe, A; J Biol Chem 1993, V268, P20175 CAPLUS
(49) Zuckerman, S; Eur J Immunol 1989, V19, P301 CAPLUS

=> d his

(FILE 'HOME' ENTERED AT 15:07:02 ON 15 SEP 2003)

FILE 'REGISTRY' ENTERED AT 15:07:15 ON 15 SEP 2003

		E	ACETOMINOPHEN
		E	ACETOMINOPHEN
		E	ACETOMINOPHEN
		E	NSAID
L1	9	S	E3
		E	ASPIRIN
L2	52	S	E3
		E	INDOMETHACIN
L3	52	S	E3
		E	KETOPROFIN
		E	KETOPROFEN
L4	50	S	E3
		E	TRILISATR
		E	TRILISATE
L5	1	S	E3
L6	1158	S	SALICYLAMIDE
L7	30	S	SODIUM SALICYLATE
L8	6694	S	SALICYLIC ACID
		E	ACETOMINOPHEN
		E	ACETAMINOPHEN
L9	130	S	E3

```
     FILE 'CAPLUS' ENTERED AT 15:20:03 ON 15 SEP 2003
L10        17725 S L2
L11        28561 S CNS
L12           28 S L10 AND L11
                 E TRAUMA
L13        11866 S E3
L14           68 S L13 AND L10
                 E HEAD
L15        94345 S E3
L16           12 S L14 AND L15
                 E ISCHEMA
L17        53069 S E5-E8
L18          356 S L17 AND L10
                 E CEREBRAL
L19        78138 S E3
L20           14 S L18 AND 19
L21           66 S L18 AND L19
L22            2 S L19 AND L12
L23          211 S L10 AND L19
L24           66 S L23 AND L17
L25            0 S L24 NOT L21
L26            2 S L12 AND L17
L27        10826 S L9
L28           46 S L5
L29           28 S L12 AND L10
                 E LUPUS
L30        11819 S E3
L31           53 S L30 AND L10
                 E ALZHEIMERS
L32         1977 S E3
L33            8 S L10 AND L32
                 E NSAIDS
L34         3367 S E3
L35           36 S L34 AND L17

=> s l11 and l12
L36           28 L11 AND L12

=> s l11 and l17
L37          685 L11 AND L17

=> s l37 and l10
L38            2 L37 AND L10

=> d l38 1-2

L38  ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2003 ACS on STN
AN   2002:657907  CAPLUS
DN   137:195592
TI   Chimeric compounds co-inducing cholinergic up-regulation and inflammation
     down-regulation, and use for treatment and/or prevention of central
     nervous system diseases
IN   Amitai, Gabriel; Adani, Rachel; Rabinovitz, Ishai; Sod-Moriah, Gali;
     Meshulam, Haim
PA   Israel Institute for Biological Research, Israel
SO   PCT Int. Appl., 139 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.       KIND  DATE           APPLICATION NO.  DATE
```

```
     ---------------  ----  --------       ---------------  --------
PI   WO 2002065977     A2   20020829       WO 2002-IL122    20020217
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
             TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
             CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     US 2002160988     A1   20021031       US 2001-906952   20010716
PRAI US 2001-269343P   P    20010220
     US 2001-906952    A    20010716
OS   MARPAT 137:195592

L38  ANSWER 2 OF 2  CAPLUS  COPYRIGHT 2003 ACS on STN
AN   2002:488246  CAPLUS
DN   137:57576
TI   Methods and compositions using ion-dependent cotransporter modulators for
     treating conditions of the central and peripheral nervous systems using
     non-synaptic mechanisms
IN   Hochman, Daryl W.
PA   Cytoscan Sciences L.L.C., USA
SO   U.S. Pat. Appl. Publ., 29 pp., Cont.-in-part of U.S. Ser. No. 470,637.
     CODEN: USXXCO
DT   Patent
LA   English
FAN.CNT 2
     PATENT NO.        KIND  DATE           APPLICATION NO.  DATE
     ---------------   ----  --------       ---------------  --------
PI   US 2002082252      A1   20020627       US 2002-56528    20020123
     US 6495601         B1   20021217       US 1999-470637   19991222
PRAI US 1998-113620P    P    19981223
     US 1999-470637     A2   19991222
     US 2001-263830P    P    20010123


=> e inflammation
E1           2     INFLAMMATIN/BI
E2           3     INFLAMMATIO/BI
E3       98265 --> INFLAMMATION/BI
E4           3     INFLAMMATIONAL/BI
E5           1     INFLAMMATIONDAMAGED/BI
E6           1     INFLAMMATIONINHIBITING/BI
E7           1     INFLAMMATIONMETAB/BI
E8        1660     INFLAMMATIONS/BI
E9           2     INFLAMMATIOON/BI
E10          1     INFLAMMATIORN/BI
E11          8     INFLAMMATIVE/BI
E12          1     INFLAMMATO/BI

=> s e3
L39      98265 INFLAMMATION/BI

=> s l39 and l11
L40       1177 L39 AND L11

=> s l40 and l12
L41         10 L40 AND L12
```

=> d l41 1-10

L41 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2003:280985 CAPLUS
DN 139:143565
TI Paracetamol effectively reduces prostaglandin E2 synthesis in brain macrophages by inhibiting enzymatic activity of cyclooxygenase but not phospholipase and prostaglandin E synthase
AU Greco, Anita; Ajmone-Cat, Maria Antonietta; Nicolini, Alessia; Sciulli, Maria Gina; Minghetti, Luisa
CS Laboratory of Pathophysiology, Istituto Superiore di Sanita, Rome, 299-00161, Italy
SO Journal of Neuroscience Research (2003), 71(6), 844-852
CODEN: JNREDK; ISSN: 0360-4012
PB Wiley-Liss, Inc.
DT Journal
LA English
RE.CNT 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:657907 CAPLUS
DN 137:195592
TI Chimeric compounds co-inducing cholinergic up-regulation and **inflammation** down-regulation, and use for treatment and/or prevention of central nervous system diseases
IN Amitai, Gabriel; Adani, Rachel; Rabinovitz, Ishai; Sod-Moriah, Gali; Meshulam, Haim
PA Israel Institute for Biological Research, Israel
SO PCT Int. Appl., 139 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002065977	A2	20020829	WO 2002-IL122	20020217
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2002160988	A1	20021031	US 2001-906952	20010716
PRAI	US 2001-269343P	P	20010220		
	US 2001-906952	A	20010716		

OS MARPAT 137:195592

L41 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1999:576796 CAPLUS
DN 131:204626
TI Compositions comprising valerian extracts, isovaleric acid or derivatives thereof with a NSAID
IN Artman, Linda D.; Balandrin, Manuel F.
PA NPS Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DT Patent

LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9944623	A1	19990910	WO 1999-US4786	19990304
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2321737	AA	19990910	CA 1999-2321737	19990304
	AU 9928945	A1	19990920	AU 1999-28945	19990304
	EP 1059930	A1	20001220	EP 1999-909827	19990304
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2002505296	T2	20020219	JP 2000-534224	19990304
	US 6383527	B1	20020507	US 2001-623384	20010222
PRAI	US 1998-76737P	A2	19980304		
	WO 1999-US4786	W	19990304		

OS MARPAT 131:204626
RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:780621 CAPLUS
DN 130:232124
TI Peripheral administration of novel anti-inflammatories can attenuate the effects of chronic **inflammation** within the **CNS** [central nervous system]
AU Hauss-Wegrzyniak, Beatrice; Willard, Lauren B.; Del Soldato, Piero; Pepeu, Giancarlo; Wenk, Gary L.
CS Memory and Aging, Division of Neural Systems, Arizona Research Laboratories, University of Arizona, Tucson, AZ, 85724, USA
SO Brain Research (1999), 815(1), 36-43
CODEN: BRREAP; ISSN: 0006-8993
PB Elsevier Science B.V.
DT Journal
LA English
RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:43243 CAPLUS
DN 128:149902
TI Modulation of Brewer's yeast-induced peripheral **inflammation** and nociception in rats by centrally administered prostaglandins and their inhibitors
AU Hore, S. K.; Dumka, V. K.; Tandan, S. K.; Tripathi, H. C.; Kumar, Dinesh
CS Division of Pharmacology and Toxicology, Indian Veterinary Research Institute, Izatnagar, 243 122, India
SO Indian Journal of Pharmacology (1997), 29(6), 416-419
CODEN: INJPD2; ISSN: 0253-7613
PB Indian Pharmacological Society
DT Journal
LA English
RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1996:646511 CAPLUS
DN 125:276575
TI Preparation of arginine analogs having nitric oxide synthase inhibitor activity
IN Broquet, Colette; Chabrier, De Lassauniere, Pierre-Etienne
PA Societe De Conseils De Recherches Et D'application, Fr.
SO PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9627593	A1	19960912	WO 1996-FR337	19960304
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN				
	CA 2215476	AA	19960912	CA 1996-2215476	19960304
	AU 9649479	A1	19960923	AU 1996-49479	19960304
	AU 700871	B2	19990114		
	EP 813529	A1	19971229	EP 1996-905907	19960304
	EP 813529	B1	20020911		
	R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE, IE, SI, LT, LV, FI				
	CN 1179774	A	19980422	CN 1996-192885	19960304
	CN 1071328	B	20010919		
	JP 11501043	T2	19990126	JP 1996-526657	19960304
	RU 2168493	C2	20010610	RU 1997-116496	19960304
	AT 223907	E	20020915	AT 1996-905907	19960304
	CZ 290747	B6	20021016	CZ 1997-2687	19960304
	SK 282664	B6	20021106	SK 1997-1121	19960304
	ES 2182964	T3	20030316	ES 1996-905907	19960304
	US 5972940	A	19991026	US 1997-913455	19970910
	HK 1013777	A1	20020705	HK 1998-110921	19980924
PRAI	GB 1995-4350	A	19950304		
	WO 1996-FR337	W	19960304		

OS MARPAT 125:276575

L41 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1996:245721 CAPLUS
DN 125:48415
TI Effect of NM441 and its active form on GABA receptor binding
AU Hori, Seiji; Shimada, Jingoro
CS Div. Clin. Pharmacol. Inst. Med. Sci., St. Marianna Univ. Sch. Med., Kawasaki, 216, Japan
SO Nippon Kagaku Ryoho Gakkai Zasshi (1996), 44(Suppl. 1), 97-101
CODEN: NKRZE5; ISSN: 1340-7007
DT Journal
LA Japanese

L41 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1994:499126 CAPLUS
DN 121:99126
TI Mechanism of quinolone-induced convulsion and anticonvulsant effect of barbiturate for this seizure
AU Kanemitsu, Keiji
CS Dep. Intern. Med. and Lab. Med., St. Marianna Univ. Sch. Med., Kawasaki, 216, Japan
SO Sei Marianna Ika Daigaku Zasshi (1993), 21(6), 1177-85

CODEN: SMIZDS; ISSN: 0387-2289
DT Journal
LA Japanese

L41 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1993:573380 CAPLUS
DN 119:173380
TI Acetylsalicylic acid and related compounds depress nociceptive activity in the thalamus by a central action: indications for the involvement of prostaglandins
AU Jurna, I.
CS Inst. Pharmakol. Toxikol., Univ. Saarlandes, Homburg/Saar, D-6650, Germany
SO Progress in Pharmacology and Clinical Pharmacology (1993), 10(1), 51-68
CODEN: PPCPEP; ISSN: 0934-9545
DT Journal; General Review
LA English

L41 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1969:113689 CAPLUS
DN 70:113689
TI N-Aralkylanthranilic acid derivatives as **CNS** [central nervous system] depressants
AU Sisodia, P.; Rao, G. S. Rama; Sidhu, Gurbachan S.; Sattur, Prolhad B.; Hashim, Riaz
CS Gandhi Med. Coll., Hyderabad, India
SO CNS (Cent. Nerv. Syst.) Drugs, Symp. (1966), 238-48 Publisher: Counc. Sci. and Ind. Res., New Delhi, India.
CODEN: 20REAT
DT Conference
LA English

=> d his

(FILE 'HOME' ENTERED AT 15:07:02 ON 15 SEP 2003)

FILE 'REGISTRY' ENTERED AT 15:07:15 ON 15 SEP 2003
E ACETOMINOPHEN
E ACETOMINOPHEN
E ACETOMINOPHEN
E NSAID
L1 9 S E3
E ASPIRIN
L2 52 S E3
E INDOMETHACIN
L3 52 S E3
E KETOPROFIN
E KETOPROFEN
L4 50 S E3
E TRILISATR
E TRILISATE
L5 1 S E3
L6 1158 S SALICYLAMIDE
L7 30 S SODIUM SALICYLATE
L8 6694 S SALICYLIC ACID
E ACETOMINOPHEN
E ACETAMINOPHEN
L9 130 S E3

FILE 'CAPLUS' ENTERED AT 15:20:03 ON 15 SEP 2003
L10 17725 S L2
L11 28561 S CNS

```
L12          28 S L10 AND L11
                E TRAUMA
L13       11866 S E3
L14          68 S L13 AND L10
                E HEAD
L15       94345 S E3
L16          12 S L14 AND L15
                E ISCHEMA
L17       53069 S E5-E8
L18         356 S L17 AND L10
                E CEREBRAL
L19       78138 S E3
L20          14 S L18 AND 19
L21          66 S L18 AND L19
L22           2 S L19 AND L12
L23         211 S L10 AND L19
L24          66 S L23 AND L17
L25           0 S L24 NOT L21
L26           2 S L12 AND L17
L27       10826 S L9
L28          46 S L5
L29          28 S L12 AND L10
                E LUPUS
L30       11819 S E3
L31          53 S L30 AND L10
                E ALZHEIMERS
L32        1977 S E3
L33           8 S L10 AND L32
                E NSAIDS
L34        3367 S E3
L35          36 S L34 AND L17
L36          28 S L11 AND L12
L37         685 S L11 AND L17
L38           2 S L37 AND L10
                E INFLAMMATION
L39       98265 S E3
L40        1177 S L39 AND L11
L41          10 S L40 AND L12

=> e parkinson
E1            2     PARKINSOGENIC/BI
E2            2     PARKINSOMISM/BI
E3        12980 --> PARKINSON/BI
E4            1     PARKINSONAPOS/BI
E5            1     PARKINSONDISEASE/BI
E6            1     PARKINSONE/BI
E7            4     PARKINSONGENIC/BI
E8            1     PARKINSONHS/BI
E9            2     PARKINSONI/BI
E10          60     PARKINSONIA/BI
E11           1     PARKINSONIAL/BI
E12           1     PARKINSONIAM/BI

=> s e3
L42       12980 PARKINSON/BI

=> s l42 and l10
L43          20 L42 AND L10

=> d l43 5-20

L43  ANSWER 5 OF 20  CAPLUS  COPYRIGHT 2003 ACS on STN
```

AN 2002:449661 CAPLUS
DN 137:33309
TI Preparation of anilinopyrimidines as JNK pathway inhibitors
IN Kois, Adam; MacFarlane, Karen J.; Satoh, Yoshitaka; Bhagwat, Shripad S.; Parnes, Jason S.; Palanki, Moorthy S. S.; Erdman, Paul E.
PA Signal Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 199 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002046170	A2	20020613	WO 2001-US46402	20011205
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002027214	A5	20020618	AU 2002-27214	20011205
PRAI	US 2000-251904P	P	20001206		
	WO 2001-US46402	W	20011205		

OS MARPAT 137:33309

L43 ANSWER 6 OF 20 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:798223 CAPLUS
DN 135:331422
TI Preparation of arylcarbonylaminopyrazolopyridine derivatives as glycogen synthase kinase 3.beta. inhibitors
IN Fukunaga, Kenji; Okabe, Hirotaka; Kohara, Toshiyuki; Fujimura, Masatake; Tanaka, Hiroshi; Takanashi, Shinichi
PA Welfide Corporation, Japan
SO PCT Int. Appl., 99 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001081345	A1	20011101	WO 2001-JP3329	20010418
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRAI	JP 2000-119198	A	20000420		

OS MARPAT 135:331422
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 7 OF 20 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:581674 CAPLUS
DN 135:132476
TI Neuroprotective, antithrombotic, and antiinflammatory uses of activated

protein C (APC)
IN Griffin, John H.; Zlokovic, Berislav Y.
PA The Scripps Research Institute, USA; The University of Southern California
SO PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001056532	A2	20010809	WO 2001-US3758	20010205
	WO 2001056532	A3	20011206		
	WO 2001056532	C2	20030109		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2001038034	A5	20010814	AU 2001-38034	20010205
	US 2002028199	A1	20020307	US 2001-777484	20010205
	EP 1255556	A2	20021113	EP 2001-910427	20010205
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRAI	US 2000-180227P	P	20000204		
	WO 2001-US3758	W	20010205		

L43 ANSWER 8 OF 20 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:464293 CAPLUS
DN 135:41780
TI Methods determining apoE genotype or phenotype for determining the prognosis of a patient with a neurological disease and identification of human subjects for clinical drug trials
IN Sevigny, Pierre; Wiebusch, Heiko; Schappert, Keith
PA Nova Molecular, Inc., Can.
SO U.S., 10 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6251587	B1	20010626	US 1997-991850	19971216
	US 2002086290	A1	20020704	US 2000-548540	20000413
PRAI	US 1997-991850	A1	19971216		

RE.CNT 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 9 OF 20 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:9523 CAPLUS
DN 134:202638
TI Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of **Parkinson**'s disease
AU Teismann, Peter; Ferger, Boris
CS Institute of Pharmacology and Toxicology, Faculty of Pharmacy, University of Marburg, Marburg, Germany
SO Synapse (New York) (2001), 39(2), 167-174
CODEN: SYNAET; ISSN: 0887-4476
PB Wiley-Liss, Inc.

DT Journal
LA English
RE.CNT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 10 OF 20 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:628201 CAPLUS
DN 133:208198
TI Use of protein conformation for the protection and release of chemical compounds
IN Latham, Keith R.
PA Innovative Technologies, LLC, USA
SO PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000052078	A1	20000908	WO 2000-US5693	20000306
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1257592	A1	20021120	EP 2000-916076	20000306
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	US 2002128177	A1	20020912	US 2001-986426	20011108
PRAI	US 1999-123146P	P	19990305		
	US 1999-411238	B2	19991004		
	WO 2000-US5693	W	20000306		

RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 11 OF 20 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:604982 CAPLUS
DN 133:291007
TI Ibuprofen protects dopaminergic neurons against glutamate toxicity in vitro
AU Casper, D.; Yaparpalvi, U.; Rempel, N.; Werner, P.
CS Neurosurgery Lab, Department of Neurological Surgery, Montefiore Medical Center, The Bronx, New York, NY, 10467, USA
SO Neuroscience Letters (2000), 289(3), 201-204
CODEN: NELED5; ISSN: 0304-3940
PB Elsevier Science Ireland Ltd.
DT Journal
LA English
RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 12 OF 20 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1999:659188 CAPLUS
DN 131:281583
TI Compositions containing a combination of a creatine compound and a neuroprotective compound for the treatment of nervous system diseases
IN Kaddurah-Daouk, Rima; Beal, M. Flint
PA Avicena Group, Inc., USA; The General Hospital Corporation

SO PCT Int. Appl., 81 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9951097	A1	19991014	WO 1999-US7340	19990402
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2327095	AA	19991014	CA 1999-2327095	19990402
AU 9933803	A1	19991025	AU 1999-33803	19990402
AU 759467	B2	20030417		
EP 1065931	A1	20010110	EP 1999-915245	19990402
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002510604	T2	20020409	JP 2000-541878	19990402
PRAI US 1998-80459P	P	19980402		
US 1999-283267	A	19990401		
WO 1999-US7340	W	19990402		

OS MARPAT 131:281583
RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 13 OF 20 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:626155 CAPLUS
DN 129:326022
TI Aspirin and salicylate protect against MPTP-induced dopamine depletion in mice
AU Aubin, Nadine; Curet, Olivier; Deffois, Annie; Carter, Chris
CS Central Nervous System Research Department, Synthelabo Recherche, Bagneux, 92225, Fr.
SO Journal of Neurochemistry (1998), 71(4), 1635-1642
CODEN: JONRA9; ISSN: 0022-3042
PB Lippincott-Raven Publishers
DT Journal
LA English
RE.CNT 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:527193 CAPLUS
DN 129:166193
TI Therapeutic treatment and prevention of infections with a bioactive material encapsulated within a biodegradable-biocompatible polymeric matrix
IN Setterstrom, Jean A.; Van Hamont, John E.; Reid, Robert H.; Jacob, Elliot; Jeyanthi, Ramasubbu; Boedeker, Edgar C.; McQueen, Charles E.; Tice, Thomas R.; Roberts, F. Donald; Friden, Phil
PA United States Dept. of the Army, USA; Van Hamont, John E.; et al.
SO PCT Int. Appl., 363 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 15

```
     PATENT NO.          KIND  DATE           APPLICATION NO.  DATE
     ---------------     ----  --------       ---------------  --------
PI   WO 9832427           A1   19980730       WO 1998-US1556   19980127
         W:  AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
             DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ,
             LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL,
             PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US,
             UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI,
             FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM,
             GA, GN, ML, MR, NE, SN, TD, TG
     US 6309669            B1   20011030       US 1997-789734   19970127
     AU 9863175            A1   19980818       AU 1998-63175    19980127
PRAI US 1997-789734        A    19970127
     US 1984-590308        B1   19840316
     US 1992-867301        A2   19920410
     US 1995-446148        A2   19950522
     US 1995-446149        B2   19950522
     US 1996-590973        B2   19960124
     WO 1998-US1556        W    19980127
RE.CNT  6     THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43  ANSWER 15 OF 20  CAPLUS  COPYRIGHT 2003 ACS on STN
AN   1998:484927  CAPLUS
DN   129:127177
TI   Pharmaceutical preparations of glutathione and methods of administration
IN   Demopoulos, Harry B.; Seligman, Myron L.
PA   Antioxidant Pharmaceuticals Corp., USA
SO   PCT Int. Appl., 52 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 3
     PATENT NO.          KIND  DATE           APPLICATION NO.  DATE
     ---------------     ----  --------       ---------------  --------
PI   WO 9829101           A1   19980709       WO 1997-US23879  19971231
         W:  AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE,
             ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS,
             LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD,
             SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI,
             FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM,
             GA, GN, ML, MR, NE, SN, TD, TG
     AU 9856205            A1   19980731       AU 1998-56205    19971231
     EP 957901             A1   19991124       EP 1997-952640   19971231
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, FI
     JP 2001507696         T2   20010612       JP 1998-530206   19971231
     US 6350467            B1   20020226       US 1999-331947   19990628
     US 2002136763         A1   20020926       US 2002-83327    20020225
PRAI US 1996-34101P        P    19961231
     WO 1997-US23879       W    19971231
     US 1999-331947        A2   19990628
RE.CNT  3     THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43  ANSWER 16 OF 20  CAPLUS  COPYRIGHT 2003 ACS on STN
AN   1998:424361  CAPLUS
DN   129:38404
TI   Method for determining the prognosis of a patient with a neurological
```

disease
IN Sevigny, Pierre; Wiebusch, Heiko; Schappert, Keith
PA Nova Molecular, Inc., Can.
SO PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9827226	A2	19980625	WO 1997-IB1641	19971216
	WO 9827226	A3	19980820		
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 6022683	A	20000208	US 1996-766975	19961216
	AU 9855717	A1	19980715	AU 1998-55717	19971216
	EP 948647	A1	19991013	EP 1997-952129	19971216
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
PRAI	US 1996-766975	A	19961216		
	WO 1997-IB1641	W	19971216		

L43 ANSWER 17 OF 20 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:338114 CAPLUS
DN 129:12755
TI Use of selected nonsteroidal antiinflammatory compounds for the prevention and the treatment of neurodegenerative diseases
IN Grilli, Mariagrazia; Pizzi, Marina; Memo, Maurizio; Spano, Pierfranco
PA Universita' Degli Studi di Brescia - Dipartimento di Scienze Biomediche, Italy; Grilli, Mariagrazia; Pizzi, Marina; Memo, Maurizio; Spano, Pierfranco
SO PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9820864	A2	19980522	WO 1997-EP6323	19971113
	WO 9820864	A3	19981015		
	W: JP, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
PRAI	IT 1996-MI2356		19961113		

OS MARPAT 129:12755

L43 ANSWER 18 OF 20 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1993:175822 CAPLUS
DN 118:175822
TI Cure for diabetes, bronchitis, arthritis, and arteriosclerosis
IN Carantinos, Spyros
PA Australia
SO Pat. Specif. (Aust.), 11 pp.
CODEN: ALXXAP
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	AU 629520	B2	19921008	AU 1988-26677	19881208
	AU 8826677	A1	19890608		
PRAI	AU 1987-5803		19871208		

L43 ANSWER 19 OF 20 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1990:637843 CAPLUS
DN 113:237843
TI Pharmaceutical composition containing ferric ammonium citrate and zinc oxide
IN Carantinos, Spyros
PA Australia
SO Eur. Pat. Appl., 5 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 372676	A1	19900613	EP 1989-305729	19890607
	R: CH, DE, ES, FR, GB, GR, IT, LI, NL, SE				
PRAI	AU 1988-1849		19881208		

L43 ANSWER 20 OF 20 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1989:206625 CAPLUS
DN 110:206625
TI Hormone treatment for central nervous system diseases such as Alzheimers disease and Parkinsons disease
IN Aroonsakul, Chaovanee
PA USA
SO U.S., 4 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4791099	A	19881213	US 1984-666254	19841029
	EP 324037	A1	19890719	EP 1988-100233	19880111
	EP 324037	B1	19970903		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	AT 157546	E	19970915	AT 1988-100233	19880111
	ES 2109914	T3	19980201	ES 1988-100233	19880111
	US 4898856	A	19900206	US 1988-156242	19880216
	JP 01216940	A2	19890830	JP 1988-39323	19880222
	JP 09216837	A2	19970819	JP 1997-38275	19880222
	US 4897389	A	19900130	US 1989-293134	19890103
	US 4902680	A	19900220	US 1989-293017	19890103
	US 4898857	A	19900206	US 1989-293132	19890203
PRAI	US 1984-666254		19841029		
	US 1986-852645		19860416		
	EP 1988-100233		19880111		
	US 1988-156242		19880216		
	JP 1988-39323		19880222		

=> d 143 18 all

L43 ANSWER 18 OF 20 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1993:175822 CAPLUS
DN 118:175822

TI Cure for diabetes, bronchitis, arthritis, and arteriosclerosis
IN Carantinos, Spyros
PA Australia
SO Pat. Specif. (Aust.), 11 pp.
CODEN: ALXXAP
DT Patent
LA English
IC ICM A61K031-19
ICS A61K033-30; A61K031-215
CC 63-6 (Pharmaceuticals)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	AU 629520	B2	19921008	AU 1988-26677	19881208
	AU 8826677	A1	19890608		
PRAI	AU 1987-5803		19871208		

AB A pharmaceutical contg. ferric ammonium citrate in admixt. with ZnO and optionally including aspirin, NaHCO3, and citric acid is effective in treating arthritis, bronchitis, diabetes, arteriosclerosis, broken bones, **Parkinson**'s disease, high blood cholesterol, liver cirrhosis, and enlargement of the prostate gland.
ST ferric ammonium citrate zinc oxide pharmaceutical
IT Antiarteriosclerotics
Anticholesteremics and Hypolipemics
Antidiabetics and Hypoglycemics
(ferric ammonium citrate and zinc oxide as)
IT Cirrhosis
Parkinsonism
(treatment of, ferric ammonium citrate and zinc oxide for)
IT Inflammation inhibitors
(antiarthritics, ferric ammonium citrate and zinc oxide as)
IT Prostate gland
(disease, hyperplasia, treatment of, ferric ammonium citrate and zinc oxide for)
IT Bronchi
(diseases, bronchitis, treatment of, ferric ammonium citrate and zinc oxide for)
IT Bone, disease
(fracture, treatment of, ferric ammonium citrate and zinc oxide for)
IT **50-78-2**, Aspirin 59-43-8, Vitamin B1, biological studies
77-92-9, Citric acid, biological studies 94-20-2, Chlorpropamide
144-55-8, Sodium bicarbonate, biological studies
RL: BIOL (Biological study)
(pharmaceuticals contg. ferric ammonium citrate and zinc oxide and, for treatment of infections and immune diseases)
IT 1314-13-2, Zinc oxide, biological studies
RL: BIOL (Biological study)
(pharmaceuticals contg. ferric ammonium citrate and, for treatment of infections and immune diseases)
IT 1185-57-5, Ferric ammonium citrate
RL: BIOL (Biological study)
(pharmaceuticals contg. zinc oxide and, for treatment of infections and immune diseases)

=> d 143 17 all

L43 ANSWER 17 OF 20 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:338114 CAPLUS
DN 129:12755
TI Use of selected nonsteroidal antiinflammatory compounds for the prevention and the treatment of neurodegenerative diseases

IN Grilli, Mariagrazia; Pizzi, Marina; Memo, Maurizio; Spano, Pierfranco
PA Universita' Degli Studi di Brescia - Dipartimento di Scienze Biomediche, Italy; Grilli, Mariagrazia; Pizzi, Marina; Memo, Maurizio; Spano, Pierfranco
SO PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K031-00
ICS A61K031-60
CC 1-11 (Pharmacology)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9820864	A2	19980522	WO 1997-EP6323	19971113
	WO 9820864	A3	19981015		

W: JP, US
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
PRAI IT 1996-MI2356 19961113
OS MARPAT 129:12755
AB Nonsteroidal antiinflammatory compds. are used for the prevention and the treatment of neurodegenerative diseases, e.g. Alzheimer's disease and **Parkinson**'s disease.
ST neurodegenerative disease nonsteroidal antiinflammatory drug; **Parkinson** disease nonsteroidal antiinflammatory drug; Alzheimer disease nonsteroidal antiinflammatory drug; NSAID neurodegenerative disease
IT Transcription factors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(AP-1 (activator protein 1); nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT Nervous system
(Huntington's chorea; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT Transcription factors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(NF-.kappa.B (nuclear factor .kappa.B); nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT Glutamate receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(NMDA-binding; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT Nervous system
(amyotrophic lateral sclerosis; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT Nervous system
(ataxia telangiectasia; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT Nervous system
(degeneration; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT AIDS (disease)
(dementia assocd. with; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT Mental disorder
(dementia, multi-infarct; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT Brain
(dentate gyrus; nonsteroidal antiinflammatory compds. for prevention

and treatment of neurodegenerative diseases)
IT Mental disorder
(diffuse Lewy body disease; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT Brain
(hippocampus, sector CA1; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT Brain
(hippocampus, sector CA3; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT Infection
(infective neurodegenerative disease; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT Nerve, disease
(injury; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT Metabolism
(metabolic neuropathies; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT Epilepsy
(neurodegenerative processes related to; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT Prion diseases
(neurodegenerative syndromes in; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT Hypoxia, animal
(neuropathy from; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT Brain, disease
(neuropathy, ischemic; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT Nerve, disease
(neuropathy; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT Cytoprotective agents
(neuroprotectants; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT Anti-Alzheimer's agents
Anti-ischemic agents
Antiparkinsonian agents
Multiple sclerosis
(nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT Glutamate receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT Anti-inflammatory agents
(nonsteroidal; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT Nerve, disease
(peripheral neuropathy, ischemic; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT Brain, disease
Spinal cord
Spinal cord
(trauma; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT 50-99-7, D-Glucose, biological studies
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)

(blood; glycemic damage-assocd. neuropathy; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)

IT 53-86-1, Indomethacin 56-86-0, L-Glutamic acid, biological studies 6384-92-5, NMDA
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)

IT 50-33-9, Phenylbutazone, biological studies 50-33-9D, Phenylbutazone, metabolites **50-78-2**, Acetylsalicylic acid **50-78-2D**, Acetylsalicylic acid, derivs. 54-21-7, Sodium salicylate 58-15-1, Aminopyrine 58-15-1D, Aminopyrine, metabolites 60-80-0, Antipyrine 60-80-0D, Antipyrine, metabolites 65-45-2, Salicylamide 65-85-0, Benzoic acid, biological studies 65-85-0D, Benzoic acid, metabolites, biological studies **69-46-5**, Calcium acetylsalicylate 87-28-5, Glycol salicylate 89-57-6, Mesalamine 118-57-0, Acetaminosalol 119-36-8, Methyl salicylate 129-20-4, Oxyphenbutazone 129-20-4D, Oxyphenbutazone, metabolites **134-55-4**, Phenyl acetylsalicylate 147-90-0, Morpholine salicylate 303-38-8, 2,3-Dihydroxybenzoic acid 303-38-8D, 2,3-Dihydroxybenzoic acid, metabolites 487-48-9, Salacetamide 490-79-9, Gentisic acid 550-97-0, 1-Naphthyl salicylate 552-94-3, Salsalate **580-02-9**, Methyl acetylsalicylate 599-79-1, Sulfasalazine **5003-48-5**, Benorylate 5104-49-4, Flurbiprofen 5104-49-4D, Flurbiprofen, metabolites 5663-71-8 6385-02-0, Sodium meclofenamate 6385-02-0D, Sodium meclofenamate, metabolites 13539-59-8, Apazone 13539-59-8D, Apazone, metabolites 13586-98-6 15307-86-5, Diclofenac 15307-86-5D, Diclofenac, metabolites 15687-27-1 15687-27-1D, metabolites 15722-48-2, Olsalazine 21256-18-8, Oxaprozin 21256-18-8D, Oxaprozin, metabolites 22071-15-4, Ketoprofen 22071-15-4D, Ketoprofen, metabolites 22204-53-1, Naproxen 22204-53-1D, Naproxen, metabolites 22494-27-5, Flufenisal 22494-42-4 26171-23-3, Tolmetin 26171-23-3D, Tolmetin, metabolites 29679-58-1, Fenoprofen 29679-58-1D, Fenoprofen, metabolites 30653-83-9, Parsalmide 36322-90-4, Piroxicam 36322-90-4D, Piroxicam, metabolites 36364-49-5, Imidazole salicylate 37933-78-1, Lysine acetylsalicylate 38194-50-2, Sulindac 38194-50-2D, Sulindac, metabolites 41340-25-4, Etodolac 41340-25-4D, Etodolac, metabolites 42924-53-8, Nabumetone 42924-53-8D, Nabumetone, metabolites 51803-78-2, Nimesulide 51803-78-2D, Nimesulide, metabolites 53597-27-6, Fendosal 59804-37-4, Tenoxicam 59804-37-4D, Tenoxicam, metabolites 62992-61-4, Etersalate 71125-38-7, Meloxicam 71125-38-7D, Meloxicam, metabolites 74103-06-3, Ketorolac 74103-06-3D, Ketorolac, metabolites 111406-87-2, Zileuton 111406-87-2D, Zileuton, metabolites
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)

IT 7440-70-2, Calcium, biological studies 39391-18-9, Cyclooxygenase
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)

=> s l7
L44 5189 L7

=> d hi
'HI' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

```
ABS --------- GI and AB
ALL --------- BIB, AB, IND, RE
APPS -------- AI, PRAI
BIB --------- AN, plus Bibliographic Data and PI table (default)
CAN --------- List of CA abstract numbers without answer numbers
CBIB -------- AN, plus Compressed Bibliographic Data
DALL -------- ALL, delimited (end of each field identified)
DMAX -------- MAX, delimited for post-processing
FAM --------- AN, PI and PRAI in table, plus Patent Family data
FBIB -------- AN, BIB, plus Patent FAM
IND --------- Indexing data
IPC --------- International Patent Classifications
MAX --------- ALL, plus Patent FAM, RE
PATS -------- PI, SO
SAM --------- CC, SX, TI, ST, IT
SCAN -------- CC, SX, TI, ST, IT (random display, no answer numbers;
              SCAN must be entered on the same line as the DISPLAY,
              e.g., D SCAN or DISPLAY SCAN)
STD --------- BIB, IPC, and NCL

IABS -------- ABS, indented with text labels
IALL -------- ALL, indented with text labels
IBIB -------- BIB, indented with text labels
IMAX -------- MAX, indented with text labels
ISTD -------- STD, indented with text labels

OBIB -------- AN, plus Bibliographic Data (original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations

HIT --------- Fields containing hit terms
HITIND ------ IC, ICA, ICI, NCL, CC and index field (ST and IT)
              containing hit terms
HITRN ------- HIT RN and its text modification
HITSTR ------ HIT RN, its text modification, its CA index name, and
              its structure diagram
HITSEQ ------ HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
FHITSTR ----- First HIT RN, its text modification, its CA index name, and
              its structure diagram
FHITSEQ ----- First HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
KWIC -------- Hit term plus 20 words on either side
OCC --------- Number of occurrence of hit term and field in which it occurs
```

To display a particular field or fields, enter the display field codes. For a list of the display field codes, enter HELP DFIELDS at an arrow prompt (=>). Examples of formats include: TI; TI,AU; BIB,ST; TI,IND; TI,SO. You may specify the format fields in any order and the information will be displayed in the same order as the format specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR, FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC to view a specified Accession Number.

```
ENTER DISPLAY FORMAT (BIB):his
'HIS' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'
```

The following are valid formats:

```
ABS --------- GI and AB
ALL --------- BIB, AB, IND, RE
APPS -------- AI, PRAI
BIB --------- AN, plus Bibliographic Data and PI table (default)
CAN --------- List of CA abstract numbers without answer numbers
CBIB -------- AN, plus Compressed Bibliographic Data
DALL -------- ALL, delimited (end of each field identified)
DMAX -------- MAX, delimited for post-processing
FAM --------- AN, PI and PRAI in table, plus Patent Family data
FBIB -------- AN, BIB, plus Patent FAM
IND --------- Indexing data
IPC --------- International Patent Classifications
MAX --------- ALL, plus Patent FAM, RE
PATS -------- PI, SO
SAM --------- CC, SX, TI, ST, IT
SCAN -------- CC, SX, TI, ST, IT (random display, no answer numbers;
              SCAN must be entered on the same line as the DISPLAY,
              e.g., D SCAN or DISPLAY SCAN)
STD --------- BIB, IPC, and NCL

IABS -------- ABS, indented with text labels
IALL -------- ALL, indented with text labels
IBIB -------- BIB, indented with text labels
IMAX -------- MAX, indented with text labels
ISTD -------- STD, indented with text labels

OBIB -------- AN, plus Bibliographic Data (original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations

HIT --------- Fields containing hit terms
HITIND ------ IC, ICA, ICI, NCL, CC and index field (ST and IT)
              containing hit terms
HITRN ------- HIT RN and its text modification
HITSTR ------ HIT RN, its text modification, its CA index name, and
              its structure diagram
HITSEQ ------ HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
FHITSTR ----- First HIT RN, its text modification, its CA index name, and
              its structure diagram
FHITSEQ ----- First HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
KWIC -------- Hit term plus 20 words on either side
OCC --------- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field
codes.  For a list of the display field codes, enter HELP DFIELDS at
an arrow prompt (=>).  Examples of formats include: TI; TI,AU; BIB,ST;
TI,IND; TI,SO.  You may specify the format fields in any order and the
information will be displayed in the same order as the format
specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR,
FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC
to view a specified Accession Number.
ENTER DISPLAY FORMAT (BIB):bib

L44  ANSWER 1 OF 5189  CAPLUS  COPYRIGHT 2003 ACS on STN
```

AN 2003:673799 CAPLUS
DN 139:185344
TI Skin cosmetics and hair preparations containing sebum secretion inhibitors
IN Hata, Yuko; Tsutsumi, Tatsuhiko
PA Maruzen Pharmaceuticals Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 5 pp.
    CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2003238379	A2	20030827	JP 2002-32721	20020208
PRAI	JP 2002-32721		20020208		

=> d his

    (FILE 'HOME' ENTERED AT 15:07:02 ON 15 SEP 2003)

    FILE 'REGISTRY' ENTERED AT 15:07:15 ON 15 SEP 2003
              E ACETOMINOPHEN
              E ACETOMINOPHEN
              E ACETOMINOPHEN
              E NSAID
L1   9 S E3
              E ASPIRIN
L2   52 S E3
              E INDOMETHACIN
L3   52 S E3
              E KETOPROFIN
              E KETOPROFEN
L4   50 S E3
              E TRILISATR
              E TRILISATE
L5   1 S E3
L6   1158 S SALICYLAMIDE
L7   30 S SODIUM SALICYLATE
L8   6694 S SALICYLIC ACID
              E ACETOMINOPHEN
              E ACETAMINOPHEN
L9   130 S E3

    FILE 'CAPLUS' ENTERED AT 15:20:03 ON 15 SEP 2003
L10   17725 S L2
L11   28561 S CNS
L12   28 S L10 AND L11
              E TRAUMA
L13   11866 S E3
L14   68 S L13 AND L10
              E HEAD
L15   94345 S E3
L16   12 S L14 AND L15
              E ISCHEMA
L17   53069 S E5-E8
L18   356 S L17 AND L10
              E CEREBRAL
L19   78138 S E3
L20   14 S L18 AND 19
L21   66 S L18 AND L19
L22   2 S L19 AND L12
L23   211 S L10 AND L19

```
L24           66 S L23 AND L17
L25            0 S L24 NOT L21
L26            2 S L12 AND L17
L27        10826 S L9
L28           46 S L5
L29           28 S L12 AND L10
                 E LUPUS
L30        11819 S E3
L31           53 S L30 AND L10
                 E ALZHEIMERS
L32         1977 S E3
L33            8 S L10 AND L32
                 E NSAIDS
L34         3367 S E3
L35           36 S L34 AND L17
L36           28 S L11 AND L12
L37          685 S L11 AND L17
L38            2 S L37 AND L10
                 E INFLAMMATION
L39        98265 S E3
L40         1177 S L39 AND L11
L41           10 S L40 AND L12
                 E PARKINSON
L42        12980 S E3
L43           20 S L42 AND L10
L44         5189 S L7

=> s l10 and l12
L45           28 L10 AND L12

=> s l44 and l42
L46            4 L44 AND L42

=> d l46 1-4

L46  ANSWER 1 OF 4  CAPLUS  COPYRIGHT 2003 ACS on STN
AN   2003:162318  CAPLUS
DN   139:111278
TI   Non-steroidal anti-inflammatory drug sodium salicylate, but not diclofenac
     or celecoxib, protects against 1-methyl-4-phenyl pyridinium-induced
     dopaminergic neurotoxicity in rats
AU   Sairam, Krishnamurthy; Saravanan, Karuppagounder S.; Banerjee, Rebecca;
     Mohanakumar, Kochupurackal P.
CS   Division of Neurosciences, Indian Institute of Chemical Biology, Calcutta,
     700 032, India
SO   Brain Research (2003), 966(2), 245-252
     CODEN: BRREAP; ISSN: 0006-8993
PB   Elsevier Science B.V.
DT   Journal
LA   English
RE.CNT  52    THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L46  ANSWER 2 OF 4  CAPLUS  COPYRIGHT 2003 ACS on STN
AN   2002:588980  CAPLUS
DN   137:135080
TI   Modification of NSAIDs by sulfur-containing functional groups
IN   Lai, Ching-San; Wang, Tingmin
PA   Medinox, Inc., USA
SO   U.S., 27 pp., Cont.-in-part of U.S. Ser. No. 602,688.
     CODEN: USXXAM
DT   Patent
```

LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6429223	B1	20020806	US 2000-715767	20001117
	US 6355666	B1	20020312	US 2000-602688	20000623
	WO 2002000167	A2	20020103	WO 2001-US19750	20010619
	WO 2002000167	A3	20020404		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2001070010	A5	20020108	AU 2001-70010	20010619
	EP 1296929	A2	20030402	EP 2001-948537	20010619
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2003088111	A1	20030508	US 2002-97197	20020312
PRAI	US 2000-602688	A2	20000623		
	US 2000-715767	A1	20001117		
	WO 2001-US19750	W	20010619		

RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L46 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1999:749471 CAPLUS
DN 132:30710
TI Salicylate protects against MPTP-induced impairments in dopaminergic neurotransmission at the striatal and nigral level in mice
AU Ferger, Boris; Teismann, Peter; Earl, Christopher D.; Kuschinsky, Klaus; Oertel, Wolfgang H.
CS Medizinisches Zentrum fur Nervenheilkunde, Klinik fur Neurologie, Medizinisches Zentrum fur Nervenheilkunde, Klinik fur Neurologie, Philipps-Universitat Marburg, Marburg, D-35033, Germany
SO Naunyn-Schmiedeberg's Archives of Pharmacology (1999), 360(3), 256-261
CODEN: NSAPCC; ISSN: 0028-1298
PB Springer-Verlag
DT Journal
LA English
RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L46 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:338114 CAPLUS
DN 129:12755
TI Use of selected nonsteroidal antiinflammatory compounds for the prevention and the treatment of neurodegenerative diseases
IN Grilli, Mariagrazia; Pizzi, Marina; Memo, Maurizio; Spano, Pierfranco
PA Universita' Degli Studi di Brescia - Dipartimento di Scienze Biomediche, Italy; Grilli, Mariagrazia; Pizzi, Marina; Memo, Maurizio; Spano, Pierfranco
SO PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

```
PI   WO 9820864        A2   19980522       WO 1997-EP6323   19971113
     WO 9820864        A3   19981015
         W:  JP, US
         RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
PRAI IT 1996-MI2356         19961113
OS   MARPAT 129:12755


=> d his

     (FILE 'HOME' ENTERED AT 15:07:02 ON 15 SEP 2003)

     FILE 'REGISTRY' ENTERED AT 15:07:15 ON 15 SEP 2003
                E ACETOMINOPHEN
                E ACETOMINOPHEN
                E ACETOMINOPHEN
                E NSAID
L1            9 S E3
                E ASPIRIN
L2           52 S E3
                E INDOMETHACIN
L3           52 S E3
                E KETOPROFIN
                E KETOPROFEN
L4           50 S E3
                E TRILISATR
                E TRILISATE
L5            1 S E3
L6         1158 S SALICYLAMIDE
L7           30 S SODIUM SALICYLATE
L8         6694 S SALICYLIC ACID
                E ACETOMINOPHEN
                E ACETAMINOPHEN
L9          130 S E3

     FILE 'CAPLUS' ENTERED AT 15:20:03 ON 15 SEP 2003
L10       17725 S L2
L11       28561 S CNS
L12          28 S L10 AND L11
                E TRAUMA
L13       11866 S E3
L14          68 S L13 AND L10
                E HEAD
L15       94345 S E3
L16          12 S L14 AND L15
                E ISCHEMA
L17       53069 S E5-E8
L18         356 S L17 AND L10
                E CEREBRAL
L19       78138 S E3
L20          14 S L18 AND 19
L21          66 S L18 AND L19
L22           2 S L19 AND L12
L23         211 S L10 AND L19
L24          66 S L23 AND L17
L25           0 S L24 NOT L21
L26           2 S L12 AND L17
L27       10826 S L9
L28          46 S L5
L29          28 S L12 AND L10
                E LUPUS
L30       11819 S E3
```

```
L31           53 S L30 AND L10
                 E ALZHEIMERS
L32         1977 S E3
L33            8 S L10 AND L32
                 E NSAIDS
L34         3367 S E3
L35           36 S L34 AND L17
L36           28 S L11 AND L12
L37          685 S L11 AND L17
L38            2 S L37 AND L10
                 E INFLAMMATION
L39        98265 S E3
L40         1177 S L39 AND L11
L41           10 S L40 AND L12
                 E PARKINSON
L42        12980 S E3
L43           20 S L42 AND L10
L44         5189 S L7
L45           28 S L10 AND L12
L46            4 S L44 AND L42

=> s l6
L47        4560 L6

=> s l47 and l42
L48            6 L47 AND L42

=> d l48 1-6

L48  ANSWER 1 OF 6  CAPLUS  COPYRIGHT 2003 ACS on STN
AN   2003:610420  CAPLUS
DN   139:164713
TI   Preparation of isoquinoline derivatives as phosphodiesterase (PDE) 7
     inhibitors
IN   Ohhata, Akira; Takaoka, Yoshikazu; Ogawa, Mikio; Nakai, Hisao; Yamamoto,
     Susumu; Ochiai, Hiroshi
PA   Ono Pharmaceutical Co., Ltd., Japan
SO   PCT Int. Appl., 665 pp.
     CODEN: PIXXD2
DT   Patent
LA   Japanese
FAN.CNT 1
     PATENT NO.         KIND  DATE           APPLICATION NO.  DATE
     ---------------    ----  --------       ---------------  --------
PI   WO 2003064389      A1    20030807       WO 2003-JP877    20030130
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS,
             LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL,
             PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA,
             UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
             TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
             CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,
             NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
             ML, MR, NE, SN, TD, TG
PRAI JP 2002-23845      A     20020131
     JP 2002-23846      A     20020131
RE.CNT  5     THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L48  ANSWER 2 OF 6  CAPLUS  COPYRIGHT 2003 ACS on STN
```

AN 2003:454113 CAPLUS
DN 139:36517
TI Preparation of 1-phenyl-oxazolidine-2-ones as protease M inhibitors for the treatment of tumor illnesses and neurodegenerative diseases
IN Buchstaller, Hans-Peter; Poeschke, Oliver; Willems, Andreas
PA Merck Patent Gmbh, Germany
SO PCT Int. Appl., 86 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003047572	A1	20030612	WO 2002-EP12162	20021031
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	DE 10159453	A1	20030618	DE 2001-10159453	20011204
PRAI	DE 2001-10159453	A	20011204		

OS MARPAT 139:36517
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L48 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:635933 CAPLUS
DN 135:215973
TI Use of peptide conjugates for enhancing drug delivery across biological membranes and tissues
IN Rothbard, Jonathan B.; Wender, Paul A.
PA Cellgate, Inc., USA
SO PCT Int. Appl., 54 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001062297	A1	20010830	WO 2001-US4459	20010209
	WO 2001062297	C2	20030109		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 2002009491	A1	20020124	US 2001-779693	20010207
	EP 1263469	A1	20021211	EP 2001-909135	20010209
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2003523982	T2	20030812	JP 2001-561360	20010209
PRAI	US 2000-182166P	P	20000214		

```
     US 2001-779693    A    20010207
     WO 2001-US4459    W    20010209
RE.CNT  8      THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
               ALL CITATIONS AVAILABLE IN THE RE FORMAT

L48  ANSWER 4 OF 6  CAPLUS  COPYRIGHT 2003 ACS on STN
AN   2001:472717  CAPLUS
DN   135:61336
TI   Preparation of triazaspirodecanones as opioid .delta. receptor agonists
IN   Tsushima, Masaki; Tadauchi, Kaori; Mori, Tomohisa; Imai, Masako; Kudo,
     Toshiaki
PA   Meiji Seika Kaisha, Ltd., Japan
SO   PCT Int. Appl., 67 pp.
     CODEN: PIXXD2
DT   Patent
LA   Japanese
FAN.CNT 1
     PATENT NO.         KIND  DATE          APPLICATION NO.  DATE
     ---------------    ----  --------      ---------------  --------
PI   WO 2001046192      A1    20010628      WO 2000-JP9080   20001221
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
             HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU,
             LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD,
             SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU,
             ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
PRAI JP 1999-364001    A    19991222
OS   MARPAT 135:61336
RE.CNT  16     THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
               ALL CITATIONS AVAILABLE IN THE RE FORMAT

L48  ANSWER 5 OF 6  CAPLUS  COPYRIGHT 2003 ACS on STN
AN   2001:380616  CAPLUS
DN   135:10004
TI   Compositions and methods for counteracting effects of reactive oxygen
     species and free radicals
IN   Shashoua, Victor E.
PA   Ceremedix, Inc., USA
SO   PCT Int. Appl., 102 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.         KIND  DATE          APPLICATION NO.  DATE
     ---------------    ----  --------      ---------------  --------
PI   WO 2001036454      A1    20010525      WO 2000-US31764  20001117
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
             HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
             LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
             SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,
             ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     EP 1232174          A1    20020821      EP 2000-978811   20001117
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
     JP 2003518477       T2    20030610      JP 2001-538943   20001117
```

```
PRAI US 1999-166381P   P    19991118
     WO 2000-US31764   W    20001117
OS   MARPAT 135:10004
RE.CNT  4     THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L48  ANSWER 6 OF 6  CAPLUS  COPYRIGHT 2003 ACS on STN
AN   1998:338114  CAPLUS
DN   129:12755
TI   Use of selected nonsteroidal antiinflammatory compounds for the prevention
     and the treatment of neurodegenerative diseases
IN   Grilli, Mariagrazia; Pizzi, Marina; Memo, Maurizio; Spano, Pierfranco
PA   Universita' Degli Studi di Brescia - Dipartimento di Scienze Biomediche,
     Italy; Grilli, Mariagrazia; Pizzi, Marina; Memo, Maurizio; Spano,
     Pierfranco
SO   PCT Int. Appl., 24 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.        KIND  DATE           APPLICATION NO.  DATE
     ---------------   ----  --------       ---------------  --------
PI   WO 9820864         A2   19980522       WO 1997-EP6323   19971113
     WO 9820864         A3   19981015
         W:  JP, US
         RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
PRAI IT 1996-MI2356          19961113
OS   MARPAT 129:12755


=> e neurotrauma
E1            1     NEUROTRAST/BI
E2            1     NEUROTRASTUM/BI
E3          111 --> NEUROTRAUMA/BI
E4           19     NEUROTRAUMATIC/BI
E5            1     NEUROTRAUMATIZED/BI
E6            5     NEUROTRAUMATOL/BI
E7            2     NEUROTRAUMATOLOGY/BI
E8            1     NEUROTREND/BI
E9            1     NEUROTRENSIN/BI
E10           2     NEUROTRICHUS/BI
E11          22     NEUROTRIMIN/BI
E12           5     NEUROTRIMINS/BI

=> s l11 and l10
L49          28 L11 AND L10

=> d his

     (FILE 'HOME' ENTERED AT 15:07:02 ON 15 SEP 2003)

     FILE 'REGISTRY' ENTERED AT 15:07:15 ON 15 SEP 2003
                E ACETOMINOPHEN
                E ACETOMINOPHEN
                E ACETOMINOPHEN
                E NSAID
L1              9 S E3
                E ASPIRIN
L2             52 S E3
                E INDOMETHACIN
L3             52 S E3
                E KETOPROFIN
```

```
                E KETOPROFEN
L4            50 S E3
                E TRILISATR
                E TRILISATE
L5             1 S E3
L6          1158 S SALICYLAMIDE
L7            30 S SODIUM SALICYLATE
L8          6694 S SALICYLIC ACID
                E ACETOMINOPHEN
                E ACETAMINOPHEN
L9           130 S E3

     FILE 'CAPLUS' ENTERED AT 15:20:03 ON 15 SEP 2003
L10        17725 S L2
L11        28561 S CNS
L12           28 S L10 AND L11
                E TRAUMA
L13        11866 S E3
L14           68 S L13 AND L10
                E HEAD
L15        94345 S E3
L16           12 S L14 AND L15
                E ISCHEMA
L17        53069 S E5-E8
L18          356 S L17 AND L10
                E CEREBRAL
L19        78138 S E3
L20           14 S L18 AND 19
L21           66 S L18 AND L19
L22            2 S L19 AND L12
L23          211 S L10 AND L19
L24           66 S L23 AND L17
L25            0 S L24 NOT L21
L26            2 S L12 AND L17
L27        10826 S L9
L28           46 S L5
L29           28 S L12 AND L10
                E LUPUS
L30        11819 S E3
L31           53 S L30 AND L10
                E ALZHEIMERS
L32         1977 S E3
L33            8 S L10 AND L32
                E NSAIDS
L34         3367 S E3
L35           36 S L34 AND L17
L36           28 S L11 AND L12
L37          685 S L11 AND L17
L38            2 S L37 AND L10
                E INFLAMMATION
L39        98265 S E3
L40         1177 S L39 AND L11
L41           10 S L40 AND L12
                E PARKINSON
L42        12980 S E3
L43           20 S L42 AND L10
L44         5189 S L7
L45           28 S L10 AND L12
L46            4 S L44 AND L42
L47         4560 S L6
L48            6 S L47 AND L42
                E NEUROTRAUMA
```

```
L49          28 S L11 AND L10

=> e alzheimer
E1            2     ALZHEIMDER/BI
E2            1     ALZHEIME/BI
E3        27161 --> ALZHEIMER/BI
E4            1     ALZHEIMERAPOS/BI
E5            1     ALZHEIMERDEMENTIACASESRESEMBLED/BI
E6            1     ALZHEIMERIC/BI
E7            1     ALZHEIMERISTS/BI
E8            1     ALZHEIMERLIKE/BI
E9         1977     ALZHEIMERS/BI
E10           2     ALZHEIMERSDISEASE/BI
E11           1     ALZHEIMR/BI
E12           1     ALZHEINER/BI

=> s e3
L50       27161 ALZHEIMER/BI

=> s l50 and l10
L51          81 L50 AND L10

=> d l51 60-81

L51  ANSWER 60 OF 81  CAPLUS  COPYRIGHT 2003 ACS on STN
AN   1999:436597  CAPLUS
DN   131:86121
TI   Role of platelet activation in dementia
AU   Van Kooten, Fop; Ciabattoni, Giovanni; Patrono, Carlo; Koudstaal, Peter J.
CS   Department Neurology, Univ. Rotterdam, Rotterdam, 3015 GD, Neth.
SO   Haemostasis (1999), Volume Date 1998, 28(3-4), 202-208
     CODEN: HMTSB7; ISSN: 0301-0147
PB   S. Karger AG
DT   Journal; General Review
LA   English
RE.CNT  59    THERE ARE 59 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L51  ANSWER 61 OF 81  CAPLUS  COPYRIGHT 2003 ACS on STN
AN   1999:412670  CAPLUS
DN   131:54044
TI   Compositions comprising nicotinylalanine and an inhibitor of glycine
     conjugation or vitamin B6, and therapeutic use
IN   Shaskan, Edward G.
PA   USA
SO   U.S., 27 pp., Cont.-in-part of U.S. Ser. No. 581,394, abandoned.
     CODEN: USXXAM
DT   Patent
LA   English
FAN.CNT 2
     PATENT NO.         KIND  DATE          APPLICATION NO.  DATE
     ---------------    ----  --------      ---------------  --------
PI   US 5916906          A    19990629      US 1997-930234   19970912
     WO 9628167          A1   19960919      WO 1996-US3435   19960313
         W:  AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE,
             ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT,
             LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,
             SG, SI
         RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR,
             IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA
PRAI US 1995-403676          19950314
     US 1995-581394          19951229
```

WO 1996-US3435 19960313
OS MARPAT 131:54044
RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L51 ANSWER 62 OF 81 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1999:103337 CAPLUS
DN 130:280248
TI Increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-.gamma. in **Alzheimer**'s disease brains
AU Kitamura, Yoshihisa; Shimohama, Shun; Koike, Hideyasu; Kakimura, Jun-Ichi; Matsuoka, Yasuji; Nomura, Yasuyuki; Gebicke-Haerter, Peter J.; Taniguchi, Takashi
CS Department of Neurobiology, Kyoto Pharmaceutical University, Kyoto, 607-8412, Japan
SO Biochemical and Biophysical Research Communications (1999), 254(3), 582-586
CODEN: BBRCA9; ISSN: 0006-291X
PB Academic Press
DT Journal
LA English
RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L51 ANSWER 63 OF 81 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:806633 CAPLUS
DN 130:57211
TI Preparation of conjugates of dithiocarbamates with drugs
IN Lai, Ching-san
PA Medinox, Inc., USA
SO PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9855453	A1	19981210	WO 1998-US10295	19980519
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5916910	A	19990629	US 1997-869158	19970604
	AU 9875828	A1	19981221	AU 1998-75828	19980519
	AU 743205	B2	20020124		
	EP 1001932	A1	20000524	EP 1998-923563	19980519
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2002511858	T2	20020416	JP 1999-502493	19980519
	US 6407135	B1	20020618	US 1999-453608	19991203
	US 2003087840	A1	20030508	US 2002-176396	20020618
PRAI	US 1997-869158	A1	19970604		
	WO 1998-US10295	W	19980519		
	US 1999-453608	A3	19991203		

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L51 ANSWER 64 OF 81 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:780621 CAPLUS
DN 130:232124
TI Peripheral administration of novel anti-inflammatories can attenuate the effects of chronic inflammation within the CNS [central nervous system]
AU Hauss-Wegrzyniak, Beatrice; Willard, Lauren B.; Del Soldato, Piero; Pepeu, Giancarlo; Wenk, Gary L.
CS Memory and Aging, Division of Neural Systems, Arizona Research Laboratories, University of Arizona, Tucson, AZ, 85724, USA
SO Brain Research (1999), 815(1), 36-43
CODEN: BRREAP; ISSN: 0006-8993
PB Elsevier Science B.V.
DT Journal
LA English
RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L51 ANSWER 65 OF 81 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:708808 CAPLUS
DN 129:310911
TI TGF-.beta.-elevating compounds and therapies for the prevention of vascular and non-vascular pathologies, and diagnostic methods
IN Grainger, David J.; Metcalfe, James C.; Kasina, Sudhakar
PA Neorx Corp., USA
SO PCT Int. Appl., 153 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9846588	A2	19981022	WO 1998-US7063	19980409
	WO 9846588	A3	19990107		
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9869598	A1	19981111	AU 1998-69598	19980409
	US 6117911	A	20000912	US 1998-57323	19980409
	US 6410587	B1	20020625	US 2000-567558	20000505
	US 2003064970	A1	20030403	US 2002-170971	20020613
PRAI	US 1997-43852P	P	19970411		
	US 1998-57323	A1	19980409		
	WO 1998-US7063	W	19980409		
	US 2000-567558	A3	20000505		

OS MARPAT 129:310911

L51 ANSWER 66 OF 81 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:695603 CAPLUS
DN 130:105154
TI Molecular characterization of the neuroprotective activity of salicylates
AU Grilli, M.; Pizzi, M.; Goffi, F.; Benarese, M.; Gerardi, G. M.; Memo, M.; Spano, P. F.
CS Division of Pharmacology Department of Biomedical Sciences and Biotechnologies School of Medicine, University of Brescia, Brescia, Italy
SO Advances in Behavioral Biology (1998), 49(Progress in Alzheimer's and Parkinson's Diseases), 99-103
CODEN: ADBBBW; ISSN: 0099-6246

PB Plenum Publishing Corp.
DT Journal
LA English
RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L51 ANSWER 67 OF 81 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:621136 CAPLUS
DN 129:254974
TI Process for increasing the therapeutic effect and reducing the toxicity of drugs, metals, and organic and inorganic compounds
IN Scherbinin, Vladimir Viktorovich; Chernyshev, Evgeny Andreevich
PA Kuzmin, Konstantin Kuzmich, Russia; Volotovsky, Andrei Vasilievich
SO PCT Int. Appl., 83 pp.
CODEN: PIXXD2
DT Patent
LA Russian
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9840103	A1	19980917	WO 1997-RU261	19970818
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	RU 2104032	C1	19980210	RU 1997-103218	19970311
	RU 2104033	C1	19980210	RU 1997-103219	19970311
	AU 9739552	A1	19980929	AU 1997-39552	19970818
PRAI	RU 1997-103218	A	19970311		
	RU 1997-103219	A	19970311		
	WO 1997-RU261	W	19970818		

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L51 ANSWER 68 OF 81 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:527193 CAPLUS
DN 129:166193
TI Therapeutic treatment and prevention of infections with a bioactive material encapsulated within a biodegradable-biocompatible polymeric matrix
IN Setterstrom, Jean A.; Van Hamont, John E.; Reid, Robert H.; Jacob, Elliot; Jeyanthi, Ramasubbu; Boedeker, Edgar C.; McQueen, Charles E.; Tice, Thomas R.; Roberts, F. Donald; Friden, Phil
PA United States Dept. of the Army, USA; Van Hamont, John E.; et al.
SO PCT Int. Appl., 363 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 15

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9832427	A1	19980730	WO 1998-US1556	19980127
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI,				

FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

	US 6309669	B1	20011030	US 1997-789734	19970127
	AU 9863175	A1	19980818	AU 1998-63175	19980127
PRAI	US 1997-789734	A	19970127		
	US 1984-590308	B1	19840316		
	US 1992-867301	A2	19920410		
	US 1995-446148	A2	19950522		
	US 1995-446149	B2	19950522		
	US 1996-590973	B2	19960124		
	WO 1998-US1556	W	19980127		

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L51 ANSWER 69 OF 81 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:484927 CAPLUS
DN 129:127177
TI Pharmaceutical preparations of glutathione and methods of administration
IN Demopoulos, Harry B.; Seligman, Myron L.
PA Antioxidant Pharmaceuticals Corp., USA
SO PCT Int. Appl., 52 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9829101	A1	19980709	WO 1997-US23879	19971231
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9856205	A1	19980731	AU 1998-56205	19971231
	EP 957901	A1	19991124	EP 1997-952640	19971231
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2001507696	T2	20010612	JP 1998-530206	19971231
	US 6350467	B1	20020226	US 1999-331947	19990628
	US 2002136763	A1	20020926	US 2002-83327	20020225
PRAI	US 1996-34101P	P	19961231		
	WO 1997-US23879	W	19971231		
	US 1999-331947	A2	19990628		

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L51 ANSWER 70 OF 81 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:424361 CAPLUS
DN 129:38404
TI Method for determining the prognosis of a patient with a neurological disease
IN Sevigny, Pierre; Wiebusch, Heiko; Schappert, Keith
PA Nova Molecular, Inc., Can.
SO PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI	WO 9827226	A2	19980625	WO 1997-IB1641	19971216
	WO 9827226	A3	19980820		
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 6022683	A	20000208	US 1996-766975	19961216
	AU 9855717	A1	19980715	AU 1998-55717	19971216
	EP 948647	A1	19991013	EP 1997-952129	19971216
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
PRAI	US 1996-766975	A	19961216		
	WO 1997-IB1641	W	19971216		

L51 ANSWER 71 OF 81 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:338114 CAPLUS
DN 129:12755
TI Use of selected nonsteroidal antiinflammatory compounds for the prevention and the treatment of neurodegenerative diseases
IN Grilli, Mariagrazia; Pizzi, Marina; Memo, Maurizio; Spano, Pierfranco
PA Universita' Degli Studi di Brescia - Dipartimento di Scienze Biomediche, Italy; Grilli, Mariagrazia; Pizzi, Marina; Memo, Maurizio; Spano, Pierfranco
SO PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9820864	A2	19980522	WO 1997-EP6323	19971113
	WO 9820864	A3	19981015		
	W: JP, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
PRAI	IT 1996-MI2356		19961113		

OS MARPAT 129:12755

L51 ANSWER 72 OF 81 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:25162 CAPLUS
DN 128:97725
TI Therapeutic methods and compositions using R-ibuprofen
IN Xiaotao, Qian; Hall, Stephen D.
PA Advanced Research and Technology Institute, USA; Xiaotao, Qian; Hall, Stephen D.
SO PCT Int. Appl., 88 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9748391	A2	19971224	WO 1997-US10762	19970620
	WO 9748391	A3	19980129		
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US,				

UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

	AU 9736415	A1	19980107	AU 1997-36415	19970620
	US 6255347	B1	20010703	US 1997-879870	19970620
PRAI	US 1996-20248P	P	19960621		
	WO 1997-US10762	W	19970620		

L51 ANSWER 73 OF 81 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1997:454047 CAPLUS
DN 127:60626
TI Method of delaying onset of **Alzheimer**'s disease symptoms with a non-steroidal anti-inflammatory agent and/or a histamine H2 receptor-blocking agent
IN Breitner, John C. S.; Welsh, Kathleen A.
PA Duke University, USA
SO U.S., 10 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5643960	A	19970701	US 1994-228019	19940415
	US 6025395	A	20000215	US 1997-843217	19970414
PRAI	US 1994-228019		19940415		

L51 ANSWER 74 OF 81 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1997:433698 CAPLUS
DN 127:55908
TI Transdermal therapeutic preparation with drug-containing backing layer
IN Horstmann, Michael; Laux, Wolfgang
PA LTS Lohmann Therapie-Systeme Gmbh, Germany
SO Ger. Offen., 4 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19546024	A1	19970612	DE 1995-19546024	19951209
	DE 19546024	C2	19980910		
	WO 9721430	A2	19970619	WO 1996-EP5411	19961204
	W: AU, CA, CN, CZ, HU, IL, JP, KR, MX, NO, NZ, PL, SI, SK, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9711764	A1	19970703	AU 1997-11764	19961204
	AU 715763	B2	20000210		
	EP 865274	A2	19980923	EP 1996-942341	19961204
	EP 865274	B1	19990929		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, FI				
	CN 1204257	A	19990106	CN 1996-198914	19961204
	AT 185069	E	19991015	AT 1996-942341	19961204
	JP 2000501718	T2	20000215	JP 1997-521703	19961204
	ES 2141548	T3	20000316	ES 1996-942341	19961204
	IL 124538	A1	20001206	IL 1996-124538	19961204
	SK 281406	B6	20010312	SK 1998-674	19961204
	CZ 289240	B6	20011212	CZ 1998-1711	19961204
	ZA 9610270	A	19970710	ZA 1996-10270	19961206
	US 6207183	B1	20010327	US 1998-91259	19980608
PRAI	DE 1995-19546024	A	19951209		

WO 1996-EP5411 W 19961204

L51 ANSWER 75 OF 81 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1996:97266 CAPLUS
DN 124:135727
TI Method and use of agents to inhibit protein polymerization, methods of identifying these agents, and use of the agents as antithrombotics and for the treatment of **Alzheimer**'s disease
IN Bjornsson, Thorir D.
PA Thomas Jefferson University, USA
SO PCT Int. Appl., 18 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9531192	A1	19951123	WO 1995-US6383	19950515
W: CA, JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
PRAI US 1994-243114		19940516		

OS MARPAT 124:135727

L51 ANSWER 76 OF 81 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1995:772802 CAPLUS
DN 123:160855
TI Use of thalidomide for treating neurocognitive disorders
IN Andrulis, Peter J., Jr.
PA Andrulis Pharmaceuticals Corp., USA
SO PCT Int. Appl., 23 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9517154	A2	19950629	WO 1994-US14743	19941222
WO 9517154	A3	19950713		
W: AU, CA, CN, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5434170	A	19950718	US 1993-172155	19931223
AU 9513751	A1	19950710	AU 1995-13751	19941222
EP 735874	A1	19961009	EP 1995-904954	19941222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
PRAI US 1993-172155		19931223		
WO 1994-US14743		19941222		

L51 ANSWER 77 OF 81 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1995:374891 CAPLUS
DN 122:142506
TI Use of hydrophilic carotenoids for the treatment of diseases having an oxidation mechanism
IN Howard, Alan Norman; Hepworth, Lawrence; Thurnham, David I.
PA Howard Foundation, UK
SO PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 4

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9500130	A1	19950105	WO 1994-GB1402	19940628

W: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KG, KP, KR, KZ, LK, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

	AU 9470056	A1	19950117	AU 1994-70056	19940628
	GB 2280110	A1	19950125	GB 1994-12938	19940628
	GB 2280110	B2	19971112		
	ZA 9404633	A	19951025	ZA 1994-4633	19940628
PRAI	GB 1993-13266	A	19930628		
	US 1994-219897	A	19940330		
	WO 1994-GB1402	W	19940628		

L51 ANSWER 78 OF 81 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1994:253358 CAPLUS
DN 120:253358
TI Cyclodextrin complexes with polymers, drugs, agrochemicals and cosmetics
IN Loftsson, Thorsteinn
PA Iceland
SO Eur. Pat. Appl., 46 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 579435	A1	19940119	EP 1993-305280	19930706
	EP 579435	B1	19990317		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	US 5324718	A	19940628	US 1992-912853	19920714
	AT 177647	E	19990415	AT 1993-305280	19930706
	ES 2132190	T3	19990816	ES 1993-305280	19930706
	US 5472954	A	19951205	US 1994-240510	19940511
PRAI	US 1992-912853		19920714		
	EP 1993-305280		19930706		

L51 ANSWER 79 OF 81 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1993:247651 CAPLUS
DN 118:247651
TI Nonsteroidal anti-rheumatoid arthritic drugs in the treatment of dementia
IN McGeer, Patrick L.; Rogers, Joseph; Sibley, John; Mcgeer, Edith
PA Can.
SO U.S., 6 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5192753	A	19930309	US 1991-689499	19910423
	WO 9324115	A1	19931209	WO 1992-CA229	19920529
	W: JP				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
	EP 642336	A1	19950315	EP 1992-910600	19920529
	EP 642336	B1	19980114		
	R: DE, FR, GB, IT				
	JP 07506559	T2	19950720	JP 1992-509619	19920529
PRAI	US 1991-689499		19910423		
	WO 1992-CA229		19920529		

L51 ANSWER 80 OF 81 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1990:637859 CAPLUS

DN 113:237859
TI Pharmaceutical composition containing a complexing agent and procaine for the treatment of symptoms from narcotic addiction, tinnitus, and **Alzheimer**'s disease
IN Sapse, Alfred T.
PA USA
SO U.S., 4 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4956391	A	19900911	US 1988-233247	19880817
	US 5064858	A	19911112	US 1990-578030	19900905
PRAI	US 1988-233247		19880817		

L51 ANSWER 81 OF 81 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1989:206625 CAPLUS
DN 110:206625
TI Hormone treatment for central nervous system diseases such as Alzheimers disease and Parkinsons disease
IN Aroonsakul, Chaovanee
PA USA
SO U.S., 4 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4791099	A	19881213	US 1984-666254	19841029
	EP 324037	A1	19890719	EP 1988-100233	19880111
	EP 324037	B1	19970903		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	AT 157546	E	19970915	AT 1988-100233	19880111
	ES 2109914	T3	19980201	ES 1988-100233	19880111
	US 4898856	A	19900206	US 1988-156242	19880216
	JP 01216940	A2	19890830	JP 1988-39323	19880222
	JP 09216837	A2	19970819	JP 1997-38275	19880222
	US 4897389	A	19900130	US 1989-293134	19890103
	US 4902680	A	19900220	US 1989-293017	19890103
	US 4898857	A	19900206	US 1989-293132	19890203
PRAI	US 1984-666254		19841029		
	US 1986-852645		19860416		
	EP 1988-100233		19880111		
	US 1988-156242		19880216		
	JP 1988-39323		19880222		

=> d l51 66 all

L51 ANSWER 66 OF 81 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:695603 CAPLUS
DN 130:105154
TI Molecular characterization of the neuroprotective activity of salicylates
AU Grilli, M.; Pizzi, M.; Goffi, F.; Benarese, M.; Gerardi, G. M.; Memo, M.; Spano, P. F.
CS Division of Pharmacology Department of Biomedical Sciences and Biotechnologies School of Medicine, University of Brescia, Brescia, Italy
SO Advances in Behavioral Biology (1998), 49(Progress in Alzheimer's and Parkinson's Diseases), 99-103

CODEN: ADBBBW; ISSN: 0099-6246
PB Plenum Publishing Corp.
DT Journal
LA English
CC 1-11 (Pharmacology)
AB Aspirin and its metabolite sodium salicylate prevent glutamate-induced neurotoxicity in rats. The neuroprotective effect of aspirin does not appear to correlate with the anti-inflammatory properties of this compd.
ST neuroprotectant salicylate antiinflammatory neurodegenerative disorder **Alzheimer**
IT Transcription factors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(NF-.kappa.B (nuclear factor .kappa.B); mol. characterization of the neuroprotective activity of salicylates)
IT Nervous system
(degeneration; mol. characterization of the neuroprotective activity of salicylates)
IT Anti-**Alzheimer**'s agents
(mol. characterization of the neuroprotective activity of salicylates)
IT Cytoprotective agents
(neuroprotectants; mol. characterization of the neuroprotective activity of salicylates)
IT Anti-inflammatory agents
(nonsteroidal; mol. characterization of the neuroprotective activity of salicylates)
IT 54-21-7, Sodium salicylate
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); MFM (Metabolic formation); THU (Therapeutic use); BIOL (Biological study); FORM (Formation, nonpreparative); USES (Uses)
(mol. characterization of the neuroprotective activity of salicylates)
IT **50-78-2**, Aspirin 69-72-7D, analogs
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(mol. characterization of the neuroprotective activity of salicylates)
RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Amin, A; Proc Natl Acad Sci USA 1995, V92, P7926 CAPLUS
(2) Curran, T; Cell 1988, V55, P395 CAPLUS
(3) Gallo, V; Proc Natl Acad Sci USA 1982, V79, P7919 CAPLUS
(4) Garthwaite, G; Neurosci Lett 1989, V97, P316 CAPLUS
(5) Grilli, M; Int Rev Cytol 1993, V143, P1 CAPLUS
(6) Grilli, M; J Biol Chem 1995, V270, P26774 CAPLUS
(7) Grilli, M; J Biol Chem 1996, V271, P15002 CAPLUS
(8) Grilli, M; Science 1996, V274, P1383 CAPLUS
(9) Guerrini, L; Proc Natl Acad Sci USA 1995, V92, P9077 CAPLUS
(10) Insel, P; Goodman and Gilman's The Pharmacological Basis of Therapeutics 1996, P617
(11) Kaltschmidt, C; Mol Cell Biol 1994, V14, P3981 CAPLUS
(12) Kaltschmidt, C; Proc Natl Acad Sci USA 1995, V92, P9618 CAPLUS
(13) Kopp, E; Science 1994, V265, P956 MEDLINE
(14) Lipton, S; New Engl J Med 1995, V330, P613
(15) McGeer, P; Brain Res Rev 1995, V21, P195 MEDLINE
(16) Pizzi, M; Eur J Neurosci 1996, V8, P1516 MEDLINE
(17) Pizzi, M; Mol Pharmacol 1996, V49, P586 CAPLUS
(18) Rogers, J; Neurology 1993, V43, P1609 MEDLINE
(19) Yan, S; Nature Med 1995, V1, P693 CAPLUS

=> d l51 65 all

L51 ANSWER 65 OF 81 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:708808 CAPLUS
DN 129:310911
TI TGF-.beta.-elevating compounds and therapies for the prevention of vascular and non-vascular pathologies, and diagnostic methods
IN Grainger, David J.; Metcalfe, James C.; Kasina, Sudhakar
PA Neorx Corp., USA
SO PCT Int. Appl., 153 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07D333-38
ICS A61K031-60; A61K031-135; G01N033-543
CC 1-12 (Pharmacology)
Section cross-reference(s): 15, 63
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9846588	A2	19981022	WO 1998-US7063	19980409
	WO 9846588	A3	19990107		
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9869598	A1	19981111	AU 1998-69598	19980409
	US 6117911	A	20000912	US 1998-57323	19980409
	US 6410587	B1	20020625	US 2000-567558	20000505
	US 2003064970	A1	20030403	US 2002-170971	20020613
PRAI	US 1997-43852P	P	19970411		
	US 1998-57323	A1	19980409		
	WO 1998-US7063	W	19980409		
	US 2000-567558	A3	20000505		

OS MARPAT 129:310911
AB A method is provided for treating a mammal having, or at risk of, an indication assocd. with a TGF-.beta. deficiency, comprising administering one or more agents that is effective to elevate the level of TGF-.beta.. The invention also provides compds. that elevate TGF-beta levels, as well as pharmaceutical compns. comprising compds. that elevate TGF-beta levels and methods for detecting diseases assocd. with endothelial cell activation.
ST TGFbeta stimulating compd therapeutic; endothelial cell activation disease diagnosis
IT Immunoglobulins
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)
(D; TGF-.beta.-elevating compds. and therapies for the prevention of vascular and non-vascular pathologies, and diagnostic methods)
IT Immunoglobulins
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)
(G2; TGF-.beta.-elevating compds. and therapies for the prevention of vascular and non-vascular pathologies, and diagnostic methods)
IT Immunoglobulins
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)
(G; TGF-.beta.-elevating compds. and therapies for the prevention of vascular and non-vascular pathologies, and diagnostic methods)
IT Heat-shock proteins

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(HSP 90; TGF-.beta.-elevating compds. and therapies for the prevention of vascular and non-vascular pathologies, and diagnostic methods)

IT Transcription factors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(I.kappa.B (inhibitor of NF-.kappa.B), .alpha.; TGF-.beta.-elevating compds. and therapies for the prevention of vascular and non-vascular pathologies, and diagnostic methods)

IT Transcription factors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(NF-.kappa.B (nuclear factor .kappa.B); TGF-.beta.-elevating compds. and therapies for the prevention of vascular and non-vascular pathologies, and diagnostic methods)

IT Cell nucleus
(NF-.kappa.B translocation to; TGF-.beta.-elevating compds. and therapies for the prevention of vascular and non-vascular pathologies, and diagnostic methods)

IT Lipoproteins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(TGF-.beta. assocn. with lipoprotein particles)

IT Animal cell
(TGF-.beta. type II receptor-contg. mammalian cell detection; TGF-.beta.-elevating compds. and therapies for the prevention of vascular and non-vascular pathologies, and diagnostic methods)

IT Anti-**Alzheimer**'s agents
Anticholesteremic agents
Antiparkinsonian agents
Antirheumatic agents
Autoimmune disease
Blood analysis
Blood vessel, disease
Body fluid
Cell proliferation
Chylomicrons
Cytotoxic agents
Diabetes mellitus
Drug delivery systems
Fibrosis
Hypertriglyceridemia
Hypolipemic agents
Immunoassay
Lupus erythematosus
Marfan syndrome
Multiple sclerosis
(TGF-.beta.-elevating compds. and therapies for the prevention of vascular and non-vascular pathologies, and diagnostic methods)

IT Tumor necrosis factors
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(TGF-.beta.-elevating compds. and therapies for the prevention of vascular and non-vascular pathologies, and diagnostic methods)

IT Glycerides, biological studies
Osteopontin
RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence); PROC (Process)
(TGF-.beta.-elevating compds. and therapies for the prevention of vascular and non-vascular pathologies, and diagnostic methods)

IT Antibodies
Immunoglobulins
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)
(TGF-.beta.-elevating compds. and therapies for the prevention of vascular and non-vascular pathologies, and diagnostic methods)

IT Estrogen receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(TGF-.beta.-elevating compds. and therapies for the prevention of vascular and non-vascular pathologies, and diagnostic methods)

IT Antiarteriosclerotics
(antiatherosclerotics; TGF-.beta.-elevating compds. and therapies for the prevention of vascular and non-vascular pathologies, and diagnostic methods)

IT Cytoprotective agents
(cardioprotective; TGF-.beta.-elevating compds. and therapies for the prevention of vascular and non-vascular pathologies, and diagnostic methods)

IT Artery, disease
(coronary, stenosis; TGF-.beta.-elevating compds. and therapies for the prevention of vascular and non-vascular pathologies, and diagnostic methods)

IT Diagnosis
(endothelial cell activation-assocd. disease; TGF-.beta.-elevating compds. and therapies for the prevention of vascular and non-vascular pathologies, and diagnostic methods)

IT Blood vessel
(endothelium, endothelial cell activation; TGF-.beta.-elevating compds. and therapies for the prevention of vascular and non-vascular pathologies, and diagnostic methods)

IT Fats and Glyceridic oils, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(fish; TGF-.beta.-elevating compds. and therapies for the prevention of vascular and non-vascular pathologies, and diagnostic methods)

IT Lipoproteins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(high-d.; TGF-.beta. assocn. with lipoprotein particles)

IT Biological transport
(intracellular, NF-.kappa.B translocation to nucleus; TGF-.beta.-elevating compds. and therapies for the prevention of vascular and non-vascular pathologies, and diagnostic methods)

IT Lipoproteins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(low-d.; TGF-.beta. assocn. with lipoprotein particles)

IT Atherosclerosis
(plaque stability; TGF-.beta.-elevating compds. and therapies for the prevention of vascular and non-vascular pathologies, and diagnostic methods)

IT Fatty acids, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polyunsatd., n-3; TGF-.beta.-elevating compds. and therapies for the prevention of vascular and non-vascular pathologies, and diagnostic methods)

IT Proliferation inhibition
(proliferation inhibitors; TGF-.beta.-elevating compds. and therapies

for the prevention of vascular and non-vascular pathologies, and diagnostic methods)

IT Wine
(red; TGF-.beta.-elevating compds. and therapies for the prevention of vascular and non-vascular pathologies, and diagnostic methods)

IT Mental disorder
(senile psychosis; TGF-.beta.-elevating compds. and therapies for the prevention of vascular and non-vascular pathologies, and diagnostic methods)

IT Blood vessel
(smooth muscle; TGF-.beta.-elevating compds. and therapies for the prevention of vascular and non-vascular pathologies, and diagnostic methods)

IT Drug interactions
(synergistic; TGF-.beta.-elevating compds. and therapies for the prevention of vascular and non-vascular pathologies, and diagnostic methods)

IT Osteoporosis
(therapeutic agents; TGF-.beta.-elevating compds. and therapies for the prevention of vascular and non-vascular pathologies, and diagnostic methods)

IT Drug delivery systems
(unit doses; TGF-.beta.-elevating compds. and therapies for the prevention of vascular and non-vascular pathologies, and diagnostic methods)

IT Lipoproteins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(very-low-d.; TGF-.beta. assocn. with lipoprotein particles)

IT Transforming growth factors
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(.alpha.-; TGF-.beta.-elevating compds. and therapies for the prevention of vascular and non-vascular pathologies, and diagnostic methods)

IT Actins
RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence); PROC (Process)
(.alpha.-; TGF-.beta.-elevating compds. and therapies for the prevention of vascular and non-vascular pathologies, and diagnostic methods)

IT Transforming growth factors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(.beta.-; TGF-.beta.-elevating compds. and therapies for the prevention of vascular and non-vascular pathologies, and diagnostic methods)

IT Transforming growth factor receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(.beta.-transforming growth factor type II; TGF-.beta.-elevating compds. and therapies for the prevention of vascular and non-vascular pathologies, and diagnostic methods)

IT Transforming growth factor receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(.beta.-transforming growth factor; TGF-.beta.-elevating compds. and therapies for the prevention of vascular and non-vascular pathologies, and diagnostic methods)

IT **50-78-2**, Aspirin **50-78-2D**, Aspirin, derivs. 67-98-1, MER25 **493-53-8** 7440-50-8D, Copper, aspirinates, biological studies 10540-29-1, Tamoxifen **23325-63-5** 32839-18-2,

Docosahexaenoic acid 32839-30-8, Eicosapentaenoic acid 79902-63-9, Simvastatin 146063-51-6
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(TGF-.beta.-elevating compds. and therapies for the prevention of vascular and non-vascular pathologies, and diagnostic methods)

IT 57-88-5, Cholesterol, biological studies
RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence); PROC (Process)
(TGF-.beta.-elevating compds. and therapies for the prevention of vascular and non-vascular pathologies, and diagnostic methods)

=> d l51 64 all

L51 ANSWER 64 OF 81 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:780621 CAPLUS
DN 130:232124
TI Peripheral administration of novel anti-inflammatories can attenuate the effects of chronic inflammation within the CNS [central nervous system]
AU Hauss-Wegrzyniak, Beatrice; Willard, Lauren B.; Del Soldato, Piero; Pepeu, Giancarlo; Wenk, Gary L.
CS Memory and Aging, Division of Neural Systems, Arizona Research Laboratories, University of Arizona, Tucson, AZ, 85724, USA
SO Brain Research (1999), 815(1), 36-43
CODEN: BRREAP; ISSN: 0006-8993
PB Elsevier Science B.V.
DT Journal
LA English
CC 1-7 (Pharmacology)
AB This study investigated whether nitroflurbiprofen (NFP) or nitro-aspirin can reduce the inflammatory response induced by continuous infusion of lipopolysaccharide (LPS) into the 4th ventricular space of the rat brain for 30 days. The chronic LPS infusion produced an extensive inflammation that was particularly evident in the hippocampus, subiculum and entorhinal and piriform cortices. Daily peripheral administration of NFP dose-dependently attenuated the brain inflammation, as indicated by the decreased d. and reactive state of microglial cells. Daily peripheral administration of nitro-aspirin also attenuated the brain inflammation, but to a much lesser degree than NFP. The results demonstrated that nonsteroidal anti-inflammatory drugs can reduce brain inflammation and that NFP is an effective anti-inflammatory agent.
ST brain inflammation inhibition nitroflurbiprofen nitroaspirin; nonsteroidal antiinflammatory drug brain inflammation
IT Encephalitis
(nitroflurbiprofen and nitroaspirin inhibition of)
IT **Alzheimer**'s disease
(nitroflurbiprofen and nitroaspirin inhibition of brain inflammation in relation to)
IT Anti-inflammatory agents
(nonsteroidal; brain inflammation inhibition by nitroflurbiprofen and nitroaspirin as)
IT **17336-14-0** 158836-71-6, Nitroflurbiprofen
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(brain inflammation inhibition by)
RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Aisen, P; Am J Psychiatr 1994, V151, P1105 MEDLINE

(2) Allison, M; N Engl J Med 1992, V327, P749 MEDLINE
(3) Altstiel, L; Prog Neuropsycho-Pharmacol Biol Psychiatr 1991, V15, P481 CAPLUS
(4) Banati, R; Glia 1993, V7, P111 MEDLINE
(5) Bannwarth, B; Therapie 1986, V41, P409 CAPLUS
(6) Breder, C; Brain Res 1996, V713, P64 CAPLUS
(7) Breitner, J; Neurobiol Aging 1996, V17, P789 MEDLINE
(8) Burrel, R; Crit Rev Microbiol 1990, V17, P188
(9) Cacabelos, R; Meth Find Exp Clin Pharmacol 1994, V16, P141 MEDLINE
(10) Chiang, C; Dev Neurosci 1994, V16, P212 CAPLUS
(11) Das, S; Neuron 1995, V14, P447 CAPLUS
(12) Eikelenboom, P; Virchows Arch B Cell Pathol 1989, V56, P259 MEDLINE
(13) Elmquist, J; J Comp Neurol 1997, V381, P119 CAPLUS
(14) Greenblatt, D; Arzneimittel-Forschung 1983, V33, P1671 CAPLUS
(15) Griffin, W; Proc Natl Acad Sci USA 1989, V86, P7611 MEDLINE
(16) Hauss-Wegrzyniak, B; Brain Res 1998, V794, P211 CAPLUS
(17) Hauss-Wegrzyniak, B; Brain Res 1998, V780, P294 CAPLUS
(18) Jenkinson, M; Br J Rheumatol 1989, V28, P86 MEDLINE
(19) Kitagawa, H; J Pharmacol Exp Therap 1990, V253, P1133 CAPLUS
(20) Macnaughton, W; Life Sci 1989, V45, P1869 CAPLUS
(21) McGeer, P; Brain Res Rev 1995, V21, P195 MEDLINE
(22) McGeer, P; Lancet 1990, V335, P1037 MEDLINE
(23) McGeer, P; Neurosci Lett 1988, V79, P195
(24) McGeer, P; Neurosci Lett 1989, V107, P341 MEDLINE
(25) Mrak, R; Human Pathol 1995, V26, P816 MEDLINE
(26) Myllykangas-Luosujarvi, R; Br J Rheumatol 1994, V33, P501 MEDLINE
(27) Rogers, J; Drug Res 1995, V45, P439 CAPLUS
(28) Rogers, J; Neurobiol Aging 1996, V17, P681 MEDLINE
(29) Rogers, J; Neurology 1993, V43, P1609 MEDLINE
(30) Roth, S; Ann Intern Med 1988, V109, P353 MEDLINE
(31) Santini, G; Eur J Pharmacol 1996, V316, P65 CAPLUS
(32) Sheng, J; Neurobiol Aging 1996, V17, P761 CAPLUS
(33) Strauss, S; Lab Invest 1992, V66, P223 MEDLINE
(34) Vandenabeele, P; Immunol Today 1991, V12, P217 CAPLUS
(35) Wallace, J; Gastroenterology 1994, V107, P173 CAPLUS
(36) Wallace, J; Trends Pharmacol Sci 1992, V13, P129 MEDLINE
(37) Watson; Paxinos 1986

=> d l51 62 all

L51 ANSWER 62 OF 81 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1999:103337 CAPLUS
DN 130:280248
TI Increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-.gamma. in **Alzheimer**'s disease brains
AU Kitamura, Yoshihisa; Shimohama, Shun; Koike, Hideyasu; Kakimura, Jun-Ichi; Matsuoka, Yasuji; Nomura, Yasuyuki; Gebicke-Haerter, Peter J.; Taniguchi, Takashi
CS Department of Neurobiology, Kyoto Pharmaceutical University, Kyoto, 607-8412, Japan
SO Biochemical and Biophysical Research Communications (1999), 254(3), 582-586
CODEN: BBRCA9; ISSN: 0006-291X
PB Academic Press
DT Journal
LA English
CC 14-10 (Mammalian Pathological Biochemistry)
Section cross-reference(s): 1
AB Recent studies suggest that inflammatory events are assocd. with plaque formation in the brains of patients with **Alzheimer**'s disease

(AD). Treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) of these patients appears to slow the progression of disease. The authors assessed the occurrence of cyclooxygenases (COX-1 and -2) and peroxisome proliferator-activated receptor-.gamma. (PPAR.gamma.) in temporal cortex from normal and AD brains using specific antibodies. In AD brains, protein levels of COX-1 were increased in both cytosolic and particulate fractions, and COX-2 protein was also increased in the particulate fraction. PPAR.gamma. level was increased in the cytosolic fraction but not in the particulate fraction. Thus, expression levels of COX-1, COX-2, and PPAR.gamma. may change in AD brains. In addn., several NSAIDs which are also PPAR.gamma. activators, such as indomethacin, inhibited COX-2 expression in glial cells. These results suggest that PPAR.gamma. activators have inhibitory effects on inflammatory events in AD brains. (c) 1999 Academic Press.

ST brain cyclooxygenase peroxisome proliferator activated receptor gamma **Alzheimer** disease

IT Cytoplasm
(cytosol; increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-.gamma. in brains from humans with **Alzheimer**'s disease)

IT Gene
(expression; increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-.gamma. in brains from humans with **Alzheimer**'s disease)

IT **Alzheimer**'s disease
Encephalitis
Neuroglia
(increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-.gamma. in brains from humans with **Alzheimer**'s disease)

IT Anti-inflammatory agents
(nonsteroidal; increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-.gamma. in brains from humans with **Alzheimer**'s disease)

IT Brain
(temporal cortex; increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-.gamma. in brains from humans with **Alzheimer**'s disease)

IT Peroxisome proliferator-activated receptors
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)
(.gamma.; increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-.gamma. in brains from humans with **Alzheimer**'s disease)

IT 39391-18-9
RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence); PROC (Process)
(1 and 2; increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-.gamma. in brains from humans with **Alzheimer**'s disease)

IT **50-78-2**, Aspirin 53-86-1, Indomethacin 41598-07-6, PGD2 87893-55-8 123653-11-2, NS398
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-.gamma. in brains from humans with **Alzheimer**'s disease)

RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Bauer, M; Eur J Biochem 1997, V243, P726 CAPLUS

(2) Bonventre, J; Nature 1997, V390, P622 CAPLUS
(3) Chang, J; Neurobiol Aging 1996, V17, P801 CAPLUS
(4) Clemens, J; Stroke 1996, V27, P527 CAPLUS
(5) Farooqui, A; Neurochem Int 1997, V30, P517 CAPLUS
(6) Forman, B; Cell 1995, V83, P803 CAPLUS
(7) Gattaz, W; Biol Psychiatry 1995, V37, P13 MEDLINE
(8) Guastadisegni, C; FEBS Lett 1997, V413, P314 CAPLUS
(9) Jiang, C; Nature 1998, V391, P82 CAPLUS
(10) Kitamura, Y; Neurosci Lett 1997, V237, P17 CAPLUS
(11) Lehmann, J; J Biol Chem 1997, V272, P3406 CAPLUS
(12) Lehtonen, J; Biochemistry 1996, V35, P9407 CAPLUS
(13) Lukiw, W; J Neurosci Res 1997, V50, P937 CAPLUS
(14) Mangelsdorf, D; Cell 1995, V83, P835 CAPLUS
(15) Mirra, S; Neurology 1991, V41, P479 MEDLINE
(16) Morita, I; J Biol Chem 1995, V270, P10902 CAPLUS
(17) Nogawa, S; J Neurosci 1997, V17, P2746 CAPLUS
(18) Oka, A; NeuroReport 1997, V8, P1161 CAPLUS
(19) Pasinetti, G; Neuroscience 1998, V87, P319 CAPLUS
(20) Ricote, M; Nature 1998, V391, P79 CAPLUS
(21) Rogers, J; Neurology 1993, V43, P1609 MEDLINE
(22) Sanz, O; Neuroscience 1997, V80, P221 CAPLUS
(23) Shimohama, S; J Neural Transm 1990, V30(Suppl), P69
(24) Shimohama, S; J Neurochem 1995, V64, P2629 CAPLUS
(25) Shimohama, S; Neurology 1993, V43, P1407 MEDLINE
(26) Spencer, A; J Biol Chem 1998, V273, P9886 CAPLUS
(27) Stephenson, D; Neurobiol Dis 1996, V3, P51 CAPLUS
(28) Tocco, G; Exp Neurol 1997, V144, P339 CAPLUS
(29) Vane, J; Ann Rev Pharmacol Toxicol 1998, V38, P97 CAPLUS

=> d l51 76 all

L51 ANSWER 76 OF 81 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1995:772802 CAPLUS
DN 123:160855
TI Use of thalidomide for treating neurocognitive disorders
IN Andrulis, Peter J., Jr.
PA Andrulis Pharmaceuticals Corp., USA
SO PCT Int. Appl., 23 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K
CC 1-11 (Pharmacology)
Section cross-reference(s): 63
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9517154	A2	19950629	WO 1994-US14743	19941222
	WO 9517154	A3	19950713		
	W: AU, CA, CN, JP				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 5434170	A	19950718	US 1993-172155	19931223
	AU 9513751	A1	19950710	AU 1995-13751	19941222
	EP 735874	A1	19961009	EP 1995-904954	19941222
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
PRAI	US 1993-172155		19931223		
	WO 1994-US14743		19941222		

AB A method is disclosed for treating a central nervous system or peripheral nervous system cholinergic deficit state in a mammalian organism in need of such treatment, the method comprising administering to said mammal an amt. of thalidomide effective in the treatment of a cholinergic deficit

state and for a time sufficient to achieve a suitable blood level to treat the cholinergic deficit state. The thalidomide may be administered with e.g. a non-steroidal antiinflammatory agent. The method of the invention may be used to treat e.g. **Alzheimer**'s disease. Capsule formulations of e.g. thalidomide and ibuprofen are included.

ST thalidomide neurocognitive disorder treatment; nervous cholinergic deficit disorder treatment thalidomide

IT Carboxylic acids, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nonsteroidal antiinflammatory; thalidomide, with or without other agent, for treating neurocognitive disorder)

IT Nootropics
Senescence
(thalidomide, with or without other agent, for treating neurocognitive disorder)

IT Mental disorder
(**Alzheimer**'s disease, thalidomide, with or without other agent, for treating neurocognitive disorder)

IT Proteins, specific or class
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(amyloid A4, inhibitors; thalidomide, with or without other agent, for treating neurocognitive disorder)

IT Lipoproteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(apo-, inhibitors; thalidomide, with or without other agent, for treating neurocognitive disorder)

IT Lipoproteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(apo-, I, agents; thalidomide, with or without other agent, for treating neurocognitive disorder)

IT Pharmaceutical dosage forms
(capsules, thalidomide, with or without other agent, for treating neurocognitive disorder)

IT Nervous system
(central, cholinergic, disease, deficiency, thalidomide, with or without other agent, for treating neurocognitive disorder)

IT Inflammation inhibitors
(nonsteroidal, thalidomide, with or without other agent, for treating neurocognitive disorder)

IT Nervous system
(peripheral, cholinergic, disease, deficiency, thalidomide, with or without other agent, for treating neurocognitive disorder)

IT Inflammation inhibitors
(steroidal, thalidomide, with or without other agent, for treating neurocognitive disorder)

IT 50-35-1, Thalidomide **50-78-2**, Aspirin 64-19-7D, Acetic acid, aryl derivs., mixts. with thalidomide 79-09-4D, Propionic acid, aryl derivs., mixts. with thalidomide 91-40-7D, Fenamic acid, derivs., mixts. with thalidomide 92-52-4D, Biphenyl, carboxylic acid derivs., mixts. with thalidomide 167273-63-4 167273-64-5 167273-65-6 167273-66-7
167273-67-8 167273-68-9 167273-69-0 167273-70-3 167273-71-4
167273-72-5 167273-73-6 167273-74-7 167273-75-8 167273-76-9
167273-77-0 167273-78-1 167273-79-2 167273-80-5 167273-81-6
167273-82-7 167273-83-8 167273-84-9 167273-85-0 167273-86-1
167273-87-2 167273-88-3 167273-89-4 167273-90-7 167273-91-8
167273-92-9 167273-93-0 167273-94-1 167273-95-2 167273-96-3
167273-97-4 167273-98-5 167273-99-6 167274-00-2 167274-01-3
167274-02-4 167274-03-5 167274-04-6 167274-05-7 167274-06-8
167274-07-9
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(thalidomide, with or without other agent, for treating neurocognitive disorder)

=> d 151 73 all

L51 ANSWER 73 OF 81 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1997:454047 CAPLUS
DN 127:60626
TI Method of delaying onset of **Alzheimer**'s disease symptoms with a non-steroidal anti-inflammatory agent and/or a histamine H2 receptor-blocking agent
IN Breitner, John C. S.; Welsh, Kathleen A.
PA Duke University, USA
SO U.S., 10 pp.
CODEN: USXXAM
DT Patent
LA English
IC ICM A61K031-60
ICS A61K031-615; A61K031-54; A61K031-44; A61K031-425; A61K031-42; A61K031-415; A61K031-40; A61K031-38; A61K031-34; A61K031-195; A61K031-19
NCL 514570000
CC 1-11 (Pharmacology)
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5643960	A	19970701	US 1994-228019	19940415
	US 6025395	A	20000215	US 1997-843217	19970414
PRAI	US 1994-228019		19940415		

AB A method is disclosed for preventing or delaying the onset of **Alzheimer**'s disease and related neurodegenerative disorders. The method involves the administration to individuals at risk of developing the disease (or disorder) a non-steroidal anti-inflammatory agent and/or a histamine H2 receptor-blocking agent. The invention also relates to a method of treating **Alzheimer**'s disease and related neurodegenerative disorders that involves the use of such agents.
ST **Alzheimer** disease NSAID H2 antihistaminic; neurodegenerative disease NSAID H2 antihistaminic
IT Apolipoproteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(E, .epsilon.4 or .epsilon.2 allele at locus for; non-steroidal anti-inflammatory agent and/or histamine H2 receptor-blocking agent for preventing, delaying, or treating **Alzheimer**'s disease and related neurodegenerative disorders)
IT Antihistamines
(H2; non-steroidal anti-inflammatory agent and/or histamine H2 receptor-blocking agent for preventing, delaying, or treating **Alzheimer**'s disease and related neurodegenerative disorders)
IT Nervous system
(degeneration; non-steroidal anti-inflammatory agent and/or histamine H2 receptor-blocking agent for preventing, delaying, or treating **Alzheimer**'s disease and related neurodegenerative disorders)
IT **Alzheimer**'s disease
Narcotics
Susceptibility (genetic)
(non-steroidal anti-inflammatory agent and/or histamine H2 receptor-blocking agent for preventing, delaying, or treating **Alzheimer**'s disease and related neurodegenerative disorders)
IT Glucocorticoids
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(non-steroidal anti-inflammatory agent and/or histamine H2 receptor-blocking agent for preventing, delaying, or treating

Alzheimer's disease and related neurodegenerative disorders)

IT Anti-inflammatory agents
(nonsteroidal; non-steroidal anti-inflammatory agent and/or histamine H2 receptor-blocking agent for preventing, delaying, or treating **Alzheimer**'s disease and related neurodegenerative disorders)

IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(.epsilon.4 or .epsilon.2 allele, for apolipoprotein E; non-steroidal anti-inflammatory agent and/or histamine H2 receptor-blocking agent for preventing, delaying, or treating **Alzheimer**'s disease and related neurodegenerative disorders)

IT **50-78-2**, Aspirin 103-90-2, Acetaminophen 22204-53-1, Naproxen
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(non-steroidal anti-inflammatory agent and/or histamine H2 receptor-blocking agent for preventing, delaying, or treating **Alzheimer**'s disease and related neurodegenerative disorders)

=> d l51 67 all

L51 ANSWER 67 OF 81 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:621136 CAPLUS
DN 129:254974
TI Process for increasing the therapeutic effect and reducing the toxicity of drugs, metals, and organic and inorganic compounds
IN Scherbinin, Vladimir Viktorovich; Chernyshev, Evgeny Andreevich
PA Kuzmin, Konstantin Kuzmich, Russia; Volotovsky, Andrei Vasilievich
SO PCT Int. Appl., 83 pp.
CODEN: PIXXD2
DT Patent
LA Russian
IC ICM A61K047-24
ICS A61K031-555
CC 1-4 (Pharmacology)
Section cross-reference(s): 4, 17, 62, 63
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9840103	A1	19980917	WO 1997-RU261	19970818
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	RU 2104032	C1	19980210	RU 1997-103218	19970311
	RU 2104033	C1	19980210	RU 1997-103219	19970311
	AU 9739552	A1	19980929	AU 1997-39552	19970818
PRAI	RU 1997-103218	A	19970311		
	RU 1997-103219	A	19970311		
	WO 1997-RU261	W	19970818		

AB The invention relates to the field of medicine, and in particular to pharmaceutical therapy, and can be used to increase the therapeutic effect and to reduce the toxicity of drugs, metals, as well as org. and inorg. compds. The embodiment of the invention requires a patient to take in addn. to the mentioned above substances, a daily dose of 0.001 - 0.1 g of 1-hydroxygermatrane (germatranol, 1-hydroxy-1-germa-2,8,9-trioxa-5-

azabicyclo[3.3.3]undecane) and its derivs. and/or the derivs. of 1-germa-2,8-dioxa-5-azacyclooctane. The organogermanic compds. could be conjugated with commonly known drugs or with fragments of their mols.. The process increases the pharmacol. potency of drugs being used to treat a wide variety of illnesses while reducing their toxicity, and notably the toxicity of org. and inorg. substances and of metals.

ST drug toxicity germatranol organogermanic compd therapy; hydroxygermatrane germadioxaazacyclooctane drug metal toxicity cosmetics; germanium org compd drug toxicity therapy; immunostimulant germanium org compd drug toxicity

IT Glycosides
RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cardiac; potentiation of therapeutic effects and toxicity redn. by germanium org. compds.)

IT Cosmetics
(creams; potentiation of therapeutic effects and toxicity redn. by germanium org. compds.)

IT Toxicity
(drug; potentiation of therapeutic effects and toxicity redn. by germanium org. compds.)

IT Cosmetics
(lotions; potentiation of therapeutic effects and toxicity redn. by germanium org. compds.)

IT Antitumor agents
(mammary gland; potentiation of therapeutic effects and toxicity redn. by germanium org. compds.)

IT Mammary gland
(neoplasm, inhibitors; potentiation of therapeutic effects and toxicity redn. by germanium org. compds.)

IT Drug delivery systems
(ointments, creams; potentiation of therapeutic effects and toxicity redn. by germanium org. compds.)

IT Periodontium
(periodontosis; potentiation of therapeutic effects and toxicity redn. by germanium org. compds.)

IT Nerve, disease
(polyneuropathy; potentiation of therapeutic effects and toxicity redn. by germanium org. compds.)

IT AIDS (disease)
Analgesics
Anti-**Alzheimer**'s agents
Anti-inflammatory agents
Antiarrhythmics
Antibacterial agents
Anticoagulants
Anticonvulsants
Antidotes
Antioxidants
Antitumor agents
Antiulcer agents
Antiviral agents
Cardiovascular agents
Cognition enhancers
Cosmetics
Dentifrices
Drug interactions
Food additives
Human herpesvirus
Human immunodeficiency virus 1
Immunostimulants
Influenza virus

Skin preparations (pharmaceutical)
Tranquilizers
(potentiation of therapeutic effects and toxicity redn. by germanium org. compds.)

IT Heavy metals
Nitrates, biological studies
Nitrites
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(potentiation of therapeutic effects and toxicity redn. by germanium org. compds.)

IT Adrenoceptor antagonists
(.alpha.-; potentiation of therapeutic effects and toxicity redn. by germanium org. compds.)

IT 64-17-5, Ethanol, biological studies 7632-00-0
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(potentiation of therapeutic effects and toxicity redn. by germanium org. compds.)

IT 7440-56-4D, Germanium, org. compds., biological studies 71682-43-4, Germatranol 71682-44-5 71682-45-6 71716-22-8 72480-80-9 88103-02-0 88103-03-1 101182-23-4 106224-61-7 122480-44-8 213538-70-6 213538-72-8 213538-73-9 213538-74-0 213538-75-1 213538-76-2 213538-78-4 213538-79-5 213538-80-8 213538-81-9 213538-82-0 213538-83-1 213538-84-2
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(potentiation of therapeutic effects and toxicity redn. by germanium org. compds.)

IT 50-06-6, Phenobarbital, biological studies **50-78-2**, Aspirin 54-42-2, Idoxuridine 56-12-2, Aminalon, biological studies 57-44-3, Barbital 65-45-2, Salicylamide 119-36-8, Methylsalicylate 144-02-5, Barbital sodium 439-14-5, Diazepam 768-94-5, Amantadine 2898-12-6, Mezapam 4076-02-2, Unitiol 5536-17-4, Vidarabin 7491-74-9, Piracetam 30266-58-1, Oxolin 30516-87-1, Azidothymidine 39322-38-8, Trichopol 51753-57-2, Phenazepam 59277-89-3, Acyclovir 63585-09-1, Foscarnet sodium
RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(potentiation of therapeutic effects and toxicity redn. by germanium org. compds.)

IT 67-52-7D, 2,4,6(1H,3H,5H)-Pyrimidinetrione, derivs.
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(potentiation of therapeutic effects and toxicity redn. by germanium org. compds.)

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Asai Germanium Research Institute; FR 2548187 A1 1985 CAPLUS
(2) Asai Germanium Research Institute Co; US 4919917 A 1990 CAPLUS
(3) Gorkovsky Meditsinsky Institut; SU 1555933 A1 1996 CAPLUS
(4) Kakimoto Norihiro; FR 2559488 A1 1985 CAPLUS
(5) Khusainov, R; Voprosy virusologii 1991, V36(1), P63 MEDLINE
(6) Sanwa Kagaku Kenkyusho Co Ltd; EP 0435693 A2 1991 CAPLUS
(7) United Inc; US 4654333 A 1987 CAPLUS

=> e impact
E1 2 IMPACR/BI
E2 1 IMPACRIS/BI
E3 254082 --> IMPACT/BI
E4 1 IMPACT2/BI
E5 1 IMPACT4/BI
E6 1 IMPACTA/BI

```
E7            1      IMPACTABILITY/BI
E8            2      IMPACTABLE/BI
E9            1      IMPACTABRASION/BI
E10           1      IMPACTACTIVATED/BI
E11           1      IMPACTACTOR/BI
E12           1      IMPACTAGE/BI

=> s e3
L52     254082 IMPACT/BI

=> s l52 and l19
L53        432 L52 AND L19

=> s l53 and l10
L54          2 L53 AND L10

=> d 154 1-2

L54  ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2003 ACS on STN
AN   2001:762124  CAPLUS
DN   137:76946
TI   Outcome in patients with symptomatic occlusion of the internal carotid
     artery or intracranial arterial lesions: a meta-analysis of the role of
     baseline characteristics and type of antithrombotic treatment
AU   Klijn, Catharina J. M.; Kappelle, L. Jaap; Algra, Ale; van Gijn, Jan
CS   University Department of Neurology, University Medical Centre Utrecht,
     Utrecht, Neth.
SO   Cerebrovascular Diseases (Basel, Switzerland) (2001), 12(3), 228-234
     CODEN: CDISE7; ISSN: 1015-9770
PB   S. Karger AG
DT   Journal
LA   English
RE.CNT  52    THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L54  ANSWER 2 OF 2  CAPLUS  COPYRIGHT 2003 ACS on STN
AN   1999:517257  CAPLUS
DN   132:2562
TI   Brain TXA2 and PGI2 levels in impact acceleration diffuse brain
     injury coupled with secondary insults
AU   Fei, Zhou; Zhang, Xiang; Yi, Shengyu; Piper, I. R.; Thomson, D.; Miller,
     J. D.
CS   Xijing Hospital, Xian, 710032, Peop. Rep. China
SO   Chinese Journal of Traumatology (English Edition) (1999), 2(1), 35-37
     CODEN: CJTRFY; ISSN: 1008-1275
PB   Chinese Journal of Traumatology (English Edition)
DT   Journal
LA   English
RE.CNT  11    THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> d l54 2 all

L54  ANSWER 2 OF 2  CAPLUS  COPYRIGHT 2003 ACS on STN
AN   1999:517257  CAPLUS
DN   132:2562
TI   Brain TXA2 and PGI2 levels in impact acceleration diffuse brain
     injury coupled with secondary insults
AU   Fei, Zhou; Zhang, Xiang; Yi, Shengyu; Piper, I. R.; Thomson, D.; Miller,
     J. D.
CS   Xijing Hospital, Xian, 710032, Peop. Rep. China
```

SO Chinese Journal of Traumatology (English Edition) (1999), 2(1), 35-37
CODEN: CJTRFY; ISSN: 1008-1275
PB Chinese Journal of Traumatology (English Edition)
DT Journal
LA English
CC 14-10 (Mammalian Pathological Biochemistry)
Section cross-reference(s): 1, 2
AB To study the changes of brain TXA2 and PGI2 levels in a new rodent model of **impact** acceleration diffuse brain injury with hypotension and hypoxia and the effect of diaspirin cross linked Hb soln. (DCLHb) on brain TXA2 and PGI2 levels. Thirty-two male SD rats were randomized into sham, head injury alone, head injury with secondary insults and injury with insults followed by DCLHb administration groups. Animals were physiol. monitored throughout the expt. and the prostanoids were measured via RIA (RIA). There were no changes in TXB2 and 6-keto-PGF1.alpha. (stable metabolites of TXA2 and PGI2) levels in injury alone group while TXB2 level in secondary insults group elevated significantly and both TXB2 and 6-keto-PGF1.alpha. levels in injury with insults followed by DCLHb administration augmented significantly in comparison with the corresponding value of sham at 4 h postimpact. The only increase in TXA2 level in secondary insults rats suggests that there may be both thrombotic episodes and vasoconstriction leading to focal increase in micro-circulatory resistance which contributes to a decreased focal **cerebral** blood flow (CBF). And it is hypothesed that DCLHb may exert its protective properties through increasing PGI2 prodn. in injured brain by affecting CBF and **cerebral** perfusion pressure (CPP).
ST TXA2 PGI2 brain injury hypotension hypoxia; diaspirin cross linked with Hb brain injury treatment
IT Hypotension
Hypoxia, animal
(brain TXA2 and PGI2 levels in **impact** acceleration diffuse brain injury coupled with secondary insults in rats)
IT Circulation
(**cerebral**; brain TXA2 and PGI2 levels in **impact** acceleration diffuse brain injury coupled with secondary insults in rats)
IT Hemoglobins
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(diaspirin cross linked with; brain TXA2 and PGI2 levels in **impact** acceleration diffuse brain injury coupled with secondary insults in rats)
IT Brain, disease
Head
(injury; brain TXA2 and PGI2 levels in **impact** acceleration diffuse brain injury coupled with secondary insults in rats)
IT Prostaglandins
RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence); PROC (Process)
(prostanoids; brain TXA2 and PGI2 levels in **impact** acceleration diffuse brain injury coupled with secondary insults in rats)
IT 35121-78-9, PGI2 57576-52-0, TXA2
RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence); PROC (Process)
(brain TXA2 and PGI2 levels in **impact** acceleration diffuse brain injury coupled with secondary insults in rats)
IT 58962-34-8
RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological

study, unclassified); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative); OCCU (Occurrence); PROC (Process)
(brain TXA2 and PGI2 levels in **impact** acceleration diffuse brain injury coupled with secondary insults in rats)

IT **578-19-8**, Diaspirin
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(crosslinked with Hb; brain TXA2 and PGI2 levels in **impact** acceleration diffuse brain injury coupled with secondary insults in rats)

RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Cole, D; Anesth Analg 1996, V83, P324
(2) Cole, D; Anesthesiology 1993, V78, P335 CAPLUS
(3) Cortbus, F; Acta Neurochir (Wien) 1994, V130, P117 MEDLINE
(4) Fei, Z; Chin J Traumatol Eng Ed 1998, V1, P49 CAPLUS
(5) Hamberg, M; Pro Natl Acad Sci (USA) 1974, V71, P3400 CAPLUS
(6) Jones, P; J Neurosurg Anesthesiol 1994, V6, P4 MEDLINE
(7) Katayama, Y; Adv Neurol 1990, V52, P105 MEDLINE
(8) Marmarou, A; J Neurosurg 1994, V80, P291 MEDLINE
(9) Nishisho, T; Neurosurgery 1996, V39, P950 MEDLINE
(10) Shohami, E; Nuerosurgery 1988, V22, P859 MEDLINE
(11) Weksler, B; Proc Natl Acad Sci USA 1977, V74, P3922 CAPLUS

=> d his

(FILE 'HOME' ENTERED AT 15:07:02 ON 15 SEP 2003)

FILE 'REGISTRY' ENTERED AT 15:07:15 ON 15 SEP 2003
E ACETOMINOPHEN
E ACETOMINOPHEN
E ACETOMINOPHEN
E NSAID
L1 9 S E3
E ASPIRIN
L2 52 S E3
E INDOMETHACIN
L3 52 S E3
E KETOPROFIN
E KETOPROFEN
L4 50 S E3
E TRILISATR
E TRILISATE
L5 1 S E3
L6 1158 S SALICYLAMIDE
L7 30 S SODIUM SALICYLATE
L8 6694 S SALICYLIC ACID
E ACETOMINOPHEN
E ACETAMINOPHEN
L9 130 S E3

FILE 'CAPLUS' ENTERED AT 15:20:03 ON 15 SEP 2003
L10 17725 S L2
L11 28561 S CNS
L12 28 S L10 AND L11
E TRAUMA
L13 11866 S E3
L14 68 S L13 AND L10
E HEAD
L15 94345 S E3

```
L16          12 S L14 AND L15
                E ISCHEMA
L17       53069 S E5-E8
L18         356 S L17 AND L10
                E CEREBRAL
L19       78138 S E3
L20          14 S L18 AND 19
L21          66 S L18 AND L19
L22           2 S L19 AND L12
L23         211 S L10 AND L19
L24          66 S L23 AND L17
L25           0 S L24 NOT L21
L26           2 S L12 AND L17
L27       10826 S L9
L28          46 S L5
L29          28 S L12 AND L10
                E LUPUS
L30       11819 S E3
L31          53 S L30 AND L10
                E ALZHEIMERS
L32        1977 S E3
L33           8 S L10 AND L32
                E NSAIDS
L34        3367 S E3
L35          36 S L34 AND L17
L36          28 S L11 AND L12
L37         685 S L11 AND L17
L38           2 S L37 AND L10
                E INFLAMMATION
L39       98265 S E3
L40        1177 S L39 AND L11
L41          10 S L40 AND L12
                E PARKINSON
L42       12980 S E3
L43          20 S L42 AND L10
L44        5189 S L7
L45          28 S L10 AND L12
L46           4 S L44 AND L42
L47        4560 S L6
L48           6 S L47 AND L42
                E NEUROTRAUMA
L49          28 S L11 AND L10
                E ALZHEIMER
L50       27161 S E3
L51          81 S L50 AND L10
                E IMPACT
L52      254082 S E3
L53         432 S L52 AND L19
L54           2 S L53 AND L10

=> s l53 and l27
L55           0 L53 AND L27

=> d his

     (FILE 'HOME' ENTERED AT 15:07:02 ON 15 SEP 2003)

     FILE 'REGISTRY' ENTERED AT 15:07:15 ON 15 SEP 2003
                E ACETOMINOPHEN
                E ACETOMINOPHEN
                E ACETOMINOPHEN
                E NSAID
```

```
L1             9 S E3
                 E ASPIRIN
L2            52 S E3
                 E INDOMETHACIN
L3            52 S E3
                 E KETOPROFIN
                 E KETOPROFEN
L4            50 S E3
                 E TRILISATR
                 E TRILISATE
L5             1 S E3
L6          1158 S SALICYLAMIDE
L7            30 S SODIUM SALICYLATE
L8          6694 S SALICYLIC ACID
                 E ACETOMINOPHEN
                 E ACETAMINOPHEN
L9           130 S E3

     FILE 'CAPLUS' ENTERED AT 15:20:03 ON 15 SEP 2003
L10        17725 S L2
L11        28561 S CNS
L12           28 S L10 AND L11
                 E TRAUMA
L13        11866 S E3
L14           68 S L13 AND L10
                 E HEAD
L15        94345 S E3
L16           12 S L14 AND L15
                 E ISCHEMA
L17        53069 S E5-E8
L18          356 S L17 AND L10
                 E CEREBRAL
L19        78138 S E3
L20           14 S L18 AND 19
L21           66 S L18 AND L19
L22            2 S L19 AND L12
L23          211 S L10 AND L19
L24           66 S L23 AND L17
L25            0 S L24 NOT L21
L26            2 S L12 AND L17
L27        10826 S L9
L28           46 S L5
L29           28 S L12 AND L10
                 E LUPUS
L30        11819 S E3
L31           53 S L30 AND L10
                 E ALZHEIMERS
L32         1977 S E3
L33            8 S L10 AND L32
                 E NSAIDS
L34         3367 S E3
L35           36 S L34 AND L17
L36           28 S L11 AND L12
L37          685 S L11 AND L17
L38            2 S L37 AND L10
                 E INFLAMMATION
L39        98265 S E3
L40         1177 S L39 AND L11
L41           10 S L40 AND L12
                 E PARKINSON
L42        12980 S E3
L43           20 S L42 AND L10
```

```
L44         5189 S L7
L45           28 S L10 AND L12
L46            4 S L44 AND L42
L47         4560 S L6
L48            6 S L47 AND L42
                 E NEUROTRAUMA
L49           28 S L11 AND L10
                 E ALZHEIMER
L50        27161 S E3
L51           81 S L50 AND L10
                 E IMPACT
L52       254082 S E3
L53          432 S L52 AND L19
L54            2 S L53 AND L10
L55            0 S L53 AND L27

=>

---Logging off of STN---


=>
Executing the logoff script...


=> LOG Y

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   388.01     446.40

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                   -15.62     -15.62

STN INTERNATIONAL LOGOFF AT 16:40:48 ON 15 SEP 2003
```

Welcome to STN International! Enter x:x

LOGINID:sssptau125rxt

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	Feb 24	PCTGEN now available on STN
NEWS 4	Feb 24	TEMA now available on STN
NEWS 5	Feb 26	NTIS now allows simultaneous left and right truncation
NEWS 6	Feb 26	PCTFULL now contains images
NEWS 7	Mar 04	SDI PACKAGE for monthly delivery of multifile SDI results
NEWS 8	Mar 24	PATDPAFULL now available on STN
NEWS 9	Mar 24	Additional information for trade-named substances without structures available in REGISTRY
NEWS 10	Apr 11	Display formats in DGENE enhanced
NEWS 11	Apr 14	MEDLINE Reload
NEWS 12	Apr 17	Polymer searching in REGISTRY enhanced
NEWS 13	SEP 09	CA/CAplus records now contain indexing from 1907 to the present
NEWS 14	Apr 21	New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX
NEWS 15	Apr 28	RDISCLOSURE now available on STN
NEWS 16	May 05	Pharmacokinetic information and systematic chemical names added to PHAR
NEWS 17	May 15	MEDLINE file segment of TOXCENTER reloaded
NEWS 18	May 15	Supporter information for ENCOMPPAT and ENCOMPLIT updated
NEWS 19	May 19	Simultaneous left and right truncation added to WSCA
NEWS 20	May 19	RAPRA enhanced with new search field, simultaneous left and right truncation
NEWS 21	Jun 06	Simultaneous left and right truncation added to CBNB
NEWS 22	Jun 06	PASCAL enhanced with additional data
NEWS 23	Jun 20	2003 edition of the FSTA Thesaurus is now available
NEWS 24	Jun 25	HSDB has been reloaded
NEWS 25	Jul 16	Data from 1960-1976 added to RDISCLOSURE
NEWS 26	Jul 21	Identification of STN records implemented
NEWS 27	Jul 21	Polymer class term count added to REGISTRY
NEWS 28	Jul 22	INPADOC: Basic index (/BI) enhanced; Simultaneous Left and Right Truncation available
NEWS 29	AUG 05	New pricing for EUROPATFULL and PCTFULL effective August 1, 2003
NEWS 30	AUG 13	Field Availability (/FA) field enhanced in BEILSTEIN
NEWS 31	AUG 15	PATDPAFULL: one FREE connect hour, per account, in September 2003
NEWS 32	AUG 15	PCTGEN: one FREE connect hour, per account, in September 2003
NEWS 33	AUG 15	RDISCLOSURE: one FREE connect hour, per account, in September 2003
NEWS 34	AUG 15	TEMA: one FREE connect hour, per account, in September 2003
NEWS 35	AUG 18	Data available for download as a PDF in RDISCLOSURE
NEWS 36	AUG 18	Simultaneous left and right truncation added to PASCAL
NEWS 37	AUG 18	FROSTI and KOSMET enhanced with Simultaneous Left and Right Truncation

AN 1998:605885 CAPLUS
DN 129:339797
TI Influence of aspirin on nerve injury of experimental **cerebral ischemia** in rabbits
AU Liu, Shi-Xiang; Hou, Jing-Bian; Yang, Qing-Zhou; Zhang, Jia-Lin; Huang, Li-Chun; Liang, Yan
CS Dep. Neurol., Kunming Gen. Hosp., Kumming, 650032, Peop. Rep. China
SO Zhongguo Bingli Shengli Zazhi (1997), 13(2), 162-164
CODEN: ZBSZEB; ISSN: 1000-4718
PB Jinan Daxue
DT Journal
LA Chinese
CC 1-11 (Pharmacology)
AB Platelet play an important role in **cerebral** ischemial nerve injury. Aspirin (ASA) had been used to treat and prevent stroke in clinic. 30 Rabbits were randomly divided into A, B and C groups. In group A ASA was given orally at a daily dosage of 15 mg/kg per rabbit for 5 days before **cerebral ischemia**; group B **cerebral ischemia** without giving ASA, and group C was normal rabbits as controls. The **cerebral** ischemial model was produced by occluding bilateral carotid arteries and bleeding from femoral artery. The results indicated that there was an obvious decrease of platelet aggregation and TXA2 and had no significance changes in free radicals increasing and Ca2+ rising from **cerebral** tissue in group A. The **cerebral** edema of group A was less severe than group B. It seemed that ASA had a protective effect on the nerve injury of **cerebral ischemia**. The derangement of ASA, platelet, free radicals and calcium ions interrelation and their significance on the nerve injury should be further studied.
ST aspirin nerve injury brain **ischemia** TXA2
IT Brain, disease
(**cerebral** cortex, **ischemia**; influence of aspirin on nerve injury of exptl. **cerebral ischemia** in rabbits)
IT Platelet aggregation inhibitors
(influence of aspirin on nerve injury of exptl. **cerebral ischemia** in rabbits)
IT Nerve, disease
(injury; influence of aspirin on nerve injury of exptl. **cerebral ischemia** in rabbits)
IT Cytoprotective agents
(neuroprotectants; influence of aspirin on nerve injury of exptl. **cerebral ischemia** in rabbits)
IT **50-78-2**, Aspirin
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(influence of aspirin on nerve injury of exptl. **cerebral ischemia** in rabbits)
IT 57576-52-0, Thromboxane A2
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(influence of aspirin on nerve injury of exptl. **cerebral ischemia** in rabbits)

=>

AN 1992:504057 CAPLUS
DN 117:104057
TI **Intrathecal** injection of acetylsalicylic acid, salicylic acid and indometacin depresses C fiber-evoked activity in the rat thalamus and spinal cord
AU Jurna, Ilmar; Spohrer, Birgit; Bock, Rudolf
CS Inst. Pharmakol. Toxikol., Univ. Saarlandes, Homburg/Saar, D-6650, Germany
SO Pain (1992), 49(2), 249-56
CODEN: PAINDB; ISSN: 0304-3959
DT Journal
LA English
CC 1-11 (Pharmacology)
AB It was aimed to assess if **intrathecal** (i.t.) injections of acetylsalicylic acid and salicylic acid depress C-fiber-evoked activity in the sensory part of the nociceptive system. In rats under urethane anesthesia, activity was elicited in single neurons in the dorsomedial part of the ventral nucleus (VDM) of the thalamus and in ascending axons of the spinal cord by supramaximal elec. stimulation of the sural nerve. Acetylsalicylic acid and salicylic acid injected i.t. significantly reduced the activity evoked in thalamic neurons. The max. depression amounted to about 50% of the activity evoked in the controls and was produced by acetylsalicylic acid at a dose of 50 .mu.g (0.28 .mu.mol)/rat and by salicylic acid at a dose of 37.5 .mu.g (0.27 .mu.mol)/rat. Indometacin injected i.t. also reduced C-fiber-evoked activity in the thalamus in a dose-dependent fashion, 100 .mu.g producing a 50% depression. Salicylic acid (37.5 .mu.g/rat, i.t.) depressed C-fiber-evoked activity in ascending axons but had no effect on A.beta. fiber-evoked activity. It is concluded that i.t. injection of acetylsalicylic acid selectively inhibits nociceptive impulse transmission in the spinal cord by an action of the salicylic acid moiety. It is possible that prostaglandins are involved in the central action of salicylic acid.
ST C fiber thalamus spinal cord analgesic; acetylsalicylate C fiber thalamus spinal cord; salicylate C fiber thalamus spinal cord; indomethacin C fiber thalamus spinal cord
IT Spinal cord
(C-fiber-evoked activity in, acetylsalicylic and salicylic acids effect on, analgesic mechanism in relation to)
IT Prostaglandins
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(in central analgesic action of salicylic acid)
IT Analgesics
(**intrathecal**, C-fiber-evoked activity inhibition by, in thalamus and spinal cord, mechanism of)
IT Nerve
(C-fiber, acetylsalicylic and salicylic acids effect on, of thalamus and spinal cord, analgesic mechanism in relation to)
IT Nerve
(nociceptive, axon, acetylsalicylic and salicylic acids effect on, of thalamus and spinal cord, analgesic mechanism in relation to)
IT Brain
(thalamus, C-fiber-evoked activity in, acetylsalicylic and salicylic acids effect on, analgesic mechanism in relation to)
IT **50-78-2**, Acetylsalicylic acid 53-86-1, Indomethacin 69-72-7, Salicylic acid, biological studies
RL: BIOL (Biological study)
(**intrathecal**, C-fiber-evoked activity inhibition by, in thalamus and spinal cord, mechanism of)

=>

AN 1981:561869 CAPLUS
DN 95:161869
TI A study on constrictor responses of dog **coronary** arteries to acetylsalicylic acid
AU Sakanashi, M.; Araki, H.; Furukawa, T.; Rokutanda, M.; Yonemura, K.
CS Med. Sch., Kumamoto Univ., Kumamoto, 860, Japan
SO Archives Internationales de Pharmacodynamie et de Therapie (1981), 252(1), 86-96
CODEN: AIPTAK; ISSN: 0003-9780
DT Journal
LA English
CC 1-4 (Pharmacodynamics)
GI



I

AB In isolated and perfused dog hearts an intracoronary **injection** of acetylsalicylic acid (I) [**50-78-2**] (10 mg) decreased **coronary** blood flow concomitant with diminution of myocardial contractile force, but did not change heart rate. Contractions were produced in isolated dog **coronary** arterial strips by I (10-4 M) and these were significantly inhibited by Ca2+-free soln., diltiazem, nifedipine, phospholipase A2, arachidonate, and prostaglandin E1. Apparently, I at a high dose produces **coronary** arterial contraction probably through inhibition of intravascular synthesis of vasodilating prostaglandins.
ST acetylsalicylate **coronary** artery contraction; prostaglandin acetylsalicylate **coronary** artery contraction
IT Prostaglandins
RL: BIOL (Biological study)
(**coronary** artery contraction from acetylsalicylic acid in relation to)
IT Artery
(**coronary**, contraction of, from aspirin, prostaglandins in relation to)
IT **50-78-2**
RL: BIOL (Biological study)
(**coronary** artery contraction by, prostaglandin in relation to)

=>

AN 1979:36972 CAPLUS
DN 90:36972
TI Entry of protein into cerebral ventricles during ventriculo-cisternal perfusion and the administration of anti-inflammatory agents
AU Haywood, J. R.; Vogh, B. P.
CS Dep. Pharmacol Ther., Univ. Florida, Gainesville, FL, USA
SO Journal of Neurochemistry (1978), 30(6), 1621-3
CODEN: JONRA9; ISSN: 0022-3042
DT Journal
LA English
CC 13-13 (Mammalian Biochemistry)
Section cross-reference(s): 1
AB During brain ventriculo-cisternal perfusion (VCP) in cats, entry of protein into the ventricles was stable over 30-150 min, after which the rate increased up to the end of the exptl. period (330 min). When the VCP procedures involved increased trauma to meningeal tissues, e.g., by using a blunted needle, the early and late stable mean rate of influx was higher and probably more direct leakage occurred due to the invasive technique itself. Gentamicin, tobramycin, acetylsalicylic acid (15-30 mg/kg i.v. or 200 .mu.M **intrathecally**), indomethacin (3.4 .mu.M), and meclofenamic acid (1.7 .mu.M) all failed to reduce the protein entry, but dexamethasone given i.v. at the beginning of perfusion (0.3 mg/kg, i.v.) and in repeated doses (0.15 mg/kg/h) lowered the initial rate of protein entry and markedly attenuated the subsequent rise in protein influx.
ST ventriculocisternal perfusion protein entry ventricle; antiinflammatory ventriculocisternal perfusion protein influx; dexamethasone ventriculocisternal perfusion protein influx; brain ventricle protein entry perfusion
IT Proteins
RL: BIOL (Biological study)
(brain ventricle influx of, in ventriculo-cisternal perfusion)
IT Cerebrospinal fluid
(protein entry into, in ventriculo-cisternal perfusion)
IT Inflammation inhibitors
(protein influx into brain ventricles in ventriculo-cisternal perfusion response to)
IT Brain
(ventricle, protein entry into, in ventriculo-cisternal perfusion)
IT 50-02-2 **50-78-2** 53-86-1 644-62-2 1403-66-3 32986-56-4
RL: BIOL (Biological study)
(protein influx into brain ventricles in ventriculo-cisternal perfusion response to)

=>

```
=> file reg
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.21

FILE 'REGISTRY' ENTERED AT 12:17:29 ON 29 SEP 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   28 SEP 2003  HIGHEST RN 594810-89-6
DICTIONARY FILE UPDATES:  28 SEP 2003  HIGHEST RN 594810-89-6

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2003

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available.  See HELP
PROPERTIES for more information.  See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> s aspirin
L1          52 ASPIRIN

=> e nsaids
E1           4     NSAH9/BI
E2           9     NSAID/BI
E3           0 --> NSAIDS/BI
E4           1     NSAN/BI
E5           1     NSANI/BI
E6           1     NSANIDI/BI
E7           1     NSANIDINE/BI
E8           2     NSANT1/BI
E9           6     NSAP1/BI
E10         16     NSB/BI
E11          2     NSB1/BI
E12          1     NSB105/BI

=> e nsaid
E1           2     NSAF/BI
E2           4     NSAH9/BI
E3           9 --> NSAID/BI
E4           1     NSAN/BI
E5           1     NSANI/BI
E6           1     NSANIDI/BI
E7           1     NSANIDINE/BI
E8           2     NSANT1/BI
E9           6     NSAP1/BI
E10         16     NSB/BI
E11          2     NSB1/BI
E12          1     NSB105/BI

=> s e3
L2           9 NSAID/BI
```

```
=> d l2 9

L2   ANSWER 9 OF 9  REGISTRY  COPYRIGHT 2003 ACS on STN
RN   204298-06-6  REGISTRY
CN   DNA (rat liver NSAID-regulated gene protein-specifying cDNA
     594-nucleic acid) (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   8: PN: WO0138579 PAGE: 13 claimed DNA
FS   NUCLEIC ACID SEQUENCE
MF   Unspecified
CI   MAN
SR   CA
LC   STN Files:   CA, CAPLUS, TOXCENTER

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
               1 REFERENCES IN FILE CA (1907 TO DATE)
               1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


=> file caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                               10.92      11.13

FILE 'CAPLUS' ENTERED AT 12:18:24 ON 29 SEP 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 29 Sep 2003  VOL 139 ISS 14
FILE LAST UPDATED: 28 Sep 2003  (20030928/ED)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.


=> e nsaids
E1            1     NSAID5/BI
E2            1     NSAIDH/BI
E3         3396 --> NSAIDS/BI
E4            3     NSAIDSS/BI
E5            1     NSAIFA/BI
E6            1     NSAIFD/BI
E7            2     NSAIIDS/BI
E8            1     NSAIO/BI
E9            6     NSAIS/BI
E10           1     NSAISS/BI
```

```
E11          2     NSAIW/BI
E12          1     NSAJDS/BI

=> s e3
L3        3396 NSAIDS/BI

=> s l1
L4       17770 L1

=> e intrathecaly
E1        1682     INTRATHECALLY/BI
E2           1     INTRATHECALTY/BI
E3           1 --> INTRATHECALY/BI
E4           1     INTRATHECHAL/BI
E5           1     INTRATHECOL/BI
E6           1     INTRATHEKAL/BI
E7           1     INTRATHELIAL/BI
E8           1     INTRATHEORY/BI
E9           4     INTRATHERAPEUTIC/BI
E10          6     INTRATHERAPY/BI
E11          6     INTRATHERM/BI
E12          1     INTRATHERMOCLINE/BI

=> s e1-e3
          1682 INTRATHECALLY/BI
             1 INTRATHECALTY/BI
             1 INTRATHECALY/BI
L5        1682 (INTRATHECALLY/BI OR INTRATHECALTY/BI OR INTRATHECALY/BI)

=> s l3 and l5
L6           6 L3 AND L5

=> d l6 1-6

L6   ANSWER 1 OF 6  CAPLUS  COPYRIGHT 2003 ACS on STN
AN   2003:122594  CAPLUS
DN   139:62895
TI   Involvement of serotonin mechanisms in the antinociceptive effect of
     S(+)-ketoprofen
AU   Diaz-Reval, M. Irene; Ventura-Martinez, Rosa; Deciga-Campos, Myrna;
     Terron, Jose A.; Cabre, Francesc; Lopez-Munoz, Francisco J.
CS   Cinvestav-IPN, Departamento de Farmacobiologia, Cinvestav-IPN, Mexico,
     C.P. 14330, Mex.
SO   Drug Development Research (2002), 57(4), 187-192
     CODEN: DDREDK; ISSN: 0272-4391
PB   Wiley-Liss, Inc.
DT   Journal
LA   English
RE.CNT  31    THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6   ANSWER 2 OF 6  CAPLUS  COPYRIGHT 2003 ACS on STN
AN   2003:79511  CAPLUS
DN   139:30426
TI   Carbachol interactions with nonsteroidal anti-inflammatory drugs
AU   Miranda, H. F.; Sierralta, F.; Pinardi, G.
CS   Pharmacology Program, ICBM, Faculty of Medicine, University of Chile,
     Santiago, 7, Chile
SO   Canadian Journal of Physiology and Pharmacology (2002), 80(12), 1173-1179
     CODEN: CJPPA3; ISSN: 0008-4212
PB   National Research Council of Canada
DT   Journal
```

LA English
RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:417314 CAPLUS
DN 138:11228
TI Paracetamol exerts a spinal, tropisetron-reversible, antinociceptive effect in an inflammatory pain model in rats
AU Alloui, Abdelkrim; Chassaing, Claude; Schmidt, Jeannot; Ardid, Denis; Dubray, Claude; Cloarec, Alix; Eschalier, Alain
CS Faculte de Medecine, Laboratoire de Pharmacologie Medicale, EMI INSERM/UdA 9904, Clermont-Ferrand, 63001, Fr.
SO European Journal of Pharmacology (2002), 443(1-3), 71-77
CODEN: EJPHAZ; ISSN: 0014-2999
PB Elsevier Science B.V.
DT Journal
LA English
RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:695300 CAPLUS
DN 136:31578
TI Interactions of prazosin with non-steroidal anti- inflammatory drugs
AU Miranda, H. F.; Pinardi, G.
CS Pharmacology Program, ICBM, Faculty of Medicine, University of Chile, Chile
SO Pharmacology Reviews and Communications (2001), 11(3), 253-262
CODEN: PHRCF6; ISSN: 1028-8945
PB Harwood Academic Publishers
DT Journal
LA English
RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1995:932070 CAPLUS
DN 124:21986
TI Intrathecal steroids to reduce pain after lumbar disk surgery: A double-blind, placebo-controlled prospective study
AU Langmayr, Johann J.; Obwegeser, Alois A.; Schwarz, Andreas B.; Laimer, Ilse; Ulmer, Hanno; Ortler, Martin
CS Universitaetsklinik Neurochirurgie, Innsbruck, 6020, Austria
SO Pain (1995), 62(3), 357-61
CODEN: PAINDB; ISSN: 0304-3959
PB Elsevier
DT Journal
LA English

L6 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1995:453105 CAPLUS
DN 122:256081
TI Central antinociceptive effects of non-steroidal anti-inflammatory drugs and paracetamol: experimental studies in the rat
AU Bjoerkman, Roland
CS Department of Pharmacology, University of Gothenburg, Goeteborg, Swed.
SO Acta Anaesthesiologica Scandinavica, Supplementum (1995), 103, 44pp.
CODEN: AASXAP; ISSN: 0515-2720
PB Munksgaard
DT Journal
LA English

=> d l6 5 all

L6 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1995:932070 CAPLUS
DN 124:21986
TI Intrathecal steroids to reduce pain after lumbar disk surgery: A double-blind, placebo-controlled prospective study
AU Langmayr, Johann J.; Obwegeser, Alois A.; Schwarz, Andreas B.; Laimer, Ilse; Ulmer, Hanno; Ortler, Martin
CS Universitaetsklinik Neurochirurgie, Innsbruck, 6020, Austria
SO Pain (1995), 62(3), 357-61
CODEN: PAINDB; ISSN: 0304-3959
PB Elsevier
DT Journal
LA English
CC 2-4 (Mammalian Hormones)
AB This double-blind, placebo-controlled prospective study investigated whether corticosteroids (beta-methasone) influence residual radicular pain after lumbar disk surgery. The study population consisted of 26 patients undergoing surgery for a herniated lumbar disk at our University Neurosurgical Department. Thirteen patients received beta-methasone **intrathecally** prior to wound closure, and 13- patients received normal saline. Main outcome measures were pain intensity graded on a 100-mm visual analog pain scale (VAS) and consumption of non-steroidal anti-inflammatory agents (**NSAIDs**). Both patient groups had comparable presurgical findings and pain intensity level (55 mm and 54 mm, resp., on a 100-mm VAS). After surgery, residual pain declined gradually in the placebo group (mean 39, 29, 24, 20 mm on days 1-4; 10 mm on day 8) and abruptly in the corticosteroid group (mean 15, 15, 11, 8, mm on days 1-4; 5 mm on day 8). Anal. of variance (ANOVA) showed a highly significant influence of time ($P<0.001$), a significant influence of steroid application ($P = 0.014$) and interaction between time and application of steroids ($P = 0.042$). Mean daily consumption of **NSAIDs** did not differ significantly in either group: 124 mg in the treatment vs. 150 mg in the placebo group ($P > 0.25$). At follow-up after 6 mo, residual radicular pain was rated equally by both groups (4 mm in the treatment vs. 5 mm in the placebo group, $P > 0.5$). Intrathecal application of steroids provides short-lasting, statistically significant pain redn. after lumbar disk surgery. Benefits of intrathecal steroids are probably outweighed by the risks assocd. with violation of the dural barrier.
ST steroid lumbar disk surgery pain
IT Pain
Surgery
(intrathecal steroids to reduce pain after lumbar disk surgery in humans)
IT Spinal column
(lumbar intervertebral disk, intrathecal steroids to reduce pain after lumbar disk surgery in humans)
IT 378-44-9, Beta-methasone
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(intrathecal steroids to reduce pain after lumbar disk surgery in humans)

=> d l6 6 all

L6 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1995:453105 CAPLUS
DN 122:256081
TI Central antinociceptive effects of non-steroidal anti-inflammatory drugs and paracetamol: experimental studies in the rat
AU Bjoerkman, Roland
CS Department of Pharmacology, University of Gothenburg, Goeteborg, Swed.
SO Acta Anaesthesiologica Scandinavica, Supplementum (1995), 103, 44pp.
CODEN: AASXAP; ISSN: 0515-2720
PB Munksgaard
DT Journal
LA English
CC 1-11 (Pharmacology)
AB These studies were undertaken to investigate the site and nature of the antinociceptive effect of **NSAIDs** (Non-Steroidal Anti-Inflammatory Drugs) and paracetamol in the central nervous system (CNS). Different nociceptive test models were employed: the tail-flick and hot-plate tests (thermoreceptors), the writhing test (visceral chemoreceptors) the "scratching, biting, licking" (SBL) behavior and the colorectal distension test (mechanoreceptors). Drugs were given i.p., intracerebroventricularly (i.c.v.), **intrathecally** (i.t.) or as local injection via cannulae implanted stereotactically. Nerve destruction was made by local injection of the neurotoxin 5,7-dihydroxytryptamine (5,7-DHT). Whole brain and spinal cord contents of serotonin and 5-hydroxyindole acetic acid (5-HIAA) were analyzed by high pressure liq. chromatog. (HPLC). Injections of diclofenac induced antinociception in visceral pain models (writhing test, colorectal distension test), but not in two models of somatosensory pain (tail-flick and hot-plate test). The antinociceptive effect of diclofenac (i.p., i.c.v., or i.t.) was reversed by i.p. naloxone. Naloxone also reversed the effect of diclofenac injected locally into thalamic and hypothalamic areas involved in pain transmission as well as in n. paragigantocellularis or n. raphe magnus. In addn., chem. destruction of the n. raphe region attenuated the antinociceptive effect of diclofenac. Inhibition of serotonergic transmission by pretreatment with methiothepin, ritanserin, parachlorophenylalanine (PCPA) or 5,7-DHT also reduced the antinociceptive effect of diclofenac in a visceral pain model. Pretreatment with diclofenac or ibuprofen blocked pain behavior (SBL) after activation of excitatory amino acid receptors of the NMDA type, but not pain behavior after activation of AMPA or substance P (SP) receptors. Paracetamol inhibited hyperalgesia after both NMDA and SP. The antinociceptive effects of diclofenac, ibuprofen and paracetamol were reversed by L-arginine, but not by D-arginine. The antinociceptive effect of diclofenac involves a central nervous component which may be elicited from several defined areas in the CNS. Part of the antinociceptive effect seems to be mediated by descending inhibitory opioid, serotonin and/or other neurotransmitter systems interfering with visceral pain impulse traffic at the spinal level. **NSAIDs** and paracetamol interfere with nociception assocd. with spinal NMDA receptor activation. This effect involves an inhibitory action on spinal nitric oxide (NO) mechanisms. Possibly, the supraspinal antinociceptive effect of **NSAIDs** may be explained by an analogous action.
ST NSAID paracetamol analgesia CNS site mechanism
IT Analgesics
Inflammation inhibitors
(central antinociceptive effects of non-steroidal anti-inflammatory drugs and paracetamol)
IT Nervous system
(central, central antinociceptive effects of non-steroidal anti-inflammatory drugs and paracetamol)
IT Receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(glutamatergic, methyl-D-aspartate-binding, in central antinociceptive

effects of non-steroidal anti-inflammatory drugs and paracetamol)
IT Neurohormones
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(neurotransmitters, in central antinociceptive effects of non-steroidal anti-inflammatory drugs and paracetamol)
IT 53-86-1, Indomethacin 54-21-7, Sodium salicylate 103-90-2, Paracetamol 15307-79-6, Diclofenac sodium 22204-53-1, Naproxen 36322-90-4, Piroxicam 51146-56-6 51146-57-7, R(-)-Ibuprofen
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(central antinociceptive effects of non-steroidal anti-inflammatory drugs and paracetamol)
IT 10102-43-9, Nitric oxide, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(in central antinociceptive effects of non-steroidal anti-inflammatory drugs and paracetamol)

=> s l4 and l5
L7 3 L4 AND L5

=> d l7 1-3

L7 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1994:289642 CAPLUS
DN 120:289642
TI Intrathecal acetylsalicylic acid and indomethacin are not analgesic for a supramaximal stimulus
AU Antognini, Joseph F.
CS Dep. Anesthesiol., Univ. California, Davis, CA, USA
SO Anesthesia & Analgesia (Baltimore, MD, United States) (1993), 76(5), 1079-82
CODEN: AACRAT; ISSN: 0003-2999
DT Journal
LA English

L7 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1985:589740 CAPLUS
DN 103:189740
TI Acetylsalicylic acid, paracetamol and morphine inhibit behavior responses to **intrathecally** administered substance P or capsaicin
AU Hunskaar, Steinar; Fasmer, Ole Bernt; Hole, Kjell
CS Dep. Physiol., Univ. Bergen, Bergen, N-5000, Norway
SO Life Sciences (1985), 37(19), 1835-41
CODEN: LIFSAK; ISSN: 0024-3205
DT Journal
LA English

L7 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1979:36972 CAPLUS
DN 90:36972
TI Entry of protein into cerebral ventricles during ventriculo-cisternal perfusion and the administration of anti-inflammatory agents
AU Haywood, J. R.; Vogh, B. P.
CS Dep. Pharmacol Ther., Univ. Florida, Gainesville, FL, USA
SO Journal of Neurochemistry (1978), 30(6), 1621-3
CODEN: JONRA9; ISSN: 0022-3042
DT Journal
LA English

```
=> d l7 3 all

L7   ANSWER 3 OF 3  CAPLUS  COPYRIGHT 2003 ACS on STN
AN   1979:36972  CAPLUS
DN   90:36972
TI   Entry of protein into cerebral ventricles during ventriculo-cisternal
     perfusion and the administration of anti-inflammatory agents
AU   Haywood, J. R.; Vogh, B. P.
CS   Dep. Pharmacol Ther., Univ. Florida, Gainesville, FL, USA
SO   Journal of Neurochemistry (1978), 30(6), 1621-3
     CODEN: JONRA9; ISSN: 0022-3042
DT   Journal
LA   English
CC   13-13 (Mammalian Biochemistry)
     Section cross-reference(s): 1
AB   During brain ventriculo-cisternal perfusion (VCP) in cats, entry of
     protein into the ventricles was stable over 30-150 min, after which the
     rate increased up to the end of the exptl. period (330 min).  When the VCP
     procedures involved increased trauma to meningeal tissues, e.g., by using
     a blunted needle, the early and late stable mean rate of influx was higher
     and probably more direct leakage occurred due to the invasive technique
     itself.  Gentamicin, tobramycin, acetylsalicylic acid (15-30 mg/kg i.v. or
     200 .mu.M intrathecally), indomethacin (3.4 .mu.M), and
     meclofenamic acid (1.7 .mu.M) all failed to reduce the protein entry, but
     dexamethasone given i.v. at the beginning of perfusion (0.3 mg/kg, i.v.)
     and in repeated doses (0.15 mg/kg/h) lowered the initial rate of protein
     entry and markedly attenuated the subsequent rise in protein influx.
ST   ventriculocisternal perfusion protein entry ventricle; antiinflammatory
     ventriculocisternal perfusion protein influx; dexamethasone
     ventriculocisternal perfusion protein influx; brain ventricle protein
     entry perfusion
IT   Proteins
     RL: BIOL (Biological study)
        (brain ventricle influx of, in ventriculo-cisternal perfusion)
IT   Cerebrospinal fluid
        (protein entry into, in ventriculo-cisternal perfusion)
IT   Inflammation inhibitors
        (protein influx into brain ventricles in ventriculo-cisternal perfusion
        response to)
IT   Brain
        (ventricle, protein entry into, in ventriculo-cisternal perfusion)
IT   50-02-2 50-78-2  53-86-1  644-62-2  1403-66-3  32986-56-4
     RL: BIOL (Biological study)
        (protein influx into brain ventricles in ventriculo-cisternal perfusion
        response to)


=> e intraventicularly
E1          1     INTRAVENT/BI
E2         22     INTRAVENTICULAR/BI
E3          6 --> INTRAVENTICULARLY/BI
E4          1     INTRAVENTION/BI
E5         19     INTRAVENTRAL/BI
E6          1     INTRAVENTRALLY/BI
E7          1     INTRAVENTRI/BI
E8          7     INTRAVENTRICALLY/BI
E9          4     INTRAVENTRICLE/BI
E10         1     INTRAVENTRICUIAR/BI
E11         1     INTRAVENTRICULALR/BI
E12      5324     INTRAVENTRICULAR/BI

=> s e2-e3
```

```
            22 INTRAVENTICULAR/BI
             6 INTRAVENTICULARLY/BI
L8          28 (INTRAVENTICULAR/BI OR INTRAVENTICULARLY/BI)

=> s l8 and l4
L9           0 L8 AND L4

=> e coranary
E1           1     CORANAPHENES/BI
E2           1     CORANARIUM/BI
E3           2 --> CORANARY/BI
E4           5     CORANATE/BI
E5          12     CORAND/BI
E6           6     CORANDOMIZATION/BI
E7          15     CORANDOMIZED/BI
E8           1     CORANDONI/BI
E9          11     CORANDS/BI
E10          1     CORANE/BI
E11          1     CORANENE/BI
E12          1     CORANF/BI

=> e coronary
E1           2     CORONARUM/BI
E2           1     CORONARVIRUS/BI
E3       50167 --> CORONARY/BI
E4           1     CORONARYARTERY/BI
E5           1     CORONARYDILATATORY/BI
E6           3     CORONARYDILATING/BI
E7           1     CORONARYDILATORS/BI
E8           1     CORONARYHEARTDISEASE/BI
E9           1     CORONARYR/BI
E10          1     CORONARYRESISTANT/BI
E11          1     CORONARYSINUS/BI
E12          1     CORONARYSYNDROME/BI

=> s e3
L10      50167 CORONARY/BI

=> s l10 and l4
L11        646 L10 AND L4

=> e injection
E1           6     INJECTIOIN/BI
E2           1     INJECTIOION/BI
E3      420947 --> INJECTION/BI
E4           1     INJECTION2/BI
E5          10     INJECTIONABLE/BI
E6          13     INJECTIONAL/BI
E7           2     INJECTIONALLY/BI
E8           1     INJECTIONAN/BI
E9           1     INJECTIONAND/BI
E10          2     INJECTIONCOOKING/BI
E11          1     INJECTIONDIODES/BI
E12         10     INJECTIONE/BI

=> s e3
L12     420947 INJECTION/BI

=> s l11 and l12
L13         23 L11 AND L12

=> d l13 10-23
```

L13 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1999:228739 CAPLUS
DN 131:53782
TI Production of Prostanoids and Nitric Oxide by Infarcted Heart in Situ and the Effect of Aspirin
AU Yamamoto, Tadahiko; Cohen, Anna M.; Kakar, N. Rani; Yamamoto, Masako; Johnson, Paul E.; Cho, Y. Kelly; Bing, Richard J.
CS Department of Experimental Cardiology, Huntington Medical Research Institutes, Pasadena, CA, 91101, USA
SO Biochemical and Biophysical Research Communications (1999), 257(2), 488-493
CODEN: BBRCA9; ISSN: 0006-291X
PB Academic Press
DT Journal
LA English
RE.CNT 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 11 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:610470 CAPLUS
DN 130:10440
TI Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial
AU Cohen, Marc; Demers, Christine; Gurfinkel, Enrique P.; Turpie, Alexander G. G.; Fromell, Gregg J.; Goodman, Shaun; Langer, Anatoly; Califf, Robert M.; Fox, Keith A. A.; Premmereur, Jerome; Bigonzi, Frederique
CS Division of Cardiology, Hahnemann Division, Allegheny University of the Health Sciences, Philadelphia, PA, 19102-1192, USA
SO American Journal of Cardiology (1998), 82(5B), 19L-24L
CODEN: AJCDAG; ISSN: 0002-9149
PB Excerpta Medica, Inc.
DT Journal
LA English
RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 12 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:466083 CAPLUS
DN 129:188157
TI Intravenous administration of the glycoprotein IIb-IIIa receptor antagonist 7E3 induces reperfusion of an acute thrombotic occlusion of the canine **coronary** artery
AU Shetler, Timothy J.; Bailey, Blanche D.; Jakubowski, Joseph A.; Jackson, Charles V.
CS Lilly Research Laboratories, Cardiovascular Research Division, Eli Lilly and Company, Indianapolis, IN, 46285-0524, USA
SO Thrombosis Research (1998), 90(2), 95-100
CODEN: THBRAA; ISSN: 0049-3848
PB Elsevier Science Inc.
DT Journal
LA English
RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 13 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:164133 CAPLUS
DN 128:266004
TI Enhancement of tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by combination with a humanized anti-glycoprotein IIb/IIIa monoclonal antibody, YM337, in a rhesus monkey model of **coronary** thrombosis

AU Kawasaki, Tomihisa; Sato, Kazuo; Suzuki, Kenichi; Sakai, Yumiko; Taniuchi, Yuta; Kaku, Seiji; Yano, Shinya; Inagaki, Osamu; Tomioka, Kenichi; Masuho, Yasuhiko; Yanagisawa, Isao; Takenaka, Toichi
CS Institute Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., Tsukuba, 305, Japan
SO Thrombosis and Haemostasis (1998), 79(3), 663-667
CODEN: THHADQ; ISSN: 0340-6245
PB F. K. Schattauer Verlagsgesellschaft mbH
DT Journal
LA English

L13 ANSWER 14 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1997:567812 CAPLUS
DN 127:214894
TI A comparison of low-molecular-weight heparin with unfractionated heparin for unstable **coronary** artery disease
AU Cohen, Marc; Demers, Christine; Gurfinkel, Enrique P.; Turpie, Alexander G. G.; Fromell, Gregg J.; Goodman, Shaun; Langer, Anatoly; Califf, Robert M.; Fox, Keith A. A.; Premmereur, Jerome; Bigonzi, Frederique
CS Division of Cardiology, Allegheny University Hospitals-Hahnemann Division, Philadelphia, PA, 19102, USA
SO New England Journal of Medicine (1997), 337(7), 447-452
CODEN: NEJMAG; ISSN: 0028-4793
PB Massachusetts Medical Society
DT Journal
LA English

L13 ANSWER 15 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1995:843056 CAPLUS
DN 123:275572
TI A new animal model of **coronary** thrombosis and effects of antithrombotic agents
AU Zhang, Weidong; Wang, Peng; Chen, Zhan; Fan, Yaming
CS Anzhen Hospital, Beijing, 100029, Peop. Rep. China
SO Chinese Medical Journal (Beijing, English Edition) (1995), 108(5), 370-2
CODEN: CMJODS; ISSN: 0366-6999
PB Chinese Medical Association
DT Journal
LA English

L13 ANSWER 16 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1995:499714 CAPLUS
DN 122:255894
TI Comparative real-time effects on platelet adhesion and aggregation under flowing conditions of in vivo aspirin, heparin, and monoclonal antibody fragment against glycoprotein IIb-IIIa
AU Turner, Nancy A.; Moake, Joel L.; Kamat, Suraj G.; Schafer, Andrew I.; Kleiman, Neal S.; Jordan, Robert; McIntire, Larry V.
CS Cox Laboratory for Biomedical Engineering, Rice University, Houston, TX, 77251, USA
SO Circulation (1995), 91(5), 1354-62
CODEN: CIRCAZ; ISSN: 0009-7322
DT Journal
LA English

L13 ANSWER 17 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1994:153339 CAPLUS
DN 120:153339
TI Combined effect of the 5-HT2 receptor antagonist DV-7028 and aspirin or heparin on **coronary** cyclic flow reductions in dogs
AU Tanaka, Tsuyoshi; Morishima, Yoshiyuki; Watanabe, Kazuo; Shibutani, Tomoko; Yasuoka, Megumi; Shibano, Toshiro

CS Explor. Res. Lab. II, Daiichi Pharm. Co. Ltd., Tokyo, 134, Japan
SO Cardiovascular Research (1993), 27(7), 1374-9
CODEN: CVREAU; ISSN: 0008-6363
DT Journal
LA English

L13 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1993:52101 CAPLUS
DN 118:52101
TI Hirudin and sulotroban improve **coronary** blood flow after reperfusion induced by the novel recombinant plasminogen activator BM 06.022 in a canine model of **coronary** artery thrombosis
AU Martin, Ulrich; Sponer, Gisbert; Strein, Klaus
CS Dep. Pharmacol., Boehringer Mannheim GmbH, Mannheim, D-6800/31, Germany
SO International Journal of Hematology (1992), 56(2), 143-53
CODEN: IJHEEY; ISSN: 0925-5710
DT Journal
LA English

L13 ANSWER 19 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1992:233034 CAPLUS
DN 116:233034
TI Cardioprotective effects of ischemic preconditioning are not mediated by prostanoids
AU Li, Yuwei; Kloner, Robert A.
CS Heart Inst., Res. Hosp. of the Good Samaritan, Los Angeles, CA, 90017, USA
SO Cardiovascular Research (1992), 26(3), 226-31
CODEN: CVREAU; ISSN: 0008-6363
DT Journal
LA English

L13 ANSWER 20 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1989:107894 CAPLUS
DN 110:107894
TI Effects of exogenous vasoconstrictors on **coronary** vascular resistance and prostacyclin production of the quiescent heart: the inhibitory effect of aspirin
AU Lee, Shwu Luan; Levitsky, Sidney; Feinberg, Harold
CS Coll. Med., Univ. Illinois, Chicago, IL, USA
SO Journal of Pharmacology and Experimental Therapeutics (1989), 248(1), 44-9
CODEN: JPETAB; ISSN: 0022-3565
DT Journal
LA English

L13 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1981:561869 CAPLUS
DN 95:161869
TI A study on constrictor responses of dog **coronary** arteries to acetylsalicylic acid
AU Sakanashi, M.; Araki, H.; Furukawa, T.; Rokutanda, M.; Yonemura, K.
CS Med. Sch., Kumamoto Univ., Kumamoto, 860, Japan
SO Archives Internationales de Pharmacodynamie et de Therapie (1981), 252(1), 86-96
CODEN: AIPTAK; ISSN: 0003-9780
DT Journal
LA English

L13 ANSWER 22 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1980:90037 CAPLUS
DN 92:90037
TI Noninvasive radioisotopic technique for detection of platelet deposition in **coronary** artery bypass grafts in dogs and its reduction with

platelet-inhibitors
AU Dewanjee, M. K.; Fuster, V.; Kaye, M. P.; Josa, M.
CS Mayo Clin. and Mayo Found., Rochester, MN, 55901, USA
SO Radiopharm. 2, Proc. Int. Symp., 2nd (1979), 361-74. Editor(s): Sorenson, James A. Publisher: Soc. Nucl. Med., Inc., New York, N. Y.
CODEN: 42GGAE
DT Conference
LA English

L13 ANSWER 23 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1979:534570 CAPLUS
DN 91:134570
TI Excitation of afferent fibers in the cardiac sympathetic nerves induced by **coronary** occlusion and **injection** of bradykinin. The influence of acetylsalicylic acid and dipyron
AU Vogt, A.; Vetterlein, F.; Dal Ri, H.; Schmidt, G.
CS Inst. Pharmakol. Toxikol., Univ. Goettingen, Goettingen, D-3400, Fed. Rep. Ger.
SO Archives Internationales de Pharmacodynamie et de Therapie (1979), 239(1), 86-98
CODEN: AIPTAK; ISSN: 0003-9780
DT Journal
LA English

=> d l13 17 all

L13 ANSWER 17 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1994:153339 CAPLUS
DN 120:153339
TI Combined effect of the 5-HT2 receptor antagonist DV-7028 and aspirin or heparin on **coronary** cyclic flow reductions in dogs
AU Tanaka, Tsuyoshi; Morishima, Yoshiyuki; Watanabe, Kazuo; Shibutani, Tomoko; Yasuoka, Megumi; Shibano, Toshiro
CS Explor. Res. Lab. II, Daiichi Pharm. Co. Ltd., Tokyo, 134, Japan
SO Cardiovascular Research (1993), 27(7), 1374-9
CODEN: CVREAU; ISSN: 0008-6363
DT Journal
LA English
CC 1-8 (Pharmacology)
GI



I

AB The aim was to study the combined effect of DV-7028 (I), a selective 5-HT2 receptor antagonist, and aspirin or heparin on cyclic flow redns. in the canine **coronary** artery. Anesthetized open chest beagle dogs under artificial respiration were used. Cyclic flow redns. were induced by partial occlusion of the left anterior descending **coronary** artery at the site of endothelial injury. After induction of cyclic flow redns., test drugs were given to the animals i.v. DV-7028 (0.1 mg.cntdot.kg-1) reduced the frequency of cyclic flow redns. by 77% and improved the nadir of **coronary** blood flow velocity that indicated the severity of cyclic flow redns. Also, aspirin (1 or 3

mg.cntdot.kg-1) or heparin (200 U.cntdot.kg-1) attenuated the cyclic flow redns. In expts. with drug combinations, DV-7028 was given to animals that had already received aspirin (1 mg.cntdot.kg-1) or heparin (200 U.cntdot.kg-1). DV-7028 (0.1 mg.cntdot.kg-1) completely abolished the cyclic flow redns. remaining after aspirin treatment in three of four animals. Heparin inhibited the cyclic flow redns. in one of five animals and the addn. of DV-7028 abolished the remaining cyclic flow redns. in the other four animals. After combined **injection** of DV-7028 with aspirin or heparin, the **coronary** blood flow with cyclical redns. returned to the baseline. The 5-HT2 receptor antagonist DV-7028 can inhibit the cyclic flow redns. that are resistant to aspirin or heparin. The combined regimen of DV-7028 and aspirin or heparin in treatment of acute **coronary** stenosis is more effective than that of aspirin or heparin alone.

ST DV7028 aspirin heparin interaction **coronary** stenosis; cyclic flow redn **coronary** DV7028 antithrombotic

IT Anticoagulants and Antithrombotics
(DV-7028 and aspirin and heparin, cyclic flow redns. inhibition by, acute **coronary** stenosis treatment in relation to)

IT Drug interactions
(additive, of DV-7028 with aspirin and heparin, cyclic flow redns. inhibition and acute **coronary** stenosis treatment in relation to)

IT Circulation
(**coronary**, DV-7028 and aspirin and heparin effect on, cyclic flow redns. inhibition and acute **coronary** stenosis treatment in relation to)

IT Artery, disease
(**coronary**, stenosis, acute, DV-7028 and aspirin and heparin in treatment of, cyclic flow redns. inhibition in relation to)

IT 133364-63-3, DV-7028
RL: BIOL (Biological study)
(cyclic flow redns. inhibition by, as 5-HT2 receptor antagonist, in **coronary** stenosis, interaction with aspirin and heparin in relation to)

IT **50-78-2**, Aspirin 9005-49-6, Heparin, biological studies
RL: BIOL (Biological study)
(cyclic flow redns. inhibition by, in **coronary** stenosis)

=> d l13 19 all

L13 ANSWER 19 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1992:233034 CAPLUS
DN 116:233034
TI Cardioprotective effects of ischemic preconditioning are not mediated by prostanoids
AU Li, Yuwei; Kloner, Robert A.
CS Heart Inst., Res. Hosp. of the Good Samaritan, Los Angeles, CA, 90017, USA
SO Cardiovascular Research (1992), 26(3), 226-31
CODEN: CVREAU; ISSN: 0008-6363
DT Journal
LA English
CC 14-5 (Mammalian Pathological Biochemistry)
Section cross-reference(s): 1
AB The mechanism of ischemic preconditioning may be mediated through the synthesis and release of prostaglandin/prostacyclin. Aspirin, an inhibitor of cyclooxygenase, could block or prevent the protective effect of preconditioning. Rats were preconditioned by episodes of 3 min of **coronary** occlusion and 5 min of reperfusion, and then subjected to 90 min of occlusion followed by 4 h of reperfusion. Aspirin (10 mg/kg) was given 10 min prior to the preconditioning. Planimetry was used to

measure area at risk (AR) following blue dye **injection** and area of necrosis (AN) after tetrazolium staining. All groups had comparable AR. AN/AR was reduced in the preconditioning group and the aspirin + preconditioning group compared with the control group. The incidence of ventricular tachycardia and/or fibrillation was also reduced in the preconditioning and aspirin + preconditioning groups. Preconditioning both with and without aspirin reduced the infarct size and the incidence of ventricular tachycardia and/or fibrillation. The effects of preconditioning were not prevented by aspirin. The cardioprotective effects of preconditioning may not be mediated by prostanoids in this rat model.

ST heart ischemia preconditioning prostaglandin mechanism aspirin

IT Prostaglandins
RL: BIOL (Biological study)
(heart ischemia preconditioning lack of mediation by)

IT Heart, disease
(ischemia, preconditioning against, prostanoids lack of role in)

IT **50-78-2**, Aspirin
RL: BIOL (Biological study)
(heart ischemia preconditioning lack of response to)

=> d l13 21 all

L13 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1981:561869 CAPLUS
DN 95:161869
TI A study on constrictor responses of dog **coronary** arteries to acetylsalicylic acid
AU Sakanashi, M.; Araki, H.; Furukawa, T.; Rokutanda, M.; Yonemura, K.
CS Med. Sch., Kumamoto Univ., Kumamoto, 860, Japan
SO Archives Internationales de Pharmacodynamie et de Therapie (1981), 252(1), 86-96
CODEN: AIPTAK; ISSN: 0003-9780
DT Journal
LA English
CC 1-4 (Pharmacodynamics)
GI



I

AB In isolated and perfused dog hearts an intracoronary **injection** of acetylsalicylic acid (I) [**50-78-2**] (10 mg) decreased **coronary** blood flow concomitant with diminution of myocardial contractile force, but did not change heart rate. Contractions were produced in isolated dog **coronary** arterial strips by I (10-4 M) and these were significantly inhibited by Ca2+-free soln., diltiazem, nifedipine, phospholipase A2, arachidonate, and prostaglandin E1. Apparently, I at a high dose produces **coronary** arterial contraction probably through inhibition of intravascular synthesis of vasodilating prostaglandins.

ST acetylsalicylate **coronary** artery contraction; prostaglandin acetylsalicylate **coronary** artery contraction

IT Prostaglandins
RL: BIOL (Biological study)
(**coronary** artery contraction from acetylsalicylic acid in

relation to)
IT Artery
(**coronary**, contraction of, from aspirin, prostaglandins in relation to)
IT **50-78-2**
RL: BIOL (Biological study)
(**coronary** artery contraction by, prostaglandin in relation to)

```
=> e intrathecal
E1            1     INTRATHCEALLY/BI
E2            2     INTRATHEACAL/BI
E3         4695 --> INTRATHECAL/BI
E4         1682     INTRATHECALLY/BI
E5            1     INTRATHECALTY/BI
E6            1     INTRATHECALY/BI
E7            1     INTRATHECHAL/BI
E8            1     INTRATHECOL/BI
E9            1     INTRATHEKAL/BI
E10           1     INTRATHELIAL/BI
E11           1     INTRATHEORY/BI
E12           4     INTRATHERAPEUTIC/BI

=> s e3-e4
          4695 INTRATHECAL/BI
          1682 INTRATHECALLY/BI
L14       5398 (INTRATHECAL/BI OR INTRATHECALLY/BI)

=> s l4 and l14
L15         12 L4 AND L14

=> d his

     (FILE 'HOME' ENTERED AT 12:17:21 ON 29 SEP 2003)

     FILE 'REGISTRY' ENTERED AT 12:17:29 ON 29 SEP 2003
L1            52 S ASPIRIN
                 E NSAIDS
                 E NSAID
L2             9 S E3

     FILE 'CAPLUS' ENTERED AT 12:18:24 ON 29 SEP 2003
                 E NSAIDS
L3          3396 S E3
L4         17770 S L1
                 E INTRATHECALY
L5          1682 S E1-E3
L6             6 S L3 AND L5
L7             3 S L4 AND L5
                 E INTRAVENTICULARLY
L8            28 S E2-E3
L9             0 S L8 AND L4
                 E CORANARY
                 E CORONARY
L10        50167 S E3
L11          646 S L10 AND L4
                 E INJECTION
L12      420947 S E3
L13           23 S L11 AND L12
                 E INTRATHECAL
L14         5398 S E3-E4
```

```
L15          12 S L4 AND L14

=> d l15 not l7
L7 IS NOT VALID HERE
For an explanation, enter "HELP DISPLAY".

=> s l15 not l7
L16          9 L15 NOT L7

=> d l16 1-9

L16  ANSWER 1 OF 9  CAPLUS  COPYRIGHT 2003 ACS on STN
AN   2003:610193  CAPLUS
DN   139:159967
TI   .kappa.-PVIIA-related conotoxins as organ protectants
IN   Pemberton-Goodman, Karen E.; Jones, Robert M.; Temple, Davis L., Jr.;
     McIntosh, J. Michael; Olivera, Baldomero M.
PA   Cognetix, Inc., USA; University of Utah Research Foundation
SO   PCT Int. Appl., 63 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.         KIND  DATE           APPLICATION NO.  DATE
     ---------------    ----  --------       ---------------  --------
PI   WO 2003063782      A2    20030807       WO 2003-US2384   20030128
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA,
             UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
             CY, DE, DK, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE,
             SI, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
             TD, TG
PRAI US 2002-352219P    P     20020129

L16  ANSWER 2 OF 9  CAPLUS  COPYRIGHT 2003 ACS on STN
AN   2003:202477  CAPLUS
DN   138:215285
TI   Use of .mu.-opioid receptor agonists and opioid receptor antagonists as
     combination drugs for the treatment of cancer
IN   Geisslinger, Gerd; Tegeder, Irmgard
PA   Paz Arzneimittel-Entwicklungs Gesellschaft m.b.H., Germany
SO   PCT Int. Appl., 26 pp.
     CODEN: PIXXD2
DT   Patent
LA   German
FAN.CNT 1
     PATENT NO.         KIND  DATE           APPLICATION NO.  DATE
     ---------------    ----  --------       ---------------  --------
PI   WO 2003020277      A1    20030313       WO 2002-EP8181   20020723
         W:  AU, CA, CN, IL, JP, MX, RU, US
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT,
             LU, MC, NL, PT, SE, SK, TR
     DE 10142996        A1    20030327       DE 2001-10142996 20010901
PRAI DE 2001-10142996   A     20010901
RE.CNT  2     THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16  ANSWER 3 OF 9  CAPLUS  COPYRIGHT 2003 ACS on STN
```

AN 2001:856855 CAPLUS
DN 136:194095
TI Antinociceptive profiles of aspirin and acetaminophen in formalin, substance P and glutamate pain models
AU Choi, Seong-Soo; Lee, Jin-Koo; Suh, Hong-Won
CS Department of Pharmacology, Hallym University, College of Medicine, and Institute of Natural Medicine, Kangwon-Do, Chunchon, 200-702, S. Korea
SO Brain Research (2001), 921(1,2), 233-239
CODEN: BRREAP; ISSN: 0006-8993
PB Elsevier Science B.V.
DT Journal
LA English
RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1997:407083 CAPLUS
DN 127:104060
TI Effects of **intrathecal** or intracerebroventricular administration of nonsteroidal anti-inflammatory drugs on a C-fiber reflex in rats
AU Bustamante, Diego; Paeile, Carlos; Willer, Jean-Claude; Le Bars, Daniel
CS Dep. of Pharmacology, Faculty of Medicine, University of Chile, Santiago, Chile
SO Journal of Pharmacology and Experimental Therapeutics (1997), 281(3), 1381-1391
CODEN: JPETAB; ISSN: 0022-3565
PB Williams & Wilkins
DT Journal
LA English

L16 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1994:261080 CAPLUS
DN 120:261080
TI **Intrathecal** injection of lysine acetylsalicylic acid in the rat: a neurotoxicological study
AU Svensson, B. A.; Karlsten, R.; Kristensen, J. D.; Sottile, A.; Bennett, A.; Gordh, T. Jr.
CS Dep. Anat., Uppsala Univ., Uppsala, Swed.
SO Acta Anaesthesiologica Scandinavica (1993), 37(8), 799-805
CODEN: AANEAB; ISSN: 0001-5172
DT Journal
LA English

L16 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1992:645527 CAPLUS
DN 117:245527
TI Antinociceptive actions of spinal nonsteroidal anti-inflammatory agents on the formalin test in the rat
AU Malmberg, Annika B.; Yaksh, Tony L.
CS Dep. Anesthesiol., Univ. California, San Diego, La Jolla, CA, USA
SO Journal of Pharmacology and Experimental Therapeutics (1992), 263(1), 136-46
CODEN: JPETAB; ISSN: 0022-3565
DT Journal
LA English

L16 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1992:504057 CAPLUS
DN 117:104057
TI **Intrathecal** injection of acetylsalicylic acid, salicylic acid and indometacin depresses C fiber-evoked activity in the rat thalamus and spinal cord

AU Jurna, Ilmar; Spohrer, Birgit; Bock, Rudolf
CS Inst. Pharmakol. Toxikol., Univ. Saarlandes, Homburg/Saar, D-6650, Germany
SO Pain (1992), 49(2), 249-56
CODEN: PAINDB; ISSN: 0304-3959
DT Journal
LA English

L16 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1988:180862 CAPLUS
DN 108:180862
TI Prostaglandins inhibit endogenous pain control mechanisms by blocking transmission at spinal noradrenergic synapses
AU Taiwo, Yetunde O.; Levine, Jon D.
CS Dep. Med., Univ. California, San Francisco, CA, 94143, USA
SO Journal of Neuroscience (1988), 8(4), 1346-9
CODEN: JNRSDS; ISSN: 0270-6474
DT Journal
LA English

L16 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1986:583773 CAPLUS
DN 105:183773
TI Spinal cord toxicity of lysine acetylsalicylate and ketamine hydrochloride given by the **intrathecal** route in the rat
AU Amiot, J. F.; Palacci, J. H.; Vedrenne, C.; Pellerin, M.
CS Dep. Anesth.-Reanim., CHG Robert-Ballanger, Aulnay-sous-Bois, F 93602, Fr.
SO Annales Francaises d'Anesthesie et de Reanimation (1986), 5(4), 462
CODEN: AFAREO; ISSN: 0750-7658
DT Journal
LA French

=> d l16 7 all

L16 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1992:504057 CAPLUS
DN 117:104057
TI **Intrathecal** injection of acetylsalicylic acid, salicylic acid and indometacin depresses C fiber-evoked activity in the rat thalamus and spinal cord
AU Jurna, Ilmar; Spohrer, Birgit; Bock, Rudolf
CS Inst. Pharmakol. Toxikol., Univ. Saarlandes, Homburg/Saar, D-6650, Germany
SO Pain (1992), 49(2), 249-56
CODEN: PAINDB; ISSN: 0304-3959
DT Journal
LA English
CC 1-11 (Pharmacology)
AB It was aimed to assess if **intrathecal** (i.t.) injections of acetylsalicylic acid and salicylic acid depress C-fiber-evoked activity in the sensory part of the nociceptive system. In rats under urethane anesthesia, activity was elicited in single neurons in the dorsomedial part of the ventral nucleus (VDM) of the thalamus and in ascending axons of the spinal cord by supramaximal elec. stimulation of the sural nerve. Acetylsalicylic acid and salicylic acid injected i.t. significantly reduced the activity evoked in thalamic neurons. The max. depression amounted to about 50% of the activity evoked in the controls and was produced by acetylsalicylic acid at a dose of 50 .mu.g (0.28 .mu.mol)/rat and by salicylic acid at a dose of 37.5 .mu.g (0.27 .mu.mol)/rat. Indometacin injected i.t. also reduced C-fiber-evoked activity in the thalamus in a dose-dependent fashion, 100 .mu.g producing a 50% depression. Salicylic acid (37.5 .mu.g/rat, i.t.) depressed C-fiber-evoked activity in ascending axons but had no effect on A.beta.

fiber-evoked activity. It is concluded that i.t. injection of acetylsalicylic acid selectively inhibits nociceptive impulse transmission in the spinal cord by an action of the salicylic acid moiety. It is possible that prostaglandins are involved in the central action of salicylic acid.

ST C fiber thalamus spinal cord analgesic; acetylsalicylate C fiber thalamus spinal cord; salicylate C fiber thalamus spinal cord; indomethacin C fiber thalamus spinal cord

IT Spinal cord
(C-fiber-evoked activity in, acetylsalicylic and salicylic acids effect on, analgesic mechanism in relation to)

IT Prostaglandins
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(in central analgesic action of salicylic acid)

IT Analgesics
(**intrathecal**, C-fiber-evoked activity inhibition by, in thalamus and spinal cord, mechanism of)

IT Nerve
(C-fiber, acetylsalicylic and salicylic acids effect on, of thalamus and spinal cord, analgesic mechanism in relation to)

IT Nerve
(nociceptive, axon, acetylsalicylic and salicylic acids effect on, of thalamus and spinal cord, analgesic mechanism in relation to)

IT Brain
(thalamus, C-fiber-evoked activity in, acetylsalicylic and salicylic acids effect on, analgesic mechanism in relation to)

IT **50-78-2**, Acetylsalicylic acid 53-86-1, Indomethacin 69-72-7, Salicylic acid, biological studies
RL: BIOL (Biological study)
(**intrathecal**, C-fiber-evoked activity inhibition by, in thalamus and spinal cord, mechanism of)

=> d l16 5 all

L16 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1994:261080 CAPLUS
DN 120:261080
TI **Intrathecal** injection of lysine acetylsalicylic acid in the rat: a neurotoxicological study
AU Svensson, B. A.; Karlsten, R.; Kristensen, J. D.; Sottile, A.; Bennett, A.; Gordh, T. Jr.
CS Dep. Anat., Uppsala Univ., Uppsala, Swed.
SO Acta Anaesthesiologica Scandinavica (1993), 37(8), 799-805
CODEN: AANEAB; ISSN: 0001-5172
DT Journal
LA English
CC 1-11 (Pharmacology)
AB Lysine acetylsalicylic acid has been reported to induce analgesic effects in humans after **intrathecal** (i.t.) injection. Before conducting further studies in humans with this drug, it is important to evaluate potential toxicol. effects on the spinal cord in animals. In the present study the effects of chronic **intrathecal** administration of provocative doses of lysine acetylsalicylic acid (L-ASA) on the rat spinal cord were evaluated using light and electron microscopy and a quant. morphometric method. The authors also investigated the effects of single doses of the drug on the spinal cord blood flow (SCBF) using the laser-Doppler flowmetry technique. No histopathol. changes or differences in no. or d. of neuronal cells could be seen after chronic administration of L-ASA as compared to controls. The SCBF decreased immediately after i.t. injection of a large dose (4 mg) of L-ASA and returned to predrug

levels within 10 min. At the end of the expt. metabolic acidosis was detected, indicating a systemic effect of acetylsalicylic acid. It is concluded that no neurotoxic effects on the spinal cord were seen after chronic i.t. injection of L-ASA. From a neurotoxicol. point of view, the authors' findings do not contraindicate the spinal use of L-ASA in humans.

ST lysine acetylsalicylic acid toxicity spinal cord; analgesic lysine acetylsalicylic acid toxicity

IT Analgesics
(lysine acetylsalicylic acid as, neurotoxicity of, to spinal cord, after **intrathecal** injection)

IT Spinal cord
(lysine acetylsalicylic acid neurotoxicity to, after **intrathecal** injection)

IT Nerve, toxic chemical and physical damage
(lysine acetylsalicylic acid toxicity to, in spinal cord, after **intrathecal** injection)

IT Acidosis
(neurotoxic effect of lysine acetylsalicylic acid in relation to, in spinal cord, after **intrathecal** injection)

IT Circulation
(of spinal cord, lysine acetylsalicylic acid effect on, neurotoxicity after **intrathecal** injection in relation to)

IT **62952-06-1**
RL: PRP (Properties)
(neurotoxicity of, to spinal cord, after **intrathecal** injection)

```
=> s cardiac injection
         95738 CARDIAC
        420947 INJECTION
L17         14 CARDIAC INJECTION
               (CARDIAC(W)INJECTION)

=> d l17 and l4
L4 IS NOT VALID HERE
For an explanation, enter "HELP DISPLAY".

=> s l17 and l4
L18          0 L17 AND L4

=> d his

     (FILE 'HOME' ENTERED AT 12:17:21 ON 29 SEP 2003)

     FILE 'REGISTRY' ENTERED AT 12:17:29 ON 29 SEP 2003
L1          52 S ASPIRIN
               E NSAIDS
               E NSAID
L2           9 S E3

     FILE 'CAPLUS' ENTERED AT 12:18:24 ON 29 SEP 2003
               E NSAIDS
L3        3396 S E3
L4       17770 S L1
               E INTRATHECALY
L5        1682 S E1-E3
L6           6 S L3 AND L5
L7           3 S L4 AND L5
               E INTRAVENTICULARLY
L8          28 S E2-E3
L9           0 S L8 AND L4
```

```
                E CORANARY
                E CORONARY
L10        50167 S E3
L11          646 S L10 AND L4
                E INJECTION
L12        420947 S E3
L13            23 S L11 AND L12
                E INTRATHECAL
L14          5398 S E3-E4
L15            12 S L4 AND L14
L16             9 S L15 NOT L7
L17            14 S CARDIAC INJECTION
L18             0 S L17 AND L4

=>

---Logging off of STN---


=>
Executing the logoff script...


=> LOG Y

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      93.44     104.57

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                      -5.21      -5.21

STN INTERNATIONAL LOGOFF AT 12:45:07 ON 29 SEP 2003
```

DN 130:105154
TI Molecular characterization of the neuroprotective activity of salicylates
AU Grilli, M.; Pizzi, M.; Goffi, F.; Benarese, M.; Gerardi, G. M.; Memo, M.; Spano, P. F.
CS Division of Pharmacology Department of Biomedical Sciences and Biotechnologies School of Medicine, University of Brescia, Brescia, Italy
SO Advances in Behavioral Biology (1998), 49(Progress in Alzheimer's and Parkinson's Diseases), 99-103
CODEN: ADBBBW; ISSN: 0099-6246
PB Plenum Publishing Corp.
DT Journal
LA English
CC 1-11 (Pharmacology)
AB Aspirin and its metabolite sodium salicylate prevent glutamate-induced neurotoxicity in rats. The neuroprotective effect of aspirin does not appear to correlate with the anti-inflammatory properties of this compd.
ST neuroprotectant salicylate antiinflammatory neurodegenerative disorder **Alzheimer**
IT Transcription factors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(NF-.kappa.B (nuclear factor .kappa.B); mol. characterization of the neuroprotective activity of salicylates)
IT Nervous system
(degeneration; mol. characterization of the neuroprotective activity of salicylates)
IT Anti-**Alzheimer**'s agents
(mol. characterization of the neuroprotective activity of salicylates)
IT Cytoprotective agents
(neuroprotectants; mol. characterization of the neuroprotective activity of salicylates)
IT Anti-inflammatory agents
(nonsteroidal; mol. characterization of the neuroprotective activity of salicylates)
IT 54-21-7, Sodium salicylate
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); MFM (Metabolic formation); THU (Therapeutic use); BIOL (Biological study); FORM (Formation, nonpreparative); USES (Uses)
(mol. characterization of the neuroprotective activity of salicylates)
IT **50-78-2**, Aspirin 69-72-7D, analogs
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(mol. characterization of the neuroprotective activity of salicylates)
RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Amin, A; Proc Natl Acad Sci USA 1995, V92, P7926 CAPLUS
(2) Curran, T; Cell 1988, V55, P395 CAPLUS
(3) Gallo, V; Proc Natl Acad Sci USA 1982, V79, P7919 CAPLUS
(4) Garthwaite, G; Neurosci Lett 1989, V97, P316 CAPLUS
(5) Grilli, M; Int Rev Cytol 1993, V143, P1 CAPLUS
(6) Grilli, M; J Biol Chem 1995, V270, P26774 CAPLUS
(7) Grilli, M; J Biol Chem 1996, V271, P15002 CAPLUS
(8) Grilli, M; Science 1996, V274, P1383 CAPLUS
(9) Guerrini, L; Proc Natl Acad Sci USA 1995, V92, P9077 CAPLUS
(10) Insel, P; Goodman and Gilman's The Pharmacological Basis of Therapeutics 1996, P617
(11) Kaltschmidt, C; Mol Cell Biol 1994, V14, P3981 CAPLUS
(12) Kaltschmidt, C; Proc Natl Acad Sci USA 1995, V92, P9618 CAPLUS
(13) Kopp, E; Science 1994, V265, P956 MEDLINE
(14) Lipton, S; New Engl J Med 1995, V330, P613
(15) McGeer, P; Brain Res Rev 1995, V21, P195 MEDLINE

(16) Pizzi, M; Eur J Neurosci 1996, V8, P1516 MEDLINE
(17) Pizzi, M; Mol Pharmacol 1996, V49, P586 CAPLUS
(18) Rogers, J; Neurology 1993, V43, P1609 MEDLINE
(19) Yan, S; Nature Med 1995, V1, P693 CAPLUS

=>

AN 1997:454047 CAPLUS
DN 127:60626
TI Method of delaying onset of **Alzheimer**'s disease symptoms with a non-steroidal anti-inflammatory agent and/or a histamine H2 receptor-blocking agent
IN Breitner, John C. S.; Welsh, Kathleen A.
PA Duke University, USA
SO U.S., 10 pp.
CODEN: USXXAM
DT Patent
LA English
IC ICM A61K031-60
ICS A61K031-615; A61K031-54; A61K031-44; A61K031-425; A61K031-42; A61K031-415; A61K031-40; A61K031-38; A61K031-34; A61K031-195; A61K031-19
NCL 514570000
CC 1-11 (Pharmacology)
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5643960	A	19970701	US 1994-228019	19940415
	US 6025395	A	20000215	US 1997-843217	19970414
PRAI	US 1994-228019		19940415		

AB A method is disclosed for preventing or delaying the onset of **Alzheimer**'s disease and related neurodegenerative disorders. The method involves the administration to individuals at risk of developing the disease (or disorder) a non-steroidal anti-inflammatory agent and/or a histamine H2 receptor-blocking agent. The invention also relates to a method of treating **Alzheimer**'s disease and related neurodegenerative disorders that involves the use of such agents.
ST **Alzheimer** disease NSAID H2 antihistaminic; neurodegenerative disease NSAID H2 antihistaminic
IT Apolipoproteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(E, .epsilon.4 or .epsilon.2 allele at locus for; non-steroidal anti-inflammatory agent and/or histamine H2 receptor-blocking agent for preventing, delaying, or treating **Alzheimer**'s disease and related neurodegenerative disorders)
IT Antihistamines
(H2; non-steroidal anti-inflammatory agent and/or histamine H2 receptor-blocking agent for preventing, delaying, or treating **Alzheimer**'s disease and related neurodegenerative disorders)
IT Nervous system
(degeneration; non-steroidal anti-inflammatory agent and/or histamine H2 receptor-blocking agent for preventing, delaying, or treating **Alzheimer**'s disease and related neurodegenerative disorders)
IT **Alzheimer**'s disease
Narcotics
Susceptibility (genetic)
(non-steroidal anti-inflammatory agent and/or histamine H2 receptor-blocking agent for preventing, delaying, or treating **Alzheimer**'s disease and related neurodegenerative disorders)
IT Glucocorticoids
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(non-steroidal anti-inflammatory agent and/or histamine H2 receptor-blocking agent for preventing, delaying, or treating **Alzheimer**'s disease and related neurodegenerative disorders)
IT Anti-inflammatory agents
(nonsteroidal; non-steroidal anti-inflammatory agent and/or histamine H2 receptor-blocking agent for preventing, delaying, or treating **Alzheimer**'s disease and related neurodegenerative disorders)

IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(.epsilon.4 or .epsilon.2 allele, for apolipoprotein E; non-steroidal anti-inflammatory agent and/or histamine H2 receptor-blocking agent for preventing, delaying, or treating **Alzheimer**'s disease and related neurodegenerative disorders)

IT **50-78-2**, Aspirin 103-90-2, Acetaminophen 22204-53-1, Naproxen
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(non-steroidal anti-inflammatory agent and/or histamine H2 receptor-blocking agent for preventing, delaying, or treating **Alzheimer**'s disease and related neurodegenerative disorders)

=>

AN 1998:780621 CAPLUS
DN 130:232124
TI Peripheral administration of novel anti-inflammatories can attenuate the effects of chronic inflammation within the CNS [central nervous system]
AU Hauss-Wegrzyniak, Beatrice; Willard, Lauren B.; Del Soldato, Piero; Pepeu, Giancarlo; Wenk, Gary L.
CS Memory and Aging, Division of Neural Systems, Arizona Research Laboratories, University of Arizona, Tucson, AZ, 85724, USA
SO Brain Research (1999), 815(1), 36-43
CODEN: BRREAP; ISSN: 0006-8993
PB Elsevier Science B.V.
DT Journal
LA English
CC 1-7 (Pharmacology)
AB This study investigated whether nitroflurbiprofen (NFP) or nitro-aspirin can reduce the inflammatory response induced by continuous infusion of lipopolysaccharide (LPS) into the 4th ventricular space of the rat brain for 30 days. The chronic LPS infusion produced an extensive inflammation that was particularly evident in the hippocampus, subiculum and entorhinal and piriform cortices. Daily peripheral administration of NFP dose-dependently attenuated the brain inflammation, as indicated by the decreased d. and reactive state of microglial cells. Daily peripheral administration of nitro-aspirin also attenuated the brain inflammation, but to a much lesser degree than NFP. The results demonstrated that nonsteroidal anti-inflammatory drugs can reduce brain inflammation and that NFP is an effective anti-inflammatory agent.
ST brain inflammation inhibition nitroflurbiprofen nitroaspirin; nonsteroidal antiinflammatory drug brain inflammation
IT Encephalitis
(nitroflurbiprofen and nitroaspirin inhibition of)
IT **Alzheimer**'s disease
(nitroflurbiprofen and nitroaspirin inhibition of brain inflammation in relation to)
IT Anti-inflammatory agents
(nonsteroidal; brain inflammation inhibition by nitroflurbiprofen and nitroaspirin as)
IT **17336-14-0** 158836-71-6, Nitroflurbiprofen
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(brain inflammation inhibition by)
RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Aisen, P; Am J Psychiatr 1994, V151, P1105 MEDLINE
(2) Allison, M; N Engl J Med 1992, V327, P749 MEDLINE
(3) Altstiel, L; Prog Neuropsycho-Pharmacol Biol Psychiatr 1991, V15, P481 CAPLUS
(4) Banati, R; Glia 1993, V7, P111 MEDLINE
(5) Bannwarth, B; Therapie 1986, V41, P409 CAPLUS
(6) Breder, C; Brain Res 1996, V713, P64 CAPLUS
(7) Breitner, J; Neurobiol Aging 1996, V17, P789 MEDLINE
(8) Burrel, R; Crit Rev Microbiol 1990, V17, P188
(9) Cacabelos, R; Meth Find Exp Clin Pharmacol 1994, V16, P141 MEDLINE
(10) Chiang, C; Dev Neurosci 1994, V16, P212 CAPLUS
(11) Das, S; Neuron 1995, V14, P447 CAPLUS
(12) Eikelenboom, P; Virchows Arch B Cell Pathol 1989, V56, P259 MEDLINE
(13) Elmquist, J; J Comp Neurol 1997, V381, P119 CAPLUS
(14) Greenblatt, D; Arzneimittel-Forschung 1983, V33, P1671 CAPLUS
(15) Griffin, W; Proc Natl Acad Sci USA 1989, V86, P7611 MEDLINE
(16) Hauss-Wegrzyniak, B; Brain Res 1998, V794, P211 CAPLUS
(17) Hauss-Wegrzyniak, B; Brain Res 1998, V780, P294 CAPLUS
(18) Jenkinson, M; Br J Rheumatol 1989, V28, P86 MEDLINE

(19) Kitagawa, H; J Pharmacol Exp Therap 1990, V253, P1133 CAPLUS
(20) Macnaughton, W; Life Sci 1989, V45, P1869 CAPLUS
(21) McGeer, P; Brain Res Rev 1995, V21, P195 MEDLINE
(22) McGeer, P; Lancet 1990, V335, P1037 MEDLINE
(23) McGeer, P; Neurosci Lett 1988, V79, P195
(24) McGeer, P; Neurosci Lett 1989, V107, P341 MEDLINE
(25) Mrak, R; Human Pathol 1995, V26, P816 MEDLINE
(26) Myllykangas-Luosujarvi, R; Br J Rheumatol 1994, V33, P501 MEDLINE
(27) Rogers, J; Drug Res 1995, V45, P439 CAPLUS
(28) Rogers, J; Neurobiol Aging 1996, V17, P681 MEDLINE
(29) Rogers, J; Neurology 1993, V43, P1609 MEDLINE
(30) Roth, S; Ann Intern Med 1988, V109, P353 MEDLINE
(31) Santini, G; Eur J Pharmacol 1996, V316, P65 CAPLUS
(32) Sheng, J; Neurobiol Aging 1996, V17, P761 CAPLUS
(33) Strauss, S; Lab Invest 1992, V66, P223 MEDLINE
(34) Vandenabeele, P; Immunol Today 1991, V12, P217 CAPLUS
(35) Wallace, J; Gastroenterology 1994, V107, P173 CAPLUS
(36) Wallace, J; Trends Pharmacol Sci 1992, V13, P129 MEDLINE
(37) Watson; Paxinos 1986

=>

AN 1999:103337 CAPLUS
DN 130:280248
TI Increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-.gamma. in **Alzheimer**'s disease brains
AU Kitamura, Yoshihisa; Shimohama, Shun; Koike, Hideyasu; Kakimura, Jun-Ichi; Matsuoka, Yasuji; Nomura, Yasuyuki; Gebicke-Haerter, Peter J.; Taniguchi, Takashi
CS Department of Neurobiology, Kyoto Pharmaceutical University, Kyoto, 607-8412, Japan
SO Biochemical and Biophysical Research Communications (1999), 254(3), 582-586
CODEN: BBRCA9; ISSN: 0006-291X
PB Academic Press
DT Journal
LA English
CC 14-10 (Mammalian Pathological Biochemistry)
Section cross-reference(s): 1
AB Recent studies suggest that inflammatory events are assocd. with plaque formation in the brains of patients with **Alzheimer**'s disease (AD). Treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) of these patients appears to slow the progression of disease. The authors assessed the occurrence of cyclooxygenases (COX-1 and -2) and peroxisome proliferator-activated receptor-.gamma. (PPAR.gamma.) in temporal cortex from normal and AD brains using specific antibodies. In AD brains, protein levels of COX-1 were increased in both cytosolic and particulate fractions, and COX-2 protein was also increased in the particulate fraction. PPAR.gamma. level was increased in the cytosolic fraction but not in the particulate fraction. Thus, expression levels of COX-1, COX-2, and PPAR.gamma. may change in AD brains. In addn., several NSAIDs which are also PPAR.gamma. activators, such as indomethacin, inhibited COX-2 expression in glial cells. These results suggest that PPAR.gamma. activators have inhibitory effects on inflammatory events in AD brains. (c) 1999 Academic Press.
ST brain cyclooxygenase peroxisome proliferator activated receptor gamma **Alzheimer** disease
IT Cytoplasm
(cytosol; increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-.gamma. in brains from humans with **Alzheimer**'s disease)
IT Gene
(expression; increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-.gamma. in brains from humans with **Alzheimer**'s disease)
IT **Alzheimer**'s disease
Encephalitis
Neuroglia
(increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-.gamma. in brains from humans with **Alzheimer**'s disease)
IT Anti-inflammatory agents
(nonsteroidal; increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-.gamma. in brains from humans with **Alzheimer**'s disease)
IT Brain
(temporal cortex; increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-.gamma. in brains from humans with **Alzheimer**'s disease)
IT Peroxisome proliferator-activated receptors
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)
(.gamma.; increased expression of cyclooxygenases and peroxisome

proliferator-activated receptor-.gamma. in brains from humans with **Alzheimer**'s disease)

IT 39391-18-9
RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence); PROC (Process)
(1 and 2; increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-.gamma. in brains from humans with **Alzheimer**'s disease)

IT **50-78-2**, Aspirin 53-86-1, Indomethacin 41598-07-6, PGD2 87893-55-8 123653-11-2, NS398
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-.gamma. in brains from humans with **Alzheimer**'s disease)

RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Bauer, M; Eur J Biochem 1997, V243, P726 CAPLUS
(2) Bonventre, J; Nature 1997, V390, P622 CAPLUS
(3) Chang, J; Neurobiol Aging 1996, V17, P801 CAPLUS
(4) Clemens, J; Stroke 1996, V27, P527 CAPLUS
(5) Farooqui, A; Neurochem Int 1997, V30, P517 CAPLUS
(6) Forman, B; Cell 1995, V83, P803 CAPLUS
(7) Gattaz, W; Biol Psychiatry 1995, V37, P13 MEDLINE
(8) Guastadisegni, C; FEBS Lett 1997, V413, P314 CAPLUS
(9) Jiang, C; Nature 1998, V391, P82 CAPLUS
(10) Kitamura, Y; Neurosci Lett 1997, V237, P17 CAPLUS
(11) Lehmann, J; J Biol Chem 1997, V272, P3406 CAPLUS
(12) Lehtonen, J; Biochemistry 1996, V35, P9407 CAPLUS
(13) Lukiw, W; J Neurosci Res 1997, V50, P937 CAPLUS
(14) Mangelsdorf, D; Cell 1995, V83, P835 CAPLUS
(15) Mirra, S; Neurology 1991, V41, P479 MEDLINE
(16) Morita, I; J Biol Chem 1995, V270, P10902 CAPLUS
(17) Nogawa, S; J Neurosci 1997, V17, P2746 CAPLUS
(18) Oka, A; NeuroReport 1997, V8, P1161 CAPLUS
(19) Pasinetti, G; Neuroscience 1998, V87, P319 CAPLUS
(20) Ricote, M; Nature 1998, V391, P79 CAPLUS
(21) Rogers, J; Neurology 1993, V43, P1609 MEDLINE
(22) Sanz, O; Neuroscience 1997, V80, P221 CAPLUS
(23) Shimohama, S; J Neural Transm 1990, V30(Suppl), P69
(24) Shimohama, S; J Neurochem 1995, V64, P2629 CAPLUS
(25) Shimohama, S; Neurology 1993, V43, P1407 MEDLINE
(26) Spencer, A; J Biol Chem 1998, V273, P9886 CAPLUS
(27) Stephenson, D; Neurobiol Dis 1996, V3, P51 CAPLUS
(28) Tocco, G; Exp Neurol 1997, V144, P339 CAPLUS
(29) Vane, J; Ann Rev Pharmacol Toxicol 1998, V38, P97 CAPLUS

=>

AN 1998:338114 CAPLUS
DN 129:12755
TI Use of selected nonsteroidal antiinflammatory compounds for the prevention and the treatment of neurodegenerative diseases
IN Grilli, Mariagrazia; Pizzi, Marina; Memo, Maurizio; Spano, Pierfranco
PA Universita' Degli Studi di Brescia - Dipartimento di Scienze Biomediche, Italy; Grilli, Mariagrazia; Pizzi, Marina; Memo, Maurizio; Spano, Pierfranco
SO PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K031-00
ICS A61K031-60
CC 1-11 (Pharmacology)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9820864	A2	19980522	WO 1997-EP6323	19971113
	WO 9820864	A3	19981015		

W: JP, US
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

PRAI IT 1996-MI2356 19961113
OS MARPAT 129:12755
AB Nonsteroidal antiinflammatory compds. are used for the prevention and the treatment of neurodegenerative diseases, e.g. Alzheimer's disease and **Parkinson**'s disease.
ST neurodegenerative disease nonsteroidal antiinflammatory drug; **Parkinson** disease nonsteroidal antiinflammatory drug; Alzheimer disease nonsteroidal antiinflammatory drug; NSAID neurodegenerative disease
IT Transcription factors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(AP-1 (activator protein 1); nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT Nervous system
(Huntington's chorea; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT Transcription factors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(NF-.kappa.B (nuclear factor .kappa.B); nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT Glutamate receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(NMDA-binding; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT Nervous system
(amyotrophic lateral sclerosis; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT Nervous system
(ataxia telangiectasia; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT Nervous system
(degeneration; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT AIDS (disease)
(dementia assocd. with; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT Mental disorder

(dementia, multi-infarct; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT Brain
(dentate gyrus; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT Mental disorder
(diffuse Lewy body disease; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT Brain
(hippocampus, sector CA1; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT Brain
(hippocampus, sector CA3; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT Infection
(infective neurodegenerative disease; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT Nerve, disease
(injury; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT Metabolism
(metabolic neuropathies; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT Epilepsy
(neurodegenerative processes related to; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT Prion diseases
(neurodegenerative syndromes in; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT Hypoxia, animal
(neuropathy from; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT Brain, disease
(neuropathy, ischemic; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT Nerve, disease
(neuropathy; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT Cytoprotective agents
(neuroprotectants; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT Anti-Alzheimer's agents
Anti-ischemic agents
Antiparkinsonian agents
Multiple sclerosis
(nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT Glutamate receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT Anti-inflammatory agents
(nonsteroidal; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT Nerve, disease
(peripheral neuropathy, ischemic; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
IT Brain, disease
Spinal cord
Spinal cord
(trauma; nonsteroidal antiinflammatory compds. for prevention and

treatment of neurodegenerative diseases)

IT 50-99-7, D-Glucose, biological studies
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)
(blood; glycemic damage-assocd. neuropathy; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)

IT 53-86-1, Indomethacin 56-86-0, L-Glutamic acid, biological studies 6384-92-5, NMDA
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)

IT 50-33-9, Phenylbutazone, biological studies 50-33-9D, Phenylbutazone, metabolites **50-78-2**, Acetylsalicylic acid **50-78-2D**, Acetylsalicylic acid, derivs. 54-21-7, Sodium salicylate 58-15-1, Aminopyrine 58-15-1D, Aminopyrine, metabolites 60-80-0, Antipyrine 60-80-0D, Antipyrine, metabolites 65-45-2, Salicylamide 65-85-0, Benzoic acid, biological studies 65-85-0D, Benzoic acid, metabolites, biological studies **69-46-5**, Calcium acetylsalicylate 87-28-5, Glycol salicylate 89-57-6, Mesalamine 118-57-0, Acetaminosalol 119-36-8, Methyl salicylate 129-20-4, Oxyphenbutazone 129-20-4D, Oxyphenbutazone, metabolites **134-55-4**, Phenyl acetylsalicylate 147-90-0, Morpholine salicylate 303-38-8, 2,3-Dihydroxybenzoic acid 303-38-8D, 2,3-Dihydroxybenzoic acid, metabolites 487-48-9, Salacetamide 490-79-9, Gentisic acid 550-97-0, 1-Naphthyl salicylate 552-94-3, Salsalate **580-02-9**, Methyl acetylsalicylate 599-79-1, Sulfasalazine **5003-48-5**, Benorylate 5104-49-4, Flurbiprofen 5104-49-4D, Flurbiprofen, metabolites 5663-71-8 6385-02-0, Sodium meclofenamate 6385-02-0D, Sodium meclofenamate, metabolites 13539-59-8, Apazone 13539-59-8D, Apazone, metabolites 13586-98-6 15307-86-5, Diclofenac 15307-86-5D, Diclofenac, metabolites 15687-27-1 15687-27-1D, metabolites 15722-48-2, Olsalazine 21256-18-8, Oxaprozin 21256-18-8D, Oxaprozin, metabolites 22071-15-4, Ketoprofen 22071-15-4D, Ketoprofen, metabolites 22204-53-1, Naproxen 22204-53-1D, Naproxen, metabolites 22494-27-5, Flufenisal 22494-42-4 26171-23-3, Tolmetin 26171-23-3D, Tolmetin, metabolites 29679-58-1, Fenoprofen 29679-58-1D, Fenoprofen, metabolites 30653-83-9, Parsalmide 36322-90-4, Piroxicam 36322-90-4D, Piroxicam, metabolites 36364-49-5, Imidazole salicylate 37933-78-1, Lysine acetylsalicylate 38194-50-2, Sulindac 38194-50-2D, Sulindac, metabolites 41340-25-4, Etodolac 41340-25-4D, Etodolac, metabolites 42924-53-8, Nabumetone 42924-53-8D, Nabumetone, metabolites 51803-78-2, Nimesulide 51803-78-2D, Nimesulide, metabolites 53597-27-6, Fendosal 59804-37-4, Tenoxicam 59804-37-4D, Tenoxicam, metabolites 62992-61-4, Etersalate 71125-38-7, Meloxicam 71125-38-7D, Meloxicam, metabolites 74103-06-3, Ketorolac 74103-06-3D, Ketorolac, metabolites 111406-87-2, Zileuton 111406-87-2D, Zileuton, metabolites
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)

IT 7440-70-2, Calcium, biological studies 39391-18-9, Cyclooxygenase
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)

=>

AN 1993:175822 CAPLUS
DN 118:175822
TI Cure for diabetes, bronchitis, arthritis, and arteriosclerosis
IN Carantinos, Spyros
PA Australia
SO Pat. Specif. (Aust.), 11 pp.
CODEN: ALXXAP
DT Patent
LA English
IC ICM A61K031-19
ICS A61K033-30; A61K031-215
CC 63-6 (Pharmaceuticals)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	AU 629520	B2	19921008	AU 1988-26677	19881208
	AU 8826677	A1	19890608		
PRAI	AU 1987-5803		19871208		

AB A pharmaceutical contg. ferric ammonium citrate in admixt. with ZnO and optionally including aspirin, NaHCO3, and citric acid is effective in treating arthritis, bronchitis, diabetes, arteriosclerosis, broken bones, **Parkinson**'s disease, high blood cholesterol, liver cirrhosis, and enlargement of the prostate gland.

ST ferric ammonium citrate zinc oxide pharmaceutical

IT Antiarteriosclerotics
Anticholesteremics and Hypolipemics
Antidiabetics and Hypoglycemics
(ferric ammonium citrate and zinc oxide as)

IT Cirrhosis
Parkinsonism
(treatment of, ferric ammonium citrate and zinc oxide for)

IT Inflammation inhibitors
(antiarthritics, ferric ammonium citrate and zinc oxide as)

IT Prostate gland
(disease, hyperplasia, treatment of, ferric ammonium citrate and zinc oxide for)

IT Bronchi
(diseases, bronchitis, treatment of, ferric ammonium citrate and zinc oxide for)

IT Bone, disease
(fracture, treatment of, ferric ammonium citrate and zinc oxide for)

IT **50-78-2**, Aspirin 59-43-8, Vitamin B1, biological studies
77-92-9, Citric acid, biological studies 94-20-2, Chlorpropamide
144-55-8, Sodium bicarbonate, biological studies
RL: BIOL (Biological study)
(pharmaceuticals contg. ferric ammonium citrate and zinc oxide and, for treatment of infections and immune diseases)

IT 1314-13-2, Zinc oxide, biological studies
RL: BIOL (Biological study)
(pharmaceuticals contg. ferric ammonium citrate and, for treatment of infections and immune diseases)

IT 1185-57-5, Ferric ammonium citrate
RL: BIOL (Biological study)
(pharmaceuticals contg. zinc oxide and, for treatment of infections and immune diseases)

=>

AN 1998:700744 CAPLUS
DN 130:60774
TI Nonsteroidal anti-inflammatory drugs increase tumor necrosis factor production in the periphery but not in the central nervous system in mice and rats
AU Sacco, Silvano; Agnello, Davide; Sottocorno, Marcello; Lozza, Gianluca; Monopoli, Angela; Villa, Pia; Ghezzi, Pietro
CS Laboratory of Neuroimmunology, "Mario Negri" Institute for Pharmacological Research, Milan, 20157, Italy
SO Journal of Neurochemistry (1998), 71(5), 2063-2070
CODEN: JONRA9; ISSN: 0022-3042
PB Lippincott-Raven Publishers
DT Journal
LA English
CC 1-7 (Pharmacology)
AB Nonsteroidal anti-inflammatory drugs (**NSAIDs**), which inhibit prostaglandin (PG) synthesis, augment prodn. of tumor necrosis factor (TNF) in most exptl. models. We investigated the effect of two **NSAIDs**, indomethacin and ibuprofen, on the prodn. of TNF in the CNS induced by intracerebroventricular injection of lipopolysaccharide (LPS). Indomethacin and ibuprofen, administered i.p., augmented (three- to ninefold) the levels of TNF in serum and peripheral organs of mice injected i.p. with LPS and in rats with adjuvant arthritis (up to a sevenfold increase). However, **NSAIDs** (i.p. or intracerebroventricularly) did not increase brain TNF prodn. induced by i.v. LPS. In fact, indomethacin decreased (1.4-1.8-fold) TNF levels in the spinal cord of rats with exptl. autoimmune encephalomyelitis and in the cortex of rats with focal cerebral **ischemia**. Systemic administration of iloprost inhibited serum TNF levels after i.p. LPS, whereas intracerebroventricular injection of iloprost or PGE2 did not inhibit brain TNF induced by intracerebroventricular LPS. Both peripheral and central TNF productions were inhibited by cAMP level-elevating agents or dexamethasone. Thus, a PG-driven neg. feedback controls TNF prodn. in the periphery but not in the CNS.
ST antiinflammatory **NSAIDs** TNF peripheral central nervous system
IT Anti-inflammatory agents
Brain
(**NSAIDs** increase TNF prodn. in peripheral but not central nervous system in mice and rats)
IT Tumor necrosis factors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(**NSAIDs** increase TNF prodn. in peripheral but not central nervous system in mice and rats)
IT Encephalomyelitis
(autoimmune; **NSAIDs** increase TNF prodn. in peripheral but not central nervous system in mice and rats)
IT Nervous system
(central; **NSAIDs** increase TNF prodn. in peripheral but not central nervous system in mice and rats)
IT Brain, disease
(**ischemia**; **NSAIDs** increase TNF prodn. in peripheral but not central nervous system in mice and rats)
IT Anti-inflammatory agents
(nonsteroidal; **NSAIDs** increase TNF prodn. in peripheral but not central nervous system in mice and rats)
IT Nervous system
(peripheral; **NSAIDs** increase TNF prodn. in peripheral but not central nervous system in mice and rats)
IT 53-86-1, Indomethacin 15687-27-1, Ibuprofen
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES

(Uses)
(**NSAIDs** increase TNF prodn. in peripheral but not central nervous system in mice and rats)
IT 60-92-4, CAMP
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(**NSAIDs** increase TNF prodn. in peripheral but not central nervous system in mice and rats)
RE.CNT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE

(1) Aggarwal, B; J Biol Chem 1985, V260, P2345 CAPLUS
(2) Asanuma, M; Neurosci Lett 1997, V225, P109 CAPLUS
(3) Bagby, G; J Appl Physiol 1994, V77, P1542 CAPLUS
(4) Benigni, F; Mol Med 1995, V1, P568 CAPLUS
(5) Breder, C; J Comp Neurol 1993, V337, P543 CAPLUS
(6) Breitner, J; Annu Rev Med 1996, V47, P401 CAPLUS
(7) Brosnan, C; Neurology 1995, V45(Suppl 6), PS16
(8) Bruce, A; Nature Med 1996, V2, P788 CAPLUS
(9) Di Santo, E; Cytokine 1997, V9, P300 CAPLUS
(10) Di Santo, E; Eur J Pharmacol 1997, V336, P197 CAPLUS
(11) Di Santo, E; Neuroimmunomodulation 1995, V2, P149 CAPLUS
(12) Dickson, D; Glia 1993, V7, P75 MEDLINE
(13) Dinarello, C; Am J Med 1982, V72, P799 CAPLUS
(14) Dinarello, C; Rev Infect Dis 1988, V10, P168 CAPLUS
(15) Faggioni, R; Infect Immun 1995, V63, P1473 CAPLUS
(16) Fattori, E; J Exp Med 1994, V180, P1243 CAPLUS
(17) Gahring, L; Neuroimmunomodulation 1996, V3, P289 CAPLUS
(18) Grundmann, H; J Infect Dis 1992, V165, P501 CAPLUS
(19) Haley, T; Br J Pharmacol 1957, V12, P12 CAPLUS
(20) Honda, A; J Biol Chem 1993, V268, P7759 CAPLUS
(21) Irani, D; J Immunol 1997, V158, P2318 CAPLUS
(22) Knudsen, P; J Immunol 1986, V137, P3189 CAPLUS
(23) Lipton, J; Peptides 1991, V12, P795 CAPLUS
(24) Liu, T; Stroke 1994, V25, P1481 CAPLUS
(25) Martich, G; J Exp Med 1991, V173, P1021 CAPLUS
(26) Meistrell, M; Shock 1997, V8, P341
(27) Mengozzi, M; Immunology 1994, V82, P207 CAPLUS
(28) Mustafa, M; Am J Dis Child 1990, V144, P883 MEDLINE
(29) Mustafa, M; J Clin Invest 1989, V84, P1253 CAPLUS
(30) Nataf, S; Acta Neurol Scand 1993, V88, P97 CAPLUS
(31) Noel, P; Life Sci 1990, V47, P1023 CAPLUS
(32) Olsson, T; Neurology 1995, V45(Suppl 6), PS11
(33) Reder, A; J Neuroimmunol 1994, V54, P117 CAPLUS
(34) Renz, H; J Immunol 1988, V141, P2388 CAPLUS
(35) Ruddle, N; J Exp Med 1990, V172, P1193 CAPLUS
(36) Saez-Llorens, X; Animicrob Agents Chemother 1990, V34, P837 CAPLUS
(37) Saukkonen, K; J Exp Med 1990, V171, P439 CAPLUS
(38) Schooltink, H; FEBS Lett 1992, V314, P280 CAPLUS
(39) Selmaj, K; Neurology 1995, V45(Suppl 6), PS44
(40) Shigeno, T; Surg Neurol 1985, V24, P47 MEDLINE
(41) Sironi, M; Int J Immunopharmacol 1992, V14, P1045 CAPLUS
(42) Sommer, N; Nature Med 1995, V1, P244 CAPLUS
(43) Spengler, R; Infect Immun 1989, V57, P2837 CAPLUS
(44) Stewart, W; Neurology 1997, V48, P626 MEDLINE
(45) Sugimoto, Y; J Biol Chem 1992, V267, P6463 CAPLUS
(46) Sugimoto, Y; Neuroscience 1994, V62, P919 CAPLUS
(47) van der Poll, T; J Immunol 1995, V155, P5397 CAPLUS
(48) Watabe, A; J Biol Chem 1993, V268, P20175 CAPLUS
(49) Zuckerman, S; Eur J Immunol 1989, V19, P301 CAPLUS

=>

AN 1979:36972 CAPLUS
DN 90:36972
TI Entry of protein into cerebral ventricles during ventriculo-cisternal perfusion and the administration of anti-inflammatory agents
AU Haywood, J. R.; Vogh, B. P.
CS Dep. Pharmacol Ther., Univ. Florida, Gainesville, FL, USA
SO Journal of Neurochemistry (1978), 30(6), 1621-3
CODEN: JONRA9; ISSN: 0022-3042
DT Journal
LA English
CC 13-13 (Mammalian Biochemistry)
Section cross-reference(s): 1
AB During brain ventriculo-cisternal perfusion (VCP) in cats, entry of protein into the ventricles was stable over 30-150 min, after which the rate increased up to the end of the exptl. period (330 min). When the VCP procedures involved increased trauma to meningeal tissues, e.g., by using a blunted needle, the early and late stable mean rate of influx was higher and probably more direct leakage occurred due to the invasive technique itself. Gentamicin, tobramycin, acetylsalicylic acid (15-30 mg/kg i.v. or 200 .mu.M **intrathecally**), indomethacin (3.4 .mu.M), and meclofenamic acid (1.7 .mu.M) all failed to reduce the protein entry, but dexamethasone given i.v. at the beginning of perfusion (0.3 mg/kg, i.v.) and in repeated doses (0.15 mg/kg/h) lowered the initial rate of protein entry and markedly attenuated the subsequent rise in protein influx.
ST ventriculocisternal perfusion protein entry ventricle; antiinflammatory ventriculocisternal perfusion protein influx; dexamethasone ventriculocisternal perfusion protein influx; brain ventricle protein entry perfusion
IT Proteins
RL: BIOL (Biological study)
(brain ventricle influx of, in ventriculo-cisternal perfusion)
IT Cerebrospinal fluid
(protein entry into, in ventriculo-cisternal perfusion)
IT Inflammation inhibitors
(protein influx into brain ventricles in ventriculo-cisternal perfusion response to)
IT Brain
(ventricle, protein entry into, in ventriculo-cisternal perfusion)
IT 50-02-2 **50-78-2** 53-86-1 644-62-2 1403-66-3 32986-56-4
RL: BIOL (Biological study)
(protein influx into brain ventricles in ventriculo-cisternal perfusion response to)

=>